Jazz Pharmaceuticals

PROXY STATEM
MENT &NT
2010 ANNUAL REPORT

STOCKHOLDER LETTER
April 2011

Dear Stockholder,

Without a doubt, 2010 was one of the most transformative years in the history 
of Jazz Pharmaceuticals.  We helped more patients than any prior year, delivered 
significant top-line growth, with net sales of our two marketed products, 
Xyrem® and Luvox CR®, reaching $170 million, and achieved our first full year 
of profitability.  As we pursue our mission to improve patients’ lives, we’ve also 
begun to demonstrate the earnings potential of our business, with a significant 
increase in earnings and cash flow during the year.  

Additional highlights of the year include:

(cid:115)(cid:0) Restructuring our balance sheet to significantly reduce interest expense 

and improve our capital structure.  We also ended the year with 
approximately $45 million in cash, an increase of $22 million during 
the fourth quarter alone.

(cid:115)(cid:0) Growing net sales of Xyrem by 47 percent over 2009, and strengthening 
its intellectual property coverage, with six new patents issued since the 
beginning of 2010.  We remain committed to defending and enforcing 
our patents.  

2010 Net Product Sales of $170M 
(Xyrem® and Luvox CR®)

$52.4
$52.4

$43.8
$43.8

$3$39.9.55
$39.5

$34.3
$34.3

1Q10
1Q10 

2Q10
2Q10 

3Q10
3Q10 

4Q10
4Q10 

Annual Net Product Sales

$170
$170

$115
$1$1$ 1515

$6$655
$65

$54
$54

)
s
n
o

i
l
l
i

m

(

s
e
l
a
S

t
e
N

$60 

$50 

$40 

$30 

$20 

$10 

$0 

$200 

$140 

$100 

)
s
n
o
i
l
l
i

m

(

s
e
l
a
S

t
e
N

(cid:115)(cid:0) Advancing our intranasal clonazepam product candidate for acute repetitive 
seizures in epilepsy.  We completed additional formulation work and now 
hope to advance this promising pipeline candidate into further clinical 
research later in 2011.

$50 

$4$4$$ 33
$43

$0 

2006
2006

2007
2007

2008
2008

2009
2009

2010
2010

Our 2010 performance also reflects the ongoing commitment and passion of 
our employees, for which I’d like to thank and acknowledge them.  

Adjusted Net Income (Loss) Per Diluted Share1

As we set a new bar for our performance this year, we have a number of strategic 
priorities.  We are focused on growing and protecting our current commercial 
business and advancing our intranasal clonazepam product candidate, while 
considering additional product opportunities.  And our financial position is strong 
and growing stronger, enabling us to continue to deliver compelling growth 
and build shareholder value.  2011 is shaping up to be another terrific year for 
Jazz Pharmaceuticals.  

Thank you for your continued interest in our company.

$3.00 

$2.00 

$1.00 

$0.00 

-$1.00 

-$2.00 

-$3.00 

-$4.00 

-$5.00 

-$6.00 

$$$11.5555
 $1.55

($($($$0000 0050505)))
($0.05)

($($$$($555 333333)))
($5.33)
2008

2009

2010

Bruce C. Cozadd
Chairman and Chief Executive Officer

1. Adjusted net income (loss) per diluted share is a non-GAAP financial 
measure that excludes certain items from GAAP net income (loss) per 
diluted share. A reconciliation of adjusted net income (loss) per diluted 
share to GAAP net income (loss) per diluted share is included in the 
attached Annual Report on Form 10-K for the year ended 
December 31, 2010.

 
 
 
 
 
 
y
x
o
r
P

®

JAZZ PHARMACEUTICALS, INC.
3180 Porter Drive
Palo Alto, California 94304

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To be Held on May 24, 2011

Dear Stockholder:

You are cordially invited to attend the 2011 annual meeting of stockholders, or the Annual Meeting, of Jazz

Pharmaceuticals, Inc., a Delaware corporation, or the Company. The Annual Meeting will be held on Tuesday,
May 24, 2011, at 11:00 a.m. local time at the Company’s offices located at 3180 Porter Drive, Palo Alto,
California 94304 for the following purposes:

1. To elect the three nominees for director named in the accompanying proxy statement, or the Proxy
Statement, to hold office as a member of the Board of Directors, the Board, until the 2014 annual
meeting of stockholders.

2. To ratify the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s

independent registered public accounting firm for the fiscal year ending December 31, 2011.

3. To approve the Internal Revenue Code Section 162(m) performance criteria and award limits under

the Company’s 2007 Equity Incentive Plan.

4. To approve, on an advisory basis, the compensation of the Company’s named executive officers as

disclosed in the Proxy Statement.

5. To indicate, on an advisory basis, the preferred frequency of the advisory vote on the compensation

of the Company’s named executive officers.

6. To conduct any other business properly brought before the meeting.

These items of business are more fully described in the Proxy Statement accompanying this notice.
The record date for the Annual Meeting is March 30, 2011. Only stockholders of record at the close of

business on that date may vote at the meeting or any adjournment thereof.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of
Stockholders to Be Held on May 24, 2011 at 11:00 a.m. local time at the Company’s offices located at
3180 Porter Drive, Palo Alto, California 94304.
The Proxy Statement and annual report to stockholders are available at https://materials.proxyvote.com/
472147.

By Order of the Board,

Carol A. Gamble
Senior Vice President, General Counsel
and Corporate Secretary

Palo Alto, California
April 8, 2011

You are cordially invited to attend the meeting in person. Whether or not you expect to attend the
meeting, please vote as soon as possible. You may vote your shares over the telephone or the internet.
If you received a proxy card or voting instruction card by mail, you may submit your proxy card or
voting instruction card by completing, signing, dating and mailing your proxy card or voting
instruction card in the envelope provided. Even if you have voted by proxy, you may still vote in
person if you attend the meeting. Please note, however, that if your shares are held of record by a
broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in
your name from that record holder.

[THIS PAGE INTENTIONALLY LEFT BLANK]

JAZZ PHARMACEUTICALS, INC.
3180 Porter Drive
Palo Alto, California 94304

PROXY STATEMENT
FOR THE 2011 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON TUESDAY, MAY 24, 2011 AT 11:00 A.M.

QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING

Why am I receiving these materials?

Our Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or
postponements of the Annual Meeting. This Proxy Statement contains important information regarding the
Annual Meeting, the proposals on which you are being asked to vote, information you may find useful in
determining how to vote and voting procedures.

y
x
o
r
P

Why did I receive a Notice in the mail regarding the internet availability of proxy materials instead of a
full set of proxy materials?

The Company is pleased to take advantage of U.S. Securities and Exchange Commission, or SEC, rules that

allow companies to furnish their proxy materials over the internet. In this regard, most of our stockholders
holding their shares in “street name” will not receive paper copies of our proxy materials (unless requested), and
will instead be sent a Notice of Internet Availability of Proxy Materials, or Notice, from the brokerage firms,
banks, dealers, or other similar organizations holding their accounts. All “street name” holders receiving a Notice
will have the ability to access the proxy materials on the website referred to in the Notice and to request to
receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or
to request a printed set of the proxy materials may be found in the Notice.

Why did I receive a full set of proxy materials in the mail instead of a Notice regarding the internet
availability of proxy materials?

The Company is providing stockholders of record who are holding shares in their own name and

stockholders who have previously requested to receive paper copies of our proxy materials with paper copies of
our proxy materials instead of a Notice. The Company intends to mail the full sets of proxy materials to the
stockholders described in the previous sentence on or about April 11, 2011.

How do I attend the Annual Meeting?

You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement.
The Annual Meeting will be held on Tuesday, May 24, 2011 at 11:00 a.m. local time at the Company’s offices
located at 3180 Porter Drive, Palo Alto, California, 94304. Directions to the Annual Meeting may be found on
our website, www.jazzpharmaceuticals.com, in the section titled “Company” under the subsection titled “Driving
Directions.” Information on how to vote in person at the Annual Meeting is discussed below. However, you do
not need to attend the Annual Meeting to vote your shares.

Who can vote at the Annual Meeting?

Only stockholders of record at the close of business on March 30, 2011 will be entitled to vote at the Annual

Meeting. On this record date, there were 40,671,360 shares of common stock outstanding and entitled to vote.

1

Stockholders of Record: Shares Registered in Your Name

If on March 30, 2011 your shares were registered directly in your name with the Company’s transfer agent,
Computershare Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote
in person at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we
urge you to vote by proxy over the telephone or on the internet as instructed below, or fill out and return a proxy
card.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If on March 30, 2011 your shares were held not in your name, but rather in an account at a brokerage firm,
bank, dealer, or other similar organization, then you are the beneficial owner of shares held in “street name” and
a Notice is being sent to you by that organization. The organization holding your account is considered to be the
stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to
direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend
the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in
person at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent.

What am I voting on?

There are five matters scheduled for a vote at the Annual Meeting:

• Election of the three nominees named below for director to hold office as a member of the Board until

the 2014 annual meeting of stockholders (Proposal 1);

• Ratification of the selection by the Audit Committee of the Board of Ernst & Young LLP as the

Company’s independent registered public accounting firm for the fiscal year ending December 31,
2011 (Proposal 2);

• Approval of the Internal Revenue Code Section 162(m) performance criteria and award limits under

the Company’s 2007 Equity Incentive Plan (Proposal 3);

• Advisory approval of the compensation of the Company’s named executive officers as disclosed in this

Proxy Statement (Proposal 4); and

• Advisory indication of the preferred frequency of the advisory vote on the compensation of the

Company’s named executive officers (Proposal 5).

What are the Board’s voting recommendations?

The Board recommends that you vote your shares:

•

•

•

•

•

“For” each of the nominees named below for director to hold office as a member of the Board until the
2014 annual meeting of stockholders (Proposal 1);

“For” ratification of the selection by the Audit Committee of the Board of Ernst & Young LLP as the
Company’s independent registered public accounting firm for the fiscal year ending December 31,
2011 (Proposal 2);

“For” approval of the Internal Revenue Code Section 162(m) performance criteria and award limits
under the Company’s 2007 Equity Incentive Plan (Proposal 3);

“For” approval, on an advisory basis, of the compensation of the Company’s named executive officers
as disclosed in this Proxy Statement (Proposal 4); and

For the option of every “3 Years” as the preferred frequency for the advisory vote on the compensation
of the Company’s named executive officers (Proposal 5).

2

What if another matter is properly brought before the Annual Meeting?

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any

other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the
accompanying proxy to vote on those matters in accordance with their best judgment.

How do I vote?

For the election of directors (Proposal 1), you may either vote “For” all the nominees to the Board or you

may “Withhold” your vote for all or any of the nominees. For the ratification of the Audit Committee of the
Board’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the
fiscal year ending December 31, 2011 (Proposal 2), you may vote “For” or “Against” or abstain from voting. For
the approval of the Internal Revenue Code Section 162(m) performance criteria and award limits under the
Company’s 2007 Equity Incentive Plan (Proposal 3), you may vote either “For” or “Against” or abstain from
voting. For the proposal regarding an advisory vote on the compensation of the Company’s named executive
officers (Proposal 4), you may vote “For” or “Against” or abstain from voting. For the proposal regarding the
frequency of the advisory vote on the compensation of the Company’s named executive officers (Proposal 5),
you may vote every “3 Years,” “2 Years,” “1 Year” or you may abstain from voting.

y
x
o
r
P

Stockholders of Record: Shares Registered in Your Name

If you are a stockholder of record, you may vote in person at the Annual Meeting, you may vote by proxy

using the enclosed proxy card, or you may vote by proxy over the telephone or on the internet as instructed
below. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote
is counted. You may still attend the Annual Meeting and vote in person even if you have already voted by proxy.

• To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive.

• To vote using a proxy card, simply complete, sign and date the enclosed proxy card and return it
promptly in the envelope provided. If you return your signed proxy card to us before the Annual
Meeting, we will vote your shares as you direct.

• To vote by telephone, dial toll-free 1-800-652-VOTE (8683) within the U.S., U.S. territories and

Canada using a touch-tone phone and follow the recorded instructions. You will be asked to provide
the company number and control number from the enclosed proxy card. Your vote must be received by
1:00 a.m., Central Time, on May 24, 2011 to be counted.

• To vote through the internet, go to www.investorvote.com/JAZZ to complete an electronic proxy card.
You will be asked to provide the company number and control number from the enclosed proxy card.
Your vote must be received by 1:00 a.m., Central Time, on May 24, 2011 to be counted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you

should have received a Notice containing voting instructions from that organization rather than from the
Company. Simply follow the voting instructions in the Notice to ensure that your vote is counted. Alternatively,
you may vote by telephone or over the internet as instructed by your broker or bank. To vote in person at the
Annual Meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the voting
instructions from your broker or bank included with the Notice, or contact your broker or bank to request a proxy
form.

We provide internet proxy voting to allow you to vote your shares online, with procedures designed to
ensure the authenticity and correctness of your proxy vote instructions. However, please be aware
that you must bear any costs associated with your internet access, such as usage charges from internet
access providers and telephone companies.

3

How many votes do I have?

On each matter to be voted upon, you have one vote for each share of common stock you own as of

March 30, 2011.

What if I return a proxy card or otherwise vote but do not make specific choices?

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record and you indicate when voting on the internet or by telephone that you

wish to vote as recommended by the Board, which recommendations are set forth under “What are the Board’s
voting recommendations?” above, or if you sign and return a proxy card without giving specific voting
instructions, then the proxy holders will vote your shares in the manner recommended by the Board on all
matters presented in this Proxy Statement and as the proxy holders may determine in their discretion with respect
to any other matters properly presented for a vote at the meeting.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If you are a beneficial owner of shares held in “street name” and you do not provide the organization that
holds your shares with specific instructions, under the rules of various national and regional securities exchanges,
the organization that holds your shares may generally vote on routine matters but cannot vote on non-routine
matters. If the organization that holds your shares does not receive instructions from you on how to vote your
shares on a non-routine matter, the organization that holds your shares will inform our inspector of elections that
it does not have the authority to vote on this matter with respect to your shares. This is generally referred to as a
“broker non-vote.” When our inspector of elections tabulates the votes for any particular matter, broker
non-votes will be counted for purposes of determining whether a quorum is present, but will not be counted
toward the vote total for any proposal. We encourage you to provide voting instructions to the organization that
holds your shares to ensure that your vote is counted on all five proposals.

Which proposals are considered “routine” or “non-routine”?

The ratification of the selection by the Audit Committee of the Board of Ernst & Young LLP as the
Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011
(Proposal 2) is a matter considered routine under applicable rules. A broker or other nominee may generally vote
on routine matters, and therefore no broker non-votes are expected to exist in connection with Proposal 2.

The election of directors (Proposal 1), the vote to approve the Internal Revenue Code Section 162(m)
performance criteria and award limits under the 2007 Equity Incentive Plan (Proposal 3), the advisory vote on the
compensation of the Company’s named executive officers (Proposal 4) and the advisory vote on the frequency of
the advisory vote on the compensation of the Company’s named executive officers (Proposal 5) are matters
considered non-routine under applicable rules. A broker or other nominee cannot vote without instructions on
non-routine matters, and therefore we expect broker non-votes on Proposals 1, 3, 4 and 5.

Who is paying for this proxy solicitation?

We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and
employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and
employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage
firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

What does it mean if I receive more than one set of proxy materials or more than one Notice, or
combination thereof?

If you receive more than one set of proxy materials or more than one Notice or a combination thereof, your
shares may be registered in more than one name or are registered in different accounts. Please follow the voting
instructions on each set of proxy materials or Notices to ensure that all of your shares are voted.

4

Can I change my vote after submitting my proxy?

Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the

record holder of your shares, you may revoke your proxy in any one of the following ways:

• You may submit another properly completed proxy card with a later date.

• You may grant a subsequent proxy by telephone or through the internet.

• You may send a timely written notice that you are revoking your proxy to the Company’s Secretary at

3180 Porter Drive, Palo Alto, California 94304.

• You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not,

y
x
o
r
P

by itself, revoke your proxy.

Your most recent proxy card or telephone or internet proxy is the one that is counted.

If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions

provided by your broker or bank.

When are stockholder proposals due for next year’s annual meeting?

Stockholders of the Company may submit proposals on matters appropriate for stockholder action at
meetings of its stockholders in accordance with Rule 14a-8 promulgated under the Securities Exchange Act of
1934, as amended, or Exchange Act. For such proposals to be included in the Company’s proxy materials
relating to its 2012 annual meeting of stockholders, all applicable requirements of Rule 14a-8 must be satisfied
and, pursuant to Rule 14a-8, such proposals must be received by the Company no later than December 13, 2011.
However, if the Company’s 2012 annual meeting of stockholders is not held between April 24, 2012 and June 23,
2012, then the deadline will be a reasonable time prior to the time the Company begins to print and mail its proxy
materials. Such proposals should be delivered to Jazz Pharmaceuticals, Inc., Attn: Secretary, 3180 Porter Drive,
Palo Alto, California 94304.

Pursuant to the Company’s bylaws, if you wish to bring a proposal before the stockholders or nominate a

director at the 2012 annual meeting of stockholders, but you are not requesting that your proposal or nomination
be included in next year’s proxy materials, you must notify the Company’s Secretary, in writing, not later than
the close of business on February 24, 2012 nor earlier than the close of business on January 25, 2012. However,
if the Company’s 2012 annual meeting of stockholders is not held between April 24, 2012 and June 23, 2012, to
be timely, notice by the stockholder must be so received not earlier than the close of business on the 120th day
prior to the 2012 annual meeting of stockholders and not later than the close of business on the later of the
90th day prior to the 2012 annual meeting of stockholders or the tenth day following the day on which public
announcement of the date of the 2012 annual meeting of stockholders is first made.

The Company also advises you to review its bylaws, which contain additional requirements about advance

notice of stockholder proposals and director nominations. Among other things, a stockholder’s notice to the
Company’s Secretary must set forth the information required by the Company’s bylaws with respect to each
matter the stockholder proposes to bring before the 2012 annual meeting of stockholders. The chairperson of the
2012 annual meeting of stockholders may determine, if the facts warrant, that a matter has not been properly
brought before the meeting and, therefore, may not be considered at the meeting. In addition, the proxy solicited
by the Board for the 2012 annual meeting of stockholders will confer discretionary voting authority with respect
to (i) any proposal presented by a stockholder at that meeting for which the Company has not been provided with
timely notice and (ii) any proposal made in accordance with the Company’s bylaws, if the 2012 proxy statement
briefly describes the matter and how management’s proxy holders intend to vote on it, if the stockholder does not
comply with the requirements of Rule 14a-4(c)(2) promulgated under the Exchange Act.

5

How are votes counted?

Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately
count “For”, “Withhold” and broker non-votes for Proposal 1, “For”, “Against,” “Abstain” and broker non-votes
for Proposals 2, 3 and 4, and “3 Years,” “2 Years,” “1 Year” and broker non-votes for Proposal 5.

Abstentions and broker non-votes will be treated as shares present for the purpose of determining the
presence of a quorum for the transaction of business at the Annual Meeting. Abstentions will be counted towards
the tabulation of shares present in person or represented by proxy and will have the same effect as an “Against”
vote on Proposals 2, 3 and 4. If you abstain from voting on Proposal 5, the abstention will not have an effect on
the outcome of the vote. Broker non-votes have no effect and will not be counted towards the vote total for any
proposal.

How many votes are needed to approve each proposal?

•

•

•

•

•

Proposal 1: For the election of directors, the three nominees receiving the most “For” votes (among
votes properly cast in person or by proxy) will be elected.

Proposal 2: The ratification of the Audit Committee’s selection of Ernst & Young LLP as the
Company’s independent registered public accounting firm for the fiscal year ending December 31,
2011 (Proposal 2) must receive a “For” vote from at least a majority of the shares represented either in
person or by proxy at the Annual Meeting and entitled to vote.

Proposal 3: The approval of the Internal Revenue Code Section 162(m) performance criteria and award
limits under the 2007 Equity Incentive Plan must receive a “For” vote from at least a majority of the
shares represented and voting either in person or by proxy at the Annual Meeting and entitled to vote.

Proposal 4: The advisory approval of compensation of named executive officers must receive a “For”
vote from at least a majority of the shares represented either in person or by proxy at the Annual
Meeting and entitled to vote, although such vote will not be binding on us.

Proposal 5: For the proposal regarding the frequency of the advisory vote on the compensation of
named executive officers, the frequency option that receives the greatest number of votes from the
holders of shares represented either in person or by proxy at the Annual Meeting and entitled to vote
will be considered the frequency preferred by the stockholders, although such vote will not be binding
on us.

What is the quorum requirement?

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders

holding at least a majority of the outstanding shares entitled to vote are present at the Annual Meeting in person
or represented by proxy. On the record date, there were 40,671,360 shares outstanding and entitled to vote.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on

your behalf by your broker, bank or other nominee) or if you vote in person at the Annual Meeting. Abstentions
and broker non-votes will be treated as shares present for the purpose of determining the presence of a quorum. If
there is no quorum, the chairperson of the Annual Meeting or a majority of shares present at the Annual Meeting
in person or represented by proxy may adjourn the Annual Meeting to another date.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results will be announced at the Annual Meeting. Final voting results are expected to be

published in a current report on Form 8-K filed by the Company with the SEC on or before the fourth business
day following the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within

6

four business days following the Annual Meeting, we intend to file a Form 8-K to publish preliminary results
and, within four business days after the final results are known to us, file an additional Form 8-K to publish the
final results.

What proxy materials are available on the internet?

Our letter to stockholders, Proxy Statement, and annual report to stockholders are available at

https://materials.proxyvote.com/472147.

y
x
o
r
P

7

PROPOSAL 1
ELECTION OF DIRECTORS

The Board is divided into three classes and each class has a three-year term. Vacancies on the Board may be

filled only by the affirmative vote of a majority of the remaining directors, even if the remaining directors
constitute less than a quorum of the Board. A director elected by the Board to fill a vacancy in a class will serve
for the remainder of the full term of that class and until the director’s successor is elected and qualified. This
applies to vacancies created by an increase in the authorized number of directors.

The Company presently has 12 directors and no vacancies on the Board. There are five directors in Class I,
the class whose term of office expires at the Annual Meeting. Two of the Class I directors, James B. Tananbaum,
M.D. and Nathaniel M. Zilkha, have advised the Board that they will not stand for reelection at the Annual
Meeting. Effective upon the expiration of the term of office for each of Dr. Tananbaum and Mr. Zilkha at the
Annual Meeting on May 24, 2011, the size of the Board will reduce to 10 members and there will be no
vacancies. As a result, there are three Class I director nominees for election at the Annual Meeting, Paul L.
Berns, Bryan C. Cressey and Patrick G. Enright, and proxies may not be voted for more than three nominees to
the Board.

Mr. Cressey was recommended for reelection to the Board by the Nominating and Corporate Governance
Committee of the Board. Mr. Enright was elected to the Board in July 2009 and was recommended for election to
the Board by the Nominating and Corporate Governance Committee when funds affiliated with his firm made a
significant equity investment in the Company. Mr. Berns was elected to the Board in June 2010 and was
recommended for election to the Board by the Nominating and Corporate Governance Committee, which
identified Mr. Berns as a potential nominee with the assistance of a third-party search firm. If elected at the
Annual Meeting, each of these nominees would serve until the 2014 annual meeting of stockholders and until his
successor is elected and has qualified, or until his death, resignation or removal. It is the Company’s policy to
invite directors and nominees for director to attend annual meetings of stockholders. One of our non-employee
directors attended the 2010 annual meeting of stockholders.

Directors are elected by a plurality of the votes of the holders of shares present in person or represented by

proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of
affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not
withheld, for the election of the three nominees named below. If any nominee becomes unavailable for election
as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee
proposed by the Nominating and Corporate Governance Committee of the Board. Each person nominated for
election has agreed to serve if elected. The Company’s management has no reason to believe that any nominee
will be unable to serve.

The following includes a brief biography of each nominee for director and each of our other current
directors, including their respective ages as of March 30, 2011. Each biography includes information regarding
the specific experience, qualifications, attributes or skills that led the Nominating and Corporate Governance
Committee and the Board to determine that the applicable nominee or other current director should serve as a
member of the Board as of the date of this Proxy Statement.

Class I Director Nominees for Election for a Three-Year Term Expiring at the 2014 Annual Meeting of
Stockholders

Paul L. Berns, age 44, has served as a member of our Board since June 2010. Since March 2006, he has

served as the President and Chief Executive Officer, and as a member of the Board, of Allos Therapeutics, Inc.
From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From
June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care

8

y
x
o
r
P

International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005.
From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and
Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he
served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, a pharmaceutical company, and from 1990
to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb
Company, a pharmaceutical company. Mr. Berns has been a director of XenoPort, Inc. since 2005. Mr. Berns
received a B.S. in Economics from the University of Wisconsin. Mr. Berns’ experience as chief executive officer
of Allos Therapeutics and Bone Care International provides significant management expertise and industry
knowledge to the Board.

Bryan C. Cressey, age 61, has served as a member of our Board since 2006. Since 2007 he has been a
Partner of Cressey and Company, LLC, and since 1998, he has been a Partner of Thoma Cressey Bravo, Inc.,
both private equity firms of which he is a founder. Funds affiliated with the Thoma Cressey Bravo firm are
among our largest stockholders. Mr. Cressey serves as the Chairman of the Board of Belden, Inc., a networking
cable technology company, and on the boards of Select Medical Corporation, a healthcare services company, and
several privately-held healthcare services companies. He received a B.A. from the University of Washington, a
J.D. from Harvard Law School and an M.B.A. from Harvard Business School. As the founder of the health care
focused private equity firm Cressey and Company, LLC and board member of several health care companies,
Mr. Cressey brings to the Board many years of experience and expertise as an investor in and advisor to
companies in the health care sector.

Patrick G. Enright, age 49, has served as a member of our Board since July 2009. Since 2006, Mr. Enright
has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. From
2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences
investment practice. Mr. Enright also has significant life sciences operations experience, beginning his career
more than 25 years ago at Sandoz (now Novartis). He currently serves on the boards of Corcept Therapeutics
Incorporated, a pharmaceutical company, and several privately-held companies. In the past five years he also
served as a director of Threshold Pharmaceuticals, Sequenom Inc., and Valentis, Inc. Mr. Enright received a B.S.
from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania. As a
venture capital investor focused on life science companies and someone who has worked in the pharmaceutical
industry, Mr. Enright brings to the Board both operating experience and financial expertise in the life sciences
industry.

The Board recommends
a vote “For” each named nominee.

Class II Directors Continuing in Office Until the 2012 Annual Meeting of Stockholders

Samuel D. Colella, age 71, has served as a member of our Board since 2004. Since 1999, he has served as

Managing Director of Versant Ventures, a venture capital firm, which he co-founded. He serves on the boards of
Genomic Health Inc., a molecular diagnostics company, Alexza Pharmaceuticals, a drug delivery company, and
several privately-held companies. In the past five years he also served as a director of Solta Medical and Symyx,
Inc. Mr. Colella received a B.S. from the University of Pittsburgh and an M.B.A. from the Stanford Graduate
School of Business. Mr. Colella brings to the Board many years of experience investing in, and serving on the
boards of, public and private life sciences companies. As an early investor in the Company, he has an intimate
knowledge of the business and strategy of our company.

James C. Momtazee, age 39, has served as a member of our Board since 2004. He is a member of KKR
Management LLC, the general partner of KKR & Co. L.P., and he has been employed by KKR since 1996.
Funds affiliated with KKR are our company’s largest stockholder. He serves on the boards of HCA Inc., a
healthcare services company, and Accellent Inc., a manufacturing and engineering services company. In the past
five years he also served as a director of Accuride Corp. and Alliance Imaging. He received an A.B. from
Stanford University and an M.B.A. from the Stanford Graduate School of Business. As a Member of KKR and a

9

board member of other health care companies, Mr. Momtazee brings to the Board significant expertise in
financing and financial matters, including expertise and experience in structuring complex financial transactions
and a broad understanding of the market related to those transactions, which is of particular use to the Board.

Rick E Winningham, age 51, has served as a member of our Board since May 2010. Since 2001, he has
served as the Chief Executive Officer and a member of the Board of Theravance, Inc., a biopharmaceutical
company, and in April 2010, he was appointed Chairman of the Board of Theravance. From 1997 to 2001, he
served as the President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and,
from 2000 to 2001, as President of Global Marketing. He is a member of the External Advisory Board for the
College of Business and Administration and Business Hall of Fame at Southern Illinois University.
Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.
Mr. Winningham’s experience in senior management positions in the pharmaceuticals industry provides
significant industry knowledge and operational and management expertise to our Board.

Class III Directors Continuing in Office Until the 2013 Annual Meeting of Stockholders

Bruce C. Cozadd, age 47, is a co-founder and has served as our Chairman and Chief Executive Officer since
April 2009. From 2003 until 2009, he served as our Executive Chairman. From 1991 until 2001, he held various
positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently
as its Executive Vice President and Chief Operating Officer, with responsibility for research and development,
manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial
Officer and Vice President, Corporate Planning and Analysis. He serves on the boards of Cerus Corporation, a
biopharmaceutical company, Threshold Pharmaceuticals, a biotechnology company, and The Nueva School and
Stanford Hospital and Clinics, both non-profit organizations. He received a B.S. from Yale University and an
M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd brings to the Board significant experience
and expertise in the management, operations and strategic planning of pharmaceuticals companies, in financing,
fund-raising and capital markets, and as a director of public and private companies and nonprofit organizations.
As our Chief Executive Officer, he brings to the Board a detailed knowledge of all of our activities.

Michael W. Michelson, age 59, has served as a member of our Board since 2004. He is a member of KKR

Management LLC, the general partner of KKR & Co. L.P., and he has been employed by KKR since 1981 where
he serves on KKR’s Investment and Management Committees. Funds affiliated with KKR are our company’s
largest stockholder. Mr. Michelson serves on the boards of HCA Inc., a healthcare services company and Biomet,
Inc., a healthcare manufacturing company. In the past five years he also served as a director of Accellent Inc. and
Alliance Imaging. He received an A.B. from Harvard College and a J.D. from Harvard Law School. As a senior
member of KKR, Mr. Michelson brings to the Board many years of finance and financing expertise, and a
breadth of expertise with many different types of companies.

Kenneth W. O’Keefe, age 44, has served as a member of our Board since 2004. Since 1997, he has been

Managing Director of Beecken Petty O’Keefe & Company, a private equity firm, which he co-founded. He
serves on the boards of several privately-held healthcare companies. He received a B.A. from Northwestern
University and an M.B.A. from the University of Chicago. As a member of the private equity firm Beecken Petty
O’Keefe, Mr. O’Keefe brings to the Board significant expertise in accounting and financial matters and in
analyzing and evaluating financial statements, as well as substantial experience managing private equity
investments. He serves or has served on the audit committee of several companies in the health care industry. As
Chair of our Audit Committee for several years, Mr. O’Keefe has detailed knowledge of our finances and
financial statements.

Alan M. Sebulsky, age 52, has served as a member of our Board since 2004. Since 2003, he has served as a
Managing Partner of Apothecary Capital LLC, an investment advisory firm. From 1994 to 2002, he held various
positions, most recently as a Managing Director, at Lincoln Capital Management, a private investment
management firm, where he was responsible for investments in the health care industry. He received a B.B.A.

10

y
x
o
r
P

and an M.S. from the University of Wisconsin, Madison. In the past five years he served as a director of Arrow
International. Mr. Sebulsky brings to the Board the perspectives of a former Wall Street healthcare stock analyst
and someone who actively follows the health care industry and manages a dedicated healthcare investment fund.

Directors with Terms Expiring at the 2011 Annual Meeting

As noted above, Dr. Tananbaum and Mr. Zilkha have advised the Board that they will not stand for

reelection at the Annual Meeting. Accordingly, their terms of office will expire at the Annual Meeting.

Dr. Tananbaum, age 47, has served as a member of our Board since 2003. Since June 2010, Dr. Tanabaum

has served as the Chief Executive Officer of Foresite Capital Management, LLC, a healthcare investment fund he
founded. From 2000 until May 2010, he was a Managing Director of Prospect Venture Partners, a venture capital
firm he co-founded. He serves on the boards of Infinity Pharmaceuticals, Inc., and several privately-held
companies. In the past five years he also served as a director of Critical Therapeutics and Vanda
Pharmaceuticals. Dr. Tananbaum was the founder of GelTex, Inc. and Theravance, Inc. He received a B.S.E.E.
from Yale University, and an M.D. and an M.B.A. from Harvard University. Dr. Tananbaum brought to the
Board his scientific, financial and operational expertise gained as a physician, founder of two life science
companies and venture capital investor focused on life science companies. As an investor focused on life science
companies who sits on numerous boards, Dr. Tananbaum has provided financial and operational expertise
regarding our industry.

Mr. Zilkha, age 35, has served as a member of our Board since October 2007. Since 2004, he has been
employed by KKR, where he is the Global Co-Head of Special Situations Investing at KKR, which includes the
firm’s activities in public and private distressed and structured investments. Previously he was a member of
KKR’s North American Private Equity team. Funds affiliated with KKR are our company’s largest stockholder.
Prior to joining KKR, Mr. Zilkha spent eight years in the Principal Investment Area of Goldman Sachs, where he
invested in private equity and principal debt transactions. Mr. Zilkha graduated from Princeton University. As an
employee of KKR, Mr. Zilkha brought to the Board his expertise in principal debt transactions and experience
working with companies in the healthcare industry.

There are no family relationships among any of our executive officers and directors.

CORPORATE GOVERNANCE AND BOARD MATTERS

Independence of Jazz Pharmaceuticals’ Board of Directors

As required under the NASDAQ Stock Market LLC, or NASDAQ, listing standards, a majority of the
members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by
the board of directors. The Board consults with internal counsel to ensure that the Board’s determinations are
consistent with relevant securities and other laws and regulations regarding the definition of “independent,”
including those set forth in pertinent listing standards of NASDAQ, as in effect from time to time. Consistent
with these considerations, after review of all relevant transactions or relationships between each director, or any
of his or her family members, and the Company , its senior management and its independent registered public
accounting firm, the Board has affirmatively determined that all of our directors are independent directors within
the meaning of the applicable NASDAQ listing standards, except that Mr. Cozadd, our Chairman and Chief
Executive Officer, is not an independent director by virtue of his employment with the Company. In addition, the
Board determined that each member of our Audit Committee, Compensation Committee and Nominating and
Corporate Governance Committee during 2010 was an independent director within the meaning of the applicable
NASDAQ listing standards and SEC rules.

Board Leadership Structure and Risk Oversight

Bruce Cozadd has served as our Chairman and Chief Executive Officer since April 2009. Prior to that, he
was our Executive Chairman from the founding of the Company in 2003. We believe that a combined Chairman/

11

Chief Executive Officer role helps provide strong, unified leadership for our management team and optimizes
communication with our Board. Mr. Cozadd has a history, throughout the existence of the Company, of
communicating on a regular basis with the independent members of our Board.

The Board believes that the Chief Executive Officer is best suited to serve as our Chairman because he is the
member of the Board who is most familiar with our business as a whole, and the most capable of identifying and
bringing to the attention of the full Board the strategic priorities and key issues facing the Company. As a person
who has spent many years in executive management, and many years serving as a director of public companies as
well as private companies and non-profit organizations, he brings both the directorial and operational
perspectives to the combined position.

We are a small company and our Board is actively involved in our key business decisions. We believe that

having a single leader for the Company is good for our business, efficiently and effectively promotes the strategic
direction and development of the Company, provides the most efficient form of communication with our Board
and promotes the active participation of our independent Board members on a regular basis. We therefore believe
that a combined Chairman/Chief Executive Officer position is currently the best governance model for the
Company.

Our Board is presently comprised of 12 directors, of whom 11 are independent. Upon the expiration of the

term of office for Dr. Tananbaum and Mr. Zilkha at the Annual Meeting on May 24, 2011, our Board will be
comprised of 10 directors, of whom nine will be independent. Individuals affiliated with some of our earliest and
longest term stockholders and with our largest stockholder are members of our Board, providing continuity, a
long-term understanding of our business, and active involvement with our management team as the Company has
matured. Our independent Board members meet without our Chief Executive Officer after each regularly
scheduled Board meeting, and also conduct more informal meetings and discussions among themselves between
meetings. When they talk without our Chief Executive Officer’s participation, one of them agrees to, and does,
update our Chief Executive Officer on the discussions. Depending on the issue, one or another of them will take
the lead in communicating with our Chief Executive Officer. While there is no formal “lead” independent
director, several directors have played this role on different issues, providing our Chief Executive Officer with
insight and expertise.

The Board has an Audit Committee, a Compensation Committee, and a Nominating and Corporate

Governance Committee. Each of these committees is comprised solely of independent directors and has a
separate chair. Our Audit Committee is responsible for overseeing the Company’s financial reporting process on
behalf of the Board and reviewing and reporting to the Board on the Company’s financial risk assessment and
management, and receives reports from our General Counsel and our Chief Regulatory and Compliance Officer
at each regularly scheduled Audit Committee meeting. Our full Board receives regular reports concerning the
financial risk reviews from the Audit Committee at Board meetings, and also receives reports concerning
material risks and concerns from our General Counsel and our Chief Regulatory and Compliance Officer at
Board meetings if there are material matters to be discussed, or if there are significant updates on outstanding
matters. Our Compensation Committee approves all compensation plans for the Company and reviews the
Company’s compensation practices to ensure that they do not encourage excessive risk taking and are appropriate
incentives for meeting both short-term and long-term objectives and increasing stockholder value over time. Our
Nominating and Corporate Governance Committee reviews the qualifications of all current and new directors and
recommends to the full Board whether the Board should elect or nominate them and oversees risks associated
with operations of the Board and its governance structure. Finally, our full Board of Directors approves all of our
material transactions, with full discussion and debate, and a review of the risks and rewards of the proposed
transaction.

We believe that our directors provide effective oversight of risk management, especially through the work

of the Audit Committee, the ongoing dialogue between the full board and our Chairman/Chief Executive Officer,
and the active participation in important company matters by our independent directors.

12

Meetings of the Board

The Board met seven times during our fiscal year ended December 31, 2010 and acted by unanimous

written consent once during the year. The Audit Committee, Compensation Committee and Nominating and
Corporate Governance Committee met a total of 16 times in 2010. All directors, other than Mr. Zilkha, attended
at least 75% of the aggregate number of meetings of the Board and of the committees on which they served held
during the portion of 2010 for which they were directors or committee members, respectively.

As required under applicable NASDAQ listing standards, in fiscal 2010, the Company’s independent
directors generally met at each regularly scheduled Board meeting, in regularly scheduled executive sessions at
which only independent directors were present.

y
x
o
r
P

Committees of the Board

The following table provides membership and meeting information for 2010 for each of the Audit

Committee, Compensation Committee and Nominating and Corporate Governance Committee:

Name

Audit

Compensation

. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Paul L. Berns(1)
Samuel D. Colella . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Bryan C. Cressey(2)
Patrick G. Enright
. . . . . . . . . . . . . . . . . . . . . . . . . .
Michael W. Michelson . . . . . . . . . . . . . . . . . . . . . .
James C. Momtazee . . . . . . . . . . . . . . . . . . . . . . . . .
Kenneth W. O’Keefe . . . . . . . . . . . . . . . . . . . . . . . .
Alan M. Sebulsky . . . . . . . . . . . . . . . . . . . . . . . . . .
James B. Tananbaum, M.D.(3) . . . . . . . . . . . . . . . . .
Total meetings in fiscal 2010 . . . . . . . . . . . . . . . . .

X
X

X*
X

8

X
X

X*

X
5

Nominating and
Corporate
Governance

X

X*

3

*

Committee Chairperson

(1) Mr. Berns was appointed to the Compensation Committee in July 2010.

(2) Mr. Cressey will step down from the Audit Committee after the Annual Meeting on May 24, 2011 and will

continue to serve as a member of our Board.

(3) Dr. Tananbaum’s term of service as a director will expire at the Annual Meeting on May 24, 2011.

Below is a description of each of the Audit Committee, Compensation Committee and Nominating and

Corporate Governance Committee. Our Board has determined that each member of each committee meets the
applicable NASDAQ rules and regulations regarding “independence” and that each member is free of any
relationship that would impair his individual exercise of independent judgment with regard to the Company.

Audit Committee

The Audit Committee of the Board oversees the Company’s corporate accounting and financial reporting

processes and audits of its financial statements. For this purpose, the Audit Committee performs several
functions. In particular, the Audit Committee:

•

•

evaluates the performance of and assesses the qualifications of the independent auditors;

determines and approves the engagement of the independent auditors;

13

•

•

determines whether to retain or terminate the existing independent auditors or to appoint and engage
new independent auditors;

determines and approves the engagement of the independent auditors to perform any proposed
permissible non-audit services;

• monitors the rotation of partners of the independent auditors on the Company’s audit engagement team

as required by applicable laws and rules;

• meets to review the Company’s annual audited financial statements and quarterly financial statements

and quarterly earnings press releases with management and the independent auditor, including
reviewing the Company’s disclosures under “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” included in our annual and quarterly reports filed with the SEC;

•

•

•

•

reviews, provides oversight of and approves or rejects transactions between the Company and any
related persons;

confers with management and the independent auditors regarding the effectiveness of our internal
control over financial reporting;

is responsible for receiving and reviewing reports concerning financial risk management, and reporting
to the Board with respect thereto; and

establishes procedures, as required under applicable laws and rules, for the receipt, retention and
treatment of complaints received by the Company regarding accounting, internal accounting controls or
auditing matters and the confidential and anonymous submission by employees of concerns regarding
questionable accounting or auditing matters.

The Audit Committee is presently composed of four directors: Messrs. Cressey, Enright, O’Keefe and

Sebulsky. Our Board has determined that Messrs. Cressey, Enright, O’Keefe and Sebulsky meet the
independence requirements of Rule 10A-3 of the Exchange Act and NASDAQ listing standards with respect to
audit committee members. Our Board has also determined that Mr. O’Keefe qualifies as an “audit committee
financial expert” within the meaning of SEC regulations. In making this determination, our Board considered the
overall knowledge, experience and familiarity of Mr. O’Keefe with accounting matters, in analyzing and
evaluating financial statements, and in managing private equity investments. Mr. O’Keefe serves as chairperson
of the Audit Committee. Mr. Cressey will step down from the Audit Committee at the Annual Meeting on
May 24, 2011, after which the Audit Committee will be composed of three directors: Messrs. Enright, O’Keefe
and Sebulsky.

The Audit Committee met eight times during 2010. The Audit Committee is governed by a written charter

approved by our Board, which charter reflects the applicable standards and requirements adopted by the SEC and
the NASDAQ. A copy of the charter can be found on our website, www.jazzpharmaceuticals.com, in the section
titled “Company” under the subsection titled “Board Committees.”

14

Report of the Audit Committee of the Board(1)

The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended

December 31, 2010 with management of the Company. The Audit Committee has discussed with the independent
registered public accounting firm the matters required to be discussed by Statement on Auditing Standards
No. 61, as amended (AICPA, Professional Standards, Vol. 1. AU section 380), as adopted by the Public
Company Accounting Oversight Board, or the PCAOB, in Rule 3200T. The Audit Committee has also received
the written disclosures and the letter from the independent registered public accounting firm required by
applicable requirements of the PCAOB regarding the independent accountants’ communications with the audit
committee concerning independence, and has discussed with the independent registered public accounting firm
that firm’s independence. Based on the foregoing, the Audit Committee recommended to the Board that the
audited financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2010.

y
x
o
r
P

Respectfully submitted,
The Audit Committee of the Board

Mr. Kenneth W. O’Keefe (Chairperson)
Mr. Bryan C. Cressey
Mr. Patrick G. Enright
Mr. Alan M. Sebulsky

Compensation Committee

The Compensation Committee is presently composed of four directors: Messrs. Berns, Colella and
Michelson and Dr. Tananbaum. Mr. Michelson serves as the chairperson of the Compensation Committee. All
members of the Compensation Committee are independent (as independence is currently defined in Rule
5605(a)(2) of the NASDAQ listing standards). Dr. Tananbaum’s term of office as a director expires at the Annual
Meeting on May 24, 2011 and he will therefore step down from the Compensation Committee at that time.
Thereafter, the Compensation Committee will be composed of three directors: Messrs. Berns, Colella and
Michelson.

The Compensation Committee held five regular meetings during 2010 and acted by unanimous written
consent two times during the year. The Compensation Committee also had a number of informal discussions and
consultations with one another and with Mr. Cozadd, our Chairman and Chief Executive Officer. The
Compensation Committee is governed by a written charter that is available on the Company’s website at
www.jazzpharmaceuticals.com in the section titled “Company” under the subsection titled “Board Committees.”

The Compensation Committee reviews and oversees our compensation policies, plans and programs, and
reviews and determines the compensation to be paid to our executive officers. Specific responsibilities of our
Compensation Committee include:

•

•

•

•

recommending to our Board for approval the compensation and other terms of employment of our
Chairman and Chief Executive Officer;

determining the compensation and other terms of employment of our other executive officers;

reviewing and approving the compensation of our other executive officers;

evaluating and recommending to our Board for approval the compensation plans and programs
advisable for us, and evaluating and recommending the modification or termination of existing plans
and programs;

(1) The material in this report is not “soliciting material”, is not deemed “filed” with the SEC and is not to be

incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation
language in any such filing.

15

• monitoring our compensation practices and policies to ensure that such practices and policies do not

present material risks to the Company; and

•

reviewing and approving the terms of any employment agreements, severance arrangements, change of
control protections and any other compensatory arrangements for our executive officers.

Compensation Committee Processes and Procedures

Typically, the Compensation Committee meets four to six times per year, generally on the same day as
regularly scheduled Board meetings and with greater frequency if necessary. The agenda for each meeting is
usually developed by our Vice President, Human Resources, our General Counsel and our Chairman and Chief
Executive Officer, and reviewed with the Chairman of the Compensation Committee. However, from time to
time, various members of management and other employees as well as outside advisors or consultants may be
invited by the Compensation Committee to make presentations, provide financial or other background
information or advice or otherwise participate in Compensation Committee meetings. Mr. Cozadd may not
participate in, or be present during, any deliberations or determinations of the Compensation Committee
regarding his compensation. The charter of the Compensation Committee grants the Compensation Committee
full access to all books, records, facilities and personnel of the Company, as well as authority to obtain, at the
expense of the Company, advice and assistance from internal and external legal, accounting or other advisors and
consultants and other external resources that the Compensation Committee considers necessary or appropriate in
the performance of its duties. In particular, the Compensation Committee has the authority to retain
compensation consultants to assist in its evaluation of executive compensation (or we may do so on behalf of the
Compensation Committee at its request), including the authority to approve the consultant’s reasonable fees and
other retention terms.

Under its charter, the Compensation Committee may form and delegate authority to subcommittees as
appropriate, including, but not limited to, a subcommittee composed of one or more members of the Board, to
grant stock awards under our equity compensation plans. The Compensation Committee has delegated authority
to Mr. Cozadd, while still also retaining authority for itself and for the Board, to approve discretionary options
grants under our 2007 Equity Incentive Plan, or the 2007 Plan, to newly hired employees who are below the Vice
President level, to employees newly promoted to below the Vice President level, and to our specialty sales
consultants as part of a sales incentive plan. The purpose of this authority is to enhance the flexibility of option
administration within the Company and to facilitate the timely grant of options to new non-officer employees of
the Company within the specified guidelines approved by the Compensation Committee. No non-officer
employee may be granted a stock option by Mr. Cozadd for more than the number of shares of our common stock
that is determined pursuant to the guidelines and policies established by the Compensation Committee from time
to time. As part of its oversight function, the Compensation Committee reviews, at each regularly-scheduled
meeting of the Compensation Committee, the list of all grants approved by Mr. Cozadd since the last regularly
scheduled meeting.

Historically, the Compensation Committee has made most significant adjustments to annual compensation
of executives and determined bonus and equity awards at one or more meetings held during the first quarter of
the year. The Compensation Committee also considers matters related to our progress in achieving our corporate
objectives under our annual cash bonus plan, or Bonus Plan, for the year, as well as high-level strategic issues,
such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans
or approaches to compensation, at various meetings throughout the year. For executives other than our Chief
Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations
submitted to the Compensation Committee by our Chief Executive Officer. While our Chief Executive Officer
discusses his recommendations with the Compensation Committee, he does not participate in determining his
own compensation. In making his recommendations, our Chief Executive Officer receives input from our Vice
President of Human Resources and has access to various third party compensation surveys and compensation
data. Our General Counsel also participates in Compensation Committee meetings, but does not participate in

16

any discussions of executive officer compensation. For all executives, as part of its deliberations, the
Compensation Committee may review and consider, as appropriate, materials such as financial reports and
projections, our progress against our corporate performance objectives, operational data, tax and accounting
information, executive stock ownership information, company stock performance data, analyses of historical
executive compensation levels and current corporate compensation levels, and recommendations of any
compensation consultants engaged by the Compensation Committee (or by the Company on behalf of the
Compensation Committee), including analyses of executive compensation paid at other companies identified by
any such consultants.

Since 2007, the Compensation Committee has engaged outside compensation consultants each year (except

for 2009) to provide a competitive compensation assessment with respect to our executive officers in making
annual compensation decisions. For 2009, as described under “Executive Compensation—Narrative Disclosure
to Summary Compensation Table” there were no salary increases for executives, and our executives took
temporary voluntary pay reductions; no compensation consultants were involved in these decisions. In late 2009,
the Compensation Committee engaged Radford, a compensation consulting firm, to provide advice in 2010 with
respect to 2010 executive compensation. In late 2010, the Compensation Committee engaged Radford again to
provide advice in 2011 with respect to 2011 executive compensation.

y
x
o
r
P

Compensation Committee Interlocks and Insider Participation

In 2010, our Compensation Committee was composed of four directors: Messrs. Berns, Colella and
Michelson and Dr. Tananbaum. None of the members of our Compensation Committee has at any time been an
officer or employee of the Company. None of our executive officers serves, or in the past fiscal year has served,
as a member of the board of directors or the compensation committee of any entity that has one or more of its
executive officers serving on our Board or Compensation Committee.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee of our Board is responsible for, among other things:

•

overseeing all aspects of our corporate governance functions on behalf of the Board;

• making recommendations to the Board regarding corporate governance issues;

•

•

•

•

•

•

identifying, reviewing, evaluating and recommending for selection candidates for membership to our
Board;

reviewing, evaluating and considering the recommendation for nomination of incumbent members of
our Board for reelection to our Board and monitoring the size of our Board;

evaluating nominations by stockholders of candidates for election to our Board;

reviewing, discussing and reporting to our Board an assessment of our Board’s performance;

recommending compensation paid to non-employee directors; and

determining adherence to our Code of Conduct of our policy statements.

The Nominating and Corporate Governance Committee believes that candidates for director should have
certain minimum qualifications, including the ability to read and understand basic financial statements, being
over 21 years of age and having the highest personal integrity and ethics. The Nominating and Corporate
Governance Committee also intends to consider such factors as possessing relevant expertise upon which to be
able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company,
demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the
commitment to rigorously represent the long-term interests of the Company’s stockholders. However, the

17

Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to
time. Members of the Nominating and Corporate Governance Committee obtain recommendations for potential
directors from their and other Board members’ contacts in our industry, and may from time to time engage a
search firm to assist in identifying potential directors.

Candidates for director nominees are reviewed in the context of the current composition of the Board, the

operating requirements of the Company and the long-term interests of stockholders. While we do not have a
formal policy on Board diversity, the Nominating and Corporate Governance Committee takes into account a
broad range of diversity considerations when assessing director candidates, including individual backgrounds and
skill sets, professional experience and other factors that contribute to our Board having an appropriate range of
expertise, talents, experiences and viewpoints, and considers those diversity considerations, in view of the needs
of the Board as a whole, when making decisions on director nominations. In the case of incumbent directors
whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these
directors’ overall service to the Company during their terms, including the number of meetings attended, level of
participation, quality of performance and any other relationships and transactions that might impair the directors’
independence, to determine whether to recommend them to the Board for a new term. In the case of new director
candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is
independent for NASDAQ purposes, which determination is based upon applicable NASDAQ listing standards,
applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate
Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications
of possible candidates after considering the function and needs of the Board. The Nominating and Corporate
Governance Committee meets to discuss and consider the candidates’ qualifications and then selects a nominee
for recommendation to the Board.

In late 2009, the Nominating and Corporate Governance Committee engaged Catalyst Advisors LLC, or
Catalyst Advisors, an executive search firm, to conduct a search on our behalf for experienced pharmaceutical
industry executives to join our Board. In 2010, Catalyst Advisors identified and recommended Messrs. Berns and
Winningham, each a chief executive officer at a publicly-traded pharmaceutical company with extensive and
relevant industry experience, as director candidates. The Nominating and Corporate Governance Committee
reviewed the background and qualifications of each of Messrs. Berns and Winningham and nominated each of
them to the Board. Messrs. Winningham and Berns were appointed to the Board in May and June 2010,
respectively.

The Nominating and Corporate Governance Committee, to date, has not adopted a formal policy with regard

to the consideration of director candidates recommended by stockholders and will consider director candidates
recommended by stockholders on a case-by-case basis, as appropriate. Stockholders wishing to recommend
individuals for consideration by the Nominating and Corporate Governance Committee may do so by delivering
a written recommendation to the Company’s Secretary at 3180 Porter Drive, Palo Alto, California 94304 and
providing the candidate’s name, biographical data and qualifications and a document indicating the candidate’s
willingness to serve if elected. The Nominating and Corporate Governance Committee does not intend to alter
the manner in which it evaluates candidates based on whether the candidate was recommended by a stockholder
or not. To date, the Nominating and Corporate Governance Committee has not received any such nominations
nor has it rejected a director nominee from a stockholder or stockholders holding more than 5% of our voting
stock.

With respect to director compensation matters, our Board, upon the recommendation of the Nominating and

Corporate Governance Committee, determines and sets non-employee director compensation. The Nominating
and Corporate Governance Committee and the Board believe that: director compensation should fairly
compensate directors for work required in a company of our size and activities; the compensation should align
directors’ interests with the long-term interest of stockholders; and the structure of the compensation should be
simple, transparent and easy to understand. In 2010, at the request of the Nominating and Corporate Governance
Committee, we reviewed our director compensation level using data for comparable companies from Radford,

18

including our peer group of pharmaceutical companies used in connection with our executive compensation
review. Based on this information, as described under “Director Compensation,” in July 2010, the Nominating
and Corporate Governance Committee recommended that the Board modify the compensation arrangements for
our non-employee directors. For information concerning the compensation of our non-employee directors, see
“Director Compensation” below.

The Nominating and Corporate Governance Committee is composed of two directors: Messrs. Colella and

Momtazee. Mr. Momtazee is chairperson of the Nominating and Corporate Governance Committee. Both
members of the Nominating and Corporate Governance Committee are independent (as independence is currently
defined in Rule 5605(a)(2) of the NASDAQ listing standards). The Nominating and Corporate Governance
Committee met three times during 2010. The Nominating and Corporate Governance Committee is governed by
a written charter that is available on the Company’s website at www.jazzpharmaceuticals.com in the section titled
“Company” under the subsection titled “Board Committees.”

y
x
o
r
P

Corporate Strategy Committee

The Board formed a Corporate Strategy Committee in the second half of 2010 to review strategic

transactions that the Company may undertake and to make recommendations to the full Board concerning such
proposed transaction. The Corporate Strategy Committee is composed of five directors: Messrs. Colella, Enright,
Momtazee, Sebulsky and Winningham. It was created to provide a forum for management to discuss potential
transactions and strategic initiatives with a portion of the Board and solicit their strategic advice and input before
pursuing such opportunities and seeking formal approval from the full Board. The Corporate Strategy Committee
reviews potential transactions to determine if they fit with the Company’s corporate goals and long-term strategy
and assists management with determining what, if any, resources should be devoted to pursuing those
opportunities. The Corporate Strategy Committee does not have a formal charter and does not hold regularly
scheduled meetings but rather meets at the request of the Company’s management when the need arises. In
addition to any formal meetings, management often seeks the advice of members of the Corporate Strategy
Committee when conducting its initial evaluation of potential transactions.

Stockholder Communications with the Board

To date, we have not adopted a formal process related to stockholder communications with the Board.
Nevertheless, every effort has been made to ensure that the views of stockholders are heard by the Board or
individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely
manner. We believe that our responsiveness to stockholder communications to the Board has been excellent. As a
result, the Board believes that there has not been a need to adopt a formal process for stockholder
communications with the Board.

Code of Conduct

The Company’s Code of Conduct applies to all officers, directors and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing
similar functions. The Code of Conduct is available on our website at www.jazzpharmaceuticals.com under the
section entitled “Company” at “Corporate Responsibility.” Stockholders may request a free copy of the Code of
Conduct by submitting a written request to Jazz Pharmaceuticals, Inc., Attention: Investor Relations, 3180 Porter
Drive, Palo Alto, California 94304. If we make any substantive amendments to the Code of Conduct or grant any
waiver from a provision of the Code of Conduct to any executive officer or director, we will promptly disclose
the nature of the amendment or waiver on our website.

19

PROPOSAL 2
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee of the Board has selected Ernst & Young LLP as the Company’s independent
registered public accounting firm for the fiscal year ending December 31, 2011 and has further directed that
management submit the selection of the independent registered public accounting firm for ratification by the
stockholders at the Annual Meeting. Ernst & Young LLP has audited the Company’s financial statements since
its inception in 2003. Representatives of Ernst & Young LLP are expected to be present at the Annual Meeting
and they will have an opportunity to make a statement if they so desire and will be available to respond to
appropriate questions.

Neither the bylaws of the Company nor other governing documents or law require stockholder ratification of

the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm. However,
the Audit Committee is submitting the selection of Ernst & Young LLP to the stockholders for ratification as a
matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will
reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its
discretion may direct the selection of different independent registered public accounting firm at any time if they
determine that such a change would be in the best interests of the Company and its stockholders.

On behalf of the Audit Committee, the Board recommends a vote “For” Proposal 2.

Independent Registered Public Accounting Firm Fees and Services

In connection with the audit of our 2010 financial statements, we entered into an engagement agreement
with Ernst & Young LLP which sets forth the terms by which Ernst & Young LLP will perform audit and interim
services for the Company. That agreement is subject to alternative dispute resolution procedures and an exclusion
of punitive damages. We have entered into a similar agreement with Ernst & Young LLP in relation to our 2011
financial statements.

The following table represents aggregate fees and expenses billed or expected to be billed to the Company

for the fiscal years ended December 31, 2010 and 2009 by Ernst & Young LLP, the Company’s independent
registered public accounting firm:

Fiscal Year Ended

2010

2009

Audit Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 888,759
158,808

$ 909,841
145,357

Total Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,047,567

$1,055,198

Audit Fees: Consists of fees and expenses for professional services rendered for the audit of our financial
statements, review of interim financial statements, assistance with registration statements filed with the Securities
and Exchange Commission and services that are normally provided by Ernst & Young LLP in connection with
statutory and regulatory filings or engagements. Related to fiscal year ended December 31, 2010, fees and
expenses of $151,003 were billed in connection with Registration Statements on Form S-3 filings and other
potential offerings. Related to fiscal year ended December 31, 2009, fees and expenses of $54,841 were billed in
connection with Registration Statements on Form S-1 and S-8 filings and other potential offerings.

Tax Fees: Consists of fees and expenses for professional services for tax compliance, tax advice and tax

planning. During the fiscal year ended December 31, 2010, fees and expenses of $87,372 were billed in
connection with tax compliance services and fees and expenses of $71,436 were billed in connection with tax
advice and planning services. During the fiscal year ended December 31, 2009, fees and expenses of $78,750
were billed in connection with tax compliance services and fees and expenses of $66,607 were billed in
connection with tax advice and planning services.

All fees described above were approved by the Audit Committee.

20

Pre-Approval Policies and Procedures

The Audit Committee has a policy and procedures for the pre-approval of audit and non-audit services
rendered by our independent registered public accounting firm, Ernst & Young LLP, and has pre-approved all
new services since that time. The policy generally pre-approves specified services in the defined categories of
audit services, audit-related services, and tax services up to specified amounts. Pre-approval may also be given as
part of the Audit Committee’s approval of the scope of the engagement of the independent auditor or on an
individual explicit case-by-case basis before the independent auditor is engaged to provide each service. The
pre-approval of services may be delegated to one or more of the Audit Committee’s members, but the decision
must be reported to the full Audit Committee at its next scheduled meeting.

The Audit Committee has determined that the rendering of certain services other than audit services by

Ernst & Young LLP is compatible with maintaining the principal accountant’s independence.

y
x
o
r
P

21

PROPOSAL 3
APPROVAL OF THE INTERNAL REVENUE CODE SECTION 162(m) PERFORMANCE CRITERIA
AND AWARD LIMITS OF THE COMPANY’S 2007 EQUITY INCENTIVE PLAN

The Company’s 2007 Equity Incentive Plan, or the 2007 Plan, provides for the grant of incentive stock
options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation
rights, performance stock awards and other forms of equity compensation, which may be granted to employees,
including officers, non-employee directors, and consultants. Our Board and stockholders originally adopted the
2007 Plan in May 2007, prior to the Company’s initial public offering. In order to allow for the future grant of
stock awards under the 2007 Plan to qualify as tax-deductible performance-based compensation under
Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, the Company is asking
stockholders to approve the material terms of the performance criteria and award limits under the 2007 Plan. The
material terms of the 2007 Plan are described below. No changes are being proposed with regard to the terms of
the 2007 Plan at this time. Stockholders are not being asked to approve any amendment to the 2007 Plan or to
reapprove the 2007 Plan itself.

Performance-based compensation and equity compensation are important elements of our executive

compensation program that we believe are necessary to retain executive officers and to incentivize them to build
short and long-term financial growth and stability, thereby enhancing stockholder value and aligning the interests
of our executive officers with our stockholders. Our Board believes that it is in the best interests of the Company
and its stockholders to ensure that awards made to the Company’s executive officers under the 2007 Plan qualify
for deductibility by the Company for federal income tax purposes. Accordingly, the 2007 Plan has been
structured in such a manner that equity awards made under it can satisfy the requirements of “performance-
based” compensation within the meaning of Section 162(m) of the Code. In general, under Section 162(m) of the
Code, in order for the Company to be able to deduct compensation in excess of $1 million paid in any one year to
our Chief Executive Officer or our three other highest compensated officers (other than our Chief Financial
Officer), or collectively, our covered employees, such compensation must qualify as performance-based. One of
the requirements of performance-based compensation for purposes of Section 162(m) of the Code is that the
material terms of the performance goals under which compensation may be paid be disclosed to and approved by
stockholders. For purposes of Section 162(m) of the Code, the material terms include the types of performance
criteria that may be used as performance factors under the 2007 Plan and the maximum number of shares subject
to any performance equity award that may be granted to any individual in any single year. With respect to the
various types of awards under the 2007 Plan, each of these aspects is discussed below, and as noted above,
stockholders are being asked under this proposal to approve each of these aspects of the 2007 Plan for purposes
of the approval requirements of Section 162(m). If our stockholders do not approve this proposal, following the
Annual Meeting, the 2007 Plan will remain in effect but we may not grant “performance-based” compensation
awards under the 2007 Plan to our covered employees and we may be forced to pay employees in other ways in
order to retain them, including through the use of non-deductible cash, which may not be in the best interests of
our stockholders.

Our Board recommends a vote “For” Proposal 3.

Plan Summary

The following summary of the material terms of the 2007 Plan is qualified in its entirety by reference to the

complete statement of the 2007 Plan, which is set forth in Annex A to this Proxy Statement.

Section 162(m) Provisions

Section 162(m) Share Limit. No employee may be granted options or stock appreciation rights (or other
stock awards whose value is determined by reference to an exercise price or strike price of at least 100% of the
fair market value of our common stock on the date the applicable stock award is granted) covering more than
2,000,000 shares of our common stock in any calendar year.

22

In the case of performance stock awards, the maximum benefit to be received by any individual in any
calendar year attributable to “performance-based” restricted stock awards or restricted stock units granted under
the 2007 Plan may not exceed the value of 2,000,000 shares of our common stock (payable in either cash or
stock).

Section 162(m) Performance Criteria. Performance goals under the 2007 Plan shall be determined by our
Board based on any one or more of the following performance criteria: (i) earnings per share; (ii) earnings before
interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization (EBITDA);
(iv) total stockholder return; (v) return on equity; (vi) return on assets, investment, or capital employed;
(vii) operating margin; (viii) gross margin; (ix) operating income; (x) net income (before or after taxes); (xi) net
operating income; (xii) net operating income after tax; (xiii) pre- and after-tax income; (xiv) pre-tax profit;
(xv) operating cash flow; (xvi) sales or revenue targets; (xvii) orders and revenue; (xviii) increases in revenue or
product revenue; (xix) expenses and cost reduction goals; (xx) improvement in or attainment of expense levels;
(xxi) improvement in or attainment of working capital levels; (xxii) economic value added (or an equivalent
metric); (xxiii) market share; (xxiv) cash flow; (xxv) cash flow per share; (xxvi) share price performance;
(xxvii) debt reduction; (xxviii) implementation or completion of projects or processes; (xxix) customer
satisfaction; (xxx) stockholders’ equity; (xxxi) quality measures; and (xxxii) to the extent that a stock award is
not intended to comply with Section 162(m) of the Code, other measures of performance selected by our Board.

y
x
o
r
P

Setting of Performance Goals. In granting a “performance-based” compensation award, the Board will set a

period of time over which the attainment of one or more goals will be measured for the purpose of determining
whether the award recipient has a vested right in or to such award. Within the time period prescribed by
Section 162(m) of the Code, the Board may establish the performance goals based upon one or more
pre-established performance criteria described in the immediately preceding paragraph. As soon as
administratively practicable following the end of the performance period, the Board will determine whether the
performance goals have been satisfied.

The Board is authorized to determine whether, when calculating the attainment of performance goals for a
performance period: (i) to exclude restructuring and/or other nonrecurring charges; (ii) to exclude exchange rate
effects, as applicable, for non-U.S. dollar denominated net sales and operating earnings; (iii) to exclude the
effects of changes to generally accepted accounting principles required by the Financial Accounting Standards
Board; (iv) to exclude the effects of any statutory adjustments to corporate tax rates; and (v) to exclude the
effects of any “extraordinary items” as determined under generally accepted accounting principles. In addition,
the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment
of performance goals.

Compensation attributable to performance-based awards under the 2007 Plan will qualify as performance-
based compensation, provided that: (i) the award is granted by a compensation committee comprised solely of
“outside directors,” (ii) the award is granted (or exercisable) only upon the achievement of an objective
performance goal established in writing by the compensation committee while the outcome is substantially
uncertain, and (iii) the compensation committee certifies in writing prior to the granting (or exercisability) of the
award that the performance goal has been satisfied.

Other Provisions of the 2007 Plan

Stock Awards. The 2007 Plan provides for the grant of incentive stock options, nonstatutory stock options,

restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and
other forms of equity compensation, which may be granted to employees, including officers, non-employee
directors, and consultants. Incentive stock options may be granted only to our employees, including to our
executive officers. All of our approximately 250 employees and our non-employee directors and consultants are
eligible to participate in the 2007 Plan.

23

Share Reserve. As of December 31, 2010, the aggregate number of shares of our common stock that have
been authorized for issuance pursuant to stock awards under the 2007 Plan is 8,223,848. The number of shares
reserved for issuance under the 2007 Plan includes shares subject to options originally granted under our 2003
Equity Incentive Plan that will become available for issuance under the 2007 Plan upon the expiration or
termination of such options for any reason prior to exercise or settlement. The number of shares of our common
stock reserved for issuance automatically increases on January 1 of each year, from January 1, 2008 to (and
including) January 1, 2017, by the least of (a) 4.5% of the total number of shares of our common stock
outstanding on December 31 of the preceding calendar year, (b) 3,000,000 shares, or (c) a lesser amount
determined by our Board. On January 1, 2011, the total number of shares reserved for issuance under the 2007
Plan increased by 1,798,166 shares pursuant to this automatic share increase provision.

If a stock award granted under the 2007 Plan expires or otherwise terminates without being exercised in full

or is settled in cash, the shares of our common stock not acquired pursuant to the stock award again become
available for subsequent issuance under the 2007 Plan. In addition, the following types of shares under the 2007
Plan will become available for the grant of new stock awards under the 2007 Plan: (a) shares that are forfeited to
or repurchased by us prior to becoming fully vested, (b) shares withheld to satisfy income and employment
withholding taxes, (c) shares used to pay the exercise price of an option in a net exercise arrangement, (d) shares
tendered to us to pay the exercise price of an option and (e) shares that are cancelled pursuant to an exchange or
repricing program. Shares issued under the 2007 Plan may be previously unissued shares or reacquired shares
bought on the open market. The maximum number of shares of our common stock that may be issued under the
2007 Plan subject to incentive stock options is 4,625,042 shares plus the automatic annual increases described
above.

Administration. Our Board has delegated its authority to administer the 2007 Plan to our compensation
committee. Subject to the terms of the 2007 Plan, our Board or an authorized committee, referred to as the plan
administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted, and the
terms and conditions of the stock awards, including the period of their exercisability and vesting. Subject to the
limitations set forth below, the plan administrator will also determine the exercise price of options granted, the
consideration to be paid for restricted stock awards, and the strike price of stock appreciation rights.

The plan administrator has the authority to:

•

•

reduce the exercise price of any outstanding option or the strike price of any outstanding stock
appreciation right;

cancel any outstanding option or stock appreciation right and to grant in exchange one or more of the
following:

•

•

•

•

new options or stock appreciation rights covering the same or a different number of shares of
common stock,

new stock awards,

cash, and/or

other valuable consideration; and

•

engage in any action that is treated as a repricing under generally accepted accounting principles.

Subject to the terms of the 2007 Plan, our Board may delegate to one or more of our executive officers the

limited authority to grant stock awards to our other executive officers and employees. Such executive officer
would be able to grant only the total number of stock awards specified by our Board and such executive officer
would not be allowed to grant a stock award to himself or herself.

Stock Options. Incentive and nonstatutory stock options may be granted pursuant to incentive and

nonstatutory stock option agreements adopted by the plan administrator. The plan administrator determines the

24

y
x
o
r
P

exercise price for a stock option provided that the exercise price of an incentive stock option and nonstatutory
stock option cannot be less than 100% of the fair market value of our common stock on the date of grant. Options
granted under the 2007 Plan vest at the rate specified by the plan administrator. Acceptable consideration for the
purchase of common stock issued upon the exercise of a stock option will be determined by the plan
administrator and may include (a) cash or check, (b) a broker-assisted cashless exercise, (c) the tender of
common stock previously owned by the optionee, (d) a net exercise of the option and (e) other legal
consideration approved by the plan administrator.

The plan administrator determines the term of stock options granted under the 2007 Plan, generally up to a

maximum of ten years. Unless the terms of an optionee’s stock option agreement provide otherwise, if an
optionee’s relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the
optionee may exercise any vested options for a period of three months following the cessation of service. If an
optionee’s service relationship with us, or any of our affiliates, ceases due to disability or death (or an optionee
dies within a certain period following cessation of service), the optionee or a beneficiary may exercise any vested
options for a period of 12 months in the event of disability, and 18 months in the event of death. The option term
may be extended in the event that the issuance of shares upon exercise of the option following termination of
service is prohibited by applicable securities laws. In no event, however, may an option be exercised beyond the
expiration of its term. Generally, an optionee may not transfer a stock option other than by will or the laws of
descent and distribution or pursuant to a domestic relations order. However, an optionee may designate a
beneficiary who may exercise the option following the optionee’s death.

Restricted Stock Awards. Restricted stock awards may be granted pursuant to restricted stock award

agreements adopted by the plan administrator. Restricted stock awards may be granted in consideration for
(a) cash or check, (b) past or future services rendered to us or our affiliates or (c) any other form of legal
consideration. Shares of common stock acquired under a restricted stock award may, but need not, be subject to a
share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan
administrator. Rights to acquire shares under a restricted stock award may be transferred only upon such terms
and conditions as set by the plan administrator.

Restricted Stock Unit Awards. Restricted stock unit awards may be granted pursuant to restricted stock unit

award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in
consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery
of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form
of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be
credited in respect to shares covered by a restricted stock unit award. Except as otherwise provided in the
applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant’s
cessation of continuous service for any reason.

Stock Appreciation Rights. Stock appreciation rights may be granted pursuant to stock appreciation rights

agreements adopted by the plan administrator. The plan administrator determines the strike price for a stock
appreciation right, which cannot be less than 100% of the fair market value of our common stock on the date of
grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product
of (a) the excess of the per share fair market value of our common stock on the date of exercise over the strike
price, multiplied by (b) the number of shares of common stock with respect to which the stock appreciation right
is exercised. A stock appreciation right granted under the 2007 Plan vests at the rate specified by the plan
administrator.

The plan administrator determines the term of stock appreciation rights granted under the 2007 Plan, up to a

maximum of ten years. If a participant’s service relationship with us, or any of our affiliates, ceases, then the
participant, or the participant’s beneficiary, may exercise any vested stock appreciation right for three months (or
such longer or shorter period specified in the stock appreciation right agreement) after the date such service
relationship ends. In no event, however, may a stock appreciation right be exercised beyond the expiration of its
term.

25

Performance Stock Awards. The 2007 Plan permits the grant of performance stock awards that may qualify

as performance-based compensation that is not subject to the $1,000,000 limitation on the income tax
deductibility of compensation paid per covered employee imposed by Section 162(m) of the Code. To assure that
the compensation attributable to one or more performance stock awards will so qualify, our Compensation
Committee can structure one or more such awards so that stock will be issued or paid pursuant to such award
only upon the achievement of certain pre-established performance goals during a designated performance period.
The maximum benefit to be received by a participant in any calendar year attributable to performance stock
awards may not exceed 2,000,000 shares of our common stock.

Other Stock Awards. The plan administrator may grant other awards based in whole or in part by reference
to our common stock. The plan administrator will set the number of shares under the award and all other terms
and conditions of such awards.

Changes to Capital Structure. In the event of certain capitalization adjustments (such as a stock split or
stock dividend), our Board will appropriately adjust (a) the number of shares reserved under the 2007 Plan,
(b) the limit on the number of shares that may be issued as stock awards to any one person in a given calendar
year for purposes of Section 162(m) of the Code and (c) the number of shares and exercise price or strike price, if
applicable, of all outstanding stock awards.

Corporate Transactions. In the event of certain significant corporate transactions, our Board has the

discretion to take one or more of the following actions with respect to outstanding stock awards, contingent upon
the closing or completion of such transaction:

•

•

•

•

•

•

arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity
(or its parent company);

arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our
common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent
company);

accelerate the vesting and exercisability of a stock award followed by the termination of the stock
award;

arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common
stock issued pursuant to a stock award;

cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised, in
exchange for appropriate cash consideration; and

arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a) the
value of the property the holder of the stock award would have received upon the exercise of the stock
award, over (b) any exercise price payable by such holder in connection with such exercise.

Our Board need not take the same action for each stock award or with regard to all participants.

Changes in Control. The form of option agreement and restricted stock unit award agreement adopted by

our Board under the 2007 Plan provides that in the event the holder’s service relationship with us or a successor
entity is terminated, actually without cause or constructively, within 12 months following, or one month prior to,
the effective date of certain specified change in control transactions, the vesting and exercisability of the option
will accelerate in full. Our Board has the discretion to provide additional acceleration of vesting and
exercisability upon or after a change in control transaction as may be provided in a stock award agreement or any
other written agreement between us or any of our affiliates and a participant.

Plan Amendments. Our Board has the authority to amend or terminate the 2007 Plan. However, no

amendment or termination of the 2007 Plan will adversely affect any rights under stock awards already granted
to a participant unless agreed to by the affected participant. We will obtain stockholder approval of amendments
to the 2007 Plan as required by applicable law.

26

Effective Date and Termination Date. Our Board originally adopted the 2007 Plan on May 1, 2007, prior to
the Company’s initial public offering. The 2007 Plan will terminate on April 30, 2017, unless sooner terminated
by our Board.

U.S. Federal Income Tax Information

The information set forth below is only a summary and does not purport to be complete. The information is
based upon current federal income tax rules and therefore is subject to change when those rules change. Because
the tax consequences to any participant may depend on his or her particular situation, each participant should
consult his or her tax adviser regarding the federal, state, local, and other tax consequences of the grant or
exercise of a stock award or the disposition of stock acquired under an award. The 2007 Plan is not qualified
under the provisions of Section 401(a) of the Code and is not subject to any of the provisions of the Employee
Retirement Income Security Act of 1974. Our ability to realize the benefit of any tax deductions described below
depends on our generation of taxable income and the recognition of the deductions are subject to the requirement
that the amounts constitute an ordinary and necessary business expense for us and are reasonable in amount, the
limitation on the deduction of executive compensation under Section 162(m) of the Code and the timely
satisfaction of our tax reporting obligations.

y
x
o
r
P

Incentive Stock Options. Incentive stock options under the 2007 Plan are intended to be eligible for the

favorable federal income tax treatment accorded “incentive stock options” under Section 422 of the Code.

There generally are no federal income tax consequences to the participant or the Company by reason of the

grant or exercise of an incentive stock option. However, the exercise of an incentive stock option may increase
the participant’s alternative minimum tax liability, if any.

If a participant holds stock acquired through exercise of an incentive stock option for more than two years

from the date on which the option is granted and more than one year from the date on which the shares are
transferred to the participant upon exercise of the option, any gain or loss on a disposition of such stock will be a
long-term capital gain or loss.

Generally, if the participant disposes of the stock before the expiration of either of these holding periods (a
“disqualifying disposition”), then at the time of disposition the participant will realize taxable ordinary income
equal to the lesser of (i) the excess of the stock’s fair market value on the date of exercise over the exercise price,
or (ii) the participant’s actual gain, if any, on the purchase and sale. The participant’s additional gain or any loss
upon the disqualifying disposition will be a capital gain or loss, which will be long-term or short-term depending
on whether the stock was held for more than one year.

To the extent the participant recognizes ordinary income by reason of a disqualifying disposition, the

Company will generally be entitled (subject to the requirement of reasonableness, the provisions of
Section 162(m) of the Code and the satisfaction of a tax reporting obligation) to a corresponding business
expense deduction in the tax year in which the disqualifying disposition occurs.

Nonstatutory Stock Options, Restricted Stock Awards and Restricted Stock Unit Awards. Nonstatutory stock

options, restricted stock awards and restricted stock unit awards granted under the 2007 Plan generally have the
following federal income tax consequences:

There are no tax consequences to the participant or the Company by reason of the grant. Upon acquisition of

the stock, the participant normally will recognize taxable ordinary income equal to the excess, if any, of the
stock’s fair market value on the acquisition date over the purchase price. However, to the extent the stock is
subject to certain types of vesting restrictions, the taxable event will be delayed until the vesting restrictions lapse
unless the participant elects to be taxed on receipt of the stock. With respect to employees, the Company is
generally required to withhold from regular wages or supplemental wage payments an amount based on the

27

ordinary income recognized. Subject to the requirement of reasonableness, the provisions of Section 162(m) of
the Code and the satisfaction of a tax reporting obligation, the Company will generally be entitled to a business
expense deduction equal to the taxable ordinary income recognized by the participant.

Upon disposition of the stock, the participant will recognize a capital gain or loss equal to the difference
between the selling price and the sum of the amount paid for such stock plus any amount recognized as ordinary
income upon acquisition (or vesting) of the stock. Such gain or loss will be long-term or short-term depending on
whether the stock was held for more than one year. Slightly different rules may apply to participants who acquire
stock subject to certain repurchase options or who are subject to Section 16(b) of the Exchange Act.

Stock Appreciation Rights. No taxable income is recognized upon the receipt of a stock appreciation right,

but upon exercise of the stock appreciation right the fair market value of the shares (or cash in lieu of shares)
received must be treated as compensation taxable as ordinary income to the participant in the year of such
exercise. Generally, with respect to employees, the Company is required to withhold from the payment made on
exercise of the stock appreciation right or from regular wages or supplemental wage payments an amount based
on the ordinary income recognized. Subject to the requirement of reasonableness, Section 162(m) of the Code
and the satisfaction of a reporting obligation, the Company will be entitled to a business expense deduction equal
to the taxable ordinary income recognized by the participant.

Potential Limitation on Company Deductions. Section 162(m) of the Code denies a deduction to any
publicly held corporation for compensation paid to certain “covered employees” in a taxable year to the extent
that compensation to such covered employee exceeds $1 million. It is possible that compensation attributable to
awards, when combined with all other types of compensation received by a covered employee from the
Company, may cause this limitation to be exceeded in any particular year.

Certain kinds of compensation, including qualified “performance-based compensation,” are disregarded for

purposes of the deduction limitation. In accordance with Treasury Regulations issued under Section 162(m),
compensation attributable to stock options and stock appreciation rights will qualify as performance-based
compensation if the award is granted by a compensation committee comprised solely of “outside directors” and
either (i) the plan contains a per-employee limitation on the number of shares for which such awards may be
granted during a specified period, the per-employee limitation is approved by the stockholders, and the exercise
price of the award is no less than the fair market value of the stock on the date of grant, or (ii) the award is
granted (or exercisable) only upon the achievement (as certified in writing by the compensation committee) of an
objective performance goal established in writing by the compensation committee while the outcome is
substantially uncertain, and the award is approved by stockholders.

Compensation attributable to stock awards will qualify as performance-based compensation under the
Treasury Regulations only if (i) the award is granted by a compensation committee comprised solely of “outside
directors,” (ii) the award is granted (or exercisable) only upon the achievement of an objective performance goal
established in writing by the compensation committee while the outcome is substantially uncertain, (iii) the
compensation committee certifies in writing prior to the granting (or exercisability) of the award that the
performance goal has been satisfied and (iv) prior to the granting (or exercisability) of the award, stockholders
have approved the material terms of the award (including the class of employees eligible for such award, the
business criteria on which the performance goal is based, and the maximum amount—or formula used to
calculate the amount—payable upon attainment of the performance goal).

Plan Benefits

We cannot currently determine the benefits or number of shares subject to stock awards that may be granted

in the future to executive officers, directors and employees under the 2007 Plan because awards under the 2007
Plan are determined by the plan administrator in its discretion.

28

The following table sets forth information about awards granted under the 2007 Plan as of March 30, 2011

to (i) our named executive officers, (ii) all current executive officers as a group (eight people), (iii) all
non-employee directors as a group (11 people), (iv) all non-executive employees (including all current officers
who are not executive officers) as a group (236 people); (v) each associate of any director or executive officer
and (vi) each other person who received or is to receive 5% of awards granted under the 2007 Plan. As of the
record date, March 30, 2011, there were options to purchase 6,023,169 shares of our common stock outstanding,
12,929 restricted stock unit awards outstanding, and 2,585,634 shares reserved for future issuance under the 2007
Plan. As of March 30, 2011, the record date, the closing price of our Common Stock as reported on the
NASDAQ Global Market was $33.11 per share.

Plan Benefits

2007 Equity Incentive Plan

y
x
o
r
P

Name

Named executive officers

Number of securities to be
issued upon exercise of
outstanding options or
vesting of outstanding
restricted stock units (#)

Bruce C. Cozadd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

900,696

Chairman and Chief Executive Officer

Robert M. Myers(1)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

494,250

President

Kathryn E. Falberg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

200,000

Senior Vice President and Chief Financial Officer

All current executive officers as a group(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,117,412

All current non-employee directors as a group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

36,536

Each associate of any director or executive officer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Each other person who received or is to receive 5% of awards granted under the 2007

Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

0

0

All current employees, including all current officers who are not executive officers, as a
group(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,387,900

(1) Mr. Myers resigned as our President and as a member of our Board effective January 14, 2011 and his

employment with the Company terminated on February 1, 2011.

(2) Does not include Mr. Myers.

29

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information as of December 31, 2010, with respect to all of the

Company’s equity compensation plans in effect on that date.

Plan Category

Equity compensation plans approved by

security holders:
2007 Equity Incentive Plan . . . . . . . . . . . . . . . . .
2007 Employee Stock Purchase Plan . . . . . . . . .
Amended and Restated 2007 Non-Employee

Number of securities to
be issued upon
exercise of outstanding
options, warrants and
rights
(a)

Weighted-average
exercise price of
outstanding
options, warrants
and rights
(b)

Number of securities
remaining available for
issuance under equity
compensation plans
(excluding securities
reflected in column (a))
(c)

5,166,096

—

$10.53(1)

1,914,503(2)
100,881(3)

Directors Stock Option Plan . . . . . . . . . . . . . .

387,500

$ 8.25

2,500 (4)

Equity compensation plans not approved by

security holders:
Amended and Restated Directors Deferred

Compensation Plan . . . . . . . . . . . . . . . . . . . . .

101,460(5)

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5,655,056

175,834(6)

2,193,718

(1)

The weighted average exercise price of outstanding options and rights under our 2007 Equity Incentive
Plan, or the 2007 Plan, includes the effect of our grant of restricted stock units under the 2007 Plan, which
restricted stock units were granted in consideration of services rendered to us and do not carry an exercise
price. The weighted average exercise price of outstanding options under the 2007 Plan as of December 31,
2010 was $10.56, excluding the grant of the restricted stock units but including shares subject to options
originally granted under our 2003 Equity Incentive Plan.

(2) As of December 31, 2010, an aggregate of 8,223,848 shares of common stock were reserved for issuance
under the 2007 Plan, of which 1,914,503 remained available for future issuance. The number of shares
reserved for issuance under the 2007 Plan includes shares subject to options originally granted under our
2003 Equity Incentive Plan that will become available for issuance under the 2007 Plan upon the expiration
or termination of such options for any reason prior to exercise or settlement. The number of shares reserved
for issuance under the 2007 Plan automatically increases on each January 1, from January 1, 2008 through
(and including) January 1, 2017, by the lesser of (a) 4.5% of the total number of shares of our common stock
outstanding on December 31 of the preceding year or (b) 3,000,000 shares (or such lesser amount as may be
approved by our Board). On January 1, 2011, the number of shares reserved for issuance under the 2007
Plan increased by 1,798,166 shares pursuant to this automatic share increase provision.

(3) As of December 31, 2010, an aggregate of 1,400,000 shares of common stock had been authorized for

issuance under our 2007 Employee Stock Purchase Plan, or the 2007 ESPP, of which 100,881 remained
available for future issuance under the 2007 ESPP, and with up to a maximum of 260,000 shares that could
be purchased in the current purchase period (after giving effect to the automatic increase on January 1, 2011
referenced below). Subsequently, the aggregate number of shares available for issuance in any six month
purchase period will be 175,000. The number of shares reserved for issuance under the 2007 ESPP
automatically increases on each January 1, from January 1, 2008 through (and including) January 1, 2017,
by the lesser of (a) 1.5% of the total number of shares of our common stock outstanding on December 31 of
the preceding calendar year or (b) 350,000 shares, (or such lesser amount as may be approved by our
Board). On January 1, 2011, the number of shares reserved for issuance under the 2007 ESPP increased by
350,000 shares pursuant to this automatic share increase provision.

(4) As of December 31, 2010, an aggregate of 473,963 shares of common stock were reserved for issuance

under our Amended and Restated 2007 Non-Employee Directors Stock Option Plan, or the 2007 Directors

30

Plan, of which 2,500 shares remained available for future issuance. The number of shares remaining
available for issuance under the 2007 Directors Plan as shown in the table above has been reduced by the
number of shares credited to our non-employee directors’ stock accounts under our Amended and Restated
Directors Deferred Compensation Plan, or the Directors Deferred Plan, prior to August 15, 2010. The
number of shares reserved for issuance under the 2007 Directors Plan automatically increases on each
January 1, from January 1, 2008 through (and including) January 1, 2017, by the sum of (a) the excess of
(i) the number of shares of common stock subject to options granted during the preceding calendar year
under the 2007 Directors Plan, over (ii) the number of shares added back to the share reserve under the 2007
Directors Plan during the preceding calendar year and (b) for the automatic annual increases occurring on or
prior to January 1, 2010 only, the aggregate number of shares credited to our non-employee directors’ stock
accounts under the Directors Deferred Plan (or such lesser amount as may be approved by our Board). In no
event may the amount of any such annual increase exceed 200,000 shares. On January 1, 2011, the number
of shares reserved for issuance under the 2007 Directors Plan increased by 197,500 shares pursuant to this
automatic share increase provision.

(5) Represents shares credited to individual non-employee director stock accounts in lieu of director fees as of

December 31, 2010 under the Directors Deferred Plan. There is no exercise price for these shares.
Distributions in shares of our common stock under the Directors Deferred Plan are funded (i) with the shares
reserved under the 2007 Directors Plan for amounts credited to our non-employee directors’ stock accounts
prior to August 15, 2010 and (ii) with shares reserved under the Directors Deferred Plan for amounts
credited to our non-employee directors’ stock accounts on or after August 15, 2010. See “Director
Compensation—Directors Deferred Compensation Plan” for a description of the Directors Deferred Plan.

(6)

Prior to August 15, 2010, amounts credited to our non-employee directors’ stock accounts pursuant to the
Directors Deferred Plan are funded with the shares reserved under the 2007 Directors Plan. In August 2010,
a separate reserve for 200,000 shares was created under the Directors Deferred Plan which funds all
distributions under this plan on or after August 15, 2010.

y
x
o
r
P

31

PROPOSAL 4
ADVISORY VOTE ON COMPENSATION OF NAMED EXECUTIVE OFFICERS

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, and

Section 14A of the Exchange Act require that we provide our stockholders with the opportunity to vote to
approve, on a nonbinding advisory basis, the compensation of our named executive officers as disclosed in this
Proxy Statement in accordance with the compensation disclosure rules of the SEC.

Our executive compensation programs have remained substantially the same for several years. Our

programs are designed to help us attract talented individuals to manage and operate all aspects of our business, to
reward those individuals fairly over time, and to retain those individuals who continue to meet our high
expectations. To do that, our executive compensation program combines short- and long-term components, cash
and equity, and fixed and contingent payments, in the proportions that we believe are the most appropriate to
incentivize and reward our executive officers for achieving our short and long-term objectives. We believe our
executive compensation program is effectively designed, working well in alignment with the interests of our
stockholders and is instrumental to achieving our business strategy.

Our Compensation Committee, comprised of only independent directors, reviews and oversees our

compensation philosophy, policies, plans and programs, reviews and determines the compensation to be paid to
our executive officers and recommends to our full Board the compensation of our Chairman and Chief Executive
Officer. Our compensation philosophy is to ensure that the total compensation packages for our executive
officers stay competitive each year by targeting 50th percentile for cash compensation and 60th percentile for
long-term incentives of our peer group and/or survey data for executive officers in similar positions with similar
responsibilities. To execute this compensation philosophy, our Compensation Committee engages outside
compensation consultants, generally yearly, to benchmark our compensation, to provide an independent review
of all aspects of our compensation programs and to provide executive compensation advice for the coming year.
The following highlights our approach to executive compensation:

• Our compensation programs apply to all employees, including our executive officers and senior
management, and other than our Executive Change in Control and Severance Benefit Plan, our
executive officers and senior management are subject to the same compensation programs, including
base salary, incentive bonus, long-term incentives, defined contribution pension plans, and life
insurance premiums paid by us, as our non-executive employees.

• Our Compensation Committee continually monitors the Company’s performance and adjusts

compensation practices accordingly. For example, our Compensation Committee agreed to a temporary
voluntary pay reduction offered by our executive officers in 2009 and accepted a recommendation of
no bonus payments for 2008 performance to our executive officers, given the Company’s financial
situation at the time.

• Because we believe it is important to our success to aggressively pursue long-term goals and to avoid
excessive risk taking, a significant portion of our executive officers’ total compensation has been, and
is expected to continue to be, comprised of stock options and other equity awards which, generally,
vest over several years or longer.

• Our Executive Change in Control and Severance Benefit Plan does not provide severance benefits
unless there are both a change in control and an eligible termination (“double trigger”), and equity
awards do not automatically accelerate upon a change in control for any executive (absent an eligible
termination) but rather at the discretion of the Board.

• We have a long-standing insider trading policy which, among other things, prohibits any of our

employees, including our executive officers, from trading in any derivatives involving our securities,
and allows trading only during open trading windows.

32

• We do not provide other forms of compensation to our executives, including:

•

•

•

•

•

no guaranteed bonuses;

no special perquisites or other personal benefits or property to our executives;

no tax gross-up payments or other reimbursements in connection with any compensation
programs;

no formal employment agreements with our executives; and

no executive retirement plans.

Our stockholders are encouraged to read the “Corporate Governance and Board Matters—Compensation
Committee,” “Executive Compensation—Summary of Compensation,” “Executive Compensation—Narrative
Disclosure to Summary Compensation Table” and the other sections of this Proxy Statement under “Executive
Compensation” for more details on our executive compensation programs and practices.

The vote on the resolution below is not intended to address any specific element of compensation; rather,

the vote relates to the compensation of our named executive officers, as described in this Proxy Statement in
accordance with the compensation disclosure rules of the SEC. Although this vote is advisory, which means that
the vote is not binding on us, our Board and the Compensation Committee will carefully review and consider the
voting results when evaluating our executive compensation program.

Accordingly, we ask our stockholders to vote on the following resolution at the Annual Meeting:

“RESOLVED, that the Company’s stockholders approve, on an advisory basis, the compensation of the
Company’s named executive officers, as disclosed in the Company’s Proxy Statement for the 2011 Annual
Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange
Commission, including the compensation tables and the narrative disclosures related to those tables.”

The Board recommends a vote “For” Proposal 4.

y
x
o
r
P

33

PROPOSAL 5
ADVISORY VOTE ON THE FREQUENCY OF
THE ADVISORY VOTE ON COMPENSATION OF NAMED EXECUTIVE OFFICERS

The Dodd-Frank Act and Section 14A of the Exchange Act also provide that stockholders must be given the

opportunity to vote, on a non-binding advisory basis, for their preference as to how frequently we should seek
future advisory votes on the compensation of our named executive officers as disclosed in accordance with the
compensation disclosure rules of the SEC, which we refer to as an advisory vote on executive compensation. By
voting with respect to this Proposal 5, stockholders may indicate whether they would prefer that we conduct
future advisory votes on executive compensation once every three, two or one year. Stockholders also may, if
they wish, abstain from casting a vote on this proposal.

Our Board has determined that an advisory vote on executive compensation that occurs once every three
years is the most appropriate alternative for the Company and therefore our Board recommends that you vote for
a three-year interval for the advisory vote on executive compensation. Our compensation programs do not change
significantly from year to year and do not contain any significant risks that we believe would be of concern to our
stockholders. While we regularly review compensation, with an in-depth review on an annual basis, a significant
portion of our executives’ total compensation has been, and is expected to continue to be, equity compensation
that is designed to enhance long-term growth and performance of the Company and incentivize our executives on
a long-term basis. An advisory vote occurring once every three years will also permit our stockholders to observe
and evaluate the impact of any changes to our executive compensation policies and practices which have
occurred since the last advisory vote on executive compensation, including changes made in response to the
outcome of a prior advisory vote on executive compensation.

We view the advisory vote on executive compensation as an additional, but not exclusive, opportunity for

our stockholders to communicate with us regarding their views on the Company’s executive compensation
programs. Although this advisory vote is not binding on us, our Board and the Compensation Committee will
take into account the outcome of the vote when considering the frequency of future advisory votes on executive
compensation. In addition, while the Board currently believes that holding an advisory vote on executive
compensation every three years will reflect the right balance of considerations in the normal course, we will
periodically reassess that view and can provide for an advisory vote on executive compensation on a more
frequent basis if changes in our compensation programs or other circumstances suggest that such a vote would be
appropriate. While the Board believes that its recommendation is appropriate at this time, the stockholders are
not voting to approve or disapprove that recommendation, but are instead asked to indicate their preferences, on
an advisory basis, as to whether the nonbinding advisory vote on executive compensation should be held every
three, two or one year.

Accordingly, we ask our stockholders to indicate their preferred voting frequency by voting for every
“3 Years,” “2 Years” or “1 Year” (or abstaining from voting) in response to the following resolution at the
Annual Meeting:

“RESOLVED, that the option of every three, two or one year that receives the greatest number of votes
from the holders of shares represented either in person or by proxy at the Annual Meeting and entitled to
vote shall be considered the preferred frequency with which the Company is to hold an advisory vote on the
compensation of the Company’s named executive officers.”

The Board recommends that you vote for the option of 3 YEARS
on Proposal 5 as the preferred frequency for the advisory vote
on the compensation of named executive officers.

34

SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership of the Company’s common stock

as of March 30, 2011 (except as noted) by: (i) each director and nominee for director; (ii) each of the executive
officers named in the Summary Compensation Table (referred to in this Proxy Statement as our “named
executive officers”); (iii) all executive officers and directors of the Company as a group; and (iv) all those known
by us to be beneficial owners of more than five percent of our common stock.

Name and Address of Beneficial Owner(1)

5% Stockholders:
Entities affiliated with Kohlberg Kravis Roberts & Co. L.P.

Beneficial Ownership(2)

Number of
Shares

Percent of
Total

y
x
o
r
P

9 West 57th Street, Suite 4200
New York, NY 10019
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KKR JP LLC(3)
KKR JP III LLC(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KKR Financial Holdings III, LLC(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10,504,338
36,445
70,156

Entities affiliated with Longitude Capital Partners, LLC(4)

. . . . . . . . . . . . . .

3,831,924

25.45%
*
*

9.21%

800 El Camino Real, Suite 220
Menlo Park, CA 94025

BlackRock, Inc.(5)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,458,174

8.50%

40 East 52nd Street
New York, NY 10022

Entities affiliated with Thoma Cressey Bravo, Inc.(6) . . . . . . . . . . . . . . . . . . .

2,432,487

5.96%

Sears Tower, 92nd Floor
22 South Wacker Drive
Chicago, IL 60606

Named Executive Officers and Directors:
Bruce C. Cozadd(7) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert M. Myers(8)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kathryn E. Falberg(9) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Paul L. Berns(10) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Samuel D. Colella(11) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bryan C. Cressey(12) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patrick G. Enright(13) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Michael W. Michelson(14)
James C. Momtazee(15)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kenneth W. O’Keefe(16) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alan M. Sebulsky(17)
James B. Tananbaum, M.D.(18)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rick E Winningham(19)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nathaniel M. Zilkha(20)
. . . . . . . . . . .
All directors and executive officers as a group (19 persons)(21)

867,284
570,845
103,501
13,458
1,711,659
2,471,862
3,878,846
28,542
26,167
1,682,497
119,527
39,375
19,375
22,873
11,564,581

2.10%
1.38%
*
*
4.19%
6.05%
9.31%
*
*
4.12%
*
*
*
*
26.54%

*

Represents beneficial ownership of less than 1%.

(1) Unless otherwise provided in the table above or in the notes below, the address for each of the beneficial

owners listed is c/o Jazz Pharmaceuticals, Inc., 3180 Porter Drive, Palo Alto, California 94304.

(2)

This table is based upon information supplied by officers, directors and principal stockholders and
Schedules 13G filed with the Securities and Exchange Commission, or the SEC. Unless otherwise indicated
in the footnotes to this table and subject to community property laws where applicable, we believe that each
of the stockholders named in this table has sole voting and investment power with respect to the shares
indicated as beneficially owned. Applicable percentages are based on 40,671,360 shares outstanding on

35

March 30, 2011, adjusted as required by rules promulgated by the SEC. The number of shares beneficially
owned includes shares of common stock issuable pursuant to the exercise of stock options and warrants that
are exercisable within 60 days of March 30, 2011, as well as shares credited to individual non-employee
director phantom stock accounts under our Directors Deferred Compensation Plan as of March 30, 2011.
Amounts credited to individual non-employee director phantom stock accounts under our Directors
Deferred Compensation Plan are payable solely in shares of our common stock, but such shares do not have
current voting or investment power. Shares issuable pursuant to our Directors Deferred Compensation Plan
and shares issuable pursuant to the exercise of stock options and warrants that are exercisable within 60 days
of March 30, 2011 are deemed to be outstanding and beneficially owned by the person to whom such shares
are issuable for the purpose of computing the percentage ownership of that person, but they are not treated
as outstanding for the purpose of computing the percentage ownership of any other person.

(3) KKR JP LLC (“KKR JP”) directly holds 9,906,501 shares and warrants to purchase 597,837 shares. KKR
Millennium Fund L.P. (“KKR Millennium Fund”) is the sole member of KKR JP. KKR Associates
Millennium L.P. (“KKR Associates Millennium”) is the sole general partner of KKR Millennium Fund.
KKR Millennium GP LLC (“KKR Millennium GP”) is the sole general partner of KKR Associates
Millennium. KKR Fund Holdings L.P. (“KKR Fund Holdings”) is the designated member of KKR
Millennium GP. KKR Fund Holdings GP Limited (“KKR Fund Holdings GP”) is a general partner of KKR
Fund Holdings. KKR Millennium Fund, KKR Associates Millennium, KKR Millennium GP, KKR Fund
Holdings and KKR Fund Holdings GP disclaim beneficial ownership of the securities held by KKR JP.

KKR JP III LLC (“KKR JP III”) directly holds 36,445 shares. KKR Partners III, L.P. (“KKR Partners III”)
is the sole member of KKR JP III. KKR III GP LLC (“KKR III GP”) is the sole general partner of KKR
Partners III. KKR Partners III and KKR III GP disclaim beneficial ownership of the securities held by KKR
JP III.

KKR Financial Holdings III, LLC (“KKR Financial Holdings III”) directly holds warrants to purchase
70,156 shares. KKR Financial Holdings LLC (“KKR Financial Holdings”) is the sole member of KKR
Financial Holdings III. KKR Financial Advisors LLC (“KKR Financial Advisors”) is the manager of KKR
Financial Holdings. Kohlberg Kravis Roberts & Co. (Fixed Income) LLC (“Kohlberg Kravis Roberts & Co.
(Fixed Income)”) is the sole member of KKR Financial Advisors. Kohlberg Kravis Roberts & Co. L.P.
(“Kohlberg Kravis Roberts & Co.”) is the holder of all of the outstanding equity interests in Kohlberg
Kravis Roberts & Co. (Fixed Income). KKR Management Holdings L.P. is the general partner of Kohlberg
Kravis Roberts & Co. KKR Management Holdings Corp. is the general partner of KKR Management
Holdings L.P. KKR Financial Holdings, KKR Financial Advisors, Kohlberg Kravis Roberts & Co. (Fixed
Income), Kohlberg Kravis Roberts & Co., KKR Management Holdings L.P. and KKR Management
Holdings Corp. disclaim beneficial ownership of the securities held by KKR Financial Holdings III.

Each of KKR Group Holdings L.P. (“KKR Group Holdings”) (as the sole shareholder of KKR Fund
Holdings GP, a general partner of KKR Fund Holdings L.P. and the sole shareholder of KKR Management
Holdings Corp.); KKR Group Limited (“KKR Group”) (as the general partner of KKR Group Holdings);
KKR & Co. L.P. (“KKR & Co.”) (as the sole shareholder of KKR Group); and KKR Management LLC
(“KKR Management”) (as the general partner of KKR & Co.) disclaim beneficial ownership of the
securities held by KKR JP and KKR Financial Holdings III.

As the designated members of KKR Management LLC and the managers of KKR III GP LLC, Messrs.
Henry R. Kravis and George R. Roberts may be deemed to be the beneficial owner of the securities held by
KKR JP, KKR JP III and KKR Financial Holdings III but disclaim beneficial ownership of such securities.
Messrs. Kravis and Roberts have also been designated as managers of KKR Millennium GP by KKR Fund
Holdings.

The entities named in this footnote (3) are sometimes referred to as the KKR Entities. Michael W.
Michelson, James C. Momtazee and Nathaniel M. Zilkha are members of our Board and are executives of
Kohlberg Kravis Roberts & Co. L.P. and/or one or more of its affiliates. Each of Messrs. Michelson,
Momtazee and Zilkha disclaim beneficial ownership of any securities beneficially owned by the KKR
Entities. The address of the KKR Entities (except KKR Financial Holdings III, KKR Financial Holdings,

36

KKR Financial Advisors and Kohlberg Kravis Roberts & Co. (Fixed Income)) and Mr. Kravis is c/o
Kohlberg Kravis Roberts & Co. L.P., 9 West 57th Street, New York, NY 10019. The address of KKR
Financial Holdings III, LLC, KKR Financial Holdings LLC, KKR Financial Advisors LLC and KKR
Financial LLC is 555 California Street, 50th Floor, San Francisco, CA 94104. The address of Messrs.
Roberts, Michelson, Momtazee and Zilkha is c/o Kohlberg Kravis Roberts & Co. L.P., 2800 Sand Hill
Road, Suite 200, Menlo Park, CA 94025.

(4) Consists of 2,827,390 shares and a warrant to acquire 929,243 shares held by Longitude Venture Partners,
L.P., and 56,667 shares and a warrant to acquire 18,624 shares held by Longitude Capital Associates, L.P.
Patrick G. Enright is a Managing Member of Longitude Capital Partners, LLC, which is the sole general
partner of each of these two entities. As such he may be deemed to have shared voting and dispositive
power with respect to shares and warrants held by those entities. Mr. Enright disclaims beneficial ownership
of all such shares and warrants, except to the extent of his proportionate pecuniary interest therein.

(5) Based upon a Schedule 13G filed with the SEC on February 4, 2011 by BlackRock, Inc. on behalf of itself

reporting beneficial ownership as of December 31, 2010. According to the Schedule 13G filed by
BlackRock, Inc., it has the sole power to vote or dispose of all of the shares held. The Schedule 13G filed by
BlackRock, Inc. provides information only as of December 31, 2010 and, consequently, the beneficial
ownership of above-mentioned reporting person may have changed between December 31, 2010 and
March 30, 2011.

y
x
o
r
P

(7)

(9)

(8)

(10)

(6) Consists of 2,259,250 shares and a warrant to acquire 135,841 shares held by Thoma Cressey Fund VII, LP
and 35,275 shares and a warrant to acquire 2,121 shares held by Thoma Cressey Friends Fund VII, LP.
Bryan C. Cressey is a partner of Thoma Cressey Equity Partners, the sponsor of these entities, the Thoma
Cressey Funds, and is deemed to have shared voting and investment power over the shares held by Thoma
Cressey Equity Partners and its affiliated entities. Mr. Cressey disclaims beneficial ownership of the shares
held by the Thoma Cressey Funds, except to the extent of his pecuniary interest therein.
Includes 582,509 shares Mr. Cozadd has the right to acquire pursuant to options exercisable within 60 days
of March 30, 2011.
Includes 156,898 shares held by Mr. Myers as of February 1, 2011 and 413,947 shares Mr. Myers has the
right to acquire pursuant to options exercisable within 60 days of March 30, 2011. Mr. Myers resigned as
our President and as a member of our Board effective January 14, 2011 and is serving as a consultant to the
Company through February 1, 2012.
Includes 52,915 shares Ms. Falberg has the right to acquire pursuant to options exercisable within 60 days of
March 30, 2011.
Includes 9,375 shares Mr. Berns has the right to acquire pursuant to options exercisable within 60 days of
March 30, 2011 and 4,083 shares issuable to Mr. Berns pursuant to our Directors Deferred Compensation Plan.
Includes 39,375 shares Mr. Colella has the right to acquire pursuant to options exercisable within 60 days of
March 30, 2011 and 8,892 shares issuable to Mr. Colella pursuant to our Directors Deferred Compensation Plan.
Also includes 1,488,676 shares and a warrant to acquire 129,613 shares held by Versant Venture Capital II,
L.P., 28,260 shares and a warrant to acquire 2,464 shares held by Versant Affiliates Fund II-A, L.P. and 13,247
shares and a warrant to acquire 1,132 shares held by Versant Side Fund II, L.P. Mr. Colella is a managing
member of Versant Ventures II, LLC, which is the general partner of each of Versant Venture Capital II, L.P.,
Versant Affiliates Fund II-A, L.P. and Versant Side Fund II, L.P., or the Versant Funds, and is deemed to have
shared voting and investment power over the shares held by the Versant Funds. Mr. Colella disclaims beneficial
ownership of the shares held by the Versant Funds, except to the extent of his pecuniary interest therein.
Includes 39,375 shares Mr. Cressey has the right to acquire pursuant to options exercisable within 60 days
of March 30, 2011 and the shares described in Note (5) above. Mr. Cressey disclaims beneficial ownership
of the shares described in Note (5) above, except to the extent of his pecuniary interest therein.
Includes 37,708 shares Mr. Enright has the right to acquire pursuant to options exercisable within 60 days of
March 30, 2011, 9,214 shares issuable to Mr. Enright pursuant to our Directors Deferred Compensation
Plan, and the shares described in Note (4) above. Mr. Enright disclaims beneficial ownership of the shares
described in Note (4) above, except to the extent of his pecuniary interest therein.

(12)

(13)

(11)

37

(14)

(15)

(16)

Includes 9,375 shares Mr. Michelson has the right to acquire pursuant to options exercisable within 60 days
of March 30, 2011 and 19,167 shares issuable to Mr. Michelson pursuant to our Directors Deferred
Compensation Plan. Mr. Michelson disclaims beneficial ownership of the shares described in Note
(3) above.

Includes 9,375 shares Mr. Momtazee has the right to acquire pursuant to options exercisable within 60 days
of March 30, 2011 and 16,792 shares issuable to Mr. Momtazee pursuant to our Directors Deferred
Compensation Plan. Mr. Momtazee disclaims beneficial ownership of the shares described in Note
(3) above.

Includes 39,375 shares Mr. O’Keefe has the right to acquire pursuant to options exercisable within 60 days
of March 30, 2011 and 21,463 shares issuable to Mr. O’Keefe pursuant to our Directors Deferred
Compensation Plan. Also includes 1,529,684 shares and a warrant to acquire 91,975 shares held by Jazz
Investors LLC. Beecken Petty O’Keefe & Company, LLC is the sole manager of Jazz Investors,
LLC. Mr. O’Keefe is one of the member managers of Beecken Petty O’Keefe & Company, LLC, and as
such may be deemed to have shared voting and dispositive power with respect to the shares beneficially
owned by Jazz Investors, LLC. Mr. O’Keefe disclaims beneficial ownership of the shares held by Jazz
Investors LLC, except to the extent of his pecuniary interest therein.

(17)

Includes 75,911 shares Mr. Sebulsky has the right to acquire pursuant to options exercisable within 60 days
of March 30, 2011 and 15,364 shares issuable to Mr. Sebulsky pursuant to our Directors Deferred
Compensation Plan.

(18) Consists solely of 39,375 shares Dr. Tananbaum has the right to acquire pursuant to options exercisable within

60 days of March 30, 2011. Dr. Tananbaum’s term of office as our director expires at the Annual Meeting on
May 24, 2011 and he has advised the Board that he will not stand for reelection at the Annual Meeting.

(19) Consists solely of 19,375 shares Mr. Winningham has the right to acquire pursuant to options exercisable

within 60 days of March 30, 2011.

(20)

(21)

Includes 9,375 shares Mr. Zilkha has the right to acquire pursuant to options exercisable within 60 days of
March 30, 2011 and 13,498 shares issuable to Mr. Zilkha pursuant to our Directors Deferred Compensation
Plan. Mr. Zilkha disclaims beneficial ownership of the shares described in Note (3) above. Mr. Zilkha’s
term of office as our director expires at the Annual Meeting on May 24, 2011 and he has advised the Board
that he will not stand for reelection at the Annual Meeting.

Includes 8,238,449 shares and warrants to purchase 1,311,013 shares held by entities affiliated with certain
of our directors, 1,478,237 shares that certain of our executive officers and directors have the right to
acquire within 60 days of March 30, 2011 through the exercise of options, and 108,473 shares issuable to
our directors under our Directors Deferred Compensation Plan. Does not include 156,898 shares held by
Mr. Myers as of February 1, 2011 and 413,947 shares that Mr. Myers has the right to acquire within 60 days
of March 30, 2011 through the exercise of options. Mr. Myers resigned as our President and as a member of
our Board effective January 14, 2011 and is serving as a consultant to the Company through February 1,
2012. See notes (2) through (20) above.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more
than ten percent of a registered class of our equity securities, to file with the SEC initial reports of ownership and
reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors
and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all
Section 16(a) forms they file.

To our knowledge, based solely on a review of the copies of such reports furnished to us and written

representations that no other reports were required, during the fiscal year ended December 31, 2010, all
Section 16(a) filing requirements applicable to our officers, directors and greater than ten percent beneficial
owners were complied with.

38

y
x
o
r
P

EXECUTIVE COMPENSATION

Summary of Compensation

The following table sets forth certain summary information for the year indicated with respect to the
compensation earned by our Chief Executive Officer and our two most highly compensated executive officers
other than our Chief Executive Officer who were serving as executive officers as of December 31, 2010. We
refer to these individuals in this Proxy Statement as our “named executive officers.”

SUMMARY COMPENSATION TABLE—FISCAL 2009 AND 2010

Name and Principal Position

Year Salary ($)(1)

Bonus
($)(2)(6)

Option
Awards
($)(3)

Non-Equity
Incentive Plan
Compensation
($)(4)

All
Other
Compensation
($)(5)

Bruce C. Cozadd . . . . . . . . . . . . . .
Chairman and Chief Executive
Officer

Robert M. Myers(6) . . . . . . . . . . . . .

President

Kathryn E. Falberg . . . . . . . . . . . . .
Senior Vice President and Chief
Financial Officer

2010 496,877
2009 442,729

— 1,163,414
— 189,260

267,300
205,300

2010 449,092 224,000
2009 420,024

623,258
— 141,945

—
193,900

2010 366,404

30,000

498,606

150,000

1,437
1,574

1,396
1,564

1,100

Total ($)

1,929,028
838,863

1,297,746
757,433

1,046,110

(1)

(2)

(3)

(4)

The dollar amounts in this column represent base salary earned during the indicated fiscal year. For more
information regarding salaries in 2009 and 2010, see “—Narrative Disclosure to Summary Compensation
Table—Base Salary” below.

The dollar amount in this column represents cash bonus made outside of our annual Bonus Plan.
Ms. Falberg joined the Company in December 2009. Pursuant to her offer of employment, the Company
paid her a signing bonus on the first regular pay day 90 days after her start date with the Company.
Mr. Myers resigned as our President and a member of our Board effective January 14, 2011 and his
employment with the Company terminated on February 1, 2011. In connection with his resignation, the
Company made a lump sum cash payment to Mr. Myers of $224,000, which equals the full annual bonus
under the Bonus Plan for 2010 that he potentially could have earned had he met all the requirements for
earning such bonus, pursuant to a separation agreement entered into between the Company and Mr. Myers.

The dollar amounts in this column represent the aggregate grant date fair value of all option awards granted
during the indicated fiscal year. These amounts have been calculated in accordance with FASB ASC Topic
718, or ASC 718, using the Black-Scholes option-pricing model and excluding the effect of estimated
forfeitures. Assumptions used in the calculation of these amounts are included in the notes to the
Company’s audited consolidated financial statements included in the Company’s Annual Report on
Form 10-K for the year ended December 31, 2010 filed with the SEC on March 8, 2011. These amounts do
not necessarily correspond to the actual value that may be recognized by the named executive officers.

The dollar amounts in this column represent the cash bonus awarded under our annual Bonus Plan for the
indicated fiscal year. For more information, see “—Narrative Disclosure to Summary Compensation
Table—Annual Bonus Plan” below.

(5) Represents group term life insurance premiums paid by the Company.

(6)

Effective January 14, 2011, Mr. Myers resigned as our President and a member of our Board. In connection
with Mr. Myers’ resignation, the Company and Mr. Myers entered into a separation agreement, pursuant to
which Mr. Myers is retained as a consultant to the Company for 12 months starting on February 1, 2011, his
employment termination date. During the 12-month period, Mr. Myers is to be compensated at a rate of
$250 per hour for services performed at the request of the Company, and the stock options previously

39

granted to Mr. Myers under the Company’s equity incentive plans will continue to vest in accordance with
their existing terms. In addition, the Company agreed, for 12 months following February 1, 2011, (i) to pay
cash severance to Mr. Myers in the form of base salary continuation payments, (ii) to make monthly cash
payments to Mr. Myers equal to applicable monthly COBRA premiums, and (iii) that, assuming the
consulting period continues for 12 months, the Company will accelerate the vesting of his outstanding stock
options such that as of the last day of the consulting period, Mr. Myers will vest in a number of shares
subject to such options as if such options had continued to vest pursuant to their terms for an additional six
months after the end of the consulting period.

Narrative Disclosure to Summary Compensation Table

Base Salary

We provide a base salary to our executive officers, the rate for which is set each year, effective March 1.
Our Compensation Committee generally aims to ensure that the total compensation packages for our executive
officers stay competitive each year by targeting 50th percentile for cash compensation and 60th percentile for
long-term incentives of our peer group and/or survey data for executive officers in similar positions with similar
responsibilities, including data from the Radford Biotech Executive Survey. Our Compensation Committee
believes this is appropriate for several reasons. We have a complex business model and are pursuing multiple
commercial and product development opportunities simultaneously with a relatively small organization. We do
not have any significant laboratories or manufacturing facilities, and therefore we conduct our development,
manufacturing and clinical activities through arrangements with third parties. As a result, our executives are
required to manage both internal and significant external resources. Competition for executive talent is intense in
our industry and in our geographic area. Our executives have many years of valuable experience in our industry,
and their continued leadership is deemed critical to our short-term and long-term success.

In early 2010, our Compensation Committee reviewed the survey and/or benchmark data referred to above

to ensure that executive base salaries as a group were within the competitive levels described above, and then
determined appropriate increases to base salaries from the prior year. As such, there was a 7% increase in the
2010 base salary rate for Mr. Cozadd from the prior year resulting from a combination of merit and adjustment
increases to his base salary rate so that his base salary rate was at a level that was generally consistent with the
50th percentile of our peer group. For Mr. Myers, there was a 1% increase in his 2010 base salary rate from the
prior year. Ms. Falberg joined us in December 2009, and therefore her initial base salary rate was unchanged for
2010. Ms. Falberg’s initial compensation arrangement is described under “—Executive Employment
Agreements” below.

In December 2008, our executive officers proposed, and our Compensation Committee accepted that, in

light of our then current economic situation, effective January 1, 2009, our executive officers would take a
temporary pay reduction of between 5% and 10% of their 2008 base salaries. Effective August 1, 2009 and based
on our improved financial situation since the beginning of 2009, the temporary pay reduction ended, and our
executive officer salaries returned to 2008 base salary levels. Because of the voluntary temporary pay reduction
taken by our executive officers at the start of 2009, our Compensation Committee did not believe it necessary to
review additional comparative compensation data when determining the 2009 base salary rates for our executive
officers.

40

The 2009 and 2010 base salary rates for our named executive officers, without regard to the voluntary pay

reductions in 2009, are set forth in the table below.

Name

2009 Base Salary
($)(1)

2010 Base Salary
($)(2)

Bruce C. Cozadd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert M. Myers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kathryn E. Falberg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

468,000
444,000
—

500,000
448,000
365,000

(1)

The named executive officers took voluntary temporary base salary rate reductions (10% for Messrs.
Cozadd and Myers) beginning January 1, 2009 through July 31, 2009. During the period of their voluntary
reductions, their base salary rates were $421,200 for Mr. Cozadd and $399,600 for Mr. Myers.

y
x
o
r
P

(2) Base salary rate beginning March 1, 2010.

Annual Bonus Plan

In accordance with our annual Bonus Plan, we maintain an annual bonus award program to reward

executive officers (and other employees) for attaining our corporate performance objectives, as well as to reward
them for their individual contributions to the achievement of those objectives. Target bonus levels under the
annual Bonus Plan are assigned based on various categories of employees. The actual bonus awarded in any year,
if any, may be more or less than the target, depending primarily on the achievement of our corporate objectives,
and an individual employee’s achievement of his or her objectives. Whether or not a bonus is paid for any year is
within the discretion of our Compensation Committee, and our Compensation Committee has the discretion to
award bonuses even if the applicable performance criteria set forth under the annual Bonus Plan have not been
met or to award a bonus based on other criteria.

In late 2009, the Compensation Committee engaged Radford to provide the Compensation Committee with

advice concerning executive compensation for 2010. In part as a result of its discussion with Radford, the
Compensation Committee determined that the bonus target for the Chief Executive Officer should be 60% (rather
than the 50% target originally provided for in the Bonus Plan) beginning with any bonus for 2010. As such, the
target bonus levels for 2010 for our named executive officers were: 60% of the applicable annual base salary
earned for Mr. Cozadd, 50% of the applicable annual base salary earned for Mr. Myers and 40% of the applicable
annual base salary earned for Ms. Falberg. For 2010, our key high-level corporate objectives approved by the
Board in early 2010 were to:

•

achieve budgeted net sales of Xyrem and Luvox CR of $160 million and budgeted cash EBITDA1 from
commercial operations of $100 million;

• manage corporate operations by achieving cash EBITDA for the entire company of $18 million

through first quarter of 2010 and $49 million for 2010;

•

•

strengthen our balance sheet by refinancing at least $75 million of our existing debt in first half of
2010; and

obtain a positive majority vote for approval from an FDA Advisory panel for JZP-6, receive FDA
approval for JZP-6 for the treatment of fibromyalgia by December 31, 2010 and conduct appropriate
activities for a launch of JZP-6 in first half of 2011.

Our key objectives also include ensuring that employees are aligned with the corporate objectives and that

the Company operates in compliance with applicable laws and regulations as an over-arching value and
requirement.

1 Cash EBITDA is calculated, for purposes of evaluating achievement of our 2010 corporate objectives, as gross
sales and royalty revenues less operating expenses (excluding stock based compensation and depreciation).

41

Each of the executive officers is responsible for meeting our corporate objectives, and each objective was

deemed important in determining the level of our performance during the year. Although the Compensation
Committee did not set individual goals for individual executive officers, certain of the named executive officer’s
responsibilities are more directly related to particular corporate objectives and may therefore be given greater
weight in the determination of the bonus amount paid to a named executive officer. As Chairman and Chief
Executive Officer, Mr. Cozadd is responsible for the Company meeting all of its objectives. Ms. Falberg, along
with Mr. Cozadd, is particularly responsible for our financing activities, and her efforts in achieving this
corporate objective had a greater impact on her bonus determination than it did for other executive officers.
Nevertheless, in a small company such as ours, each executive is expected to contribute in significant ways to the
achievement of most, if not all, of our corporate objectives.

In approving the corporate objectives for 2010, the expectation of the Board was that it would be unlikely

that all of the corporate objectives would be achieved for the year. In this regard, the Board has historically
approved corporate objectives that have been stretch objectives beyond those that would reasonably be expected
to be attained in any given year, and our corporate objectives historically have not been achieved at the 100%
level. Our Compensation Committee determines the size of the total bonus pool under the annual Bonus Plan,
which is based primarily on the Board’s determination of our success in achieving our corporate objectives for
the plan year. The Compensation Committee also determines the portion of the pool, if any, that will be allocated
to the executive officers as a group and the individual bonuses for each of our executive officers and vice
presidents. Mr. Cozadd provides input to the Compensation Committee with respect to bonuses for executive
officers and vice presidents other than his own compensation. For 2010, the Compensation Committee did not
quantify or assign specific percentage criteria to the various corporate objectives under the annual Bonus Plan,
but rather sought to approve a bonus payout that generally reflected the Board’s determination of the level of
achievement of our corporate objectives, after taking into account the key corporate objectives listed above.

With respect to the achievement of our 2010 corporate objectives, after considering the input of Mr. Cozadd,
our Compensation Committee determined that we had far exceeded the targets of certain key objectives, achieved
most of our other objectives, and missed one key objective. In evaluating our performance against our corporate
objectives for 2010, the Compensation Committee believed the following were highly significant: (i) our
achievement of profitability in 2010 that far exceeded our target, (ii) our attaining and exceeding net sales and
commercial EBITDA targets for 2010; (iii) our significant reduction of operating expenses and strengthening of
our balance sheet, primarily through the successful refinancing of our senior secured debt in June 2010; (iv) our
success in raising equity capital in a public offering in May 2010, and (v) our receipt of a complete response
letter from the FDA in October 2010 stating that the FDA cannot approve our new drug application for JZP-6 in
its present form. After balancing our outstanding 2010 financial and operational performance against our
unsuccessful effort to obtain FDA approval for JZP-6 in 2010, our Compensation Committee approved a total
corporate bonus payout of 90% of the total target bonus pool.

The actual bonus award amounts under the annual Bonus Plan for Mr. Cozadd and Ms. Falberg were

determined by multiplying the percentage achievement determined by the Compensation Committee by the target
bonus percentage set forth in our Bonus Plan (60% for Mr. Cozadd and 40% for Ms. Falberg) by the actual salary
earned during the year. All of our named executive officers contributed significantly to our achievement of our
key objectives in 2010, and the Compensation Committee (with approval from the Board with regard to
Mr. Cozadd) determined that the company achievement rate of 90% was applicable for Mr. Cozadd. As Ms
Falberg was particularly responsible for strengthening our balance sheet and exceeded the target set at the
beginning of 2010, the Compensation Committee approved a higher achievement rate for her. Because
Mr. Myers resigned his position in January 2011, in connection with his separation from the Company, the
Compensation Committee approved a lump sum cash payment to him of $224,000, which equals the full annual
bonus under the Bonus Plan for 2010 that he potentially could have earned had he met all the requirements for
earning such bonus.

For 2009, as set forth in the Bonus Plan, the target bonus levels for Messrs. Cozadd and Myers were 50% of

their then applicable annual salary earned. In early 2010, after considering the input of Mr. Cozadd, the Board

42

determined that we had achieved most, but not all, of our key corporate objectives for 2009. Based on the
Board’s determination of the level of achievement of our corporate objectives for 2009, our Compensation
Committee approved a total corporate bonus payout of 78% of the total target bonus pool. Our actual bonus
award amounts under the annual Bonus Plan are determined by multiplying the percentage achievement
determined by the Compensation Committee by the target bonus percentage set forth in our Bonus Plan by the
actual salary earned during the year. In determining the specific bonus award amounts for our named executive
officers for 2009 under the annual Bonus Plan, our Compensation Committee desired to ensure that the different
voluntary salary reductions taken by various executive officers (and other company officers) from January 1,
2009 through July 31, 2009 did not impact relative bonus awards among executive officers. Accordingly, in
setting individual bonuses, the Compensation Committee set aside from the executive portion of the total bonus
pool an amount sufficient to offset the individual voluntary salary reductions, and then allocated the remainder of
the pool against salaries without taking effect of the voluntary reductions. Because all of our named executive
officers contributed significantly to our achievement of our key objectives in 2009, the Compensation Committee
(with approval from the Board with regard to Mr. Cozadd) determined that the same achievement rate was
applicable for each of Mr. Cozadd and Mr. Myers.

The cash bonus awards for 2009 and 2010 under the Bonus Plan for our named executive officers were as

y
x
o
r
P

follows:

Name

Total Bonus under
Bonus Plan for 2009 ($)(1)

Total Bonus under
Bonus Plan for 2010 ($)

Bruce C. Cozadd . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robert M. Myers(2)
. . . . . . . . . . . . . . . . . . . . . . . . . . .
Kathryn E. Falberg(3) . . . . . . . . . . . . . . . . . . . . . . . . . .

205,300
193,900
—

267,300
—
150,000

(1)

The bonus for 2009 was calculated by determining the amount of the temporary voluntary salary reduction
($27,300 for Mr. Cozadd and $25,900 for Mr. Myers) for each executive, and adding to it to the bonus
amount determined under the Bonus Plan for 2009 as described above, but subject to the total amount of the
bonus pool available for executives.

(2) Mr. Myers resigned as our President and a member of our Board effective January 14, 2011 and his

employment with the Company terminated on February 1, 2011. In connection with his separation from the
Company, the Compensation Committee approved a lump sum cash payment to him of $224,000, which
equals the full annual bonus under the Bonus Plan for 2010 that he potentially could have earned had he met
all the requirements for earning such bonus.

(3) Ms. Falberg joined the Company in December 2009 and did not receive a bonus for that year.

In late 2010, the Compensation Committee again engaged Radford to provide the Compensation Committee

with advice concerning executive compensation for 2011. In part as a result of its discussion with Radford, the
Compensation Committee determined that the bonus target for the Chief Executive Officer should be 65% (rather
than the 60% target stated in the Bonus Plan) beginning with any bonus for 2011.

Stock Option Awards

In March 2010, the Compensation Committee used Radford data in reviewing the levels of stock option

grants to our named executive officers and again sought to ensure a level of annual grants for our named
executive officers as a group at approximately the 60th percentile of the annual grants for executive officers in
similar positions with similar responsibilities at our peer companies chosen for 2010. As a result, stock options
were granted under the 2007 Plan as follows: options for 140,000 shares to Mr. Cozadd, options for 75,000
shares to Mr. Myers, and options for 60,000 shares to Ms. Falberg. The options have a 10 year term and vested as
to 25% of the shares in March 2011, and vest as to the remainder of the shares in 36 equal monthly installments
thereafter. Pursuant to Mr. Myer’s separation agreement with the Company, he is retained as a consultant to the
Company for 12 months starting on February 1, 2011, his employment termination date, and the options for

43

75,000 shares granted to Mr. Myers in March 2010 continue to vest during his consulting period; and subject to
continuous service, on the last day of his consulting period, Mr. Myers will vest in an additional number of
shares subject to these options as if such options had continued to vest pursuant to their terms for an additional
six months after the end of the consulting period. The exercise price of the options is $11.48 per share, the fair
market value of our common stock on the date of grant, determined in accordance with the terms of our 2007
Plan.

In January 2009, we granted stock options to our named executive officers under our 2007 Plan described

above. In determining the number of stock option grants to the named executive officers in January 2009, the
Compensation Committee considered the benchmark data from our peer group companies provided by
Compensia, Inc., a compensation consultant, as well as Radford survey data, with a goal of ensuring a level of
long-term incentive compensation for our named executive officers as a group at approximately the 60th
percentile of long-term incentive compensation for executive officers in similar positions with similar
responsibilities at our peer companies. Accordingly, after considering these factors, Messrs. Cozadd and Myers
each received grants of stock options reflecting their respective positions in the Company. As a result, stock
options were granted under the 2007 Plan as follows: options for 200,000 shares to Mr. Cozadd and options for
150,000 shares to Mr. Myers. The options have a 10 year term and vested as to 331 /3% of the shares in
January 2010, and vest as to the remainder of the shares in 24 equal monthly installments thereafter. Pursuant to
Mr. Myer’s separation agreement with the Company, the options for 150,000 shares granted to Mr. Myers in
January 2009 continue to vest during his consulting period; and subject to continuous service, will fully vest in
January 2011. The exercise price of the options is $1.25 per share, the fair market value of our common stock on
the date of grant, determined in accordance with the terms of our 2007 Plan.

The 2007 Plan became effective in connection with our initial public offering. A brief description of certain

of the permissible terms of stock options and other stock awards granted under the 2007 Plan, including the
Board’s discretion to take certain actions with respect to outstanding stock awards in the event of certain
significant corporate transactions and the provisions of the form of option agreement under the 2007 Plan in the
event of certain specified change in control transactions, is provided under “Proposal 3 Approval of the Internal
Revenue Code Section 162(m) Performance Criteria and Award Limits of the Company’s 2007 Equity Incentive
Plan—Plan Summary” above.

44

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth, for the fiscal year ended December 31, 2010, certain information regarding

outstanding equity awards at fiscal year end for our named executive officers.

OUTSTANDING EQUITY AWARDS AT 2010 FISCAL-YEAR END TABLE

Name

Bruce C. Cozadd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Robert M. Myers(5)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Kathryn E. Falberg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

y
x
o
r
P

Option Awards

Number of
Securities
Underlying
Unexercised
Options
(#)

Number of
Securities
Underlying
Unexercised
Options
(#)

Exercisable Unexercisable

Option
Exercise
Price
($)

—
127,777
71,000
24,849
164,120
54,707
54,707

—
86,176
50,000
19,326
164,120
54,707
54,707

—
25,000

140,000(1)
72,223(2)
35,500(3)
15,813(4)

0
0
0

75,000(1)
54,167(2)
23,000(3)
12,299(4)

0
0
0

60,000(1)
75,000(6)

11.48
1.25
7.96
19.37
15.09
30.18
45.27

11.48
1.25
7.96
19.37
15.09
30.18
45.27

11.48
7.35

Option
Expiration
Date

03/07/20
01/20/19
05/15/18
02/26/17
02/17/14
02/17/14
02/17/14

03/07/20
01/20/19
05/15/18
02/26/17
02/17/14
02/17/14
02/17/14

03/07/20
12/06/19

(1)

(2)

(3)

(4)

The shares subject to this stock option award vested as to 25% of the shares on March 8, 2011, and vest as
to the remainder of the shares in 36 equal monthly installments thereafter.

The shares subject to this stock option award vested as to 331/3% of the shares on January 21, 2010, and vest
as to the remainder of the shares in 24 equal monthly installments thereafter.

The shares subject to this stock option award vested as to 50% of the shares subject to the option on April 8,
2010, and vest as to the remainder of the shares in 24 equal monthly installments thereafter.

The shares subject to this stock option award vested as to 331/3% of the shares on February 27, 2010, and
vest as to the remainder of the shares in 24 equal monthly installments thereafter.

(5) Mr. Myers resigned as our President and a member of our Board effective January 14, 2011. In connection
with his resignation, Mr. Myers and the Company entered into a separation agreement pursuant to which he
is retained as a consultant to the Company for 12 months starting on February 1, 2011, his employment
termination date. The separation agreement provides for the outstanding stock options held by Mr. Myers
under the Company’s equity incentive plans to continue to vest during his consulting period in accordance
with their existing terms. Assuming his consulting period continues for 12 months, the Company will
accelerate the vesting of his outstanding stock options such that as of the last day of the consulting period,
Mr. Myers will vest in a number of shares subject to his stock options as if such options had continued to
vest pursuant to their terms for an additional six months after the end of the consulting period.

(6)

The shares subject to this stock option award vested as to 25% of the shares on December 1, 2010, and vest
as to the remainder of the shares in 36 equal monthly installments thereafter.

45

Executive Employment Agreements

We do not have an employment agreement in effect with any of our executive officers or employees. Like

other employees, our executives are eligible for annual salary increases and participation in our annual Bonus
Plan.

In connection with Ms. Falberg’s offer of employment, her initial compensation with us included an initial

base salary of $365,000, subject to annual review and adjustments, a hiring bonus of $30,000, and her
participation in our annual Bonus Plan for an annual bonus targeted at 40% of her base salary earned, dependent
on our achievement of corporate objectives, as determined by the Board. The offer letter also provided for the
grant of an option, subject to approval by our Compensation Committee, to purchase 100,000 shares of our
common stock under the 2007 Plan having an exercise price equal to the fair market value of the common stock
on the grant date. The option vests over four years, with 25% vesting one year after her employment start date
and the remainder vesting in equal monthly installments thereafter. Ms. Falberg is eligible to receive all benefits
extended to other similarly-situated employees at the Company, which include becoming a party to our Amended
and Restated Executive Change in Control and Severance Benefit Plan, which is described below.

Post-Termination Compensation

Amended and Restated Executive Change in Control and Severance Benefit Plan

General. In May 2007, the Board adopted a Change in Control and Severance Benefit Plan, effective May 1,

2007, or the Severance Benefit Plan, that provided for certain severance benefits to our non-executive officer
Vice Presidents in connection with specified termination events. In February 2009, the Board approved an
amendment and restatement of the Severance Benefit Plan (as so amended and restated, the Amended Severance
Benefit Plan), to include our named executive officers in the Amended Severance Benefit Plan and to modify the
severance payments for Senior Vice Presidents who were previously Vice Presidents and were therefore covered
by the Severance Benefit Plan as Vice Presidents. Prior to such amendment and restatement, only Vice Presidents
were covered by the Severance Benefit Plan. In addition, the plan was amended to clarify that no benefits would
be payable if a change of control resulted from arrangements with our then senior lenders.

Under the Amended Severance Benefit Plan, in the event that an officer’s employment terminates due to an

Involuntary Termination Without Cause or a Constructive Termination, each as defined in the Amended
Severance Benefit Plan, within 12 months following a Change in Control, as defined in the Amended Severance
Benefit Plan, and assuming all of the other conditions of the Amended Severance Benefit Plan are met, then each
officer who is a participant in the Amended Severance Benefit Plan would be entitled to the following benefits
under the Amended Severance Benefit Plan:

•

a single lump sum cash severance payment, payable on the first payroll date following the termination,
equal to the sum of:

•

(1) the officer’s base salary in effect during the last regularly scheduled payroll period
immediately preceding the termination (without, as a general matter, giving effect to any
voluntary pay reduction taken by the officer during the 12 months preceding the date of
termination), or the Applicable Base Salary, plus (2) the product of (i) the Applicable Base Salary
multiplied by (ii) the greater of any annual bonus, as a percentage of annual base salary paid in the
year of determination, paid to the officer in respect of either of the last two calendar years prior to
the date of termination (subject to an alternative calculation as well as a reduction for officers who
have not been employed for the entire calendar year prior to the date of termination), multiplied
by (iii) the quotient obtained by dividing: (a) the sum of the number of full months that an officer
is employed in the year of an applicable termination and 12, by (b) 12;

• multiplied by 150% for the Chairman and Chief Executive Officer or President (currently only
Mr. Cozadd after Mr. Myers’ resignation), 125% for Senior Vice Presidents (which currently
includes Ms. Falberg), or 100% for Vice Presidents;

46

•

•

full payment of all of the applicable COBRA premiums for any health, dental or vision plan sponsored
by the Company for a period of up to (i) 18 months for the Chairman and Chief Executive Officer or
President, (ii) 15 months for Senior Vice Presidents, and (iii) 12 months for Vice Presidents, provided
that the officer timely elects continued coverage; and

acceleration in full of the vesting and exercisability, and termination of any of our repurchase rights,
with respect to outstanding options and other equity awards held by the officers.

The double trigger for payment of benefits under the Amended Severance Benefit Plan was selected because

it was considered to be industry standard and appropriately protects our named executive officers and other
officers in the event of termination of their employment following a Change in Control, but not solely as a result
of a Change in Control. In addition, as a general matter, in order to be eligible to receive benefits under the
Amended Severance Benefit Plan, our named executive officers and other officers must execute a general waiver
and release of claims, and such release must become effective in accordance with its terms. All other benefits
(such as life insurance, disability coverage and 401(k) plan coverage) will terminate as of the officer’s
termination date (except to the extent that a conversion privilege may be available thereunder).

y
x
o
r
P

If any of the severance benefits payable under the Amended Severance Benefit Plan would constitute a
“parachute payment” within the meaning of Section 280G of the Code, subject to the excise tax imposed by
Section 4999 of the Code, a named executive officer may receive a reduced amount of the affected severance
benefits (the Amended Severance Benefit Plan does not provide for the gross up of any excise taxes imposed by
Section 4999 of the Code). No named executive officer would receive benefits under the Amended Severance
Benefit Plan if (i) the named executive officer has entered into an individually negotiated employment agreement
that provides for severance or change in control benefits, (ii) the named executive officer is entitled to receive
benefits under another severance benefit plan maintained by us, (iii) the named executive officer voluntarily
terminates employment with us to accept employment with another entity that is controlled, directly or indirectly,
by us or is otherwise affiliated with us or (iv) the named executive officer does not confirm in writing that he or
she is subject to agreements with us relating to proprietary and confidential information. In addition, benefits
would be terminated under the Amended Severance Benefit Plan if the named executive officer willfully
breaches his or her agreements with us relating to proprietary and confidential information or engages in certain
non-solicitation or business interference activities.

Potential Payments Upon Termination. The following table sets forth the potential severance payments and
benefits under the Amended Severance Benefit Plan to which the named executive officers would be entitled in
connection with specified termination events, as if the named executive officers’ employment had terminated as
of December 31, 2010. Other than as described above under “Proposal 3 Approval of the Internal Revenue Code
Section 162(m) Performance Criteria and Award Limits of the Company’s 2007 Equity Incentive Plan—Plan
Summary” and “—Summary of Compensation” and “—Narrative Disclosure to Summary Compensation Table”
with respect to the terms of Mr. Myers’ separation agreement, there are no other agreements, arrangements or
plans that entitle any named executive officers to severance, perquisites or other benefits upon termination of
employment or a change in control. For purposes of the below table, we have assumed that none of the potential
severance benefits payable under the Amended Severance Benefit Plan would be subject to the excise tax
imposed by Section 4999 of the Code and therefore would not be reduced in accordance with the terms of the
Amended Severance Benefit Plan.

47

POTENTIAL PAYMENTS UPON TERMINATION AS OF DECEMBER 31, 2010

Name

Benefit

Bruce C. Cozadd . . . . . . . . . . . . . . . . . . . . Lump Sum Cash Severance Payment

COBRA Payments
Vesting Acceleration(2)

Benefit Total

Robert M. Myers(3) . . . . . . . . . . . . . . . . . . . Lump Sum Cash Severance Payment

COBRA Payments
Vesting Acceleration(2)

Benefit Total

Kathryn E. Falberg(4)

. . . . . . . . . . . . . . . . . Lump Sum Cash Severance Payment

COBRA Payments
Vesting Acceleration(2)

Benefit Total

Involuntary Termination
Without Cause or
Constructive Termination in
Connection with a Change of
Control($)(1)

1,408,013
25,535
6,848,096

8,281,644

1,258,941
31,258
4,843,636

6,133,835

777,286
20,235
1,725,000

2,522,521

(1)

(2)

These benefits would be payable under the Amended Severance Benefit Plan if the Involuntary Termination
Without Cause or Constructive Termination occurred within 12 months following a Change in Control and
assuming such termination took place on December 31, 2010. The forms of option agreements adopted by
the Board under the 2007 Plan (and its predecessor plan) provide for the same vesting acceleration benefit as
shown here under the Amended Severance Benefit Plan, therefore no separate vesting acceleration benefit is
listed.

The value of stock option vesting acceleration is based on the closing stock price of $19.68 per share for our
common stock as reported on the NASDAQ Global Market on December 31, 2010, minus the exercise price
of the unvested option shares subject to acceleration.

(3) Mr. Myers resigned as our President and a member of our Board effective January 14, 2011 and his

employment with the Company terminated on February 1, 2011. See “—Summary of Compensation” and
“—Narrative Disclosure to Summary Compensation Table” above for a description of the benefits
Mr. Myers received under his separation agreement with the Company entered into in January 2011.

(4) Ms. Falberg joined the Company in December 2009 and did not receive an annual bonus for 2009. The

bonus component of her lump sum cash severance payment is calculated using average compensation of all
similarly situated employees at the Company.

Other Compensatory Arrangements

Employee Stock Purchase Plan

Additional long-term equity incentives are provided through our 2007 Employee Stock Purchase Plan, as
amended and restated, or the ESPP, in which all regular employees, including executive officers, employed by us
or by any of our affiliates may participate and may contribute, normally through payroll deductions, up to 15% of
their earnings for the purchase of our common stock under the ESPP. The ESPP is implemented through a series
of offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with a duration
of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will
have one or more purchase dates on which shares of our common stock will be purchased for employees
participating in the offering. Unless otherwise determined by the Board, common stock is purchased for accounts
of employees participating in the ESPP at a price per share equal to the lower of (a) 85% of the fair market value

48

of a share of our common stock on the first date of an offering or (b) 85% of the fair market value of a share of
our common stock on the date of purchase.

401(k) Plan

Our employees are eligible to participate in our 401(k) plan. Our 401(k) plan is intended to qualify as a tax

qualified plan under Section 401 of the Code. Our 401(k) plan provides that each participant may contribute a
portion of his or her pretax compensation, up to a statutory limit, which for most employees was $16,500 in 2010
(with a larger “catch up” limit for older employees). Employee contributions are held and invested by the plan’s
trustee. Our 401(k) plan also permits us to make discretionary contributions and matching contributions, subject
to established limits and a vesting schedule. To date, we have not made any contributions to the plan on behalf of
participating employees.

y
x
o
r
P

Additional Benefits

Executive officers are eligible to participate in all of the Company’s benefit plans, such as medical, dental,

vision short-term disability, long-term disability, group life insurance, Section 125 flexible spending accounts
and our employee stock purchase plan, in each case generally on the same basis as other employees. We also
have a flexible benefits healthcare plan and a flexible benefits childcare plan under which employees can set
aside pre-tax funds to pay for qualified health care expenses and qualified childcare expenses not reimbursed by
insurance.

Pension Benefits

Our named executive officers did not participate in, or otherwise receive any benefits under, any pension or

retirement plan sponsored by us during the year ended December 31, 2010.

Nonqualified Deferred Compensation

During the year ended December 31, 2010, our named executive officers did not contribute to, or earn any
amounts with respect to, any defined contribution or other plan sponsored by us that provides for the deferral of
compensation on a basis that is not tax-qualified.

DIRECTOR COMPENSATION

Cash Compensation Arrangements

Prior to July 2010, each member of our Board who was not an employee or an officer of the Company
received the following compensation for Board services, as applicable: (i) a $30,000 annual retainer for service
as a Board member; (ii) a $15,000 supplemental annual retainer for service as chair of the Audit Committee;
(iii) a $10,000 supplemental annual retainer for service as chair of the Compensation Committee; and (iv) a
$5,000 supplemental annual retainer for service as chair of each other committee of the Board. For purposes of
non-employee directors that were appointed or elected other than on August 15 of any given year, a pro-rata
portion of all cash retainers for the period from such non-employee director’s appointment or election to the next
subsequent August 15 was deemed earned and payable on the date of the first regularly scheduled meeting of the
Board that took place not less than 31 days following the date of such non-employee director’s appointment or
election (provided such date was in a “window period” as defined under the Company’s stock trading policy), or
in the event such date was not in a window period, the next subsequent date which was in a window period.
Payments of cash retainers were subject to a non-employee director’s election pursuant to our Directors Deferred
Compensation Plan. Any amounts deferred pursuant to our Directors Deferred Compensation Plan are credited to
a phantom stock account, as described below. Our non-employee directors are also reimbursed for their travel
and other reasonable expenses incurred in attending Board or committee meetings.

49

Our Board amended and restated our non-employee director compensation program in July 2010. Pursuant

to the amended compensation program, for periods beginning August 15, 2010, with each period from August 15
of any year until August 14 of the following year, each non-employee director who is providing Board services
prior to the start of a new period will receive the following cash compensation for his or her services, as
applicable, which amounts will be earned and payable in advance in two equal semi-annual installments on
August 15 of any year and February 15 of the following year:

•

•

•

a $35,000 annual retainer for service as a Board member for each period;

a supplemental annual retainer for each period for the Chairs in the following amounts: $20,000 for the
Chair of the Audit Committee; $15,000 for the Chair of the Compensation Committee; and $10,000 for
the Chair of the Nominating and Corporate Governance Committee; and

a supplemental annual retainer for each period for each member of the following committees other than
the Chairs, in the following amounts: $10,000 for members of the Audit Committee; $7,500 for
members of the Compensation Committee; $5,000 for members of the Nominating and Corporate
Governance Committee; and $5,000 for members of the Corporate Strategy Committee.

For a new director joining the Board on or after August 15 of any period, the cash compensation described

above will be earned and payable in advance on (1) the 31st day following the individual’s initial election or
appointment to the Board and (2) if such 31st day is prior to February 15 of the period in which he or she is first
elected or appointed, February 15 of such period. In addition, the cash compensation described above will be pro
rated for the then on-going period in which he or she is first elected or appointed based on the number of days the
director serves on the Board and each committee, as applicable (beginning with the date of the first Board
meeting the new director attends as a director on or after the date of his/her initial election or appointment to the
Board) until the next August 15. If the director is first entitled to a cash compensation prior to February 15 of a
period, the director would receive the pro-rated amount of the cash compensation for the on-going semi-annual
period in which he or she first attends such meeting, and the full semi-annual amount of the cash compensation
for the remaining semi-annual period on February 15. Notwithstanding the foregoing payment schedules, a
director is permitted to defer receipt of his or her cash compensation pursuant to Directors Deferred
Compensation Plan.

Directors Deferred Compensation Plan

In May 2007, our Board adopted the Directors Deferred Compensation Plan, which was first amended by
our Board in December 2008 and was then amended and restated by our Board in August 2010 (as so amended
and restated, the Directors Deferred Plan). The Directors Deferred Plan allows each non-employee director to
elect to defer receipt of all or a portion of his or her annual retainer fees to a future date or dates. Amounts
deferred under the Directors Deferred Plan are credited as shares of common stock to a phantom stock account,
the number of which are based on the amount of the retainer fees deferred divided by the market value of our
common stock on the first trading day of the first open window period following the date the retainer fees are
deemed earned. On the 10th business day following the day of separation from our Board or the occurrence of a
change in control, or as soon thereafter as practical once the non-employee director has provided the necessary
information for electronic deposit of shares of our common stock, each non-employee director will receive (or
commence receiving, depending upon whether the director has elected to receive distributions from his or her
phantom stock account in a lump sum or in installments over time) a distribution of his or her phantom stock
account, in shares of our common stock (i) reserved under our 2007 Non-Employee Directors Stock Option Plan
prior to August 15, 2010 and (ii) from a new reserve of 200,000 shares set up under our Directors Deferred Plan
after August 15, 2010. The Directors Deferred Plan may be amended or terminated at any time by our Board, and
in form and operation is intended to be compliant with Section 409A of the Code.

50

2007 Non-Employee Directors Stock Option Plan

Our 2007 Non-Employee Directors Stock Option Plan became effective in connection with our initial public

offering and was amended and restated by our Board in August 2010 (as so amended and restated, the 2007
Directors Plan). The 2007 Directors Plan provides for the automatic grant of nonstatutory stock options to
purchase shares of our common stock to our non-employee directors over their period of service on our Board.
The number of shares reserved for issuance under the 2007 Directors Plan automatically increases on each
January 1, from January 1, 2008 through January 1, 2017, by the sum of (a) the excess of (i) the number of shares
of common stock subject to options granted during the preceding calendar year under the 2007 Directors Plan,
over (ii) the number of shares added back to the share reserve under the 2007 Directors Plan during the preceding
calendar year and (b) for the automatic annual increases occurring on or prior to January 1, 2010 only, the
aggregate number of shares credited to our non-employee directors’ stock accounts under the Directors Deferred
Plan (or such lesser amount as may be approved by our Board).

y
x
o
r
P

Pursuant to the terms of the 2007 Directors Plan, any individual who first becomes a non-employee director
is automatically granted an option to purchase 30,000 shares of our common stock. Each initial option vests with
respect to one-third of the shares on the first anniversary of the date of grant, and the balance in a series of 24
successive equal monthly installments thereafter. In addition, each individual who is serving as a non-employee
director on the first trading day on or after August 15 of each year is automatically granted an option to purchase
12,500 shares of our common stock on such date. The shares subject to each such annual option vest in a series of
12 successive equal monthly installments measured from the date of grant. All stock options granted under the
2007 Directors Plan have a maximum term of ten years, and the exercise price of each option granted under the
2007 Directors Plan is equal to 100% of the fair market value of our common stock on the date of grant.

If a non-employee director’s service relationship with us, or any of our affiliates, whether as a

non-employee director or subsequently as an employee, director or consultant of ours or an affiliate, ceases for
any reason other than disability or death, or after any 12-month period following a change in control, the
optionee may exercise any vested options for a period of three months following the cessation of service. If such
an optionee’s service relationship with us, or any of our affiliates, ceases due to disability or death (or an
optionee dies within a certain period following cessation of service), the optionee or a beneficiary may exercise
the option for a period of 12 months in the event of disability, and 18 months in the event of death. If such an
optionee’s service terminates within 12 months following a specified change in control transaction, the optionee
may exercise the option for a period of 12 months following the effective date of such a transaction. The option
term may be extended in the event that exercise of the option following termination of service is prohibited by
applicable securities laws. In no event, however, may an option be exercised beyond the expiration of its term.

In the event of certain significant corporate transactions, all outstanding options under the 2007 Directors
Plan may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company).
If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such
options, then (a) with respect to any such options that are held by optionees then performing services for us or
our affiliates, the vesting and exercisability of such options will be accelerated in full and such options will be
terminated if not exercised prior to the effective date of the corporate transaction and (b) all other outstanding
options will terminate if not exercised prior to the effective date of the corporate transaction. Our Board may also
provide that the holder of an outstanding option not assumed in the corporate transaction will surrender such
option in exchange for a payment equal to the excess of (a) the value of the property that the optionee would have
received upon exercise of the option, over (b) the exercise price otherwise payable in connection with the option.
In addition, the vesting and exercisability of options held by non-employee directors who are either required to
resign their position in connection with a specified change in control transaction or are removed from their
position in connection with such a change in control will be accelerated in full.

51

Director Compensation Table

The following table sets forth certain information with respect to the compensation of all non-employee
directors of the Company for the fiscal year ended December 31, 2010. Mr. Cozadd, our Chairman and Chief
Executive Officer, and Mr. Myers, our former President and a former director, are not listed in the following
table since they are, or were, employees of the Company and did not receive any additional compensation for
serving on our Board or its committees.

2010 DIRECTOR COMPENSATION

Name

Fees Earned or
Paid in Cash or
Deferred Stock
($)(1)

Option Awards
($)(2)(3)

Total
($)

Paul L Berns(4)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Samuel D. Colella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bryan C. Cressey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patrick G. Enright
Michael W. Michelson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
James C. Momtazee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kenneth W. O’Keefe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alan M. Sebulsky . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
James B. Tananbaum, M.D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rick E. Winningham(5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nathaniel M. Zilkha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

27,168
26,250
22,500
25,000
25,000
25,000
27,500
25,000
21,250
28,466
17,500

239,827
73,219
73,219
73,219
73,219
73,219
73,219
73,219
73,219
295,684
73,219

266,995
99,469
95,719
98,219
98,219
98,219
100,719
98,219
94,469
324,150
90,719

(1) Represents 50% of fees payable for the compensation year that runs from August 15, 2010 to August 14,

2011, or the 2010 Compensation Year. The remaining 50% of fees payable for the 2010 Compensation Year
were earned by our non-employee directors on February 15, 2011 subject to their continuous service on the
Board. Pursuant to the current non-employee director compensation program, the total fees for each of our
non-employee directors are earned and payable in advance in two equal semi-annual installments on
August 15 and February 15 of each year subject to their continuous service as of such dates. Each director in
the table above, other than Messrs. Cressey and Winningham and Dr. Tananbaum, elected to defer his cash
retainer fees for the 2010 Compensation Year pursuant to the Directors Deferred Compensation Plan. The
number of shares credited to individual non-employee director phantom stock accounts under our Directors
Deferred Compensation Plan as of December 31, 2010 was as follows: 3,309 shares for Mr. Berns; 7,936
shares for Mr. Colella; 8,303 shares for Mr. Enright; 18,256 shares for Mr. Michelson; 15,881 shares for
Mr. Momtazee; 20,461 shares for Mr. O’Keefe; 14,453 shares for Mr. Sebulsky; and 12,861 shares for
Mr. Zilkha. The term of office for Mr. Zilkha will expire at our Annual Meeting on May 24, 2011 and the
outstanding shares then credited to his non-employee director phantom stock account will be distributed to
him in accordance with the terms of our Directors Deferred Compensation Plan.

(2)

(3)

The dollar amounts in this column represent the aggregate grant date fair value of all option awards granted
during the year ended December 31, 2010. These amounts have been calculated in accordance with ASC
718, using the Black-Scholes option-pricing model and excluding the effect of estimated forfeitures.
Assumptions used in the calculation of these amounts are included in the notes to the Company’s audited
consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2010 filed with the SEC on March 8, 2011. These amounts do not necessarily
correspond to the actual value that may be recognized by our directors.

The aggregate number of shares subject to outstanding stock options held by the directors listed in the table
above as of December 31, 2010 was as follows: 42,500 shares for each of Messrs. Berns, Colella, Cressey,
O’Keefe and Winningham and Dr. Tananbaum; 52,500 for Mr. Enright; 12,500 shares for each of
Messrs. Michelson, Momtazee and Zilkha; and 79,036 shares for Mr. Sebulsky.

52

y
x
o
r
P

(4) Mr. Berns joined the Board in June 2010. In addition to the fees earned for the 2010 Compensation Year, he
was also paid $5,918, the pro-rata portion of a $30,000 annual retainer for service as a director from his
appointment to August 15, 2010.

(5) Mr. Winningham joined the Board in May 2010. In addition to the fees earned for the 2010 Compensation
Year, he was also paid $8,466, the pro-rata portion of a $30,000 annual retainer for service as a director
from his appointment to August 15, 2010.

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Policy and Procedures for Review of Related Party Transactions

In 2007, we adopted a Related Party Transaction Policy that sets forth our procedures for the identification,

review, consideration and approval or ratification of “related-person transactions.” For purposes of our policy
only, a “related-person transaction” is a transaction, arrangement or relationship (or any series of similar
transactions, arrangements or relationships) in which the Company and any “related person” are, were or will be
participants in which the amount involves exceeds $120,000. Transactions involving compensation for services
provided to the Company as an employee or director are not covered by this policy. A “related person” is any
executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including
any of their immediate family members and any entity owned or controlled by such persons.

Under the policy, if a transaction has been identified as a related-person transaction (including any
transaction that was not a related-person transaction when originally consummated or any transaction that was
not initially identified as a related-person transaction prior to consummation), our management must present
information regarding the related-person transaction to our Audit Committee (or, if Audit Committee approval
would be inappropriate, to another independent body of our Board) for review, consideration and approval or
ratification. The presentation must include a description of, among other things, the material facts, the interests,
direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on
terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or
from employees generally. Under the policy, we will, on an annual basis, collect information that our General
Counsel deems reasonably necessary from each director, executive officer and (to the extent feasible) significant
stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the
terms of the policy. In addition, under our Code of Conduct, our employees and directors have an affirmative
responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a
conflict of interest to our General Counsel, or, if the employee is an executive officer, to our Board. In
considering related-person transactions, our Audit Committee (or other independent body of our Board) will take
into account the relevant available facts and circumstances including, but not limited to, the risks, costs and
benefits to us, the terms of the transaction, the availability of other sources for comparable services or products
and, if applicable the impact on a director’s independence in the event that the related person is a director,
immediate family member of a director or an entity with which a director is affiliated.

The policy requires that, in determining whether to approve, ratify or reject a related-person transaction, our

Audit Committee (or other independent body of our Board) must consider, in light of known circumstances,
whether the transaction is, or is not inconsistent with, our best interests and those of our stockholders, as our
Audit Committee (or other independent body of our Board) determines in the good faith exercise of its discretion.

We have regularly reviewed our Related Party Transaction Policy with input and advice from our outside

counsel and have determined that no changes or update to the policy was necessary to date.

53

Certain Transactions With or Involving Related Persons

Sales of Securities

July 2009 Private Placement. In July 2009, we sold an aggregate of 1,895,734 immediately separable units
in a private placement to certain entities affiliated with Longitude Capital Partners, LLC, or Longitude Capital,
with each unit consisting of one share of our common stock and a warrant to purchase 0.5 of a share of common
stock at a price per unit of $3.6925 for aggregate consideration of approximately $7.0 million. In the aggregate,
we issued and sold 1,895,734 shares of common stock and warrants to purchase up to an aggregate of 947,867
additional shares of common stock to the Longitude Capital purchasers pursuant to a securities purchase
agreement. Each warrant has an exercise price of $4.00 per share. We refer to these issuances below as the July
2009 Private Placement. Although the July 2009 Private Placement occurred after the adoption of our Related
Party Transaction Policy, our Related Party Transaction Policy did not require that we obtain prior approval of
this transaction by our Audit Committee (or other independent body of our Board) since at the time we entered
into the securities purchase agreement pursuant to which the July 2009 Private Placement was effected, neither
the Longitude Capital purchasers nor Patrick G. Enright, managing member of Longitude Capital and currently a
member of our Board, were “related persons” within the meaning of our Related Party Transaction Policy.
However, in accordance with our Related Party Transaction Policy, we submitted the July 2009 Private
Placement to the Audit Committee for review and ratification at their first regularly-scheduled meeting following
the transaction and the Audit Committee ratified the transaction in accordance with our Related Party
Transaction Policy.

2010 Common Stock Offering. In 2010 we issued 7,000,000 shares of our common stock in an underwritten

public offering of which 838,323 shares were purchased from the underwriter by Longitude Capital. The
remaining shares were purchased from the underwriter by third party investors on the same terms and conditions.
Longitude Capital was not involved in the negotiation or review of the terms of this offering. Longitude Capital’s
participation in this offering was reviewed and pre-approved by our Audit Committee in accordance with our
Related Party Transaction Policy. Our Board was also informed of Longitude Capital’s potential participation in
the offering when it approved the transaction.

Senior Secured Notes and Related Warrants

From March 2008 to June 2010, we had outstanding senior secured notes issued by JPI Commercial, LLC,

or JPIC, our wholly-owned subsidiary, in 2008, or the JPIC Notes, originally in the aggregate principal amount of
$120.0 million, of which $7.1 million in principal amount was held by KKR Financial Holdings III, LLC, or
KFN, an entity affiliated with Kohlberg Kravis Roberts & Co. L.P., which is a significant stockholder of ours.
During 2009, we made total interest payments under the JPIC Notes of $23.6 million, of which $1.3 million was
made to KFN.

In November 2009, we entered into an amendment and waiver agreement pursuant to which the holders of the

JPIC Notes waived our prior events of default under a senior secured note and warrant purchase agreement, or the
Senior Note Agreement, we entered into with such holders and the other agreements related thereto, and pursuant to
which the Senior Note Agreement was amended to, among other things, (i) require us to make certain scheduled
principal payments on the JPIC Notes totaling $40.0 million commencing on March 31, 2010 and ending on
March 31, 2011 and (ii) reduced the minimum cash balance required to be maintained by us under certain
circumstances. Pursuant to the amendment and waiver agreement, the warrants to purchase our common stock that
we issued in connection with the issuance of the senior secured notes by Orphan Medical, Inc., our other wholly-
owned subsidiary, in 2005, or the Orphan Notes, and the JPIC Notes were each amended to reduce the respective
exercise prices of such warrants, such that the exercise price of the warrants we issued in connection with the
issuance of the Orphan Notes, or the Orphan Warrants, was reduced from $20.36 to $9.34 per share. As of the date
of the amendment and waiver agreement, KFN held Orphan Warrants exercisable for 70,156 shares. The
amendment and waiver agreement also provides for certain amendments to our registration obligations with respect
to the JPIC Warrants. In addition, we agreed to pay to the holders of the JPIC Notes a restructuring fee totaling

54

$500,000, payable on the maturity date of the JPIC Notes (or upon earlier repayment in full of the JPIC Notes), of
which $28,500 was paid to KFN when we retired the JPIC Notes as discussed below. Although the issuance of the
JPIC Notes and our entry into the Senior Note Agreement in connection therewith (and the issuance of warrants to
purchase our common stock pursuant thereto) occurred after the adoption of our Related Party Transaction Policy,
our Related Party Transaction Policy did not require that we obtain approval or ratification of this transaction by our
Audit Committee (or other independent body of our Board) since at the time we entered into the transaction, KFN
did not purchase any additional notes or warrants in the transaction and KFN’s participation in the transaction was
limited to exchanging its Orphan Note for the same principal amount of JPIC Notes. Our Board was, however,
aware of KFN’s participation in the transaction when it approved the transaction.

In 2010, we retired all of the then outstanding JPIC Notes by repaying $119.5 million in their aggregate
principal amount, of which $6.8 million in principal amount was paid to KFN. For the period from January 1,
2010 until the date the JPIC Notes were extinguished, total interest payments under the JPIC Notes were $8.1
million, of which $461,000 was made to KFN. In addition to the restructuring fee discussed above, we paid
prepayment penalties to the holders of the JPIC Notes in 2010 totaling $8.0 million, of which $455,000 was paid
to KFN.

y
x
o
r
P

Indemnification Agreements

We have entered into indemnity agreements with each of our directors, executive officers and vice
presidents that require us to indemnify such persons against any and all expenses (including attorneys’ fees),
witness fees, judgments, fines, settlements and other amounts incurred (including expenses of a derivative action)
in connection with any action, suit or proceeding or alternative dispute resolution mechanism, inquiry hearing or
investigation, whether threatened, pending or completed, to which any such person may be made a party by
reason of the fact that such person is or was a director, an officer or an employee of us or any of our affiliated
enterprises, provided that such person’s conduct did not constitute a breach of his or her duty of loyalty to us or
our stockholders, and was not an act or omission not in good faith or which involved intentional misconduct or a
knowing violation of laws. The indemnity agreements also set forth certain procedures that will apply in the
event of a claim for indemnification thereunder. The indemnity agreements with certain of our directors further
provide that, with respect to a director that is serving on our Board at the direction of a venture or other
investment fund or entity, or fund, with respect to such indemnitee’s service as a director, officer, employee,
agent and/or fiduciary of the Company, our obligations under the indemnity agreement are the primary source of
indemnification and advancement, we are required to make all expense advances, and we are liable for all of such
indemnitee’s expenses, to the extent required by the indemnity agreement, our amended and restated certificate
of incorporation and amended and restated bylaws, without regard to any rights the indemnitee may have against
the fund, and we irrevocably waive, relinquishes and releases any and all claims against the fund for contribution,
subrogation or any other recovery of any kind in connection with our obligations under the indemnity agreement.
We believe that these agreements are necessary to attract and retain qualified persons as officers and directors of
the Company. We also maintain directors’ and officers’ liability insurance.

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (such as brokers) to satisfy the

delivery requirements for Notices and proxy materials with respect to two or more stockholders sharing the same
address by delivering a single Notice or a single set of proxy materials, as applicable, addressed to those
stockholders. This process, which is commonly referred to as “householding,” potentially means extra
convenience for stockholders and cost savings for companies.

A number of brokers with account holders who are the Company’s stockholders will be “householding”

Notices and our proxy materials. A single Notice or a single set of proxy materials, as applicable, may be
delivered to multiple stockholders sharing an address unless contrary instructions have been received from the

55

affected stockholders. Once you have received notice from your broker that it will be “householding”
communications to your address, “householding” will continue until you are notified otherwise or until you
revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to
receive a separate Notice or set of proxy materials, as applicable, in the future you may: (1) notify your broker,
(2) direct your written request to Jazz Pharmaceuticals, Inc., Attention: Investor Relations, at 3180 Porter Drive,
Palo Alto, California 94304 or (3) contact the Company’s Investor Relations department at (650) 496-3777.
Stockholders who currently receive multiple copies of Notices or proxy materials at their address and would like
to request “householding” of their communications should contact their broker. In addition, the Company will
promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of a
Notice or set of proxy materials to a stockholder at a shared address to which a single Notice or set of proxy
materials, as applicable, was delivered.

OTHER MATTERS

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any

other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the
accompanying proxy to vote on such matters in accordance with their best judgment.

By Order of the Board,

Carol A. Gamble
Senior Vice President, General Counsel
and Corporate Secretary

April 8, 2011

The Company will mail without charge, upon written request, a copy of the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2010, including the consolidated financial
statements, schedules and list of exhibits, and any particular exhibit specifically requested. Requests
should be sent to: Jazz Pharmaceuticals, Inc., Corporate Secretary, 3180 Porter Drive, Palo Alto,
California 94304. The Annual Report on Form 10-K is also available at www.jazzpharmaceuticals.com.

56

y
x
o
r
P

Annex A

JAZZ PHARMACEUTICALS, INC.
2007 EQUITY INCENTIVE PLAN

APPROVED BY THE BOARD: MAY 1, 2007
APPROVED BY THE STOCKHOLDERS: MAY 9, 2007
TERMINATION DATE: APRIL 30, 2017

1. GENERAL.

(a) Successor and Continuation of Prior Plan. The Plan is intended as the successor to and continuation

of the Company’s 2003 Equity Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional
stock awards shall be granted under the Prior Plan. Any shares remaining available for issuance pursuant to the
exercise of options or settlement of stock awards under the Prior Plan shall become available for issuance
pursuant to Stock Awards granted hereunder. Any shares subject to outstanding stock awards granted under the
Prior Plan that expire or terminate for any reason prior to exercise or settlement shall become available for
issuance pursuant to Stock Awards granted hereunder. On the Effective Date, all outstanding stock awards
granted under the Prior Plan shall be deemed to be stock awards granted pursuant to the Plan, but shall remain
subject to the terms of the Prior Plan with respect to which they were originally granted. All Stock Awards
granted subsequent to the effective date of this Plan shall be subject to the terms of this Plan.

(b) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees,

Directors and Consultants.

(c) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive

Stock Options, (ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards,
(v) Stock Appreciation Rights, (vi) Performance Stock Awards, and (vii) Other Stock Awards.

(d) Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of
persons eligible to receive Stock Awards as set forth in Section 1(b), to provide incentives for such persons to
exert maximum efforts for the success of the Company and any Affiliate, and to provide a means by which such
eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through
the granting of Stock Awards.

2. ADMINISTRATION.

(a) Administration by Board. The Board shall administer the Plan unless and until the Board delegates

administration of the Plan to a Committee or Committees, as provided in Section 2(c).

(b) Powers of Board. The Board shall have the power, subject to, and within the limitations of, the express

provisions of the Plan:

(i) To determine from time to time (A) which of the persons eligible under the Plan shall be granted

Stock Awards; (B) when and how each Stock Award shall be granted; (C) what type or combination of types of
Stock Award shall be granted; (D) the provisions of each Stock Award granted (which need not be identical),
including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to a
Stock Award; and (E) the number of shares of Common Stock with respect to which a Stock Award shall be
granted to each such person.

(ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and

revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any
defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it
shall deem necessary or expedient to make the Plan or Stock Award fully effective.

A-1

(iii) To settle all controversies regarding the Plan and Stock Awards granted under it.

(iv) To accelerate the time at which a Stock Award may first be exercised or the time during which a

Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the
Stock Award stating the time at which it may first be exercised or the time during which it will vest.

(v) To effect, at any time and from time to time, with the consent of any adversely affected Participant,

(1) the reduction of the exercise price of any outstanding Option or the strike price of any outstanding Stock
Appreciation Right; (2) the cancellation of any outstanding Option or Stock Appreciation Right and the grant in
substitution therefor of (a) a new Option or Stock Appreciation Right under the Plan or another equity plan of the
Company covering the same or different number of shares of Common Stock, (b) a Restricted Stock Award, (c) a
Restricted Stock Unit Award, (d) an Other Stock Award, (e) cash, and/or (f) other valuable consideration as
determined by the Board in its sole discretion; or (3) any other action that is treated as a repricing under generally
accepted accounting principles.

(vi) To suspend or terminate the Plan at any time. Suspension or termination of the Plan shall not

impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written
consent of the affected Participant.

(vii) To amend the Plan in any respect the Board deems necessary or advisable, including, without

limitation, relating to Incentive Stock Options and certain nonqualified deferred compensation under
Section 409A of the Code and/or to bring the Plan or Stock Awards granted under the Plan into compliance
therewith, subject to the limitations, if any, of applicable law. However, except as provided in Section 9(a)
relating to Capitalization Adjustments, stockholder approval shall be required for any amendment of the Plan that
either (i) materially increases the number of shares of Common Stock available for issuance under the Plan,
(ii) materially expands the class of individuals eligible to receive Stock Awards under the Plan, (iii) materially
increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of
Common Stock may be issued or purchased under the Plan, (iv) materially extends the term of the Plan, or
(v) expands the types of Stock Awards available for issuance under the Plan, but in each of (i) through (v) only to
the extent required by applicable law or listing requirements. Except as provided above, rights under any Stock
Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (i) the
Company requests the consent of the affected Participant, and (ii) such Participant consents in writing.

(viii) To submit any amendment to the Plan for stockholder approval, including, but not limited to,

amendments to the Plan intended to satisfy the requirements of (i) Section 162(m) of the Code and the
regulations thereunder regarding the exclusion of performance-based compensation from the limit on corporate
deductibility of compensation paid to Covered Employees, (ii) Section 422 of the Code regarding Incentive Stock
Options, or (iii) Rule 16b-3.

(ix) To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of

any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable than
previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not
subject to Board discretion; provided however, that, the rights under any Stock Award shall not be impaired by
any such amendment unless (i) the Company requests the consent of the affected Participant, and (ii) such
Participant consents in writing. Notwithstanding the foregoing, subject to the limitations of applicable law, if
any, the Board may amend the terms of any one or more Stock Awards without the affected Participant’s consent
if necessary to maintain the qualified status of the Stock Award as an Incentive Stock Option or to bring the
Stock Award into compliance with Section 409A of the Code and the related guidance thereunder.

(x) Generally, to exercise such powers and to perform such acts as the Board deems necessary or

expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan
or Stock Awards.

A-2

(xi) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in

the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the
United States.

(c) Delegation to Committee.

(i) General. The Board may delegate some or all of the administration of the Plan to a Committee or

Committees. If administration is delegated to a Committee, the Committee shall have, in connection with the
administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the
Committee, including the power to delegate to a subcommittee of the Committee any of the administrative
powers the Committee is authorized to exercise (and references in the Plan to the Board shall thereafter be to the
Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the
Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently
administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers
previously delegated.

y
x
o
r
P

(ii) Section 162(m) and Rule 16b-3 Compliance. In the sole discretion of the Board, the Committee

may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of
two or more Non-Employee Directors, in accordance with Rule 16b-3. In addition, the Board or the Committee,
in its sole discretion, may (A) delegate to a Committee who need not be Outside Directors the authority to grant
Stock Awards to eligible persons who are either (I) not then Covered Employees and are not expected to be
Covered Employees at the time of recognition of income resulting from such Stock Award, or (II) not persons
with respect to whom the Company wishes to comply with Section 162(m) of the Code, or (B) delegate to a
Committee who need not be Non-Employee Directors the authority to grant Stock Awards to eligible persons
who are not then subject to Section 16 of the Exchange Act.

(d) Delegation to Officers. The Board may delegate to one or more Officers the authority to do one or both
of the following (i) designate Officers and Employees of the Company or any of its Subsidiaries to be recipients
of Options (and, to the extent permitted by Delaware law, other Stock Awards) and the terms thereof, and
(ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such
Officers and Employees; provided, however, that the Board resolutions regarding such delegation shall specify
the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officers
and that such Officer may not grant a Stock Award to himself or herself. Notwithstanding anything to the
contrary in this Section 2(d), the Board may not delegate to an Officer authority to determine the Fair Market
Value of the Common Stock pursuant to Section 13(u)(iii) below.

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in
good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.

3.

SHARES SUBJECT TO THE PLAN.

(a) Share Reserve. Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the
aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards under the Plan shall
not exceed four million six hundred twenty-five thousand forty-two (4,625,042) shares, subject to reduction as
set forth below. Such share reserve consists of (i) the two million one hundred twenty-five thousand forty-two
(2,125,042) shares reserved for issuance under the Prior Plan, plus (ii) an additional two million five hundred
thousand (2,500,000) shares reserved for issuance under the Plan, but such aggregate number shall be reduced by
any unused shares of Common Stock remaining available on the Effective Date for the future grant of stock
awards under the Prior Plan. In addition, the number of shares of Common Stock available for issuance under the
Plan shall automatically increase on January 1st of each year commencing in 2008 and ending on (and including)
January 1, 2017, in an amount equal to the lesser of (i) four and one-half percent (4.5%) of the total number of
shares of Common Stock outstanding on December 31st of the preceding calendar year, or (ii) the number of
shares of stock (not to exceed three million (3,000,000) shares) determined by the Board of Directors.

A-3

Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year, to provide that there
shall be no increase in the share reserve for such calendar year or that the increase in the share reserve for such
calendar year shall be a lesser number of shares of Common Stock than would otherwise occur pursuant to the
preceding sentence. Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq
Rule 4350(i)(1)(A)(iii) or, if applicable, NYSE Listed Company Manual Section 303A.08, or AMEX Company
Guide Section 711 and such issuance shall not reduce the number of shares available for issuance under the Plan.

(b) Reversion of Shares to the Share Reserve. If any (i) Stock Award shall for any reason expire or

otherwise terminate, in whole or in part, without having been exercised in full, (ii) shares of Common Stock
issued to a Participant pursuant to a Stock Award are forfeited back to or repurchased by the Company because
of the failure to meet a contingency or condition required for the vesting of such shares, (iii) a Stock Award is
settled in cash, (iv) if any shares of Common Stock are cancelled in accordance with the cancellation and regrant
provisions of Section 3(b)(v), then the shares of Common Stock not issued under such Stock Award, or forfeited
to or repurchased by the Company, shall revert to and again become available for issuance under the Plan. If any
shares subject to a Stock Award are not delivered to a Participant because such shares are withheld for the
payment of taxes or the Stock Award is exercised through a reduction of shares subject to the Stock Award (i.e.,
“net exercised”) or an appreciation distribution in respect of a Stock Appreciation right is paid in shares of
Common Stock, the number of shares subject to the Stock Award that are not delivered to the Participant shall
remain available for subsequent issuance under the Plan. If the exercise price of any Stock Award is satisfied by
tendering shares of Common Stock held by the Participant (either by actual delivery or attestation), then the
number of shares so tendered shall remain available for issuance under the Plan.

(c) Incentive Stock Option Limit. Notwithstanding anything to the contrary in this Section 3(c), subject to
the provisions of Section 9(a) relating to Capitalization Adjustments the aggregate maximum number of shares of
Common Stock that may be issued pursuant to the exercise of Incentive Stock Options shall be four million six
hundred twenty-five thousand forty-two (4,625,042) shares of Common Stock plus the amount of any increase in
the number of shares that may be available for issuance pursuant to Stock Awards pursuant to Section 3(a).

(d) Source of Shares. The stock issuable under the Plan shall be shares of authorized but unissued or

reacquired Common Stock, including shares repurchased by the Company on the open market.

4. ELIGIBILITY.

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of
the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections
424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees,
Directors and Consultants.

(b) Ten Percent Stockholders. A Ten Percent Stockholder shall not be granted an Incentive Stock Option
unless the exercise price of such Option is at least one hundred ten percent (110%) of the Fair Market Value of
the Common Stock on the date of grant and the Option is not exercisable after the expiration of five (5) years
from the date of grant.

(c) Section 162(m) Limitation. Subject to the provisions of Section 9(a) relating to Capitalization

Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the
Code, no Employee shall be eligible to be granted during any calendar year Stock Awards whose value is
determined by reference to an increase over an exercise or strike price of at least one hundred percent (100%) of
the Fair Market Value of the Common Stock on the date the Stock Award is granted covering more than two
million (2,000,000) shares of Common Stock.

(d) Consultants. A Consultant shall be eligible for the grant of a Stock Award only if, at the time of grant, a
Form S-8 Registration Statement under the Securities Act (“Form S-8”) is available to register either the offer or
the sale of the Company’s securities to such Consultant.

A-4

5. OPTION PROVISIONS.

Each Option shall be in such form and shall contain such terms and conditions as the Board shall deem
appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at
the time of grant, and, if certificates are issued, a separate certificate or certificates shall be issued for shares of
Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an
Incentive Stock Option, then the Option shall be a Nonstatutory Stock Option. The provisions of separate
Options need not be identical; provided, however, that each Option Agreement shall conform to (through
incorporation of provisions hereof by reference in the Option Agreement or otherwise) the substance of each of
the following provisions:

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option shall be
exercisable after the expiration of ten (10) years from the date of its grant or such shorter period specified in the
Option Agreement.

y
x
o
r
P

(b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the
exercise price of each Option shall be not less than one hundred percent (100%) of the Fair Market Value of the
Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option
may be granted with an exercise price lower than one hundred percent (100%) of the Fair Market Value of the
Common Stock subject to the Option if such Option is granted pursuant to an assumption or substitution for
another option in a manner consistent with the provisions of Section 424(a) of the Code (whether or not such
options are Incentive Stock Options).

(c) Consideration. The purchase price of Common Stock acquired pursuant to the exercise of an Option

shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by
any combination of the methods of payment set forth below. The Board shall have the authority to grant Options
that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain
methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.
The methods of payment permitted by this Section 5(c) are:

(i) by cash, check, bank draft or money order payable to the Company;

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board
that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the
Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the
sales proceeds;

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;

(iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares

of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that
does not exceed the aggregate exercise price; provided, however, the Company shall accept a cash or other
payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied
by such reduction in the number of whole shares to be issued; provided, further, that shares of Common Stock
will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable
upon exercise are reduced to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the
Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or

(v) in any other form of legal consideration that may be acceptable to the Board in its sole discretion

and permissible under applicable law.

A-5

(d) Transferability of Options. The Board may, in its sole discretion, impose such limitations on the
transferability of Options as the Board shall determine. In the absence of such a determination by the Board to
the contrary, the following restrictions on the transferability of Options shall apply:

(i) Restrictions on Transfer. An Option shall not be transferable except by will or by the laws of

descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the
Optionholder; provided, however, that the Board may, in its sole discretion, permit transfer of the Option in a
manner that is not prohibited by applicable tax and securities laws upon the Optionholder’s request.

(ii) Domestic Relations Orders. Notwithstanding the foregoing, an Option may be transferred

pursuant to a domestic relations order, provided, however, that if an Option is an Incentive Stock Option, such
Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(iii) Beneficiary Designation. Notwithstanding the foregoing, the Optionholder may, by delivering

written notice to the Company, in a form provided by or otherwise satisfactory to the Company and any broker
designated by the Company to effect Option exercises, designate a third party who, in the event of the death of
the Optionholder, shall thereafter be entitled to exercise the Option. In the absence of such a designation, the
executor or administrator of the Optionholder’s estate shall be entitled to exercise the Option.

(e) Vesting of Options Generally. The total number of shares of Common Stock subject to an Option may
vest and therefore become exercisable in periodic installments that may or may not be equal. The Option may be
subject to such other terms and conditions on the time or times when it may or may not be exercised (which may
be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The
vesting provisions of individual Options may vary. The provisions of this Section 5(e) are subject to any Option
provisions governing the minimum number of shares of Common Stock as to which an Option may be exercised.

(f) Termination of Continuous Service. In the event that an Optionholder’s Continuous Service terminates
(other than upon the Optionholder’s death or Disability), the Optionholder may exercise his or her Option (to the
extent that the Optionholder was entitled to exercise such Option as of the date of termination of Continuous
Service) but only within such period of time ending on the earlier of (i) the date three (3) months following the
termination of the Optionholder’s Continuous Service (or such longer or shorter period specified in the Option
Agreement), or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after
termination of Continuous Service, the Optionholder does not exercise his or her Option within the time specified
herein or in the Option Agreement (as applicable), the Option shall terminate.

(g) Extension of Termination Date. An Optionholder’s Option Agreement may provide that if the exercise

of the Option following the termination of the Optionholder’s Continuous Service (other than upon the
Optionholder’s death or Disability) would be prohibited at any time solely because the issuance of shares of
Common Stock would violate the registration requirements under the Securities Act, then the Option shall
terminate on the earlier of (i) the expiration of a period of three (3) months after the termination of the
Optionholder’s Continuous Service during which the exercise of the Option would not be in violation of such
registration requirements, or (ii) the expiration of the term of the Option as set forth in the Option Agreement.

(h) Disability of Optionholder. In the event that an Optionholder’s Continuous Service terminates as a
result of the Optionholder’s Disability, the Optionholder may exercise his or her Option (to the extent that the
Optionholder was entitled to exercise such Option as of the date of termination of Continuous Service), but only
within such period of time ending on the earlier of (i) the date twelve (12) months following such termination of
Continuous Service (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of
the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the
Optionholder does not exercise his or her Option within the time specified herein or in the Option Agreement (as
applicable), the Option shall terminate.

(i) Death of Optionholder. In the event that (i) an Optionholder’s Continuous Service terminates as a result

of the Optionholder’s death, or (ii) the Optionholder dies within the period (if any) specified in the Option

A-6

Agreement after the termination of the Optionholder’s Continuous Service for a reason other than death, then the
Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of
death) by the Optionholder’s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by a person designated to exercise the option upon the Optionholder’s death, but only within the
period ending on the earlier of (i) the date eighteen (18) months following the date of death (or such longer or
shorter period specified in the Option Agreement), or (ii) the expiration of the term of such Option as set forth in
the Option Agreement. If, after the Optionholder’s death, the Option is not exercised within the time specified
herein or in the Option Agreement (as applicable), the Option shall terminate.

(j) Non-Exempt Employees. No Option granted to an Employee who is a non-exempt employee for
purposes of the Fair Labor Standards Act shall be first exercisable for any shares of Common Stock until at least
six months following the date of grant of the Option. The foregoing provision is intended to operate so that any
income derived by a non-exempt employee in connection with the exercise or vesting of an Option will be
exempt from his or her regular rate of pay.

y
x
o
r
P

6.

PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS.

(a) Restricted Stock Awards. Each Restricted Stock Award Agreement shall be in such form and shall

contain such terms and conditions as the Board shall deem appropriate. To the extent consistent with the
Company’s Bylaws, at the Board’s election, shares of Common Stock may be (x) held in book entry form subject
to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y) evidenced
by a certificate, which certificate shall be held in such form and manner as determined by the Board. The terms
and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and
conditions of separate Restricted Stock Award Agreements need not be identical, provided, however, that each
Restricted Stock Award Agreement shall conform to (through incorporation of the provisions hereof by reference
in the agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check,
bank draft or money order payable to the Company; (B) past or future services actually or to be rendered to the
Company or an Affiliate; or (C) any other form of legal consideration that may be acceptable to the Board in its
sole discretion and permissible under applicable law.

(ii) Vesting. Shares of Common Stock awarded under a Restricted Stock Award Agreement may be

subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.

(iii) Termination of Participant’s Continuous Service. In the event a Participant’s Continuous

Service terminates, the Company may receive via a forfeiture condition or a repurchase right, any or all of the
shares of Common Stock held by the Participant which have not vested as of the date of termination of
Continuous Service under the terms of the Restricted Stock Award Agreement.

(iv) Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award
Agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the
Restricted Stock Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock
awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock
Award Agreement.

(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement shall be in such form
and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of
Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of
separate Restricted Stock Unit Award Agreements need not be identical, provided, however, that each Restricted
Stock Unit Award Agreement shall conform to (through incorporation of the provisions hereof by reference in
the agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the

consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the

A-7

Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common
Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be
acceptable to the Board in its sole discretion and permissible under applicable law.

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such
restrictions or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems
appropriate.

(iii) Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common

Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the
Board and contained in the Restricted Stock Unit Award Agreement.

(iv) Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as

it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common
Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such
Restricted Stock Unit Award.

(v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of Common
Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted
Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted
into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as
determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason
of such dividend equivalents will be subject to all the terms and conditions of the underlying Restricted Stock
Unit Award Agreement to which they relate.

(vi) Termination of Participant’s Continuous Service. Except as otherwise provided in the
applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not
vested will be forfeited upon the Participant’s termination of Continuous Service.

(vii) Compliance with Section 409A of the Code. Notwithstanding anything to the contrary set forth

herein, any Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of
Section 409A of the Code shall incorporate terms and conditions necessary to avoid the consequences of
Section 409A(a)(1) of the Code. Such restrictions, if any, shall be determined by the Board and contained in the
Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award.

(c) Stock Appreciation Rights. Each Stock Appreciation Right Agreement shall be in such form and shall

contain such terms and conditions as the Board shall deem appropriate. Stock Appreciation Rights may be
granted as stand-alone Stock Awards or in tandem with other Stock Awards. The terms and conditions of Stock
Appreciation Right Agreements may change from time to time, and the terms and conditions of separate Stock
Appreciation Right Agreements need not be identical; provided, however, that each Stock Appreciation Right
Agreement shall conform to (through incorporation of the provisions hereof by reference in the agreement or
otherwise) the substance of each of the following provisions:

(i) Term. No Stock Appreciation Right shall be exercisable after the expiration of ten (10) years from

the date of its grant or such shorter period specified in the Stock Appreciation Right Agreement.

(ii) Strike Price. Each Stock Appreciation Right will be denominated in shares of Common Stock

equivalents. The strike price of each Stock Appreciation Right shall not be less than one hundred percent
(100%) of the Fair Market Value of the Common Stock equivalents subject to the Stock Appreciation Right on
the date of grant.

(iii) Calculation of Appreciation. The appreciation distribution payable on the exercise of a Stock

Appreciation Right will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value

A-8

(on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common Stock equal to
the number of share of Common Stock equivalents in which the Participant is vested under such Stock
Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right on such
date, over (B) the strike price.

(iv) Vesting. At the time of the grant of a Stock Appreciation Right, the Board may impose such
restrictions or conditions to the vesting of such Stock Appreciation Right as it, in its sole discretion, deems
appropriate.

(v) Exercise. To exercise any outstanding Stock Appreciation Right, the Participant must provide

written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right
Agreement evidencing such Stock Appreciation Right.

y
x
o
r
P

(vi) Payment. The appreciation distribution in respect of a Stock Appreciation Right may be paid in
Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by
the Board and set forth in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right.

(vii) Termination of Continuous Service. In the event that a Participant’s Continuous Service

terminates, the Participant may exercise his or her Stock Appreciation Right (to the extent that the Participant
was entitled to exercise such Stock Appreciation Right as of the date of termination of Continuous Service) but
only within such period of time ending on the earlier of (A) the date three (3) months following the termination
of the Participant’s Continuous Service (or such longer or shorter period specified in the Stock Appreciation
Right Agreement), or (B) the expiration of the term of the Stock Appreciation Right as set forth in the Stock
Appreciation Right Agreement. If, after termination of Continuous Service, the Participant does not exercise his
or her Stock Appreciation Right within the time specified herein or in the Stock Appreciation Right Agreement
(as applicable), the Stock Appreciation Right shall terminate.

(viii) Compliance with Section 409A of the Code. Notwithstanding anything to the contrary set forth

herein, any Stock Appreciation Rights granted under the Plan that are not exempt from the requirements of
Section 409A of the Code shall incorporate terms and conditions necessary to avoid the consequences described
in Section 409A(a)(1) of the Code. Such restrictions, if any, shall be determined by the Board and contained in
the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right.

(d) Performance Stock Awards. A Performance Stock Award is either a Restricted Stock Award or
Restricted Stock Unit Award that may be granted or may vest based upon the attainment during a Performance
Period of certain Performance Goals. A Performance Stock Award may, but need not, require the completion of a
specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be
achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals
have been attained shall be conclusively determined by the Committee in its sole discretion. The maximum
benefit to be received by any Participant in a calendar year attributable to Performance Stock Awards described
in this Section 6(d) shall not exceed the value of two million (2,000,000) shares of Common Stock. In addition,
to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that
cash may be used in payment of Performance Stock Awards.

(e) Other Stock Awards. Other forms of Stock Awards valued in whole or in part by reference to, or

otherwise based on, Common Stock may be granted either alone or in addition to Stock Awards provided for
under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board
shall have sole and complete authority to determine the persons to whom and the time or times at which such
Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to
be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.

A-9

7. COVENANTS OF THE COMPANY.

(a) Availability of Shares. During the terms of the Stock Awards, the Company shall keep available at all

times the number of shares of Common Stock required to satisfy such Stock Awards.

(b) Securities Law Compliance. The Company shall seek to obtain from each regulatory commission or
agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue
and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking
shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common
Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to
obtain from any such regulatory commission or agency the authority that counsel for the Company deems
necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from
any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until
such authority is obtained.

(c) No Obligation to Notify. The Company shall have no duty or obligation to any holder of a Stock Award
to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company shall
have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a
Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or
obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.

8. MISCELLANEOUS.

(a) Use of Proceeds. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall

constitute general funds of the Company.

(b) Corporate Action Constituting Grant of Stock Awards. Corporate action constituting a grant by the

Company of a Stock Award to any Participant shall be deemed completed as of the date of such corporate action,
unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the
Stock Award is communicated to, or actually received or accepted by, the Participant.

(c) Stockholder Rights. No Participant shall be deemed to be the holder of, or to have any of the rights of a

holder with respect to, any shares of Common Stock subject to such Stock Award unless and until (i) such
Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms, and (ii) the
issuance of the Common Stock pursuant to such exercise has been entered into the books and records of the
Company.

(d) No Employment or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or other
instrument executed thereunder or in connection with any Stock Award granted pursuant to the Plan shall confer
upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the
time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the
employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant
pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a
Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate
law of the state in which the Company or the Affiliate is incorporated, as the case may be.

(e) Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value

(determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are
exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and
any Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed
such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options,
notwithstanding any contrary provision of the applicable Option Agreement(s).

(f) Investment Assurances. The Company may require a Participant, as a condition of exercising or
acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as

A-10

y
x
o
r
P

to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser
representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and
business matters and that he or she is capable of evaluating, alone or together with the purchaser representative,
the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the
Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s
own account and not with any present intention of selling or otherwise distributing the Common Stock. The
foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (x) the
issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been
registered under a then currently effective registration statement under the Securities Act, or (y) as to any
particular requirement, a determination is made by counsel for the Company that such requirement need not be
met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to
the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting
the transfer of the Common Stock.

(g) Withholding Obligations. Unless prohibited by the terms of a Stock Award Agreement, the Company

may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award
by any of the following means (in addition to the Company’s right to withhold from any compensation paid to
the Participant by the Company) or by a combination of such means: (i) causing the Participant to tender a cash
payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise
issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common
Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such
lower amount as may be necessary to avoid classification of the Stock Award as a liability for financial
accounting purposes); (iii) withholding cash from a Stock Award settled in cash; (iv) withholding payment from
any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock
Award Agreement.

(h) Electronic Delivery. Any reference herein to a “written” agreement or document shall include any

agreement or document delivered electronically or posted on the Company’s intranet.

(i) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine
that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a
portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to
be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code.
Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an
employee. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual
percentages, Participants may receive payments, including lump sum payments, following the Participant’s
termination of employment or retirement, and implement such other terms and conditions consistent with the
provisions of the Plan and in accordance with applicable law.

(j) Compliance with Section 409A. To the extent that the Board determines that any Stock Award granted

under the Plan is subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock
Award shall incorporate the terms and conditions necessary to avoid the consequences described in
Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements shall be
interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other
interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that
may be issued or amended after the Effective Date. Notwithstanding any provision of the Plan to the contrary, in
the event that following the Effective Date the Board determines that any Stock Award may be subject to
Section 409A of the Code and related Department of Treasury guidance (including such Department of Treasury
guidance as may be issued after the Effective Date), the Board may adopt such amendments to the Plan and the
applicable Stock Award Agreement or adopt other policies and procedures (including amendments, policies and
procedures with retroactive effect), or take any other actions, that the Board determines are necessary or

A-11

appropriate to (1) exempt the Stock Award from Section 409A of the Code and/or preserve the intended tax
treatment of the benefits provided with respect to the Stock Award, or (2) comply with the requirements of
Section 409A of the Code and related Department of Treasury guidance.

9. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board shall appropriately

and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to
Section 3(a); (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of
Incentive Stock Options pursuant to Section 3(c); (iii) the class(es) and maximum number of securities that may
be awarded to any person pursuant to Section 4(c) and 6(d); and (iv) the class(es) and number of securities and
price per share of stock subject to outstanding Stock Awards. The Board shall make such adjustments, and its
determination shall be final, binding and conclusive.

(b) Dissolution or Liquidation. Except as otherwise provided in a Stock Award Agreement, in the event of

a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting
of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right
of repurchase) shall terminate immediately prior to the completion of such dissolution or liquidation, and the
shares of Common Stock subject to the Company’s repurchase rights may be repurchased by the Company
notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided,
however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested,
exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not
previously expired or terminated) before the dissolution or liquidation is completed but contingent on its
completion.

(c) Corporate Transaction. The following provisions shall apply to Stock Awards in the event of a
Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other
written agreement between the Company or any Affiliate and the holder of the Stock Award or unless otherwise
expressly provided by the Board at the time of grant of a Stock Award. Except as otherwise stated in the Stock
Award Agreement, in the event of a Corporate Transaction, then, notwithstanding any other provision of the
Plan, the Board shall take one or more of the following actions with respect to Stock Awards, contingent upon
the closing or completion of the Corporate Transaction:

(i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring

corporation’s parent company) to assume or continue the Stock Award or to substitute a similar stock award for
the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the
stockholders of the Company pursuant to the Corporate Transaction);

(ii) arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect

of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or
the surviving or acquiring corporation’s parent company);

(iii) accelerate the vesting of the Stock Award (and, if applicable, the time at which the Stock Award

may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board shall determine
(or, if the Board shall not determine such a date, to the date that is five (5) days prior to the effective date of the
Corporate Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the
effective time of the Corporate Transaction;

(iv) arrange for the lapse of any reacquisition or repurchase rights held by the Company with respect to

the Stock Award;

(v) cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised
prior to the effective time of the Corporate Transaction, in exchange for such cash consideration as the Board, in
its sole discretion, may consider appropriate; and

A-12

(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of

(A) the value of the property the holder of the Stock Award would have received upon the exercise of the Stock
Award, over (B) any exercise price payable by such holder in connection with such exercise.

The Board need not take the same action with respect to all Stock Awards or with respect to all Participants.

(d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and
exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such
Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and
the Participant. A Stock Award may vest as to all or any portion of the shares subject to the Stock Award
(i) immediately upon the occurrence of a Change in Control, whether or not such Stock Award is assumed,
continued, or substituted by a surviving or acquiring entity in the Change in Control, or (ii) in the event a
Participant’s Continuous Service is terminated, actually or constructively, within a designated period following
the occurrence of a Change in Control. In the absence of such provisions, no such acceleration shall occur.

y
x
o
r
P

10. TERMINATION OR SUSPENSION OF THE PLAN.

(a) Plan Term. The Board may suspend or terminate the Plan at any time. Unless terminated sooner, the
Plan shall terminate on the day before the tenth (10th) anniversary of the earlier of (i) the date the Plan is adopted
by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Stock Awards may be
granted under the Plan while the Plan is suspended or after it is terminated.

(b) No Impairment of Rights. Suspension or termination of the Plan shall not impair rights and obligations

under any Stock Award granted while the Plan is in effect except with the written consent of the affected
Participant.

11. EFFECTIVE DATE OF PLAN.

The Plan shall become effective on the IPO Date, but no Stock Award shall be exercised (or, in the case of a

Restricted Stock Award, Restricted Stock Unit Award, or Other Stock Award shall be granted) unless and until
the Plan has been approved by the Stockholders of the Company, which approval shall be within twelve
(12) months before or after the date the Plan is adopted by the Board.

12. CHOICE OF LAW.

The law of the State of Delaware shall govern all questions concerning the construction, validity and

interpretation of this Plan, without regard to that state’s conflict of laws rules.

13. DEFINITIONS.

As used in the Plan, the following definitions shall apply to the capitalized terms indicated below:

(a) “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such

terms are defined in Rule 405 of the Securities Act. The Board shall have the authority to determine the time or
times at which “parent” or “subsidiary” status is determined within the foregoing definition.

(b) “Board” means the Board of Directors of the Company.

(c) “Capitalization Adjustment” means any change that is made in, or other events that occur with respect

to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the
receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend,

A-13

combination of shares, exchange of shares, change in corporate structure or other transaction not involving the
receipt of consideration by the Company). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company shall not be treated as a transaction “without the receipt of consideration” by the
Company.

(d) “Cause” means with respect to a Participant, the occurrence of any of the following events: (i) such
Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the
laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in,
a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any
contract or agreement between the Participant and the Company or of any statutory duty owed to the Company;
(iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets;
or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous
Service is either for Cause or without Cause shall be made by the Company in its sole discretion. Any
determination by the Company that the Continuous Service of a Participant was terminated with or without
Cause for the purposes of outstanding Stock Awards held by such Participant shall have no effect upon any
determination of the rights or obligations of the Company or such Participant for any other purpose.

(e) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions,

of any one or more of the following events:

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company

representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding
securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a
Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company
by an investor, any affiliate thereof or any other Exchange Act Person from the Company in a transaction or
series of related transactions the primary purpose of which is to obtain financing for the Company through the
issuance of equity securities or (B) solely because the level of Ownership held by any Exchange Act Person (the
“Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of
a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding,
provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the
acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the
Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred,
increases the percentage of the then outstanding voting securities Owned by the Subject Person over the
designated percentage threshold, then a Change in Control shall be deemed to occur;

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or

indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar
transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting
power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent
(50%) of the combined outstanding voting power of the parent of the surviving Entity in such merger,
consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the
outstanding voting securities of the Company immediately prior to such transaction;

(iii) the stockholders of the Company approve or the Board approves a plan of complete dissolution or

liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur,
except for a liquidation into a parent corporation;

(iv) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all

of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other
disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity,
more than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by
stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting
securities of the Company immediately prior to such sale, lease, license or other disposition; or

A-14

(v) individuals who, on the date the Plan is adopted by the Board, are members of the Board (the

“Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board;
provided, however, that if the appointment or election (or nomination for election) of any new Board member
was approved or recommended by a majority vote of the members of the Incumbent Board then still in office,
such new member shall, for purposes of the Plan, be considered as a member of the Incumbent Board.

For avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other

transaction effected exclusively for the purpose of changing the domicile of the Company.

Notwithstanding the foregoing or any other provision of the Plan, the definition of Change in Control (or

any analogous term) in an individual written agreement between the Company or any Affiliate and the
Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement;
provided, however, that if no definition of Change in Control or any analogous term is set forth in such an
individual written agreement, the foregoing definition shall apply.

y
x
o
r
P

The Board may, in its sole discretion and without a Participant’s consent, amend the definition of “Change

in Control” to conform to the definition of “Change in Control” under Section 409A of the Code, and the
regulations thereunder.

(f) “Code” means the Internal Revenue Code of 1986, as amended.

(g) “Committee” means a committee of one (1) or more Directors to whom authority has been delegated by

the Board in accordance with Section 2(c).

(h) “Common Stock” means the common stock of the Company.

(i) “Company” means Jazz Pharmaceuticals, Inc., a Delaware corporation.

(j) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the
board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or
payment of a fee for such service, shall not cause a Director to be considered a “Consultant” for purposes of the
Plan.

(k) “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as

an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the
Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in
the entity for which the Participant renders such service, provided that there is no interruption or termination of
the Participant’s service with the Company or an Affiliate, shall not terminate a Participant’s Continuous Service;
provided, however, if the Entity for which a Participant is rendering services ceases to qualify as an “Affiliate,”
as determined by the Board in its sole discretion, such Participant’s Continuous Service shall be considered to
have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the
Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether
Continuous Service shall be considered interrupted in the case of: (i) any leave of absence approved by the Board
or the chief executive officer of the Company, including sick leave, military leave or any other personal leave; or
(ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of
absence shall be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as
may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence
agreement or policy applicable to the Participant, or as otherwise required by law.

(l) “Corporate Transaction” means the occurrence, in a single transaction or in a series of related

transactions, of any one or more of the following events:

(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion,

of the consolidated assets of the Company and its Subsidiaries;

A-15

(ii) a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the

Company;

(iii) the consummation of a merger, consolidation or similar transaction following which the Company

is not the surviving corporation; or

(iv) the consummation of a merger, consolidation or similar transaction following which the Company

is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger,
consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise.

(m) “Covered Employee” means the chief executive officer and the four (4) other highest compensated

officers of the Company for whom total compensation is required to be reported to stockholders under the
Exchange Act, as determined for purposes of Section 162(m) of the Code.

(n) “Director” means a member of the Board.

(o) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be
expected to result in death or can be expected to last for a continuous period of not less than 12 months, as
provided in Section 22(e)(3) and 409A(a)(2)(c)(i) of the Code.

(p) “Effective Date” means the effective date of the Plan as set forth in Section 11.

(q) “Employee” means any person employed by the Company or an Affiliate. However, service solely as a

Director, or payment of a fee for such services, shall not cause a Director to be considered an “Employee” for
purposes of the Plan.

(r) “Entity” means a corporation, partnership, limited liability company or other entity.

(s) “Exchange Act” means the Securities Exchange Act of 1934, as amended.

(t) “Exchange Act Person” means any natural person, Entity or “group” (within the meaning of
Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (i) the
Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of
the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company
or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of
such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially
the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner,
directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined
voting power of the Company’s then outstanding securities.

(u) “Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i) If the Common Stock is listed on any established stock exchange or traded on the Nasdaq Global

Select Market or the Nasdaq Global Market, the Fair Market Value of a share of Common Stock shall be the
closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange (or
the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination,
as reported in The Wall Street Journal or such other source as the Board deems reliable.

A-16

(ii) If the Common Stock is listed or traded on the Nasdaq Capital Market, the Fair Market Value of a

share of Common Stock shall be the mean between the bid and asked prices for the Common Stock on the date of
determination, as reported in The Wall Street Journal or such other source as the Board deems reliable. Unless
otherwise provided by the Board, if there is no closing sales price (or closing bid if no sales were reported) for
the Common Stock on the date of determination, then the Fair Market Value shall be the mean between the bid
and asked prices for the Common Stock on the last preceding date for which such quotation exists.

(iii) In the absence of such markets for the Common Stock, the Fair Market Value shall be determined

by the Board in good faith and in a manner that complies with Section 409A of the Code.

(v) “Incentive Stock Option” means an Option which qualifies as an “incentive stock option” within the

meaning of Section 422 of the Code and the regulations promulgated thereunder.

y
x
o
r
P

(w) “IPO Date” means the date of the underwriting agreement between the Company and the underwriter(s)
managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the
initial public offering.

(x) “Non-Employee Director” means a Director who either (i) is not a current employee or officer of the
Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an
Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as
to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the
Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure
would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which
disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-
employee director” for purposes of Rule 16b-3.

(y) “Nonstatutory Stock Option” means an Option that does not qualify as an Incentive Stock Option.

(z) “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the

Exchange Act and the rules and regulations promulgated thereunder.

(aa) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of

Common Stock granted pursuant to the Plan.

(bb) “Option Agreement” means a written agreement between the Company and an Optionholder

evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and
conditions of the Plan.

(cc) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable,

such other person who holds an outstanding Option.

(dd) “Other Stock Award” means an award based in whole or in part by reference to the Common Stock

which is granted pursuant to the terms and conditions of Section 6(d).

(ee) “Other Stock Award Agreement” means a written agreement between the Company and a holder of an

Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock
Award Agreement shall be subject to the terms and conditions of the Plan.

(ff) “Outside Director” means a Director who either (i) is not a current employee of the Company or an

“affiliated corporation” (within the meaning of Treasury Regulations promulgated under Section 162(m) of the

A-17

Code), is not a former employee of the Company or an “affiliated corporation” who receives compensation for
prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an
officer of the Company or an “affiliated corporation,” and does not receive remuneration from the Company or
an “affiliated corporation,” either directly or indirectly, in any capacity other than as a Director, or (ii) is
otherwise considered an “outside director” for purposes of Section 162(m) of the Code.

(gg) “Own,” “Owned,” “Owner,” “Ownership” A person or Entity shall be deemed to “Own,” to have
“Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly
or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting
power, which includes the power to vote or to direct the voting, with respect to such securities.

(hh) “Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable,

such other person who holds an outstanding Stock Award.

(ii) “Performance Criteria” means the one or more criteria that the Board shall select for purposes of

establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to
establish such Performance Goals may be based on any one of, or combination of, the following: (i) earnings per
share; (ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and
amortization (EBITDA); (iv) total stockholder return; (v) return on equity; (vi) return on assets, investment, or
capital employed; (vii) operating margin; (viii) gross margin; (ix) operating income; (x) net income (before or
after taxes); (xi) net operating income; (xii) net operating income after tax; (xiii) pre- and after-tax income;
(xiv) pre-tax profit; (xv) operating cash flow; (xvi) sales or revenue targets; (xvii) orders and revenue;
(xviii) increases in revenue or product revenue; (xix) expenses and cost reduction goals; (xx) improvement in or
attainment of expense levels; (xxi) improvement in or attainment of working capital levels; (xxii) economic value
added (or an equivalent metric); (xxiii) market share; (xxiv) cash flow; (xxv) cash flow per share; (xxvi) share
price performance; (xxvii) debt reduction; (xxviii) implementation or completion of projects or processes;
(xxix) customer satisfaction; (xxx) stockholders’ equity; (xxxi) quality measures; and (xxxii) to the extent that a
Stock Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected
by the Board. Partial achievement of the specified criteria may result in the payment or vesting corresponding to
the degree of achievement as specified in the Stock Award Agreement. The Board shall, in its sole discretion,
define the manner of calculating the Performance Criteria it selects to use for such Performance Period.

(jj) “Performance Goals” means, for a Performance Period, the one or more goals established by the Board

for the Performance Period based upon the satisfaction of the Performance Criteria. Performance Goals may be
based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business
segments, and in either absolute terms or relative to the performance of one or more comparable companies or
the performance of one or more relevant indices. At the time of the grant of any Stock Award, the Board is
authorized to determine whether, when calculating the attainment of Performance Goals for a Performance
Period: (i) to exclude restructuring and/or other nonrecurring charges; (ii) to exclude exchange rate effects, as
applicable, for non-U.S. dollar denominated net sales and operating earnings; (iii) to exclude the effects of
changes to generally accepted accounting standards required by the Financial Accounting Standards Board;
(iv) to exclude the effects of any statutory adjustments to corporate tax rates; and (v) to exclude the effects of any
“extraordinary items” as determined under generally accepted accounting principles. In addition, the Board
retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of
Performance Goals.

(kk) “Performance Period” means one or more periods of time, which may be of varying and overlapping

duration, as the Committee may select, over which the attainment of one or more Performance Goals will be
measured for the purpose of determining a Participant’s right to and the payment of a Performance Stock Award.

(ll) “Performance Stock Award” means an award of shares of Common Stock which is granted pursuant to

the terms and conditions of Section 6(d).

A-18

(mm) “Plan” means this Jazz Pharmaceuticals, Inc. 2007 Equity Incentive Plan.

(nn) “Prior Plan” means the Company’s 2003 Equity Incentive Plan as in effect immediately prior to the

Effective Date.

(oo) “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to

the terms and conditions of Section 6(a).

(pp) “Restricted Stock Award Agreement” means a written agreement between the Company and a holder

of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each
Restricted Stock Award Agreement shall be subject to the terms and conditions of the Plan.

y
x
o
r
P

(qq) “Restricted Stock Unit Award” means a right to receive shares of Common Stock which is granted

pursuant to the terms and conditions of Section 6(b).

(rr) “Restricted Stock Unit Award Agreement” means a written agreement between the Company and a

holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award
grant. Each Restricted Stock Unit Award Agreement shall be subject to the terms and conditions of the Plan.

(ss) “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3,

as in effect from time to time.

(tt) “Securities Act” means the Securities Act of 1933, as amended.

(uu) “Stock Appreciation Right” means a right to receive the appreciation on Common Stock that is granted

pursuant to the terms and conditions of Section 6(c).

(vv) “Stock Appreciation Right Agreement” means a written agreement between the Company and a holder

of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each
Stock Appreciation Right Agreement shall be subject to the terms and conditions of the Plan.

(ww) “Stock Award” means any right to receive Common Stock granted under the Plan, including an
Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance
Stock Award, or any Other Stock Award.

(xx) “Stock Award Agreement” means a written agreement between the Company and a Participant
evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to
the terms and conditions of the Plan.

(yy) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than fifty percent
(50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors
of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation
shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or
indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which
the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital
contribution) of more than fifty percent (50%) .

(zz) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to

Section 424(d) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of
all classes of stock of the Company or any Affiliate.

A-19

[THIS PAGE INTENTIONALLY LEFT BLANK]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

(Mark One)
È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

1934

‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

OF 1934

For the fiscal year ended December 31, 2010
or

For the transition period from

to

Commission File Number: 001-33500

JAZZ PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

05-0563787
(I.R.S. Employer Identification No.)

3180 Porter Drive
Palo Alto, CA 94304
(650) 496-3777
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common Stock, par value $0.0001 per share

Name of each exchange on which registered

The NASDAQ Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:
None

K
-
0
1
m
r
o
F

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities

Act. Yes ‘ No È

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the

Act. Yes ‘ No È

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes È No ‘

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files). Yes ‘ No ‘

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not

be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. È

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of
the Exchange Act.

Large accelerated filer ‘ Accelerated filer È Non-accelerated filer ‘

Smaller reporting company È

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ‘ No È
The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant as of June 30, 2010, based upon
the last sale price reported for such date on the NASDAQ Global Market, was $146,122,278. The calculation of the aggregate market value
of voting and non-voting stock excludes 20,188,209 shares of the registrant’s common stock held by executive officers, directors, and
stockholders that the registrant has concluded are affiliates of the registrant. Exclusion of such shares should not be construed to indicate
that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant
or that such person is controlled by or under common control with the registrant.

As of February 28, 2011, a total of 40,294,596 shares of the registrant’s Common Stock, $0.0001 par value, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive Proxy Statement for the 2011 Annual Meeting of Stockholders to be filed with the Securities and

Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are
incorporated by reference in Part III, Items 10-14 of this Form 10-K.

JAZZ PHARMACEUTICALS, INC.
2010 ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

PART I

Item 1.

Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 1A.

Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 1B.

Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 2.

Item 3.

Item 4.

Item 5.

Item 6.

Item 7.

Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(Removed and Reserved) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART II

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Selected Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Management’s Discussion and Analysis of Financial Condition and Results of Operations . . .

Item 7A. Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 8.

Item 9.

Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure . . .

Item 9A.

Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 9B.

Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART III

Item 10.

Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 11.

Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 13.

Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . . .

Item 14.

Principal Accounting Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 15.

Exhibits and Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART IV

Page

3

3

21

41

41

42

43

44

44

46

48

61

62

63

63

65

65

65

65

65

65

65

66

66

73

In this report, “Jazz Pharmaceuticals,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals, Inc. and its
consolidated subsidiaries. We own or have rights to various copyrights, trademarks, and trade names used in our
business, including the following: Jazz Pharmaceuticals®; Xyrem® (sodium oxybate) oral solution; Luvox CR®
(fluvoxamine maleate) Extended-Release Capsules; and Luvox® (fluvoxamine maleate). This report also includes
trademarks, service marks, and trade names of other companies.

2

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our
management’s beliefs and assumptions and on information currently available to our management. In some
cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,”
“would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential” and similar
expressions intended to identify forward-looking statements. These statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results, performance, time frames or achievements to
be materially different from any future results, performance, time frames or achievements expressed or implied
by the forward-looking statements. We discuss many of these risks, uncertainties and other factors in this Annual
Report on Form 10-K in greater detail under the heading “Risk Factors.” Given these risks, uncertainties and
other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-
looking statements represent our estimates and assumptions only as of the date of this filing. You should read this
Annual Report on Form 10-K completely and with the understanding that our actual future results may be
materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary
statements. Except as required by law, we assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-
looking statements, even if new information becomes available in the future.

K
-
0
1
m
r
o
F

Item 1.

Business

Overview

PART I

We are a specialty pharmaceutical company focused on the identification, development and

commercialization of pharmaceutical products to meet important unmet medical needs. Since we were founded
in 2003, we have built a commercial and development organization and assembled a portfolio of products and
product candidates that currently includes our two marketed products, which generated net product sales of
$170.0 million in 2010, and product candidates in various stages of clinical development. We currently market
two products: Xyrem (sodium oxybate), which is the only product approved by the United States Food and Drug
Administration, or FDA, for the treatment of both cataplexy and excessive daytime sleepiness in patients with
narcolepsy; and Luvox CR (fluvoxamine maleate) marketed for the treatment of obsessive compulsive disorder.
We promote these products in the United States through our experienced specialty sales force targeting sleep
specialists, neurologists, pulmonologists and psychiatrists. We are building our portfolio of products through a
combination of internal development, acquisition and in-licensing activities. Our current product candidates are
JZP-6 (sodium oxybate) for the treatment of fibromyalgia, JZP-8 (intranasal clonazepam) for the treatment of
acute repetitive seizures in epilepsy, and solid oral dosage forms of sodium oxybate.

We are building a sustainable pharmaceutical company by:

•

•

•

Growing and protecting our sodium oxybate business, including growing sales of Xyrem in its
approved indications, continuing to invest in our franchise, and enforcing our intellectual property
covering sodium oxybate and our restricted distribution system;

Developing additional products and advancing our pipeline though continued investment in research
and development activities targeted at areas of significant unmet need where our product candidates
may offer significant benefits to patients; and

Leveraging our commercial capabilities, including our sales and marketing organization, and our
regulatory, safety and clinical organizations, by in-licensing or acquiring additional products and
product candidates targeted towards specialty physician audiences.

3

Marketed Products

Xyrem (sodium oxybate) oral solution

Xyrem is a sodium oxybate oral solution approved in the United States for the treatment of excessive
daytime sleepiness and cataplexy in patients with narcolepsy. Sodium oxybate, the active pharmaceutical
ingredient in Xyrem, is a formulation of the sodium salt of γ-hydroxybutyrate, an endogenous neurotransmitter
and metabolite of γ-aminobutyric acid. Xyrem is the only treatment approved by the FDA for both excessive
daytime sleepiness and cataplexy in patients with narcolepsy. Xyrem was approved for the treatment of cataplexy
in patients with narcolepsy in 2002, and was approved for its second indication, the treatment of excessive
daytime sleepiness in patients with narcolepsy, in 2005. The American Academy of Sleep Medicine recommends
Xyrem as a standard of care for the treatment of both excessive daytime sleepiness and cataplexy associated with
narcolepsy.

Narcolepsy is a chronic neurologic disorder caused by the brain’s inability to regulate sleep-wake cycles.
The primary symptoms of narcolepsy include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-
onset and waking hallucinations and fragmented nighttime sleep. These symptoms can lead to a variety of
complications, such as limitations on education and employment opportunities, driving or machinery accidents,
difficulties at work resulting in disability, forced retirement or job dismissal and depression. Excessive daytime
sleepiness is the most common symptom of narcolepsy and is present in all narcolepsy patients. Excessive
daytime sleepiness is a chronic, pervasive sleepiness that triggers sudden irresistible and overwhelming urges to
sleep (inadvertent naps and sleep attacks). Cataplexy, the sudden loss of muscle tone, can be one of the most
debilitating symptoms of narcolepsy. Cataplexy is present in between 60% and 100% of patients with narcolepsy.
Cataplexy can range from slight weakness or a drooping of the face to the complete loss of muscle tone and it is
often triggered by strong emotional reactions such as laughter, anger or surprise. Cataplexy can severely impair a
patient’s quality of life and ability to function.

According to the National Institutes of Health, 150,000 to 200,000 individuals in the United States are
affected by narcolepsy; however, the National Heart Lung and Blood Institute estimates that only approximately
25% of those patients have been diagnosed with narcolepsy. Xyrem is currently being used to treat approximately
8,000 to 9,000 patients in the United States, and we believe there are additional patients with narcolepsy and
cataplexy and/or excessive daytime sleepiness who could benefit from treatment with Xyrem.

We are developing solid oral dosage forms for sodium oxybate, which is currently administered as a twice

nightly liquid. Our objective is to improve patient convenience and compliance.

In 2010, our net product sales of Xyrem were $142.6 million.

Commercialization and Distribution

We promote Xyrem in the United States through our specialty sales force. Our marketing, sale and
distribution of Xyrem are subject to a risk management plan which was required in conjunction with Xyrem’s
approval by the FDA.

Under the Xyrem risk management plan, the Xyrem Success Program®, Xyrem is distributed through a
single central pharmacy, Express Scripts Specialty Distribution Services and its affiliate Curascript, Inc., or
Express Scripts, with which we have an exclusive relationship. The central pharmacy maintains physician and
patient registries, and the product may not be stocked in retail pharmacies. Each physician and patient receives
materials concerning the risks and benefits of the product before the physician can prescribe, or a patient can
receive, Xyrem. Whenever a prescription is received by the central pharmacy, the central pharmacy verifies the
prescription and obtains additional information by contacting the patient’s insurance company. The central
pharmacy also speaks with the patient before it ships any Xyrem to the patient. The central pharmacy ships the
product directly to the patient by a courier service, and the patient or his/her designee signs for the package. The
initial shipment may only be for a one-month supply and physicians may only prescribe up to six months of
supply of Xyrem at one time.

4

K
-
0
1
m
r
o
F

Pursuant to our exclusive agreement, Express Scripts distributes Xyrem and provides customer support
services related to the sale and marketing of Xyrem in the United States. Our agreement, which has been in effect
since July 2002, expires on June 30, 2012, subject to automatic one-year extensions until either party provides
notice to the other of its intent to terminate the agreement at least 120 days prior to the end of the then current
term. Under the agreement, we own all of the standard operating procedures, business rules and intellectual
property, and the agreement provides for Express Scripts to assist in the orderly transfer of the services Express
Scripts provides to us and the related intellectual property, including that of the patient database, to any new
pharmacy we engage.

Outside the United States, we have licensed to UCB Pharma Limited, or UCB, the exclusive right to market

Xyrem for the treatment of narcolepsy in 54 countries in exchange for milestone and royalty payments to us.
UCB currently markets the product in 15 countries in Europe. We are entitled to commercial milestone payments
from UCB of up to $6.0 million specifically associated with UCB’s sales of Xyrem for the treatment of
narcolepsy and royalties on all commercial sales of Xyrem by UCB. The term of our agreement with UCB, as it
applies to Xyrem for the treatment of narcolepsy, extends to the later of the expiration of our associated patent
rights in the territories covered by the agreement or ten years from the date of European Medicines Agency, or
EMA, approval to commercially promote and distribute Xyrem for the treatment of narcolepsy, subject to
automatic extension unless and until UCB terminates the agreement. UCB may terminate our agreement for any
reason upon 12 months’ notice. We are responsible for supplying Xyrem to UCB in exchange for supply price
payments. We have licensed to Valeant Canada Limited, or Valeant, the Canadian marketing rights to Xyrem for
the treatment of narcolepsy. We supply Xyrem to UCB and Valeant.

Xyrem is a controlled substance in the United States and, therefore its manufacturing and distribution are
highly restricted. Quotas from the United States Drug Enforcement Administration, or DEA, are required in order
to manufacture and package sodium oxybate. Since the DEA typically grants quota on an annual basis and
requires a detailed submission and justification for the request, obtaining a DEA quota is a difficult and time
consuming process. The final product and active pharmaceutical ingredient are manufactured for us by single
source contract manufacturers.

Intellectual Property

The FDA has granted Xyrem orphan drug status in the United States for excessive daytime sleepiness in
patients with narcolepsy, which provides marketing exclusivity in the United States until November 2012 for this
indication. Xyrem is covered by nine patents, of which seven are listed in the FDA’s approved drug products
with therapeutic equivalence evaluation document, or Orange Book. Of the patents listed in the Orange Book,
two are formulation patents expiring in 2020 and four are method of use patents covering the distribution of
Xyrem, three of which expire in 2024 and one of which expires in 2022. We have an additional method of use
patent covering Xyrem’s use in narcolepsy which expires in 2019. A process patent and a distribution system
patent not listed in the Orange Book also cover the product and expire in 2019 and 2024, respectively. In addition
to our issued patents, we have a number of patent applications covering Xyrem pending. On October 18, 2010,
we received a Paragraph IV Patent certification notice, or Paragraph IV certification, from Roxane Laboratories,
Inc., or Roxane, indicating that it had filed an abbreviated new drug application, or ANDA, with the FDA
requesting approval to market a generic version of Xyrem. On November 22, 2010, we filed a lawsuit against
Roxane in response to Roxane’s Paragraph IV certification in the United States District Court for the District of
New Jersey. For a description of this matter and related risks, please see “Item 3. Legal Proceedings” and
“Item 1A. Risk Factors” under the heading “If generic products that compete with Xyrem are approved, sales of
Xyrem may be adversely affected.”

Luvox CR (fluvoxamine maleate) Extended-Release Capsules

We market Luvox CR for the treatment of obsessive compulsive disorder. Luvox CR received FDA
approval in 2008. Luvox CR incorporates the SODAS™ drug delivery technology, developed by Elan Pharma
International Limited, or Elan, which is designed to minimize peak-to-trough plasma fluctuations over a 24-hour
period and enable once-a-day dosing.

5

Obsessive compulsive disorder is a chronic anxiety disorder characterized by persistent, unwanted thoughts,

or obsessions, and repetitive behaviors or rituals, or compulsions. According to the National Institute of Mental
Health, obsessive compulsive disorder affects approximately 2.2 million adults in the United States. According to
an article published in the International Journal of Clinical Practice, it is estimated that 60% of patients with
obsessive compulsive disorder worldwide receive no treatment for their disorder. Patients with obsessive
compulsive disorder use rituals to help control anxiety related to their obsessive thoughts, and these rituals
become disruptive to their daily life.

We licensed the rights to market Luvox CR in the United States from Solvay Pharmaceuticals, Inc., or
Solvay, which was subsequently acquired by Abbott Laboratories, or Abbott. Solvay assigned to us its rights and
obligations under its license and supply agreement with Elan, and we sublicensed back to Solvay the rights under
that agreement outside of the United States. Under a supply agreement with Abbott, we are responsible for
purchasing, and Abbott is responsible for providing us with, the active pharmaceutical ingredient necessary to
manufacture Luvox CR. We are responsible for providing the active pharmaceutical ingredient free of charge to
Elan under the license and supply agreement with Elan. Elan has the right and obligation to manufacture the
worldwide commercial requirements of Luvox CR. We are responsible for satisfying Abbott’s commercial
requirements of Luvox CR outside of the United States in exchange for supply price payments to us. Luvox CR
is not currently marketed outside the United States. Under the terms of the license agreement as amended, we
have paid Abbott $39.0 million through 2010 and we owe Abbott $4.5 million in 2011 and $5.0 million in 2012.
If we pay these amounts when due, the payments due in 2012 will decrease to $4.5 million. We have also agreed
to pay Abbott $5.0 million in 2015 if our net sales of Luvox CR reach a cumulative amount of $100 million on or
before December 31, 2014 and no AB-rated generic version of Luvox CR has been or is being sold in the United
States as of December 31, 2014.

Our license and supply agreements with Abbott will remain in force until terminated by either Abbott or us

as a result of an uncured breach by the other party. The license and supply agreement with Elan that was assigned
to us by Solvay will expire upon the later of (i) 10 years after commercial launch of Luvox CR or (ii) the last to
expire patent licensed under the agreement with Elan. In addition, either we or Elan may terminate the license
agreement in the event of an uncured material breach or in the event of a change of ownership of the other party
in excess of 40% or an acquisition of 20% or more of the equity of the other party by a third party offering
competing products.

The FDA approval for Luvox CR also included an indication for social anxiety disorder. We have been in
discussions with the FDA about removing the social anxiety disorder indication from the label, and we expect
that, if the indication is removed, the obligation to complete the remaining Phase IV studies in social anxiety
disorder patients will also terminate.

Intellectual Property

Luvox CR is covered by a patent owned by Elan with claims covering the orally administered formulation

of extended-release fluvoxamine that requires the release of fluvoxamine over a period of not less than 12 hours.
This patent is listed in the Orange Book, and expires in 2020. In August 2009, we received a Paragraph IV
Certification from Actavis Elizabeth, LLC, or Actavis, advising that Actavis had filed an ANDA with the FDA
seeking approval to market a generic version of Luvox CR. In September 2009, we received an additional
Paragraph IV Patent Certification notice from Anchen Pharmaceuticals, Inc., or Anchen, advising that Anchen
has filed an ANDA with the FDA for a generic version of Luvox CR. We and Elan filed lawsuits in response to
the Paragraph IV certifications. In August 2010, we and Elan entered into settlement agreements with Anchen
and granted a sublicense to Anchen of our rights to have manufactured, market and sell a generic version of
Luvox CR. The sublicense will commence on February 15, 2013 or earlier upon the occurrence of certain events.
The lawsuit against Actavis is pending in the United States District Court for the District of Delaware. For a
more detailed description of our disputes with Anchen and Actavis, please see “Item 3. Legal Proceedings.”

6

Clinical Development Pipeline

We have a number of product candidates in various stages of clinical development. In 2010, 2009 and 2008

we spent $25.6 million, $36.6 million and $70.0 million, respectively, on research and development activities.

JZP-6 (sodium oxybate)

Our most advanced product candidate is JZP-6, which uses sodium oxybate, the active pharmaceutical
ingredient in Xyrem, for the treatment of fibromyalgia, which is a chronic condition characterized by widespread
pain. According to the American College of Rheumatology, approximately two to four percent of the U.S.
population suffers from fibromyalgia. Fibromyalgia is believed to be a central nervous system condition,
resulting from neurological changes in how the brain perceives and responds to pain. In addition to pain, the
main symptoms are fatigue, disturbed sleep and morning stiffness.

We completed two randomized, double-blind, placebo-controlled Phase III pivotal clinical trials and a long-

term safety trial as part of the development program for JZP-6 in fibromyalgia. These studies demonstrated
positive results and were used in support of our new drug application, or NDA, filed with the FDA. In our trials,
sodium oxybate was generally well tolerated, with the majority of adverse events reported being mild to
moderate in nature.

K
-
0
1
m
r
o
F

Our NDA for JZP-6 was accepted for filing by the FDA in February 2010. The FDA’s Arthritis Advisory
Committee and Drug Safety and Risk Management Advisory Committee reviewed JZP-6 at a joint meeting in
August 2010 and voted 20-2 against approval of the NDA as submitted. In October 2010, the FDA sent us a
complete response letter, or CRL, stating that the FDA cannot approve the NDA in its present form. In the letter,
the FDA discussed a number of topics, including the need for additional clinical studies, the appropriate patient
population, methods for ensuring safe use, the proposed Risk Evaluation and Mitigation Strategy, or REMS,
program, concentration of the formulation and the trade name for the product. We have had additional
communications with the FDA, but have not yet finalized our plans with respect to JZP-6. We do not currently
know the timing or cost of the continued development of JZP-6, if its development will be continued, or whether
the NDA for JZP-6 will be approved by the FDA.

UCB has the right to market JZP-6 for the treatment of fibromyalgia in 54 countries outside the United
States. UCB has submitted an application to the European Medicines Agency for approval to market and promote
JZP-6, and if it is approved, we are entitled to a milestone payment of up to $25 million, royalties on UCB’s sales
of JZP-6 and additional commercial milestone payments of up to $100 million. No product has been approved in
Europe for the treatment of fibromyalgia. The term of our agreement with UCB, as it applies to JZP-6, extends to
the later of the expiration of our associated patent rights in the territories covered by the agreement or ten years
from the date of EMA approval to commercially promote and distribute the product for the treatment of
fibromyalgia, subject to automatic extension unless UCB provides 12 months’ notice. UCB may terminate our
agreement for any reason upon 12 months’ notice and may terminate its rights to JZP-6 for the treatment of
fibromyalgia on six months’ notice at any time prior to the receipt of marketing approval of JZP-6 for
fibromyalgia in the European Union. We are responsible for supplying JZP-6 to UCB in exchange for supply
price payments.

JZP-8 (intranasal clonazepam)

We are developing JZP-8, an intranasal formulation of clonazepam, for the treatment of acute repetitive

seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens. Acute
repetitive seizures are bouts of multiple seizures occurring over a short period of time. According to an article
published in the New England Journal of Medicine, approximately 30% of epilepsy patients are unresponsive, or
refractory, to treatment despite being on an effective dose of an antiepilepsy regimen, and a subset of these
refractory patients experience acute repetitive seizures. Currently available treatment options are limited for
patients who experience acute repetitive seizures.

7

We have received orphan drug designation from the FDA for this product candidate. We completed a
Phase II clinical trial of JZP-8 to evaluate the safety and efficacy of two dosage strengths, and the preliminary
findings were encouraging. We subsequently conducted additional formulation activities and a pharmacokinetic
study during 2010 which resulted in plasma concentrations that were dose proportional. We are currently
planning for an additional Phase II study for later in 2011.

Sales and Marketing

As of February 28, 2011, we had a specialty sales force consisting of approximately 120 full-time sales
professionals, which includes our Specialty Sales Consultants, Regional Sales Managers, and Area Business
Directors, who currently promote Xyrem and Luvox CR. Our sales force calls primarily on sleep specialists,
psychiatrists, neurologists and pulmonologists.

We have established marketing, commercial operations and account management, and trade and distribution

departments to support our sales efforts. We also employ third party vendors, such as advertising agencies,
market research firms and suppliers of marketing and other sales support related services to assist with our
commercial activities.

Competition

The pharmaceutical industry is highly competitive and characterized by a number of established, large
pharmaceutical companies as well as specialty pharmaceutical companies that market psychiatry and neurology
products. Most of these companies have financial resources and marketing capabilities substantially greater than
ours. Our ability to continue to grow over the long-term also requires that we compete successfully with other
specialty pharmaceutical companies for product and product candidate acquisition and in-licensing opportunities.
Some of these competitors include Cephalon, Inc., Shire Pharmaceuticals, Inc., Endo Pharmaceuticals Holdings,
Inc. and Forest Laboratories, Inc. These established companies may have a competitive advantage over us due to
their size and financial resources.

Our products and product candidates may also compete in the future with new products currently under
development by others. Any products that we develop are likely to be in a highly competitive market, and many
of our competitors may succeed in developing products that may render our products obsolete or noncompetitive.
In particular, our most significant marketed product and late-stage product candidates face competition as
described below:

•

Xyrem. Xyrem is the only product approved for the treatment of both cataplexy and excessive daytime
sleepiness in patients with narcolepsy. No products other than Xyrem are approved for the treatment of
cataplexy. The only other products approved by the FDA for the treatment of excessive daytime
sleepiness in patients with narcolepsy are Provigil® (modafinil) and Nuvigil® (armodafinil), which are
marketed by Cephalon. Provigil and Nuvigil are also approved for the treatment of excessive daytime
sleepiness in patients with obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder.
Xyrem is often used in conjunction with stimulants and wakefulness promoting drugs, which are
administered during the day. During the pivotal Phase III trials of Xyrem for use in patients with
narcolepsy, approximately 80% of patients maintained concomitant stimulant use.

As an alternative to Xyrem, cataplexy is often treated with tricyclic antidepressants and selective
serotonin or norepinephrine reuptake inhibitors, although these products are not approved by the FDA
for the treatment of cataplexy. Tricyclic antidepressants are a class of antidepressant drugs first used in
the 1950s. The use of these drugs can often result in somnolence, which exacerbates the excessive
daytime sleepiness already experienced by all patients with narcolepsy.

•

Luvox CR. The market for drugs to treat obsessive compulsive disorder is very fragmented. We believe
that, in addition to Luvox CR, a large number of branded and generic drugs are used for the treatment

8

of this disorder. Seven branded products, including Luvox CR, and generic equivalents of many of
these, have been approved by the FDA for the treatment of obsessive compulsive disorder, and we
believe that other products are regularly used to treat this disorder. We believe that none of these
products has a significant percentage of the market.

The presence in a particular patient of more than one psychiatric condition is an important
consideration by physicians in the selection of drugs to treat obsessive compulsive disorder. Certain
drugs are approved for one or more well recognized psychiatric disorders such as major depressive
disorder, which may give them broader recognition and use by physicians and patients than Luvox CR,
which is indicated only for the treatment of obsessive compulsive disorder and social anxiety disorder.

•

Product Candidates. With respect to our current and potential future product candidates, we believe
that our ability to successfully compete will depend on, among other things:

-

-

-

-

-

-

-

-

the timing and scope of regulatory approvals;

efficacy, safety and reliability of our product candidates;

product acceptance by physicians, other health care providers and patients;

protection of our proprietary rights and the level of generic competition;

obtaining reimbursement for product use in approved indications;

our ability to supply commercial quantities of a product to the market;

our ability to recruit and retain skilled employees; and

our ability to expand and grow our specialty sales force.

K
-
0
1
m
r
o
F

Customers and Financial Information about Geographic Areas

In the United States, Xyrem is sold to one specialty pharmacy which ships Xyrem directly to patients.
Luvox CR is sold primarily to distributors who distribute the product to pharmacies. During 2010, the specialty
pharmacy for Xyrem was Express Scripts, and the principal distributors for Luvox CR in the United States were
Cardinal Health, McKesson and AmerisourceBergen. Outside the United States, UCB Pharma is our principal
distributor for Xyrem. We do not have rights to Luvox CR outside the United States.

Information on total revenues attributed to domestic and foreign sources is included in Note 14 to our

consolidated financial statements.

Manufacturing

We do not have, and do not intend to establish in the near term, our own manufacturing capability for our

products or product candidates, or their active pharmaceutical ingredients, or the capability to package our
products. We have entered into manufacturing and supply agreements with third parties for Xyrem and Luvox
CR. For each of our marketed and approved products, we utilize a single supplier for the active pharmaceutical
ingredient and a separate drug product manufacturer.

In April 2010, we entered into an agreement with a new supplier for sodium oxybate, Siegfried (USA) Inc.,

or Siegfried. We intend to seek FDA approval of Siegfried as our supplier as soon as possible. We expect
Siegfried to be approved by the FDA as a supplier in the second half of 2011; however we cannot be certain that
this will occur. We have the right to purchase a portion of our worldwide requirements of sodium oxybate from
other suppliers. The agreement with Siegfried expires in April 2015, subject to automatic three-year extensions
until either party provides notice to the other of its intent to terminate the agreement at least 18 months before the
end of the then current term. We can also terminate the agreement upon 30 days’ notice on or after December 31,
2011 if Siegfried has not obtained the required approvals to manufacture sodium oxybate or obtained

9

manufacturing quota for sodium oxybate from the DEA for the calendar year 2011. During the term of the
agreement and, under certain circumstances for 18 months after the agreement terminates, Siegfried is not
permitted to manufacture sodium oxybate for any other company.

Our 2010 supplies of sodium oxybate were manufactured under an exclusive agreement by Lonza, Inc., or

Lonza. Lonza formally notified us in March 2010 that our agreement for the supply of sodium oxybate would
terminate on December 31, 2011. Under the agreement, Lonza has an obligation to meet our sodium oxybate
supply needs through 2011. We believe that our current inventory levels of sodium oxybate are sufficient to meet
our needs for 2011; we expect our new supplier, Siegfried, to obtain quota and manufacture supplies to meet our
2012 needs.

We have an agreement with Patheon Pharmaceuticals, or Patheon, which became effective in 2008, under

which we have agreed to purchase, and Patheon has agreed to supply, our worldwide supply of Xyrem. The
initial term of the agreement with Patheon extends until December 2012 and may be extended, at our option, for
additional two-year terms.

Quotas from the DEA are required in order to manufacture and package sodium oxybate and Xyrem.
Siegfried and Patheon each require quota from the DEA to supply us with sodium oxybate and Xyrem. Since the
DEA typically grants quota on an annual basis and requires a detailed submission and justification for the
request, obtaining a sufficient DEA quota can be a difficult and time consuming process. The need for quota can
prevent us from building significant inventories.

Pursuant to our supply agreement with Abbott, we are responsible for purchasing, and Abbott is responsible

for providing us with, fluvoxamine maleate, the active pharmaceutical ingredient necessary to manufacture
Luvox CR. Abbott (through its predecessor Solvay which it acquired in 2010) assigned to us its rights and
obligations under its license and supply agreement with Elan. Pursuant to the license and supply agreement with
Elan, we are responsible for providing the active pharmaceutical ingredient free of charge to Elan, and Elan has
the right and obligation to manufacture the worldwide commercial requirements of Luvox CR. Abbott has
purchased the fluvoxamine maleate it supplied to us from Lonza, and, therefore, Lonza, through Abbott, was our
sole supplier of fluvoxamine maleate, the active pharmaceutical ingredient in Luvox CR. Lonza sold its United
States facility where it manufactured fluvoxamine maleate to a third party that currently continues to supply
Abbott, and therefore us, with fluvoxamine maleate. Any new manufacturer or new site would need to be
approved by the FDA.

Manufacturers and suppliers of our products and product candidates are subject to the FDA’s current Good
Manufacturing Practices, or cGMP, requirements, DEA regulations and other rules and regulations prescribed by
foreign regulatory authorities. We depend on our third party suppliers and manufacturers for continued
compliance with cGMP requirements and applicable foreign standards.

Government Regulation

The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of our

products are subject to extensive regulation by governmental authorities in the United States and in other
countries. In the United States, the FDA, under the Federal Food, Drug and Cosmetic Act, or FDCA, and its
implementing regulations, regulates pharmaceutical products. Several of our products and product candidates are
regulated as controlled substances and are subject to additional regulation by the DEA under the Controlled
Substances Act. Failure to comply with applicable U.S. requirements may subject us to administrative or judicial
sanctions, such as FDA refusal to approve pending NDAs, withdrawal of approval of approved products, warning
letters, untitled letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, suspension of licenses, civil penalties and/or criminal prosecution.

Drug Approval Process

To obtain FDA approval of a product candidate, we must, among other things, submit data supporting safety

and efficacy as well as detailed information on the manufacture and composition of the product candidate and

10

proposed labeling. The testing and collection of data and the preparation of necessary applications are expensive
and time-consuming. The FDA may not act quickly or favorably in reviewing these applications, and we may
encounter significant difficulties or costs in our efforts to obtain FDA approvals that could delay or preclude us
from marketing our products.

The steps required before a drug may be approved for marketing in the United States generally include:
preclinical laboratory tests and animal tests; submission to the FDA of an Investigational New Drug Application,
or IND, for human clinical testing, which must become effective before human clinical trials commence;
adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug product for
each indication; the submission to the FDA of an NDA; satisfactory completion of an FDA inspection of the
manufacturing facilities at which the product is made, analyzed and stored to assess compliance with cGMP;
potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA; and
FDA review and approval of the NDA.

An applicant must submit to the FDA the results of the preclinical and clinical trials, together with, among

other things, detailed information on the manufacture and composition of the product candidate and proposed
labeling, in the form of an NDA, including payment of a user fee. The FDA reviews all NDAs submitted before it
accepts them for filing and may request additional information rather than, or before, accepting an NDA for
filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the
goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has
ten months in which to complete its initial review of a standard NDA and respond to the applicant, and six
months for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and priority
NDAs. The review process and the PDUFA goal date may be extended by three months if the FDA requests or
the NDA sponsor otherwise provides additional information or clarification regarding information already
provided in the submission within the last three months before the PDUFA goal date.

K
-
0
1
m
r
o
F

After the FDA evaluates the NDA and the manufacturing facilities, it issues an approval letter or a complete
response letter. A complete response letter generally outlines the deficiencies in the submission and may require
substantial additional testing or information in order for the FDA to reconsider the application. If and when those
deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an
approval letter. The FDA may also refer an application to the appropriate advisory committee, typically a panel
of clinicians, for review, evaluation and a recommendation as to whether the application should be approved. The
FDA is not bound by the recommendations of the advisory committee.

The FDA has various programs, including fast track, priority review, and accelerated approval (Subpart H),
that are intended to expedite or simplify the process for reviewing drugs, and/or provide for approval on the basis
surrogate endpoints or restricted distribution. Generally, drugs that may be eligible for one or more of these
programs are those for serious or life-threatening conditions, those with the potential to address unmet medical
needs, and those that provide meaningful benefit over existing treatments. We cannot be sure that any of our
product candidates will qualify for any of these programs, or that, if a product candidate does qualify, that the
review time will be shorter than a standard review.

After approval, certain changes to the approved product, such as adding new indications, making certain

manufacturing changes, or making certain additional labeling claims, are subject to further FDA review and
approval. Obtaining approval for a new indication generally requires that additional clinical studies be conducted.
We cannot be sure that any additional approval for new indications for any product will be approved on a timely
basis, or at all.

Often, even after a drug has been approved by the FDA for sale, the FDA may require that certain post-
approval requirements be satisfied, including the conduct of additional clinical studies. If such post-approval
conditions are not satisfied, the FDA may withdraw its approval of the drug. In addition, holders of an approved
NDA are required to: report certain adverse reactions to the FDA; comply with certain requirements concerning

11

advertising and promotional labeling for their products; and continue to have quality control and manufacturing
procedures conform to cGMP after approval.

We monitor adverse events resulting from the use of our commercial products, as does the FDA, and we file

periodic reports with the FDA concerning adverse events. The FDA reviews these events and reports, and if it
determines that any events and/or reports indicate a trend or signal, the FDA can require a change in a product
label, restrict sales and marketing and/or require or conduct other actions. In the past year, two potential safety
issues or risks were listed for Xyrem by the FDA on its adverse event reporting system based on FDA’s review
of reported adverse events; however, the FDA has not indicated that it has determined a causal relationship
between Xyrem and the two potential safety issues. The FDA and other governmental authorities also actively
enforce regulations prohibiting off-label promotion, and the government has levied large civil and criminal fines
against companies for alleged improper promotion. The government has also required companies to enter into
complex corporate integrity agreements and/or non-prosecution agreements that can impose significant reporting
and other burdens on the affected companies.

The FDA periodically inspects the sponsor’s records related to safety reporting and/or manufacturing

facilities; this latter effort includes assessment of compliance with cGMP. Accordingly, manufacturers must
continue to expend time, money, and effort in the area of production and quality control to maintain cGMP
compliance. Discovery of problems with a product after approval may result in restrictions on a product,
manufacturer, or holder of an approved NDA, including withdrawal of the product from the market.

The approval process described above is premised on the applicant being the owner of, or having obtained a
right of reference to, all of the data required to prove the safety and effectiveness of a drug product. This type of
marketing application, sometimes referred to as a “full” or “stand-alone” NDA, is governed by Section 505(b)(1)
of the FDCA. A Section 505(b)(1) NDA contains full reports of investigations of safety and effectiveness, which
includes the results of preclinical studies and clinical trials, together with detailed information on the
manufacture and composition of the product, in addition to other information. As an alternate path to FDA
approval of, for example, new indications or improved formulations of previously-approved products, a company
may submit a Section 505(b)(2) NDA, instead of a “stand-alone” or “full” NDA filing under Section 505(b)(1).
Section 505(b)(2) of the FDCA was enacted as part of the Hatch-Waxman Act. Section 505(b)(2) permits the
submission of an NDA where at least some of the information required for approval comes from studies not
conducted by or for the applicant and for which the applicant has not obtained a right of reference. For example,
the Hatch-Waxman Act permits the applicant to rely upon the FDA’s findings of safety and effectiveness for an
approved product. The FDA may also require companies to perform additional studies or measurements to
support the change from the approved product. The FDA may then approve the new drug product for all or some
of the label indications for which the referenced product has been approved, or for a new indication sought by the
Section 505(b)(2) applicant.

To the extent that the Section 505(b)(2) applicant is relying on the FDA’s findings for an already-approved

product, the applicant is required to certify that there are no Orange Book-listed patents for that product or that
for each Orange Book-listed patent the listed patent has expired, or will expire on a particular date and approval
is sought after patent expiration, or the listed patent is invalid or will not be infringed by the manufacture, use or
sale of the new product.

A certification that the new product will not infringe the already approved product’s Orange Book-listed

patents or that such patents are invalid is called a paragraph IV certification. If the applicant does not challenge
the listed patents, the Section 505(b)(2) application will not be approved until all the listed patents claiming the
referenced product have expired, as well as any additional period of exclusivity that might be obtained for
completing pediatric studies pursuant to the FDA’s written request. The Section 505(b)(2) application may also
not be approved until any applicable non-patent exclusivity, such as exclusivity for obtaining approval of a new
chemical entity, listed in the Orange Book for the referenced product has expired.

12

K
-
0
1
m
r
o
F

If the applicant has provided a paragraph IV certification to the FDA, the applicant must also send notice of
the paragraph IV certification to the holder of the NDA and the relevant patent holders once the 505(b)(2) NDA
has been accepted for filing by the FDA. The NDA and patent holders may then initiate a legal challenge to the
paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of their receipt of a
paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2) NDA until the
earliest of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case
that is favorable to the Section 505(b)(2) applicant. For drugs with five-year exclusivity if an action for patent
infringement is initiated after year four of that exclusivity period, then the 30-month stay period is extended by
such amount of time so that 7.5 years has elapsed since the approval of the NDA with the five-year exclusivity
period. This period could be extended by six months if the NDA sponsor obtains pediatric exclusivity. Thus, a
Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its
products only to be subject to significant delay and patent litigation before its products may be commercialized.
Alternatively, if the listed patent holder does not file a patent infringement lawsuit within the required 45-day
period, the applicant’s 505(b)(2) NDA will not be subject to the 30-month stay.

The Hatch-Waxman Act

Under the Hatch-Waxman Act, newly-approved drugs and indications may benefit from a statutory period
of non-patent marketing exclusivity. The Hatch-Waxman Act provides five-year marketing exclusivity to the first
applicant to gain approval of an NDA for a new chemical entity, meaning that the FDA has not previously
approved any other new drug containing the same active moiety. The Hatch-Waxman Act prohibits having an
effective approval date for an abbreviated new drug application, or ANDA, or a Section 505(b)(2) NDA for
another version of such drug during the five-year exclusive period; however, as explained above, submission of
an ANDA or Section 505(b)(2) NDA containing a paragraph IV certification is permitted after four years, which
may trigger a 30-month stay of approval of the ANDA or Section 505(b)(2) NDA. Protection under the Hatch-
Waxman Act will not prevent the submission or approval of another “full” NDA; however, the applicant would
be required to conduct its own preclinical and adequate and well-controlled clinical trials to demonstrate safety
and effectiveness. The Hatch-Waxman Act also provides three years of marketing exclusivity for the approval of
new and supplemental NDAs, including Section 505(b)(2) NDAs, for, among other things, new indications,
dosages, or strengths of an existing drug, if new clinical investigations that were conducted or sponsored by the
applicant are determined by the FDA to be essential to the approval of the application.

In addition to non-patent marketing exclusivity, the Hatch-Waxman Act amended the FDCA to require each

NDA sponsor to submit with its application information on any patent that claims the active pharmaceutical
ingredient, drug product (formulation and composition), and method-of-use for which the applicant submitted the
NDA and with respect to which a claim of patent infringement could reasonably be asserted if a person not
licensed by the owner engaged in the manufacture, use or sale of the drug, and we have done this. Generic
applicants that wish to rely on the approval of a drug listed in the Orange Book must certify to each listed patent,
as discussed above. We intend to submit for Orange Book listing all relevant patents for our products and product
candidates, and to vigorously defend any Orange Book-listed patents for our approved products. In November
2010, we filed a lawsuit against Roxane in response to Roxane’s Paragraph IV certification relating to Xyrem.
For a description of this matter, please see “Item 3. Legal Proceedings.”

The Hatch-Waxman Act also permits a patent term extension of up to five years as compensation for patent
term lost during product development and the FDA regulatory review process. However, a patent term extension
cannot extend the remaining term of a patent beyond a total of 14 years after the FDA approves a marketing
application. The patent term extension period is generally equal to the sum of one-half the time between the
effective date of an IND and the submission date of an NDA, and all of the time between the submission date of
an NDA and the approval of that application, up to a total of five years. Only one patent applicable to a
regulatory review period, that represents the first commercial marketing of that drug, is eligible for the extension,
and it must be applied for prior to expiration of the patent. The U.S. Patent and Trademark Office, in consultation
with the FDA, reviews and approves the application for patent term extension. We will consider applying for a

13

patent term extension for some of our patents, to add patent life beyond the expiration date if we meet the legal
requirements permitting an extension, and the expected length of clinical trials and other factors involved in the
submission of an NDA.

Food and Drug Administration Amendments Act of 2007

On September 27, 2007, the Food and Drug Administration Amendments Act, or the FDAAA, was enacted

into law, amending both the FDCA and the Public Health Service Act. The FDAAA makes a number of
substantive and incremental changes to the review and approval processes in ways that could make it more
difficult or costly to obtain approval for new pharmaceutical products, or to produce, market and distribute
existing pharmaceutical products. Most significantly, the law changes the FDA’s handling of postmarketing drug
product safety issues by giving the FDA authority to require post approval studies or clinical trials, to request that
safety information be provided in labeling, or to require an NDA applicant to submit and execute a REMS.
Xyrem is subject to REMS requirements, and we expect that JZP-6, if approved, will be subject to a REMS
requirement. Xyrem was approved before 2007 with a risk mitigation program which is a “deemed REMS” in the
view of the FDA, and we are working with the FDA to develop an amended REMS for Xyrem under FDAAA.
We will work with the FDA if the agency determines that REMS are necessary for our other products or our
product candidates.

Orphan Drug Designation and Exclusivity

Some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient
populations as orphan drugs. The FDA grants orphan drug designation to drugs intended to treat a rare disease or
condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in
the United States for which there is no reasonable expectation that the cost of developing and making available in
the United States a drug for this type of disease or condition will be recovered from sales in the United States for
that drug. In the United States, orphan drug designation must be requested before submitting an application for
marketing approval. An orphan drug designation does not shorten the duration of the regulatory review and
approval process. If a product which has an orphan drug designation subsequently receives the first FDA
approval for the indication for which it has such designation, the product is entitled to orphan drug exclusivity,
which means the FDA may not approve any other application to market the same drug for the same indication for
a period of seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity. Competitors may receive approval of different drugs or biologics for the indications for
which the orphan product has exclusivity.

The FDA designated and approved Xyrem as an orphan drug for each of excessive daytime sleepiness and

cataplexy in patients with narcolepsy. The period of orphan drug exclusivity for cataplexy in patients with
narcolepsy expired in July 2009 and the period of orphan drug exclusivity for excessive daytime sleepiness in
patients with narcolepsy will expire in November 2012. In December 2007, we received orphan drug designation
from the FDA for JZP-8.

Other Regulatory Requirements

In addition to regulation by the FDA and certain state regulatory agencies, the DEA imposes various
registration, recordkeeping and reporting requirements, procurement and manufacturing quotas, labeling and
packaging requirements, security controls and a restriction on prescription refills on certain pharmaceutical
products under the Controlled Substances Act. The states also impose similar requirements for handling
controlled substances. A principal factor in determining the particular requirements, if any, applicable to a
product is the actual or potential abuse profile. Sodium oxybate, in the form of an active pharmaceutical
ingredient, is regulated by the DEA as a Schedule I controlled substance, a category reserved for products
believed to present the highest risk of substance abuse and with no approved medicinal use. When contained in
Xyrem, sodium oxybate is regulated as a Schedule III controlled substance. JZP-6 (and our solid oral dosage

14

K
-
0
1
m
r
o
F

forms of sodium oxybate) and JZP-8 will likely be regulated as controlled substances if approved for marketing
by the FDA. Controlled substances are subject to DEA and state regulations relating to manufacturing, storage,
distribution and physician prescription procedures, and the DEA regulates the amount of certain of the scheduled
substance that would be available for clinical trials and commercial distribution. Sodium oxybate, as a Schedule I
substance, is subject to additional controls, including quotas that limit the amount of product that can be
manufactured each year. As a Schedule III drug, Xyrem is subject to limitations on prescription refills. The third
parties who perform our clinical and commercial manufacturing, distribution, dispensing and clinical studies for
Xyrem, JZP-6 and our solid oral dosage forms of sodium oxybate are required to maintain necessary DEA
registrations and state licenses. The DEA periodically inspects facilities for compliance with its rules and
regulations. Failure to comply with current and future regulations of the DEA or relevant state authorities could
lead to a variety of sanctions, including revocation or denial of renewal of DEA registrations, fines, injunctions,
or civil or criminal penalties, and could harm our business and financial condition.

We are also subject to a variety of regulations in countries outside the United States governing clinical trials

and the marketing of other products. Outside of the United States, our ability to market a product depends upon
receiving a marketing authorization from the appropriate regulatory authorities. The requirements governing the
conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to
country. In any country, however, we will only be permitted to commercialize our products if the appropriate
regulatory authority is satisfied that we have presented adequate evidence of safety, quality and efficacy.
Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities
of foreign countries must be obtained prior to the commencement of marketing of the product in those countries.
The time needed to secure approval may be longer or shorter than that required for FDA approval. The regulatory
approval and oversight process in other countries includes all of the risks associated with regulation by the FDA
and certain state regulatory agencies as described above. A World Health Organization (WHO)
subcommittee plans to further evaluate the scheduling of sodium oxybate under the international drug control
treaties, which could result in a recommendation to the U.N. Commission on Narcotic Drugs to place Xyrem in a
more restrictive schedule, thereby causing a more restrictive scheduling of this product in Europe and certain
other countries than its current Schedule IV controlled substance status, and in a more restrictive schedule in the
United States than its current Schedule III controlled substance status. The WHO review process is long and
complicated and the timing and outcome of the review process is uncertain.

Pharmaceutical Pricing and Reimbursement

In both U.S. and foreign markets, our ability to commercialize our products successfully, and to attract
commercialization partners for our products, depends in significant part on the availability of adequate financial
coverage and reimbursement from third party payors, including, in the United States, governmental payors such
as the Medicare and Medicaid programs, managed care organizations, and private health insurers. Third party
payors are increasingly challenging the prices charged for medicines and examining their cost effectiveness, in
addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to
demonstrate the cost effectiveness of our products. Even with studies, our products may be considered less safe,
less effective or less cost-effective than existing products, and third party payors may not provide coverage and
reimbursement for our product candidates, in whole or in part.

Political, economic and regulatory influences are subjecting the healthcare industry in the United States to

fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory
proposals to change the healthcare system in ways that could significantly affect our business. We anticipate that
the United States Congress, state legislatures and the private sector will continue to consider and may adopt
healthcare policies intended to curb rising healthcare costs. These cost containment measures include: controls on
government funded reimbursement for drugs; new or increased requirements to pay prescription drug rebates to
government health care programs, controls on healthcare providers; challenges to the pricing of drugs or limits or
prohibitions on reimbursement for specific products through other means; requirements to try less expensive
products or generics before a more expensive branded product; changes in drug importation laws; expansion of

15

use of managed care systems in which healthcare providers contract to provide comprehensive healthcare for a
fixed cost per person; and public funding for cost effectiveness research, which may be used by government and
private third party payors to make coverage and payment decisions.

We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare

industry or third party coverage and reimbursement may be enacted in the future or what effect such legislation,
regulations or policies would have on our business. Any cost containment measures, including those listed above,
or other healthcare system reforms that are adopted, could have a material adverse effect on our ability to operate
profitably.

Our products may also face competition from lower priced products from foreign countries that have placed

price controls on pharmaceutical products. Proposed federal legislative changes may expand consumers’ ability
to import lower priced versions of our and competing products from Canada. Further, several states and local
governments have implemented importation schemes for their citizens, and, in the absence of federal action to
curtail such activities, we expect other states and local governments to launch importation efforts. The
importation of foreign products that compete with our products could negatively impact our business and
prospects.

Patents and Proprietary Rights

We actively seek to patent, or to obtain licenses to or to acquire third party patents, to protect our products,
inventions and improvements that we consider important to the development of our business. We own fourteen
issued U.S. patents and have rights to one other U.S. issued patent. In addition to the issued U.S. patents, we own
or have rights to 12 pending U.S. patent applications and more than 100 issued and pending foreign patents and
patent applications. Our owned and licensed patents and patent applications cover formulations of our products
and product candidates, uses of our products and product candidates to treat particular conditions, drug delivery
technologies and delivery profiles relating to our products and product candidates and methods for producing our
products and product candidates. However, patent protection is not available for the active pharmaceutical
ingredients in most of our products and product candidates, including Xyrem, Luvox CR, JZP-8 and JZP-6.
Patents extend for varying periods according to the date of the patent filing or grant and the legal term of patents
in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can
vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal
remedies in the country. The patents and patent applications that relate to our products and product candidates
include the following:

•

•

Xyrem. Xyrem is covered by two U.S. formulation patents, both of which are listed in the Orange Book
and both having an expiration date in 2020. Xyrem is also covered in the U.S. by five method of use
patents covering the distribution system for Xyrem, four of which are listed in the Orange Book. Four
of those patents will expire in 2024 and the fifth in 2022. In December 2010, an additional patent that
will expire in 2019 issued in the United States covering the method of use of Xyrem for the treatment
of narcolepsy; it is also listed in the Orange Book. Xyrem is also covered by a U.S. patent covering a
process for preparing the formulation, not listed in the Orange Book, that expires in 2019. A Xyrem
formulation patent has issued in 18 other countries and will expire in 2019. It is currently pending in
two additional countries. In addition to the issued patents, a number of patent applications related to
Xyrem are pending in the U.S.

Luvox CR. Luvox CR is covered by U.S. Patent No. 7,465,462 owned by Elan with claims covering the
orally administered formulation of extended-release fluvoxamine that requires the release of
fluvoxamine over a period of not less than 12 hours. This patent is listed in the Orange Book, and will
expire in 2020. We obtained a license to this patent as a result of Solvay’s assignment of its license and
supply agreement with Elan to us in connection with our exclusive license of the rights to market and
distribute Luvox CR in the United States. A continuation application is pending in the United States.

16

K
-
0
1
m
r
o
F

•

Product candidates. We expect that our distribution patents and both of our current formulation patents
associated with Xyrem will be applicable to JZP-6. We also own patents and patent applications with
claims covering the use of sodium oxybate for the treatment of fibromyalgia that will expire in the
United States in 2017 and in 29 other countries in 2018. We have filed U.S. and foreign patent
applications with claims covering JZP-8. These applications would, if issued, expire in 2027. The
claims do not cover the JZP-8 composition of matter.

We cannot be certain that any of our patent applications, or those of our licensors, will result in issued
patents. In addition, because the patent positions of pharmaceutical companies are highly uncertain and involve
complex legal and factual questions, the patents we own and license, or any further patents we may own or
license, may not prevent other companies from developing similar or therapeutically equivalent products. In
recent years, several companies have been extremely aggressive in challenging patents covering pharmaceutical
products, and the challenges have often been successful. We cannot assure you that our patents will not be
challenged by third parties or that we will be successful in any defense we undertake. Failure to successfully
defend a patent challenge could materially and adversely affect our business.

On October 18, 2010, we received a Paragraph IV Certification from Roxane that it filed an ANDA with the
FDA requesting approval to market a generic version of Xyrem. Roxane’s Paragraph IV Certification alleges that
all of our patents listed for Xyrem in Orange Book on the date of the Paragraph IV Certification are invalid,
unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit
against Roxane in response to Roxane’s Paragraph IV Certification in the United States District Court for the
District of New Jersey. On January 14, 2011, we received an additional Paragraph IV Certification from Roxane
alleging that our method of use patent for the use of Xyrem in the treatment of narcolepsy that issued in
December 2010 would not be infringed by Roxane’s proposed generic product. We amended our lawsuit against
Roxane on February 4, 2011 to include the additional patent in the litigation in response to Roxane’s additional
Paragraph IV Certification. We cannot assure you that this lawsuit or any other lawsuit we may bring will
prevent the introduction of generic products for any particular length of time or at all. For a more detailed
description of our dispute with Roxane, please see “Item 3. Legal Proceedings.”

In August 2009, we received a Paragraph IV Certification notice from Actavis advising that Actavis has

filed an ANDA, with the FDA seeking approval to market a generic version of Luvox CR. In September 2009,
we received a Paragraph IV Certification notice from Anchen advising that Anchen has filed an ANDA with the
FDA for a generic version of Luvox CR. Actavis’ Paragraph IV Certification alleged that the United States patent
covering Luvox CR, which is owned by Elan and licensed to us, is invalid on the basis that the inventions
claimed therein were obvious. Anchen’s Paragraph IV Certification alleged that Elan’s patent will not be
infringed by Anchen’s manufacture, use or sale of the generic product for which the ANDA was submitted and
that the patent is invalid on the basis that the inventions claimed therein were obvious. We and Elan filed
lawsuits in response to the Paragraph IV certifications. In August 2010, we and Elan entered into settlement
agreements with Anchen and granted a sublicense to Anchen of our rights to have manufactured, market and sell
a generic version of Luvox CR. The sublicense will commence on February 15, 2013 or earlier upon the
occurrence of certain events. The lawsuit against Actavis remains pending in the United States District Court for
the District of Delaware. For a more detailed description of our dispute with Anchen and Actavis, please see
“Item 3. Legal Proceedings.”

We cannot ensure that others will not be issued patents that may prevent the sale of our products or require

licensing and the payment of significant fees or royalties. Furthermore, to the extent that any of our future
products or methods is not patentable or infringe the patents of third parties, or in the event that our patents or
future patents fail to give us an exclusive position in the subject matter claimed by those patents, our business
could be adversely affected. We may be unable to avoid infringement of third party patents and may have to
obtain a license, defend an infringement action, or challenge the validity of the patents in court. A license may be
unavailable on terms and conditions acceptable to us, if at all. Patent litigation is costly and time consuming, and
we may be unable to prevail in any such patent litigation or devote sufficient resources to even pursue such

17

litigation. If we do not obtain a license under necessary patents, are found liable for infringement, or are not able
to have such patents declared invalid, we may be liable for significant money damages, encounter significant
delays in bringing products to market, or be precluded from participating in the manufacture, use or sale of
products or methods of treatment requiring such licenses.

We have also applied for a number of trademarks and service marks to further protect the proprietary
position of our products. We own 66 registered trademarks and service marks in the United States and 31
registered trademarks and service marks in other jurisdictions. We also have three pending trademark and service
mark applications in the United States and four pending trademark and service mark applications in other
jurisdictions. We also rely on our trade secrets and those of our licensors, as well as other unpatented proprietary
information, to protect our products. To the extent that our products have a competitive edge as a result of our
reliance on trade secrets and unpatented know-how, our competitive position may be compromised if others
independently develop products using the same or similar technologies or trade secrets.

We seek to protect our trade secrets and proprietary knowledge in part through confidentiality agreements
with our employees, consultants, advisors and collaboration partners. Nevertheless, these agreements may not
effectively prevent disclosure of our confidential information and may not provide us with an adequate remedy in
the event of unauthorized disclosure of our confidential information. In addition, if our employees, consultants,
advisors or collaboration partners develop inventions or processes independently or jointly with us that may be
applicable to our products under development, disputes may arise about ownership or proprietary rights to those
inventions and processes. Such inventions and processes will not necessarily become our property, but may
remain the property of those third parties or their employers. Protracted and costly litigation could be necessary
to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain patent and trade secret
protection, for any reason, could have a material adverse effect on our business.

Employees

As of February 28, 2011, we had 242 full-time employees. Of the full-time employees, 142 were engaged in
sales and marketing, 52 were engaged in manufacturing, product development and clinical activities, and 48 were
engaged in general and administrative activities. None of our employees is represented by a labor union, and we
consider our employee relations to be good.

Executive Officers of the Registrant

The following table sets forth certain information concerning our executive officers as of February 28, 2011:

Name

Age

Position

Bruce C. Cozadd . . . . . . . . . . . . . .
Russell J. Cox . . . . . . . . . . . . . . . .
Michael A. DesJardin . . . . . . . . . .
Mark G. Eller, Ph.D. . . . . . . . . . . .
Kathryn E. Falberg . . . . . . . . . . . .
Carol A. Gamble . . . . . . . . . . . . . .
Janne L.T. Wissel . . . . . . . . . . . . .
Joan E. Colligan . . . . . . . . . . . . . .

47 Chairman and Chief Executive Officer
47
53
54
50
58
55
59 Executive Director and Principal Accounting Officer

Senior Vice President, Sales and Marketing
Senior Vice President, Product Development
Senior Vice President, Research and Clinical Development
Senior Vice President and Chief Financial Officer
Senior Vice President, General Counsel and Corporate Secretary
Senior Vice President and Chief Regulatory and Compliance Officer

Bruce C. Cozadd is a co-founder and has served as our Chairman and Chief Executive Officer since April

2009. From 2003 until 2009, he served as our Executive Chairman. From 1991 until 2001, he held various
positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently
as its Executive Vice President and Chief Operating Officer, with responsibility for research and development,
manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial
Officer and Vice President, Corporate Planning and Analysis. He serves on the boards of Cerus Corporation, a

18

biopharmaceutical company, Threshold Pharmaceuticals, a biotechnology company, and The Nueva School and
Stanford Hospital and Clinics, both non-profit organizations. He received a B.S. from Yale University and an
M.B.A. from the Stanford Graduate School of Business.

Russell J. Cox was appointed our Senior Vice President, Sales and Marketing in January 2011. Prior to that
he served as our Vice President of Marketing from July 2010. From 2007 to 2009, he was Senior Vice President
and Chief Commercial Officer at Ipsen Group and previously Vice President of Marketing at Tercica, Inc.
(acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, he was with Scios Inc. (acquired by
Johnson and Johnson later in 2003), where he also held the role of Vice President, Marketing. Prior to 2003,
Mr. Cox was with Genentech, Inc. for 12 years, where he was a Product Team Leader (PTL) responsible for the
Growth Hormone franchise and led numerous product launches as a Group Product Manager. Mr. Cox received a
B.S. in Biomedical Science from Texas A&M University.

Michael A. DesJardin has served as our Senior Vice President, Product Development since May 2008. Prior

to that he served as Vice President, Product Development since July 2004. From 1995 to 2004, he served in
positions of increasing responsibility at ALZA Corporation, most recently as Executive Director for Implant
Research and Development. Prior to 1995, he worked for 15 years in chemical development, with several
assignments in API manufacturing at The Dow Chemical Company and Marion Merrell Dow (now Sanofi-
Aventis). Mr. DesJardin holds a B.S. in Chemical Engineering from the University of California, Berkeley and is
a registered Professional Engineer in the State of California.

K
-
0
1
m
r
o
F

Mark G. Eller, Ph.D. has served as our Senior Vice President, Research and Clinical Development since
May 2008. Prior to that he served as Vice President, Research since May 2005. From 2001 to 2005, he was Vice
President, Clinical Pharmacology at Quintiles Inc. From 1988 to 2001, Dr. Eller served in positions of increasing
responsibility at Hoechst Marion Roussel Inc. (now Sanofi-Aventis) and its predecessor companies, most
recently as Senior Director, Global Biodynamics. Prior to 1988, he held positions with The Upjohn Company and
the University of Cincinnati, College of Pharmacy. Dr. Eller holds a Ph.D. in Pharmaceutics from the University
of Iowa and received his B.S. in Pharmacy from the University of Iowa, College of Pharmacy.

Kathryn E. Falberg has served as our Senior Vice President and Chief Financial Officer since December
2009. From February 2009 to November 2009, Ms. Falberg was Chief Financial Officer and Chief Operating
Officer at ARCA biopharma, Inc., a biopharmaceutical company. From 2001 until February 2009, Ms. Falberg
worked as an active investor and consultant to small companies and served as a corporate director and audit
committee chair for several companies. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she
served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President,
Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg received an M.B.A. and
B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant.
Ms. Falberg currently serves on the boards of Halozyme Therapeutics, a biopharmaceutical company and QLT,
Inc., a pharmaceutical company.

Carol A. Gamble was appointed as our Senior Vice President in 2004 and has served as our General Counsel

and Corporate Secretary since 2003. From 2002 to 2003, she served as a consultant to various companies in the
pharmaceutical industry. From 2000 to 2002, she served as General Counsel and Corporate Secretary of
Aerogen, Inc., a biopharmaceutical company later acquired by Nektar Therapeutics. From 1988 to 2000, she held
various positions with ALZA Corporation, most recently as its Senior Vice President and Chief Corporate
Counsel. Ms. Gamble received a B.S. from Syracuse University and a J.D. from the University of California,
Berkeley, Boalt Hall.

Janne L. T. Wissel has served as our Senior Vice President and Chief Regulatory and Compliance Officer
since October 2007. Prior to that she served as our Senior Vice President of Development from 2004 to 2007, and
previously she served as our Vice President of Development. From 1981 to 2003, she held various positions at
ALZA Corporation, most recently as its Senior Vice President, Operations, with responsibility for ALZA

19

Corporation’s global regulatory, quality, general operations and manufacturing activities. She has led the
development, registration and launch of more than 20 pharmaceutical products in the neurology, pediatric
psychiatry, endocrinology, urology and oncology areas. Ms. Wissel received a B.S. from the University of
California, Davis and an M.B.A. from the University of Phoenix.

Joan E. Colligan has served as our Controller since July 2004, and in March 2009 she was designated by

our Board as our principal accounting officer and she served as acting principal financial officer from March to
December 2009. From 2000 to 2004, she served as Controller for research and development at ALZA
Corporation. Ms. Colligan received a B.S.C. and an M.B.A. from Santa Clara University.

About Jazz Pharmaceuticals

We were incorporated in California in March 2003 and reincorporated in Delaware in January 2004. Our

principal offices are located at 3180 Porter Drive, Palo Alto, California, 94304, and our telephone number is
650-496-3777. Our website address is www.jazzpharmaceuticals.com. Information found on, or accessible
through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K. Service
marks, trademarks and trade names appearing in this Annual Report on Form 10-K are the property of their
respective owners.

Available Information

We file electronically with the U.S. Securities and Exchange Commission our annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. We make available on our website at
www.jazzpharmaceuticals.com, free of charge, copies of these reports as soon as reasonably practicable after we
electronically file such material with, or furnish it to the SEC. Further copies of these reports are located at the
SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the
Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. The SEC maintains a website
that contains reports, proxy and information statements, and other information regarding our filings, at
www.sec.gov.

20

Item 1A. Risk Factors

We have identified the following risks and uncertainties that may have a material adverse effect on our

business, financial condition or results of operations. The risks described below are not the only ones we face.
Additional risks not presently known to us or that we currently believe are immaterial may also significantly
impair our business operations. Our business could be harmed by any of these risks. The trading price of our
common stock could decline due to any of these risks, and you may lose all or part of your investment.

Risks Relating to Our Business

We are dependent on sales of Xyrem to generate the cash necessary to operate our business and to meet our
ongoing financial obligations, and, if we are not able to maintain or increase sales of Xyrem, it would have a
material adverse effect on our business, financial condition, results of operations and growth prospects.

We are dependent on sales of Xyrem to generate the cash necessary to operate our business and to meet our

ongoing financial obligations, and our future plans assume that sales of Xyrem will increase. While Xyrem
product sales increased in the year ended December 31, 2010 compared to the same period in 2009, and we
expect significant Xyrem sales growth for 2011 compared to 2010, we cannot assure you that Xyrem sales will
continue to grow. We have periodically significantly increased the price of Xyrem, most recently in November
2010, and we cannot assure you that price increases we have taken or may take in the future have not, or will not
in the future, negatively affect Xyrem sales volumes.

K
-
0
1
m
r
o
F

In addition to other risks described herein, our ability to maintain or increase Xyrem product sales is subject
to a number of risks and uncertainties, the most important of which are discussed below, including those related
to:

•

•

•

•

•

•

•

the potential introduction of a generic version of Xyrem;

our manufacturing partners’ ability to obtain sufficient quota from the Drug Enforcement Agency, or
DEA, to satisfy our needs for Xyrem;

any supply or distribution problems arising with any of our manufacturing and distribution partners, all
of whom are sole source providers for us;

changed or increased regulatory restrictions, including changes to our risk management program for
Xyrem;

changes in healthcare laws and policy, including changes in requirements for rebates, reimbursement
and coverage by federal healthcare programs;

changes to our label, including our black box warning, that further restrict how we market and sell
Xyrem; and

continued acceptance of Xyrem as safe and effective by physicians and patients.

These and the other risks described in these risk factors related to Xyrem’s product sales could have a

material adverse effect on our ability to maintain or increase sales of Xyrem.

If prescriptions and revenue from sales of Xyrem do not continue or increase as expected, we may be
required to reduce our operating expenses, decrease our efforts in support of our products or seek to raise
additional funds, all of which could have a material adverse effect on our business, financial condition, results of
operations and growth prospects, or we may not be able to acquire, in-license or develop new products to grow
our business.

If generic products that compete with Xyrem are approved, sales of Xyrem may be adversely affected.

Although Xyrem is covered by patents covering its formulation, distribution system and method of use, we
cannot assure you that third parties will not attempt to invalidate or design around the patents, or assert that they

21

are invalid or otherwise unenforceable, and introduce generic equivalents of Xyrem. Once orphan drug
exclusivity for Xyrem in the United States for the treatment of excessive daytime sleepiness in patients with
narcolepsy expires in November 2012, other companies could possibly introduce generic equivalents of Xyrem if
they do not infringe our patents covering Xyrem or can demonstrate that our patents are invalid or unenforceable.

On October 18, 2010, we received notice from Roxane Laboratories, Inc, or Roxane, that it filed an
abbreviated new drug application, or ANDA, with the U.S. Food and Drug Administration, or FDA, requesting
approval to market a generic version of Xyrem. If the application is approved, and a generic version of Xyrem is
introduced, our sales of Xyrem would be adversely affected. Additional ANDAs could also be filed requesting
approval to market generic forms of Xyrem; if those applications for generics were approved and the generics
were launched, sales of Xyrem would further decrease.

Roxane has sent us Paragraph IV certifications with respect to our patents listed before February 2011 in the

FDA’s approved drug products with therapeutic equivalence evaluation documents, or Orange Book, covering
Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. A Paragraph
IV certification is a certification by a generic applicant that patents covering the branded product are invalid,
unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. The FDA will
not approve an ANDA for a generic form of a product unless the submitting manufacturer either files a Paragraph
IV certification with respect to the patents listed in the FDA’s Orange Book for that product or all of those
patents expire. We have filed a lawsuit against Roxane, but we cannot assure you that the lawsuit will prevent the
introduction of a generic version of Xyrem for any particular length of time, or at all.

After the introduction of a generic competitor, a significant percentage of the prescriptions written for a

product generally may be filled with the generic version, resulting in a loss in sales of the branded product,
including for indications for which the generic version has not been approved for marketing by the FDA. Generic
competition often results in decreases in the prices at which branded products can be sold, particularly when
there is more than one generic available in the marketplace. In addition, legislation enacted in the United States
allows for, and in a few instances in the absence of specific instructions from the prescribing physician mandates,
the dispensing of generic products rather than branded products where a generic equivalent is available. Generic
competition for Xyrem could have a material adverse effect on our business, financial condition, results of
operations and growth prospects.

The manufacture, distribution and sale of Xyrem is subject to significant restrictions, and these restrictions
subject us to increased risks and uncertainties, may give advantages to our competitors, and could limit our
supply of Xyrem any of which could limit sales of Xyrem.

The DEA limits the quantity of certain Schedule I controlled substances that may be produced in the United

States in any given calendar year through a quota system. Because the active pharmaceutical ingredient of
Xyrem, sodium oxybate, is a Schedule I controlled substance, our current and new suppliers of sodium oxybate
and our product manufacturer must obtain DEA quotas in order to supply us with sodium oxybate and Xyrem.
Since the DEA typically grants quotas on an annual basis and requires a detailed submission and justification for
each request, obtaining a DEA quota is a difficult and time consuming process. If our commercial or clinical
requirements for sodium oxybate or Xyrem exceed our suppliers’ and product manufacturer’s DEA quotas, our
suppliers and product manufacturer would need quota increases from the DEA, which could be difficult and time
consuming to obtain and might not ultimately be obtained on a timely basis, or at all. We cannot assure you that
our suppliers will receive sufficient quota from the DEA to meet our needs, and if we and our suppliers cannot
obtain as much quota as is needed, on a timely basis, or at all, our business, financial condition, results of
operations and growth prospects could be materially and adversely affected.

As a condition of approval of Xyrem, the FDA mandated that we maintain a risk management program for

Xyrem under which all Xyrem that we sell in the United States must be shipped directly to patients through a
single central pharmacy. The process under which patients receive Xyrem under the Xyrem risk management

22

program is cumbersome. While we have an agreement with the central pharmacy for Xyrem, Express Scripts
Specialty Distribution Services, or Express Scripts, through June 2012, if the central pharmacy does not fulfill its
contractual obligations to us, or refuses or fails to adequately serve patients, shipments of Xyrem and our sales
would be adversely affected. If we change our central pharmacy, new contracts might be required with
government and other insurers who pay for Xyrem, and the terms of any new contracts could be less favorable to
us than current agreements. In addition, any new central pharmacy would need to be registered with the DEA and
would also need to implement the particular processes, procedures and activities necessary to distribute Xyrem
under the risk management plan approved by the FDA. Transitioning to a new central pharmacy could result in
product shortages, which would adversely affect sales of Xyrem in the United States, and/or result in additional
costs and expenses for us, and/or take a significant amount of time, any of which could materially and adversely
affect our business, financial condition, results of operations and growth prospects.

Xyrem was approved in 2002 with a risk management plan that is not under the current Risk Evaluation and

Mitigation Strategy, or REMS, as it is structured today by the FDA. The FDA has required that existing risk
management programs be converted to the newer REMS structure under the Food and Drug Administration
Amendments Act of 2007. While we have been in discussions with the FDA about converting our current risk
management plan for Xyrem to a REMS under the new structure, those discussions have not been completed. We
cannot assure you that the FDA will not impose new and onerous requirements under the new REMS structure
that could make it more difficult or expensive for us to distribute Xyrem or could adversely affect our sales or
make competition easier.

K
-
0
1
m
r
o
F

The risk management plan for Xyrem includes some unique features that provide information about adverse

events, including deaths, that is generally not available for other products not subject to a similar risk
management plan, and may also provide information on adverse events that are not related to the use of Xyrem.
As a result, this information, which we report regularly to the FDA, could result in FDA requiring changes to the
Xyrem label or other action by FDA or by us which could have an adverse affect on Xyrem’s commercial
success.

The FDA has required that Xyrem’s label include a boxed warning regarding the risk of abuse. A boxed

warning is the strongest type of warning that the FDA can require for a drug product and warns prescribers that
the drug carries a significant risk of serious or even life-threatening adverse effects. A boxed warning also
means, among other things, that the product cannot be advertised through reminder ads, ads which mention the
pharmaceutical brand name but not the indication or medical condition it treats. In addition, Xyrem’s FDA
approval under the FDA’s Subpart H regulations requires that all of the promotional materials for Xyrem be
provided to the FDA for review at least 30 days prior to the intended time of first use.

If we are not able to maintain or increase sales of Luvox CR in the near term, it could have an adverse effect
on our financial condition and results of operations.

Our plans assume that sales of Luvox CR will increase in 2011. While Luvox CR product sales increased in
the year ended December 31, 2010 compared to the same period in 2009, and we expect Luvox CR sales growth
in 2011 as compared to 2010, we cannot assure you that Luvox CR sales will continue to grow.

We have been in discussions with the FDA concerning our remaining Phase IV clinical study commitment

related to social anxiety disorder, or SAD, and as a result of these discussions, in April 2010 we submitted a
labeling supplement to the new drug application, or NDA, for Luvox CR to remove the SAD indication from the
label. We have not been promoting Luvox CR for social anxiety disorder since April 2010; however, we cannot
assure you that that the removal of the SAD indication from the Luvox CR label, if it occurs, will not have a
negative impact on our Luvox CR product sales.

Although Luvox CR is covered by a product-specific patent issued to Elan Pharma International Limited, or

Elan, expiring in 2020, other companies could manufacture and sell generic equivalents of Luvox CR in ways

23

that are not covered by the claims of the patent after the expiration of three years of marketing exclusivity, which
ended in February 2011. In August 2009, we received a Paragraph IV certification notice from Actavis Elizabeth,
LLC, or Actavis, advising that Actavis has filed an ANDA with the FDA seeking approval to market a generic
version of Luvox CR. In September 2009, we received a Paragraph IV certification notice from Anchen
Pharmaceuticals, Inc., or Anchen, advising that Anchen has filed an ANDA with the FDA for a generic version
of Luvox CR. We filed lawsuits against both companies after receipt of their certifications. We and Elan entered
into settlement agreements with Anchen granting Anchen a sublicense of our rights to have manufactured,
market and sell a generic version of Luvox CR commencing on February 15, 2013 or earlier upon the occurrence
of certain events. The lawsuit against Actavis is pending in the United States District Court for the District of
Delaware, but, we cannot assure you that this lawsuit will prevent the introduction of an additional generic form
of Luvox CR for any particular length of time, or at all.

We depend on single source suppliers and manufacturers for each of our products and product candidates.
The loss of any of these suppliers or manufacturers, or delays or problems in the supply or manufacture of
our products for commercial sale or our product candidates for use in our clinical trials, could materially and
adversely affect our business, financial condition, results of operations and growth prospects.

We do not have, and do not intend to establish in the near term, our own manufacturing or packaging
capability for our products or product candidates, or their active pharmaceutical ingredients. In part due to the
limited market size for our approved products, we have entered into manufacturing and supply agreements with
single source suppliers and manufacturers for our commercialized products and product candidates. If our
suppliers and contract manufacturers do not manufacture our products or product candidates without interruption
or do not comply with their obligations to us under our supply and manufacturing arrangements, we may not
have adequate remedies for any breach, and their failure to supply us could result in a shortage of our products or
product candidates.

The availability of our products for commercial sale depends upon our ability to procure the ingredients,
packaging materials and finished products we need. If one of our suppliers or product manufacturers fails or refuses
to supply us for any reason, it would take a significant amount of time and expense to qualify a new supplier or
manufacturer. The loss of one of our suppliers or product manufacturers could require us to obtain regulatory
clearance in the form of a “prior approval supplement” and to incur validation and other costs associated with the
transfer of the active pharmaceutical ingredient or product manufacturing process. We believe that it could take as
long as two years to qualify a new supplier or manufacturer, and we may not be able to obtain active pharmaceutical
ingredients, packaging materials or finished products from new suppliers or manufacturers on acceptable terms and
at reasonable prices, or at all. Should we lose either an active pharmaceutical ingredient supplier or a product
manufacturer, we could run out of salable product to meet market demands or investigational product for use in
clinical trials while we wait for FDA approval of a new active pharmaceutical ingredient supplier or product
manufacturer. For Xyrem or sodium oxybate, any new supplier or manufacturer would also need to be registered
with the DEA and obtain a DEA quota. In addition, the FDA must approve suppliers of the active and inactive
pharmaceutical ingredients and certain packaging materials used in our products, as well as suppliers of finished
products. The qualification of new suppliers and manufacturers could potentially delay the manufacture of our
products and product candidates and result in shortages in the marketplace or for our clinical trials, or both,
particularly since we do not have secondary sources of supply of the active pharmaceutical ingredient or backup
manufacturers for our products and product candidates. For example, we entered into an agreement with a new
supplier for sodium oxybate, Siegfried (USA) Inc., or Siegfried, and we intend to seek FDA approval of Siegfried as
our supplier as soon as possible. We expect Siegfried to be approved by the FDA as a supplier in the second half of
2011, but we cannot be certain this will occur. If there are delays in qualifying the new manufacturer or the new
manufacturer is unable to obtain a sufficient quota from the DEA, there could be a shortage of Xyrem and sodium
oxybate for the marketplace or for use in our clinical studies, or both.

Failure by our third party manufacturers to comply with regulatory requirements could adversely affect their

ability to supply products to us. All facilities and manufacturing techniques used for the manufacture of

24

K
-
0
1
m
r
o
F

pharmaceutical products must be operated in conformity with the FDA’s current Good Manufacturing Practices,
or cGMP, requirements. In complying with cGMP requirements, our suppliers must continually expend time,
money and effort in production, record-keeping and quality assurance and control to ensure that our products and
product candidates meet applicable specifications and other requirements for product safety, efficacy and quality.
DEA regulations also govern facilities where controlled substances such as sodium oxybate are manufactured.
Manufacturing facilities are subject to periodic unannounced inspection by the FDA, the DEA and other
regulatory authorities, including state authorities. Failure to comply with applicable legal requirements subjects
the suppliers to possible legal or regulatory action, including shutdown, which may adversely affect their ability
to supply us with the ingredients or finished products we need.

Any delay in supplying, or failure to supply, products by any of our suppliers could result in our inability to

meet the commercial demand for our products in the United States and our partners’ needs outside the United
States, or our needs for use in clinical trials, and could adversely affect our business, financial condition, results
of operations and growth prospects.

We may not be able to successfully identify and acquire, in-license or develop additional products or product
candidates to grow our business, and, even if we are able to do so, we may not be able to successfully identify
and manage the risks associated with integrating acquisitions, including acquisitions of a company or
business unit, or other new products or product candidates.

We intend to grow our business over the long-term by acquiring or in-licensing and developing additional

products and product candidates that we believe have significant commercial potential. Any growth through
acquisition or in-licensing will depend upon the availability of suitable acquisition or in-license products and
product candidates on acceptable prices, terms and conditions, and any growth through development will depend
upon our identifying and obtaining product candidates, our ability to develop those product candidates and the
availability of funding to complete the development of, obtain regulatory approval for and commercialize these
product candidates. Even if appropriate opportunities are available, we may not be able to successfully identify
them, or we may not have the financial resources necessary to pursue them. Other companies, many of which
may have substantially greater financial, marketing and sales resources, compete with us for these opportunities.

In addition, integrating an acquisition, including the acquisition of a company or business unit, or an
in-licensed product or product candidate, may create unforeseen operating difficulties and expenses for us,
including: the diversion of management time and focus from operating our current business; unanticipated
liabilities for activities of or related to an acquired company or product before the acquisition; failure to retain
employees or to smoothly integrate related departments; and failure to successfully develop and commercialize
acquired products and product candidates. We cannot assure you that we will be able to successfully manage
these risks or other anticipated and unanticipated problems in connection with integrating an acquisition,
including the acquisition of a company or business unit, or in-licensed product or product candidate, and, if we
are not successful in identifying and managing these risks and uncertainties effectively, it could have a material
adverse effect on our business.

The commercial success of our products depends upon attaining market acceptance by physicians, patients,
third party payors and the medical community.

Even if our product candidates are approved for sale by the appropriate regulatory authorities, physicians

may not prescribe our products, in which case we would not generate the revenues we anticipate. Market
acceptance of any of our products by physicians, patients, third party payors and the medical community depends
on:

•

•

the clinical indications for which a product is approved, including any restrictions placed upon the
product in connection with its approval, such as a REMS or labeling restrictions;

prevalence of the disease or condition for which the product is approved and the severity of side
effects;

25

•

•

•

•

•

•

acceptance by physicians and patients of each product as a safe and effective treatment;

perceived advantages over alternative treatments;

relative convenience and ease of administration;

the cost of treatment in relation to alternative treatments, including generic products;

the extent to which the product is approved for inclusion on formularies of hospitals and managed care
organizations; and

the availability of adequate reimbursement by third parties.

To help patients afford our products, we have various programs to assist them, including a patient assistance
program, a Xyrem voucher program and coupon programs for both of our products. Coupon programs, including
our program for Xyrem, have recently received some negative publicity, and it is possible that new legislation
could be enacted to restrict or otherwise negatively affect these programs, which could have a negative effect on
our sales.

From time to time, there is negative publicity about illicit gamma-hydroxybutyrate, or GHB, and its effects,

including with respect to illegal use, overdoses, serious injury and death. Because sodium oxybate, the active
pharmaceutical ingredient in Xyrem, is a derivative of GHB, Xyrem sometimes also receives negative mention in
publicity relating to GHB. Patients, physicians and regulators may therefore view Xyrem as the same as or
similar to illicit GHB. In addition, there are regulators and some law enforcement agencies that oppose the
prescription and use of Xyrem generally because of its connection to GHB. Xyrem’s label includes information
about adverse events from GHB. We could also be adversely affected if any of our products or any similar
products distributed by other companies prove to be, or are asserted to be, harmful to consumers. Because of our
dependence upon patient and physician perceptions, any adverse publicity associated with illness or other adverse
effects resulting from the use or misuse of our products or any similar products distributed by other companies
could materially and adversely affect our business, financial condition, results of operations and growth
prospects.

We face substantial competition from other companies, including companies with greater resources than we
have.

With respect to all of our existing and future products, we may compete with companies selling or working
to develop products that may be more effective, safer or less costly than our products. The markets for which we
are developing products are competitive and include generic and branded products, some of which are marketed
by major pharmaceutical companies that have significantly greater financial resources and expertise in research
and development, preclinical testing, conducting clinical trials, obtaining regulatory approvals, manufacturing
and marketing and selling approved products than we do.

Smaller or earlier stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large, established companies. Our commercial opportunities may be reduced or
eliminated if our competitors develop and commercialize generic or branded products that are safer or more
effective, have fewer side effects or are less expensive than our products.

Many of our competitors have far greater financial resources and a larger number of personnel to market

and sell their products than we do. Our competitors may obtain FDA or other regulatory approvals for their
product candidates more rapidly than we may and may market their products more effectively than we do. If we
are unable to demonstrate to physicians that, based on experience, clinical data, side-effect profiles and other
factors, our products are preferable to other therapies, we may not generate meaningful revenues from the sales
of our products.

26

K
-
0
1
m
r
o
F

We currently have a relatively small sales organization compared with most other pharmaceutical companies
with marketed products. If our specialty sales force and sales organization is not appropriately sized to
adequately promote any potential future products, the commercial opportunity for our potential future
products may be diminished.

We have a relatively small number of sales representatives compared with the number of sales
representatives of most other pharmaceutical companies with marketed products. Each of our sales
representatives is responsible for a territory of significant size. Future commercial products may require
expansion of our sales force and sales support organization, and we may need to commit significant additional
funds, management and other resources to the growth of our sales organization before the commercial launch of
those product candidates. We may not be able to achieve any necessary growth in a timely or cost-effective
manner or realize a positive return on our investment, and we may not have the financial resources to achieve the
necessary growth in a timely manner or at all. We also have to compete with other pharmaceutical and life
sciences companies to recruit, hire, train and retain sales and marketing personnel, and turnover in our sales force
and marketing personnel could negatively affect sales of our products.

We depend upon UCB to market and promote Xyrem outside the United States, and we are dependent upon
our collaboration with UCB for the development and potential commercialization of JZP-6 for the treatment
of fibromyalgia in major markets outside of the United States.

We have exclusively licensed to UCB Pharma Limited, or UCB, the rights to market and promote Xyrem in
54 countries outside of the United States. In addition, under the terms of our collaboration with UCB, we granted
UCB the exclusive right to commercialize JZP-6, which UCB would market under the Xyrem trade name, for the
treatment of fibromyalgia in the same territories in which UCB has the right to market and promote Xyrem for
patients with narcolepsy. UCB has announced that it has filed for European Medicines Agency, or EMA,
approval of JZP-6 for fibromyalgia, which UCB intends to market in Europe under the Xyrem trade name if
JZP-6 is approved in Europe. However, there are currently no approved fibromyalgia treatments in the European
Union, and we cannot assure you that the EMA will approve JZP-6 for fibromyalgia. For example, in October
2008, April 2009 and July 2009 panels of European regulators recommended against approving Cymbalta, Lyrica
and Savella, respectively, as treatments for fibromyalgia. UCB has the right to terminate our collaboration on
12-months’ notice (or less in certain circumstances), and UCB may terminate its rights to JZP-6 for the
fibromyalgia indication on six-months’ notice at any time prior to the receipt of marketing approval of JZP-6 for
fibromyalgia in the European Union. If UCB terminates our collaboration or terminates its rights to JZP-6 for the
fibromyalgia indication, we would need to find another party or parties to commercialize Xyrem and/or JZP-6 in
UCB’s territories. We may be unable to do this on acceptable terms, or at all.

A failure to prove that our product candidates are safe and effective in clinical trials would require us to
discontinue their development, which could materially and adversely affect our business, financial condition,
results of operations and growth prospects.

Significant additional research and development, financial resources and additional personnel will be
required to obtain necessary regulatory approvals for our current and any future product candidates and to
develop them into commercially viable products. As a condition to regulatory approval, each product candidate
must undergo extensive and expensive clinical trials to demonstrate to a statistically significant degree that the
product candidate is safe and effective. If a product candidate fails at any stage of development, we will not be
able to commercialize it and we will not receive any return on our investment from that product candidate.

All of our product candidates, other than JZP-6, are in Phase II, or earlier, clinical trials. Clinical testing can

take many years to complete, especially for product candidates that are in Phase II, or earlier, clinical trials, and
failure can occur any time during the clinical trial process. In addition, the results from early clinical trials may
not be predictive of results obtained in later and larger clinical trials, and product candidates in later clinical trials
may fail to show the desired safety and efficacy despite having progressed successfully through initial clinical

27

testing. A number of companies in the pharmaceutical industry, including us, have suffered significant setbacks
in clinical trials, even in advanced clinical trials after showing positive results in earlier clinical trials. Our
product candidates are subject to competition for clinical study sites and patients from other therapies under
development that may delay the enrollment in or initiation of our clinical trials. Many of these companies have
far greater financial and human resources than we do.

To grow our sodium oxybate business, we have and may in the future conduct additional studies in different

diseases or conditions or with additional or different doses or dosage forms. We cannot assure you that adverse
events or other information obtained during the course of any of these studies will not result in action by the FDA
or otherwise that could have a material adverse effect on the Xyrem commercial product as well as the candidate
we are studying.

The FDA or foreign regulatory authorities may require us to conduct unanticipated additional clinical trials,

which could result in additional expense and delays in bringing our product candidates to market. For example,
we received a complete response letter, or CRL, from the FDA concerning our JZP-6 product candidate, which
required additional clinical studies in order for JZP-6 to be approved for the treatment of fibromyalgia. We do
not know whether we will undertake additional studies of JZP-6 or otherwise continue to seek approval of JZP-6,
and if we did so, if any such studies or other of our efforts would be successful and result in approval of JZP-6.
Any failure or delay in completing clinical trials for our product candidates would prevent or delay their
commercialization, which could materially and adversely affect our business, financial condition, results of
operations and growth prospects.

We rely on third parties to conduct clinical trials for our product candidates, and if they do not properly and
successfully perform their legal and regulatory obligations, as well as their contractual obligations to us, we
may not be able to obtain regulatory approvals for our product candidates.

We design the clinical trials for our product candidates, but rely on contract research organizations and other
third parties to assist us in managing, monitoring and otherwise carrying out these trials, including with respect to
site selection, contract negotiation and data management. We do not control these third parties and, as a result,
they may not treat our clinical studies as their highest priority, or in the manner in which we would prefer, which
could result in delays. We are responsible for confirming that each of our clinical trials is conducted in
accordance with its general investigational plan and protocol, as well as FDA’s and foreign regulatory agencies’
requirements, commonly referred to as good clinical practices, for conducting, recording and reporting the results
of clinical trials to ensure that the data and results are credible and accurate and that the trial participants are
adequately protected. The FDA enforces good clinical practices through periodic inspections of trial sponsors,
principal investigators and trial sites. If we, our contract research organizations or our study sites fail to comply
with applicable good clinical practices, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA may require us to perform additional clinical trials before approving our marketing applications.
We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with
good clinical practices. In addition, our clinical trials must be conducted with product produced under the FDA’s
cGMP regulations. Our failure, or the failure of our contract manufacturers, to comply with these regulations
may require us to repeat or redesign clinical trials, which would delay the regulatory approval process.

If third parties do not successfully carry out their duties under their agreements with us, if the quality or

accuracy of the data they obtain is compromised due to failure to adhere to our clinical protocols or regulatory
requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, our
clinical trials may not meet regulatory requirements. If our clinical trials do not meet regulatory requirements or
if these third parties need to be replaced, our clinical trials may be extended, delayed, suspended or terminated. If
any of these events occur, we may not be able to obtain regulatory approval of our product candidates.

28

K
-
0
1
m
r
o
F

We are a small company and our employees must work on many important and diverse matters at the same
time. If we fail to attract, retain and motivate key personnel, or to retain our executive management team, or if
we cannot provide additional resources to perform important tasks, we may be unable to successfully sustain
or grow our business.

Our success and our ability to grow depend in part on our continued ability to attract, retain and motivate

highly qualified personnel and on our ability to develop and maintain important relationships with leading
academic institutions, clinicians and scientists. As a small company, we are highly dependent upon our executive
management team and other key personnel, all of whom work on many complex matters that are critical to our
success. The loss of services of any one or more members of our executive management team or other key
personnel could delay or prevent the successful completion of some of our key activities. We do not carry “key
person” insurance. Any employee may terminate his or her employment at any time without notice and without
cause or good reason.

To grow our company we will need additional personnel. Competition for qualified personnel in the life

sciences industry has historically been intense. If we cannot timely attract and retain quality personnel on
acceptable terms, our failure to do so could adversely affect our business, financial condition, results of
operations and growth prospects.

Risks Related to Our Intellectual Property

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret

protection of our products and product candidates, their use and the methods used to manufacture and, in some
cases, distribute them, as well as successfully defending these patents against third party challenges. Our ability
to protect our products and product candidates from unauthorized making, using, selling, offering to sell or
importation by third parties depends on the extent to which we have rights under valid and enforceable patents, or
have trade secrets that cover these activities.

The patent position of pharmaceutical companies can be highly uncertain and involve complex legal and
factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in
interpretations of patent laws in the United States and other countries may diminish the value of our intellectual
property. Even if we are able to obtain patents covering our products and product candidates, any patent may be
challenged, invalidated, held unenforceable or circumvented. For example, even though we have nine patents
covering Xyrem, with expiration dates between 2019 and 2024, and seven of the patents are listed in the FDA’s
Orange Book, an ANDA was filed requesting permission from the FDA to market a generic form of Xyrem. We
have received notices from the company that filed the ANDA stating that the ANDA included Paragraph IV
certifications with respect to our patents listed in the FDA’s Orange Book before February 2011. In the case of
Luvox CR, Actavis’ Paragraph IV certification alleges that the Elan patent, which is listed in the Orange Book
for Luvox CR, is invalid. The expiration date for the Elan patent at issue is May 10, 2020.

The existence of a patent will not necessarily prevent other companies from developing similar or
therapeutically equivalent products or protect us from claims of third parties that our products infringe their
issued patents, which may require licensing and the payment of significant fees or royalties. Competitors may
successfully challenge our patents, produce similar products that do not infringe our patents, or manufacture
products in countries where we have not applied for patent protection or that do not respect our patents.
Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents, our licensed
patents or in third party patents.

29

The degree of future protection to be afforded by our proprietary rights is uncertain because legal means

afford only limited protection and may not adequately protect our rights or permit us to gain or keep our
competitive advantage. For example:

•

•

•

•

•

•

•

•

others may be able to make products that are similar to our product candidates but that are not covered
by the claims of our patents, or for which we are not licensed under our license agreements;

we or our licensors or partners might not have been the first to make the inventions covered by our
issued patents or pending patent applications or the pending patent applications or issued patents of our
licensors or partners;

we or our licensors or partners might not have been the first to file patent applications for these
inventions;

others may independently develop similar or alternative products without infringing our intellectual
property rights;

our pending patent applications may not result in issued patents;

our issued patents and the issued patents of our licensors or partners may not provide us with any
competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third
parties;

we may not develop additional proprietary products that are patentable; or

the patents of others may have an adverse effect on our business.

We also may rely on trade secrets and other unpatented proprietary information to protect our technology,

especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are
difficult to protect. Although we use reasonable efforts to protect our trade secrets and other unpatented
proprietary information, our employees, consultants, advisors and partners may unintentionally or willfully
disclose our proprietary information to competitors, and we may not have adequate remedies for such
disclosures. If our employees, consultants, advisors and partners develop inventions or processes independently,
or jointly with us, that may be applicable to our products under development, disputes may arise about ownership
or proprietary rights to those inventions and processes. Enforcing a claim that a third party illegally obtained and
is using any of our inventions or trade secrets is expensive and time consuming, and the outcome is
unpredictable. In addition, courts outside of the United States are sometimes less willing to protect trade secrets.
Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.

Our research and development collaborators may have rights to publish data and other information to which
we have rights. In addition, we sometimes engage individuals or entities to conduct research that may be relevant
to our business. While the ability of these individuals or entities to publish or otherwise publicly disclose data
and other information generated during the course of their research is subject to contractual limitations, these
contractual provisions may be insufficient or inadequate to protect our trade secrets and may impair our patent
rights. If we do not apply for patent protection prior to such publication, or if we cannot otherwise maintain the
confidentiality of our innovations and other confidential information, then our ability to obtain patent protection
or protect our proprietary information may be jeopardized. Moreover, a dispute may arise with our research and
development collaborators over the ownership of rights to jointly developed intellectual property. Such disputes,
if not successfully resolved, could lead to a loss of rights and possibly prevent us from pursuing certain new
products or product candidates.

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other
intellectual property rights and we may be unable to protect our rights to, or commercialize, our products.

Our ability, and that of our partners, to commercialize any approved products will depend, in part, on our

ability to obtain patents, enforce those patents and operate without infringing the proprietary rights of third

30

K
-
0
1
m
r
o
F

parties. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal and
factual questions. We have filed multiple U.S. patent applications and foreign counterparts, and may file
additional U.S. and foreign patent applications related thereto. There can be no assurance that any issued patents
we own or control will provide sufficient protection to conduct our business as presently conducted or as
proposed to be conducted. Moreover, in part because of prior research performed and patent applications
submitted in the same manner or similar fields, there can be no assurance that any patents will issue from the
patent applications owned by us, or that we will remain free from infringement claims by third parties.

If we choose to go to court to stop someone else from pursuing the inventions claimed in our patents, our

licensed patents or our partners’ patents, that individual or company has the right to ask the court to rule that
these patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive and
would consume time and other resources, even if we were successful in stopping the infringement of these
patents. In addition, there is a risk that the court will decide that these patents are not valid and that we do not
have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of
these patents is upheld, the court will refuse to stop the other party on the ground that the other party’s activities
do not infringe our rights to these patents or that it is in the public interest to permit the infringing activity. We
have filed and are prosecuting a lawsuit against Roxane related to the Paragraph IV certifications delivered to us
with respect to Xyrem. We and Elan are prosecuting a lawsuit against Actavis related to the Paragraph IV
certification delivered to us with respect to Luvox CR. We cannot assure you that these, or other lawsuits we may
file in the future, will be successful in stopping the infringement of our patents, that any such litigation will be
cost-effective, or that the litigation will have a satisfactory result for us.

A third party may claim that we or our manufacturing or commercialization partners are using inventions

covered by the third party’s patent rights and may go to court to stop us from engaging in our normal operations
and activities, including making or selling our products. Patent infringement lawsuits are costly and could affect
our results of operations and divert the attention of management and development personnel. There is a risk that
a court could decide that we or our partners are infringing third party patent rights which could be very costly to
us and have a material adverse effect on our business.

The pharmaceutical and life sciences industry has produced a proliferation of patents, and it is not always

clear to industry participants, including us, which patents cover various types of products or methods. The
coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we
are sued for patent infringement, we would need to demonstrate that our products or methods do not infringe the
patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, and we may not be
able to do this.

Because some patent applications in the United States may be maintained in secrecy until the patents are
issued, because patent applications in the United States and many foreign jurisdictions are typically not published
until 18 months after filing, and because publications in the scientific literature often lag behind actual
discoveries, we cannot be certain that others have not filed patent applications for inventions covered by our
licensors’ or our issued patents or pending applications, or that we or our licensors were the first inventors. Our
competitors may have filed, and may in the future file, patent applications covering subject matter similar to ours.
Any such patent application may have priority over our or our licensors’ patents or applications and could further
require us to obtain rights to issued patents covering such subject matter. If another party has filed a U.S. patent
application on inventions similar to ours, we may have to participate in an interference proceeding declared by
the U.S. Patent and Trademark Office to determine priority of invention in the United States. The costs of these
proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of
our U.S. patent position with respect to such inventions.

Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than

we can because they have substantially greater resources. In addition, any uncertainties resulting from the
initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds
necessary to continue our operations.

31

Risks Related to Our Industry

The regulatory approval process is expensive, time consuming and uncertain and may prevent us or our
partners from obtaining approvals for the commercialization of some or all of our product candidates.

The research, testing, manufacturing, selling and marketing of pharmaceutical products are subject to
extensive regulation by FDA and other regulatory authorities in the United States and other countries, and
regulations differ from country to country. Approval in the United States, or in any jurisdiction, does not ensure
approval in other jurisdictions. The regulatory approval process is lengthy, expensive and uncertain, and we may
be unable to obtain approval for our product candidates. We are not permitted to market our product candidates
in the United States until we receive approval from the FDA, generally of an NDA. Obtaining approval of an
NDA can be a lengthy, expensive and uncertain process, and the FDA has substantial discretion in the approval
process. For example, we have spent significant time and money developing our JZP-6 product candidate, and
although we believe our clinical studies have shown the product candidate to be safe and effective, we received a
CRL from the FDA in October 2010 related to JZP-6 that stated that the FDA cannot approve the NDA in its
present form.

In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may
subject our company to administrative or judicially imposed sanctions, including warning letters, untitled letters,
civil and criminal penalties, injunctions, product seizure or detention, product recalls, total or partial suspension
of production and refusal to approve pending NDAs or supplements to approved NDAs. If we are unable to
obtain regulatory approval of our product candidates, we will not be able to commercialize them and recoup our
research and development costs.

Healthcare law and policy changes, including those based on recently enacted legislation, may impact our
business in ways that we cannot currently predict and these changes could have a material adverse effect on
our business and financial condition.

In March 2010, the President signed the Patient Protection and Affordable Care Act, as amended by the

Health Care and Education Affordability Reconciliation Act, or the Healthcare Reform Act. This law
substantially changes the way health care is financed by both governmental and private insurers, and significantly
impacts the pharmaceutical industry. The Healthcare Reform Act contains a number of provisions that are
expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that
may affect our business include those governing enrollment in federal healthcare programs, reimbursement
changes, fraud and abuse and enforcement. These changes will impact existing government healthcare programs
and will result in the development of new programs, including Medicare payment for performance initiatives and
improvements to the physician quality reporting system and feedback program.

Additional provisions of the Healthcare Reform Act, some of which become effective in 2011, may
negatively affect our revenues in the future. For example, as part of the Healthcare Reform Act’s provisions
closing a funding gap that currently exists in the Medicare Part D prescription drug program (commonly known
as the “donut hole”), we will be required to provide a 50% discount on branded prescription drugs dispensed to
beneficiaries within this donut hole. We expect that the Healthcare Reform Act and other healthcare reform
measures that may be adopted in the future could have a material adverse effect on our industry generally and on
our ability to maintain or increase our product sales or successfully commercialize our product candidates,
including JZP-6, or could limit or eliminate our future spending on development projects.

In addition to the Healthcare Reform Act, there will continue to be proposals by legislators at both the

federal and state levels, regulators and third-party payors to keep healthcare costs down while expanding
individual healthcare benefits. Certain of these changes could impose limitations on the prices we will be able to
charge for our products and any approved product candidates or the amounts of reimbursement available for
these products from governmental agencies or third-party payors, or may increase the tax obligations on

32

K
-
0
1
m
r
o
F

pharmaceutical companies such as ours. The enactment and implementation of any future healthcare reform
legislation or policies could have a material adverse effect on our business and financial condition.

We are subject to significant ongoing regulatory obligations and oversight, which may result in significant
additional expense and limit our ability to commercialize our products.

We are subject to significant ongoing regulatory obligations, such as safety reporting requirements and
additional post-marketing obligations, including regulatory oversight of the promotion and marketing of our
products. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and
recordkeeping for our products are, and any of our product candidates that may be approved by the FDA will be,
subject to extensive and ongoing regulatory requirements. If we receive regulatory approvals to sell our products,
the FDA and foreign regulatory authorities may impose significant restrictions on the indicated uses or marketing
of our products, or impose requirements for burdensome post-approval study commitments. The terms of any
product approval, including labeling, may be more restrictive than we desire and could affect the commercial
potential of the product. If we become aware of previously unknown problems with any of our products in the
United States or overseas or at our contract manufacturers’ facilities, a regulatory agency may impose restrictions
on our products, our contract manufacturers or on us. In such an instance, we could experience a significant drop
in the sales of the affected products, our product revenues and reputation in the marketplace may suffer, and we
could become the target of lawsuits.

The FDA and other governmental authorities also actively enforce regulations prohibiting off-label

promotion, and the government has levied large civil and criminal fines against companies for alleged improper
promotion. The government has also required companies to enter into complex corporate integrity agreements
and/or non-prosecution agreements that impose significant reporting and other burdens on the affected
companies. For example, our predecessor company was investigated for off-label promotion of Xyrem, and we
are subject to a corporate integrity agreement through mid-2012 as a result of that investigation. The
investigation resulted in significant fines and penalties, which we guaranteed and have been paying; the final
payment is due in 2012.

We are also subject to regulation by regional, national, state and local agencies, including the DEA, the
Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of
Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign
countries in which we commercialize our products. The Federal Food, Drug, and Cosmetic Act, the Public Health
Service Act and other federal and state statutes and regulations govern to varying degrees the research,
development, manufacturing and commercial activities relating to prescription pharmaceutical products,
including preclinical testing, approval, production, labeling, sale, distribution, import, export, post-market
surveillance, advertising, dissemination of information, promotion, marketing, and pricing to government
purchasers and government health care programs. Our manufacturing partners are subject to many of the same
requirements, which include obtaining sufficient quota from the DEA each year to manufacture sodium oxybate,
Xyrem and JZP-6.

The federal health care program anti-kickback statute prohibits, among other things, knowingly and
willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing,
ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under
Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to
arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary
managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors
protecting certain common manufacturer business arrangements and activities from prosecution, the exemptions
and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing,
purchases or recommendations of our products may be subject to scrutiny if they do not qualify for an exemption
or safe harbor. We seek to comply with the exemptions and safe harbors whenever possible, but our practices
may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability.

33

The Federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a

false claim for payment to the federal government, or knowingly making, or causing to be made, a false
statement to get a false claim paid. Many pharmaceutical and other health care companies have been investigated
and have reached substantial financial settlements with the federal government under these laws for a variety of
alleged marketing activities, including providing free product to customers with the expectation that the
customers would bill federal programs for the product; providing consulting fees, grants, free travel, and other
benefits to physicians to induce them to prescribe the company’s products; and inflating prices reported to private
price publication services, which are used to set drug payment rates under government health care programs.
Companies have been prosecuted for causing false claims to be submitted because of the marketing of their
products for unapproved, and thus non-reimbursable, uses. Pharmaceutical and other health care companies have
also been prosecuted on other legal theories of Medicare and Medicaid fraud.

The majority of states also have statutes or regulations similar to the federal anti-kickback law and false

claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in
several states, apply regardless of the payor. Several states now require pharmaceutical companies to report
expenses relating to the marketing and promotion of pharmaceutical products and to report gifts and payments to
individual physicians in the states. Other states prohibit providing meals to prescribers or other marketing related
activities. Still other states require the posting of information relating to clinical studies and their outcomes. In
addition, California, Nevada, and Massachusetts require pharmaceutical companies to implement compliance
programs or marketing codes. Currently, several additional states are considering similar proposals.

Compliance with various federal and state laws is difficult and time consuming, and companies that violate

them may face substantial penalties. The potential sanctions include civil monetary penalties, exclusion of a
company’s products from reimbursement under government programs, criminal fines and imprisonment. Because
of the breadth of these laws and the lack of extensive legal guidance in the form of regulations or court decisions,
it is possible that some of our business activities could be subject to challenge under one or more of these laws.
Such a challenge could have a material adverse effect on our business, financial condition, results of operations
and growth prospects.

The number and complexity of both federal and state laws continues to increase, and additional

governmental resources are being added to enforce these laws and to prosecute companies and individuals who
are believed to be violating them. In particular, the Healthcare Reform Act includes a number of provisions
aimed at strengthening the government’s ability to pursue anti-kickback and false claims cases against
pharmaceutical manufacturers and other healthcare entities, including substantially increased funding for
healthcare fraud enforcement activities, enhanced investigative powers, amendments to the False Claims Act that
make it easier for the government and whistleblowers to pursue cases for alleged kickback and false claim
violations and, beginning in March 2013 for payments made in 2012, public reporting of payments by
pharmaceutical manufacturers to physicians and teaching hospitals nationwide. While it is too early to predict
what effect these changes will have on our business, we anticipate that government scrutiny of pharmaceutical
sales and marketing practices will continue for the foreseeable future and subject us to the risk of government
investigations and enforcement actions. Responding to a government investigation or enforcement action would
be expensive and time-consuming, and could have a material adverse effect on our business, financial condition,
results of operations and growth prospects.

If we or any of our partners fail to comply with applicable regulatory requirements, we or they could be

subject to a range of regulatory actions that could affect our or our partners’ ability to commercialize our
products and could harm or prevent sales of the affected products, or could substantially increase the costs and
expenses of commercializing and marketing our products. Any threatened or actual government enforcement
action could also generate adverse publicity and require that we devote substantial resources that could otherwise
be used in other aspects of our business.

34

K
-
0
1
m
r
o
F

If we fail to comply with our reporting and payment obligations under the Medicaid rebate program or other
governmental pricing programs, we could be subject to additional reimbursement requirements, penalties,
sanctions and fines which could have a material adverse effect on our business, financial condition, results of
operations and growth prospects.

We participate in the federal Medicaid rebate program established by the Omnibus Budget Reconciliation
Act of 1990, as well as several state supplemental rebate programs. Under the Medicaid rebate program, we pay a
rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid
beneficiaries and paid for by a state Medicaid program under a fee-for-service arrangement, as a condition of
having federal funds being made available to the states for our drugs under Medicaid and Medicare Part B. Those
rebates are based on pricing data reported by us on a monthly and quarterly basis to the Centers for Medicare and
Medicare Services, or CMS, the federal agency which administers the Medicaid drug rebate program. These data
include the average manufacturer price, or AMP, and in the case of innovator products, the best price for each
drug. As a result of the enactment of the Healthcare Reform Act, rebates now also are due on the utilization of
Medicaid managed care organizations, effective March 23, 2010.

Pursuant to the Healthcare Reform Act, and effective for rebate periods beginning in the first quarter 2010,
the minimum amount of the Medicaid rebate for each unit of a drug has been increased. For innovator products,
in general a drug marketed under an NDA, the minimum rebate has been increased from 15.1% to 23.1% of the
AMP for that product, or if it is greater, the difference between the AMP and the best price for the product. The
23.1% rebate amount is lowered to 17.1% for certain clotting factor and pediatric drug products. For
non-innovator products, in general a drug marketed under an ANDA, the rebate amount has been increased from
11% to 13.1% of the AMP for drug. The Medicaid rebate for innovator products also includes an additional
rebate amount if price increases for the drug exceed the rate of inflation since the product’s launch. The
Healthcare Reform Act changes this additional rebate formula for certain products that qualify as line extensions
of existing drugs, effective for rebate periods beginning with drugs paid for by a state as of the first quarter 2010,
so that the rebate for these products can be increased and based on the additional rebate for the original drug. It
also caps the total rebate amount for innovator drugs at 100% of the AMP for the drug. In addition, the
Healthcare Reform Act changes the definition of AMP, effective for AMP prices reported for the fourth quarter
of 2010, and additional legislation is currently pending that would further amend the AMP definition. CMS has
yet to issue regulations to implement any of the enacted statutory changes.

We cannot assure that there will not be additional increases in rebates or other costs and charges from
government agencies. Regulations continue to be issued and coverage expanded by various governmental
agencies relating to these programs, increasing the cost and complexity of compliance.

Pricing and rebate calculations vary among products and programs. The calculations are complex and are
often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate
amount is computed each quarter based on our submission to CMS of our current AMP and best prices for the
quarter. If we become aware that our reporting for prior quarters was incorrect, or has changed as a result of
recalculation of the pricing data, we are obligated to resubmit the corrected AMP or best price for that quarter.
Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past
quarters, depending on the nature of the correction as well as changes in the 340B ceiling prices based on those
rebate calculations, as discussed below, such that refunds to covered entities that purchased at the earlier prices
may be due. In addition to retroactive rebates and the potential for 340B ceiling price refunds, if we are found to
have knowingly submitted false average manufacturer price or best price information to the government, we may
be liable for civil monetary penalties in the amount of $100,000 per item of false information, and, in September
2010, CMS and the Office of the Inspector General indicated that they intend to more aggressively pursue
companies who fail to report this data to the government in a timely manner. Governmental agencies may also
make changes in program interpretations, requirements or conditions of participation, some of which may have
implications for amounts previously estimated or paid. CMS recently published information stating that many
companies’ monthly and quarterly submissions are incomplete or incorrect. We cannot assure you that our
submissions will not be found by CMS to be incomplete or incorrect.

35

Federal law requires that any company that participates in the Medicaid rebate program also participate in
the Public Health Service’s 340B pharmaceutical pricing program in order for federal funds to be available for
the manufacturer’s drugs under Medicaid and Medicare Part B. The 340B pricing program requires participating
manufacturers to agree to charge statutorily-defined covered entities no more than the 340B ceiling price for the
manufacturer’s covered outpatient drugs. These covered entities include a variety of community health clinics
and other entities that receive health services grants from the Public Health Service, as well as hospitals that
serve a disproportionate share of poor patients and children. The 340B ceiling price is calculated using a statutory
formula which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the
Medicaid drug rebate program. This means that to the extent the Healthcare Reform Act, as discussed above,
changes the statutory and regulatory definitions of AMP and the Medicaid rebate amount, these changes also will
affect the 340B ceiling price. The Healthcare Reform Act expands the 340B drug pricing program to include new
covered entity types, effective for drugs purchased on or after January 1, 2010, although drugs that have received
an orphan drug designation under section 526 of the Federal Food Drug and Cosmetic Act are exempt from the
ceiling price requirement for the new categories of covered entities. The Healthcare Reform Act also obligates
the Secretary of the Department of Health and Human Services to create regulations and processes to improve the
integrity of the program and to update the agreement that manufacturers must sign to participate in the program
to obligate manufacturers to sell to covered entities if they sell to any other purchaser and to report to the
government the ceiling prices for its drugs. In addition, Congress is currently considering legislation that, if
passed, would further expand the 340B program to require participating manufacturers to agree to provide 340B
discounted pricing on drugs used in the inpatient setting by certain covered entity hospitals, where those drugs
are used for the covered entity’s uninsured inpatients.

Reimbursement may not be available for our products, which could diminish our sales or affect our ability to
sell our products profitably.

In both U.S. and foreign markets, our ability to commercialize our products successfully and to attract
strategic partners for our products depends in significant part on the availability of adequate financial coverage
and reimbursement from third party payors, including, in the United States, governmental payors such as the
Medicare and Medicaid programs, managed care organizations and private health insurers. Third party payors
decide which drugs they will pay for and establish reimbursement and co-pay levels. Third party payors are
increasingly challenging the prices charged for medical products and services and examining their cost
effectiveness, in addition to their safety and efficacy. In some cases, for example, third party payors try to
encourage the use of less expensive generic products through their prescription benefits coverage and
reimbursement and co-pay policies. We may need to conduct expensive pharmacoeconomic studies in order to
demonstrate the cost-effectiveness of our products. Even with studies, our products may be considered less safe,
less effective or less cost-effective than existing products, and third party payors may not provide coverage and
reimbursement for our products, in whole or in part. We cannot predict actions third party payors may take, or
whether they will limit the coverage and level of reimbursement for our products or refuse to provide any
coverage at all. For example, because Luvox CR is competing in a market with both branded and generic
products, reimbursement by government and private payors may be more challenging than for new chemical
entities. We cannot be sure that reimbursement amounts, or the lack of reimbursement, will not reduce the
demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels,
we may not be able to effectively commercialize our products.

In recent years, there have been a number of legislative and regulatory changes in and proposals to change

the healthcare system in ways that could impact our ability to sell our products profitably. These changes and
proposals include measures that would limit or prohibit payments for some medical treatments or subject the
pricing of drugs to government control and regulations changing the rebates we are required to provide. For
example, a final rule published by the Department of Defense, or DoD, in March 2009, implementing the terms
of the National Defense Authorization Act of 2008, established a program under which DoD expects rebates
from pharmaceutical manufacturers on all prescriptions of “covered” prescription drugs (including innovator
drugs and biologics) filled under the TRICARE retail pharmacy program from January 28, 2008 forward, unless

36

K
-
0
1
m
r
o
F

DoD agrees to a waiver or compromise of amounts due. Additionally, under the final rule, to remain eligible for
inclusion on the DoD Uniform Formulary, a pharmaceutical manufacturer must enter into a pricing agreement
under which it agrees to pay rebates to DoD on TRICARE retail pharmacy utilization on a prospective basis.
These rebates are meant to enable DoD to access pricing that is either close to or equal to “Federal Ceiling
Prices,” defined under the Veterans Health Care Act of 1992. Per the process set forth in this rule, we entered
into a retail rebate agreement with DoD in July 2009. These legislative and regulatory changes, including our
entering into the retail rebate agreement with DoD, could impact our ability to maximize revenues in the Federal
marketplace. As discussed above, recent legislative changes to the 340B drug pricing program, the Medicaid
drug rebate program, and the Medicare Part D prescription drug benefit also could impact our revenues.

We expect to experience pricing pressures in connection with the sale of our products due to the trend

toward managed health care, the increasing influence of health maintenance organizations and additional
legislative proposals. If we fail to successfully secure and maintain reimbursement coverage for our products or
are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and
our business will be harmed.

Product liability and product recalls could harm our business.

The development, manufacture, testing, marketing and sale of pharmaceutical products entail significant
risk of product liability claims or recalls. Side effects of, or manufacturing defects in, the products sold by us
could result in exacerbation of a patient’s condition, serious injury or impairments or even death. This could
result in product liability claims and/or recalls of one or more of our products. Both Xyrem and Luvox CR have
boxed warnings in their labels. We expect that the label for JZP-6, if it is approved by the FDA, will also have a
boxed warning, and will include adverse events seen in narcolepsy and fibromyalgia trials, as well as post-
marketing safety information.

Product liability claims may be brought by individuals seeking relief for themselves, or by groups seeking to

represent a class. While we have not had to defend against any product liability claims to date, as sales of our
products increase, we believe it is likely product liability claims will be made against us. We cannot predict the
frequency, outcome or cost to defend any such claims.

Product liability insurance coverage is expensive, can be difficult to obtain and may not be available in the

future on acceptable terms, if at all. Partly as a result of product liability lawsuits related to pharmaceutical
products, product liability and other types of insurance have become more difficult and costly for pharmaceutical
companies to obtain. Our product liability insurance may not cover all of the future liabilities we might incur in
connection with the development, manufacture or sale of our products. In addition, we may not continue to be
able to obtain insurance on satisfactory terms or in adequate amounts.

A successful claim or claims brought against us in excess of available insurance coverage could subject us
to significant liabilities and could have a material adverse effect on our business, financial condition, results of
operations and growth prospects. Such claims could also harm our reputation and the reputation of our products,
adversely affecting our ability to market our products successfully. In addition, defending a product liability
lawsuit is expensive and can divert the attention of key employees from operating our business.

Product recalls may be issued at our discretion or at the discretion of our suppliers, government agencies

and other entities that have regulatory authority for pharmaceutical sales. Any recall of our products could
materially adversely affect our business by rendering us unable to sell that product for some time and by
adversely affecting our reputation. A recall could also result in product liability claims.

37

Risks Relating to Our Financial Condition

To grow our business, we will need to commit substantial resources, which could result in future losses or
otherwise limit our opportunities or affect our ability to operate our business.

To grow our business over the longer-term, we will need to commit substantial resources to in-licensing and/or
acquiring new products and product candidates, and to costly and time-consuming product development and clinical
trials of our product candidates. We will also need to continue to invest in our commercial operations. Our future
capital requirements will depend on many factors, including many of those discussed above, such as:

•

•

•

•

•

•

•

•

the revenues from our commercial products and the costs of our commercial operations;

whether or not there is generic competition for our products;

the acquisition and/or licensing cost for any new products and product candidates;

the scope, rate of progress, results and costs of our development and clinical activities;

the cost and timing of obtaining regulatory approvals and of compliance with laws and regulations;

the cost of preparing, filing, prosecuting, defending and enforcing patent claims and other intellectual
property rights;

the cost of investigations, litigation and/or settlements related to regulatory activities; and

changes in laws and regulations, including, for example, health care reform legislation.

One of our corporate goals is to expand our business through the licensing, acquisition and/or development of
additional products and product candidates. We cannot assure you that our funds will be sufficient to fund these
activities if opportunities arise, and we may be unable to expand our business if we do not have sufficient capital
or cannot borrow or raise additional capital on attractive terms. In addition, if we use a substantial amount of
borrowings or our funds to acquire or in-license products or product candidates, we may not have sufficient
additional funds to conduct all of our operations in the manner we would otherwise choose.

The terms of our credit agreement could restrict our operations, particularly our ability to respond to changes
in our business or to take specified actions.

The terms of our credit agreement include, and any future indebtedness may include, a number of restrictive

covenants that impose significant operating and financial restrictions on us, including restrictions on our ability
to take actions that may be in our best interests. The terms of our credit agreement include operating covenants
restricting, among other things, our ability to: incur additional indebtedness and liens; effect mergers,
consolidations and other fundamental changes; dispose of significant assets or enter into sale-leaseback
transactions; pay dividends or make other restricted payments; make loans, advances or other investments
including acquisitions of companies and products; and enter into transactions with affiliates. In addition, the
terms of our credit agreement include financial covenants requiring us, among other things, to: maintain a certain
consolidated fixed charge coverage ratio; maintain a certain leverage ratio; and maintain minimum liquidity. Our
failure to comply with any of these covenants could result in a default under the terms of the credit agreement,
which could permit the lenders to declare all or part of the outstanding borrowings to be immediately due and
payable. Although we currently have sufficient funds to repay our debt, if our outstanding borrowings were to be
accelerated, or if we have used significant amounts of our cash for other purposes, we might not have sufficient
funds to repay those borrowings, and any such acceleration would have a material adverse effect on our business,
financial condition and results of operations.

Our ability to use our net operating losses to offset potential taxable income and related income taxes that
would otherwise be due could be limited if we do not generate taxable income in a timely manner or if an
“ownership change” pursuant to Section 382 of the Internal Revenue Code is triggered.

We have significant net operating loss carryforwards, or NOLs. Our ability to use our NOLs to offset

potential future taxable income and related income taxes that would otherwise be due is dependent upon our

38

generation of future taxable income before the expiration dates of the NOLs, and we cannot predict with certainty
when, or whether, we will generate sufficient taxable income to use all of our NOLs. In addition, realization of
our NOLs to offset potential future taxable income and related income taxes that would otherwise be due could
be restricted by annual limitations on use of NOLs triggered by an “ownership change” under Section 382 of the
Internal Revenue Code and similar state provisions, based on a calculation related to our market capitalization.
An “ownership change” may occur if, during a three-year period, there is a change of 50% or more in the
percentage ownership of our company by 5% shareholders or shareholder groups, as defined in the Code. If we
generate taxable income, a limitation on our ability to utilize some or all of our NOLs could adversely affect our
results of operations.

In July 2009, we entered into an NOL preservation lock-up agreement with most of our significant

stockholders that restricts transferability of all of the shares of our common stock held by the stockholders who
entered into the agreement, which expires in July 2011 unless terminated earlier under certain circumstances, in
order to reduce the risk that we will undergo an “ownership change” within the meaning of Section 382(g) of the
Internal Revenue Code prior to that time. We have the right to grant waivers under the agreement if requested by
one or more parties and if the conditions set forth in the agreement are met, and we have done so. Section 382 of
the Internal Revenue Code is an extremely complex provision with respect to which there are many uncertainties.
Although the NOL preservation lock-up agreement is intended to reduce the risk of such an “ownership change”
before June 2011, we cannot assure you that such an ownership change will not occur. In addition, we have not
requested a ruling from the Internal Revenue Service, or IRS, regarding whether we have not experienced an
“ownership change” since 2005, and, therefore, we have not established whether the IRS agrees with us that our
NOLs have been effectively preserved for purposes of Section 382 of the Internal Revenue Code.

K
-
0
1
m
r
o
F

Risks Relating to Our Common Stock

The market price of our common stock may be volatile, and the value of your investment could decline
significantly.

Investors who purchase our common stock may not be able to sell their shares at or above the purchase
price. The price of our stock has fluctuated significantly from time to time and has increased substantially in the
past year, and we cannot predict if it will continue to do so. The risk factors described above relating to our
business and products could cause the price of our common stock to fluctuate significantly. In addition, the stock
market in general, including the market for life sciences companies, have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of those companies.
These broad market and industry factors may seriously harm the market price of our common stock, regardless of
our operating performance. In addition, our stock price may be dependent upon the valuations and
recommendations of the analysts who cover our business, and if our results do not meet our analysts’ forecasts
and expectations, our stock price could decline as a result of analysts lowering their valuations and
recommendations or otherwise. In the past, following periods of volatility in the market, securities class-action
litigation has often been instituted against companies. Such litigation, if instituted against us, could result in
substantial costs and diversion of management’s attention and resources, which could materially and adversely
affect our business, financial condition, results of operations and growth prospects.

Future sales of our common stock in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market or the perception that
these sales might occur, could depress the market price of our common stock, and could impair our ability to
raise capital through the sale of additional equity securities. As of February 28, 2011, we had 40,294,596 shares
of common stock outstanding, all of which shares are eligible for sale in the public market, subject in some cases
to the volume limitations and manner of sale and other requirements under Rule 144, and the restrictions under
our NOL preservation lock-up agreement which expires in July 2011.

39

As of February 28, 2011, the holders of up to approximately 13,161,817 shares of common stock, based on

shares outstanding as of that date, were entitled to certain rights with respect to the registration of such shares
under the Securities Act of 1933, as amended, under an amended and restated investor rights agreement that we
entered into with these holders in June 2007. In addition, upon exercise of outstanding options by our executive
officers, our executive officers will be entitled to rights under the amended and restated investor rights agreement
with respect to registration of the shares of common stock acquired on exercise. If such holders, by exercising
their registration rights, sell a large number of shares, they could adversely affect the market price for our
common stock. If in the future we file a registration statement and include shares held by these holders pursuant
to the exercise of their registration rights, these sales may impair our ability to raise capital. We also entered into
a registration rights agreement pursuant to which we filed a registration statement covering the resale of the
562,192 shares underlying the warrants that we issued in connection with the issuance of senior secured notes
that were repaid in June 2010. In addition, we have filed registration statements on Form S-8 under the Securities
Act to register the shares of our common stock reserved for issuance under our stock option and employee stock
purchase plans, and intend to file additional registration statements on Form S-8 to register the shares
automatically added each year to the share reserves under these plans.

We entered into a committed equity financing facility, or CEFF, in May 2008 with Kingsbridge Capital
Limited, or Kingsbridge, which we amended in November 2009. The perceived risk of dilution from sales of our
common stock to or by Kingsbridge in connection with the CEFF in the future may cause holders of our common
stock to sell their shares, or it may encourage short selling by market participants, which could contribute to a
decline in our stock price. If we were to draw down funds under the CEFF and Kingsbridge acquires shares in
connection with a drawdown, there are no restrictions on its ability to sell those shares or engage in other
transactions that could put downward pressure on the price of our common stock. If we sell shares to Kingsbridge
under the CEFF, they will be issued at a discount from the average price of our common stock. This will have a
dilutive effect on the holdings of our current stockholders, and may result in downward pressure on the price of
our common stock. The CEFF expires in December 2012.

Pursuant to the terms of an investor rights agreement dated July 7, 2009, we entered into in connection with

a private placement completed on July 7, 2009, we filed a registration statement under the Securities Act
registering the resale of the 1,895,734 shares of common stock we issued to the investors pursuant to a securities
purchase agreement we entered into with the investors on July 6, 2009, as well as the 947,867 shares of common
stock underlying the warrants we issued to the investors pursuant to the securities purchase agreement. In
addition, if we propose to register any of our securities under the Securities Act, either for our own account or for
the account of others, the investors are entitled to notice of the registration and are entitled to include, at our
expense, their shares of common stock in the registration and any related underwriting, provided, among other
conditions, that the underwriters may limit the number of shares to be included in the registration.

Our executive officers and directors, together with their respective affiliates, own a significant percentage of
our stock and will be able to exercise significant influence over matters subject to stockholder approval.

As of February 28, 2011, our executive officers and directors, together with the stockholders with which our
executive officers and directors are affiliated or associated, beneficially owned approximately 51% of our capital
stock. Accordingly, our executive officers and directors, together with their respective affiliates or associates, are
able to determine the composition of our board of directors, retain the voting power to approve all matters
requiring stockholder approval, including mergers and other business combinations, and continue to have
significant influence over our operations. This concentration of ownership could have the effect of delaying or
preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain
control of us, which in turn could have a material adverse effect on the market value of our common stock, and
may prevent attempts by our stockholders to replace or remove our board of directors or management.

40

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could
discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and
may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make

it more difficult for a third party to acquire us, or for a change in the composition of our board of directors or
management to occur, even if doing so would benefit our stockholders. These provisions include:

•

•

•

•

•

•

•

authorizing the issuance of “blank check” preferred stock, the terms of which may be established and
shares of which may be issued without stockholder approval;

dividing our board of directors into three classes;

limiting the removal of directors by the stockholders;

eliminating cumulative voting rights and therefore allowing the holders of a majority of the shares of
our common stock to elect all of the directors standing for election, if they should so choose;

prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken
at a meeting of our stockholders;

eliminating the ability of stockholders to call a special meeting of stockholders; and

establishing advance notice requirements for nominations for election to the board of directors or for
proposing matters that can be acted upon at stockholder meetings.

K
-
0
1
m
r
o
F

In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally
prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an
interested stockholder for a period of three years following the date on which the stockholder became an
interested stockholder, unless, among other exceptions, such transactions are approved by our board of directors.
This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by
or beneficial to our stockholders. Further, because some corporate takeovers occur through an acquirer’s
purchase, in the public market or otherwise, of sufficient stock to give it control of a company, the NOL
preservation lock-up agreement, which restricts the transferability of our securities, could have the effect of
delaying or discouraging such a takeover of us.

We have never declared or paid dividends on our capital stock and we do not anticipate paying dividends in
the foreseeable future.

We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We

currently plan to invest all available funds and future earnings in the development and growth of our business and
in the payment of our obligations. In addition, the terms of our credit agreement include, and any future
indebtedness may include, a covenant restricting our ability to pay dividends. As a result, capital appreciation, if
any, of our common stock will be your sole source of potential gain for the foreseeable future.

Item 1B. Unresolved Staff Comments

None.

Item 2.

Properties

Our corporate headquarters are located in Palo Alto, California, where we occupy approximately 44,000
square feet of office space under a lease which expires in September 2012. We have the right to extend the term
for up to an additional four years.

41

Item 3.

Legal Proceedings

On October 18, 2010, we received a Paragraph IV Patent Certification notice, or Paragraph IV Certification,
from Roxane Laboratories, Inc., or Roxane, that it filed an abbreviated new drug application, or ANDA, with the
FDA requesting approval to market a generic version of Xyrem. Roxane’s Paragraph IV Certification alleges that
all five patents listed for Xyrem in Orange Book on the date of the Paragraph IV Certification are invalid,
unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit
against Roxane in response to Roxane’s Paragraph IV Certification in the United States District Court for the
District of New Jersey. We are seeking a permanent injunction to prevent Roxane from introducing a generic
version of Xyrem. In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against
Roxane, FDA approval of Roxane’s ANDA will be stayed until the earlier of (i) 30 months from our October 18,
2010 receipt of Roxane’s Paragraph IV certification notice or (ii) a District Court decision finding that the
identified patents are invalid, unenforceable or not infringed. On January 14, 2011, we received an additional
Paragraph IV Certification from Roxane alleging that the additional method of use patent for the use of Xyrem in
the treatment of narcolepsy that issued in December 2010 and is listed in the Orange Book would not be
infringed by Roxane’s proposed generic product. We amended our lawsuit against Roxane on February 4, 2011
to include the additional patent in the litigation in response to Roxane’s additional Paragraph IV Certification.
We cannot predict or determine the outcome of this matter.

In August 2009, we received a Paragraph IV Certification from Actavis Elizabeth, LLC, or Actavis,
advising that Actavis has filed an ANDA with the FDA seeking approval to market a generic version of
Luvox CR. In September 2009, we received an additional Paragraph IV Certification notice from Anchen
Pharmaceuticals, Inc., or Anchen, advising that Anchen has filed an ANDA with the FDA seeking approval to
market a generic version of Luvox CR. We have not been informed as to the timing or status of the FDA’s
review of either party’s filing, or whether either filer has complied with FDA requirements for proving
bioequivalence. Actavis’ Paragraph IV Certification alleges that the United States patent covering Luvox CR,
which is owned by Elan Pharma International Limited, or Elan, and licensed to us, is invalid on the basis that the
inventions claimed therein were obvious. Anchen’s Paragraph IV Certification alleges that the Elan patent will
not be infringed by Anchen’s manufacture, use or sale of the generic product for which the ANDA was submitted
and that the Elan patent is invalid on the basis that the inventions claimed therein were obvious. On October 6,
2009, we and Elan, as plaintiffs, filed a lawsuit against Actavis, Anchen, and Anchen Incorporated, the parent of
Anchen, in the United States District Court for the District of Delaware claiming infringement of the Elan patent
by the defendants in response to the Paragraph IV Certifications filed by Actavis and Anchen. On October 14,
2009, we and Elan, as plaintiffs, also filed a lawsuit in the United States District Court for the Central District of
California against Anchen claiming infringement of the Elan patent based upon Anchen’s Paragraph IV
Certification. In both cases, the plaintiffs were seeking a permanent injunction that prevented Actavis and
Anchen from introducing a generic version of Luvox CR prior to the expiration of the Elan patent.

On August 25, 2010, we and Elan entered into settlement agreements with Anchen. Under the agreements,

we, Elan and Anchen have agreed to dismiss all of the claims brought in the litigation without prejudice, Anchen
has agreed not to contest the validity or enforceability of the Elan patent in the United States, and we, Elan and
Anchen have agreed to release each other from all claims arising in the litigation or relating to the product
Anchen intends to market under its ANDA. Settlement agreements of ANDA litigation can be reviewed by the
Federal Trade Commission and the U.S. Department of Justice at their discretion. In addition, we have granted a
sublicense to Anchen of our rights to have manufactured, market and sell a generic version of Luvox CR in the
United States. The sublicense is non-transferable, non-sublicensable and royalty-free and is exclusive even as to
us and Elan (except with respect to Luvox CR) for a period of time. The sublicense will commence on
February 15, 2013 or earlier upon the occurrence of certain events. On October 5, 2010, the United States District
Court for the Central District of California dismissed the case against Anchen without prejudice. On the same
date, the United States District Court for the District of Delaware also dismissed the case against Anchen without
prejudice.

42

The lawsuit against Actavis is pending in the United States District Court for the District of Delaware. The

court has not scheduled any hearing dates in this case. We cannot predict or determine the outcome of this
matter.

From time to time we are involved in legal proceedings arising in the ordinary course of business. We
believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse
effect on our results of operations or financial condition.

Item 4.

(Removed and Reserved)

K
-
0
1
m
r
o
F

43

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of

Equity Securities

Market Information

The following table sets forth the high and low intraday sales prices of our common stock, par value

$0.0001, on the NASDAQ Global Market under the symbol “JAZZ” from January 1, 2009 through December 31,
2010 for the periods indicated.

Calendar Quarter—2009
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First Quarter
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Calendar Quarter—2010
First Quarter
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

High

Low

$ 2.10
$ 5.27
$11.88
$ 9.28

$13.95
$12.19
$11.90
$20.28

$0.58
$0.52
$3.59
$6.01

$8.01
$6.38
$7.51
$9.61

On February 28, 2011, the last reported sales price per share of our common stock was $24.63 per share.

Holders of Common Stock

As of February 28, 2011, there were 38 holders of record of our common stock.

Dividends

Under the terms of the senior secured credit agreement we entered into in June 2010 with a lender, we are
not permitted to pay any cash dividends on any shares of our capital stock. Subject to preferences that may be
applicable to any then outstanding preferred stock, holders of common stock are entitled to receive dividends, if
any, as may be declared from time to time by our board of directors out of legally available funds. We have never
declared or paid any cash dividends and we do not presently plan to pay cash dividends in the foreseeable future.

Unregistered Sales of Equity Securities

On November 10, 2010, we issued 150,000 shares of our common stock pursuant to the exercise of a
warrant held by Kingsbridge Capital Limited, or Kingsbridge. The warrant, which was exercised for cash, had an
exercise price of $9.20 per share resulting in aggregate consideration to us of $1.4 million. In issuing the shares
upon exercise of the warrant to Kingsbridge, we relied on the exemption provided by Section 4(2) of the
Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder as a transaction by an issuer
not involving a public offering.

44

Performance Measurement Comparison(1)

The following graph shows the total stockholder return on the last day of each month of an investment of

$100 in cash on June 1, 2007, the date of our initial public offering, for (i) our common stock; (ii) the NASDAQ
Composite Index; (iii) the NASDAQ Pharmaceutical Index and (iv) the NASDAQ Biotechnology Index through
December 31, 2010. We are included in the NASDAQ Pharmaceutical Index and the NASDAQ Biotechnology
Index. Because the NASDAQ Biotechnology Index is one of the market sector indices published by the
NASDAQ Stock Market and the NASDAQ Pharmaceutical Index is no longer a published index, we have
decided to use the NASDAQ Biotechnology Index going forward. Pursuant to applicable Securities and
Exchange Commission rules, all values assume reinvestment of the full amount of all dividends; however no
dividends have been declared on our common stock to date. The stockholder return shown in the graph below is
not necessarily indicative of future performance, and we do not make or endorse any predictions as to future
stockholder returns.

$120

$100

$80

$60

$40

$20

$0

COMPARISON OF 43 MONTH CUMULATIVE TOTAL RETURN(2)
Among Jazz Pharmaceuticals Inc., the NASDAQ Composite Index,
the NASDAQ Pharmaceutical Index and the NASDAQ Biotechnology Index

K
-
0
1
m
r
o
F

6/07

6/07

7/07

8/07

9/07

10/07

11/07

12/07

1/08

2/08

3/08

4/08

5/08

6/08

7/08

8/08

9/08

10/08

11/08

12/08

1/09

2/09

3/09

4/09

5/09

6/09

7/09

8/09

9/09

10/09

11/09

12/09

1/10

2/10

3/10

4/10

5/10

6/10

7/10

8/10

9/10

10/10

11/10

12/10

Jazz Pharmaceuticals, Inc

NASDAQ Composite

NASDAQ Pharmaceutical

NASDAQ Biotechnology

(1) This section is not “soliciting material”, is not deemed “filed” with the SEC and is not to be incorporated by
reference into any filing of Jazz Pharmaceuticals, Inc., under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective
of any general incorporation language in any such filing.

(2)

Information used in the graph was obtained from Research Data Group, Inc.

45

Item 6.

Selected Financial Data

The following selected consolidated financial data should be read together with our consolidated financial

statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” appearing elsewhere in this Annual Report on Form 10-K. The selected consolidated
financial data in this section is not intended to replace our consolidated financial statements and the
accompanying notes. Our historical results are not necessarily indicative of our future results.

We derived the consolidated statements of operations data for the years ended December 31, 2010, 2009 and

2008 and the consolidated balance sheet data as of December 31, 2010 and 2009 from our audited consolidated
financial statements appearing elsewhere in this Annual Report on Form 10-K. The consolidated statements of
operations data for the years ended December 31, 2007 and 2006, and the selected consolidated balance sheet
data as of December 31, 2008, 2007, and 2006 are derived from our audited consolidated financial statements not
included in this Annual Report on Form 10-K.

Year Ended December 31,

2010

2009

2008

2007

2006

(In thousands, except per share amounts)

Consolidated Statements of Operations Data:
Revenues:

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $170,006 $115,108 $ 64,637 $ 53,536 $

Product sales, net
Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,637
1,138

2,203
11,138

1,739
1,138

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

173,781

128,449

67,514

Operating expenses:

Cost of product sales (excluding amortization of acquired

developed technology and intangible asset impairment) . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for government settlement . . . . . . . . . . . . . . . . . . . . . .

13,559
25,612
68,996
7,825
—
—

9,638
36,561
58,652
7,668
—
—

13,924
69,963
111,401
12,828
29,763
—

1,156
10,611

65,303

8,903
69,792
78,540
9,217
20,160
17,469

43,299
594
963

44,856

6,968
54,956
51,384
9,600
—
—

Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . .

115,992

112,519

237,879

204,081

122,908

Income (loss) from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense (including $570, $1,183, $1,179, $4,104 and
$4,047 for the years ended December 31, 2010, 2009, 2008,
2007 and 2006, respectively, pertaining to a related party) . . .
Other (expense) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on extinguishment of development financing obligation . .
Gain on sale of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on extinguishment of debt (including $701 pertaining to a

57,789
6

15,930
34

(170,365)
1,834

(138,778)
5,942

(78,052)
2,307

(12,728)
(2)

(22,796)
(4)

(19,742)
16

(13,647)
1,797
—
5,860

(14,129)
(1,109)
31,592
—

—
3,918

—
—

—
—

—

related party) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(12,287)

—

—

—

Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Beneficial conversion feature . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32,778
—

(6,836)
—

(184,339)

(138,826)

—

—

(59,391)
(21,920)

Income (loss) attributable to common stockholders . . . . . . . . . . . . . . . $ 32,778 $ (6,836) $(184,339) $(138,826) $ (81,311)

Net income (loss) per share attributable to common stockholders:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

0.90 $

(0.23) $

(7.19) $

(10.04) $(6,254.69)

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

0.83 $

(0.23) $

(7.19) $

(10.04) $(6,254.69)

Weighted-average common shares used in computing net income

(loss) per share attributable to common stockholders:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

36,343

30,018

25,646

13,829

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

39,411

30,018

25,646

13,829

13

13

46

Balance Sheet Data:
Cash, cash equivalents and marketable securities . . . . . . . . . .
Working capital (deficit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Liability under government settlement, non-current . . . . . . . .
Long-term debt, current and non-current (including $6,552,
$6,747, $23,474 and $23,213 as of December 31, 2009,
2008, 2007 and 2006, respectively, held by a related
party) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated deficit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total stockholders’ equity (deficit) . . . . . . . . . . . . . . . . . . . . .

As of December 31,

2010

2009

2008

2007

2006

(In thousands)

$ 44,794
14,522
135,729
6,978

$ 15,595
(22,287)
107,396
10,658

$ 25,907
(129,492)
117,498
13,063

$ 102,945
79,235
207,554
14,881

$ 78,948
61,043
214,571

—

40,693
(474,866)
30,551

114,866
(507,644)
(72,830)

118,534
(500,808)
(92,878)

75,116
(316,469)
54,992

74,283
(177,643)
(176,296)

K
-
0
1
m
r
o
F

47

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction
with the consolidated financial statements and notes to consolidated financial statements included elsewhere in
this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and
uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and
uncertainties that characterize our business. In particular, we encourage you to review the risks and
uncertainties described in Part I Item 1A. “Risk Factors” included elsewhere in this report. These risks and
uncertainties could cause actual results to differ materially from those projected in forward-looking statements
contained in this report or implied by past results and trends.

Overview

We are a specialty pharmaceutical company focused on the identification, development and

commercialization of pharmaceutical products to meet important unmet medical needs. Since we were founded
in 2003, we have built a commercial and development organization and assembled a portfolio of products and
product candidates that currently includes our two marketed products, which generated net product sales of
$170.0 million in 2010, and product candidates in various stages of clinical development. We currently market
two products: Xyrem (sodium oxybate), which is the only product approved by the United States Food and Drug
Administration, or FDA, for the treatment of both cataplexy and excessive daytime sleepiness in patients with
narcolepsy; and Luvox CR (fluvoxamine maleate) marketed for the treatment of obsessive compulsive disorder.
We promote these products in the United States through our experienced specialty sales force targeting sleep
specialists, neurologists, pulmonologists and psychiatrists. We are building our portfolio of products through a
combination of internal development, acquisition and in-licensing activities. Our current product candidates are
JZP-6 (sodium oxybate) for the treatment of fibromyalgia, JZP-8 (intranasal clonazepam) for the treatment of
acute repetitive seizures in epilepsy, and solid oral dosage forms of sodium oxybate.

2010 was our first year of profitability, driven by substantial increases in product sales, in particular an
increase in sales of Xyrem. We raised $56.8 million in equity capital in May 2010, which we used to pay down a
portion of our then outstanding senior secured notes. In June 2010, we repaid the remainder of the senior secured
notes, using cash on hand and the proceeds from a new $50.0 million three-year term loan. The new term loan
bears interest at a variable rate which was 5.75% during 2010, as compared to the 15% interest rate on the senior
secured notes we retired. As of December 31, 2010, we had $44.8 million of cash and cash equivalents and
$41.7 million principal amount outstanding under our new term loan. Because of our history of losses prior to
2010, we have significant net operating losses with which to offset current and potential future taxable income.

We are dependent on sales of Xyrem, which accounted for 84% of our net product sales in 2010. During
2010, an abbreviated new drug application, or ANDA, was filed with the FDA by a third party seeking to market
a generic form of Xyrem. We have sued that third party for infringement of our patents, and the litigation is
ongoing. We cannot predict the timing or outcome of this litigation. If an ANDA for Xyrem is approved and a
generic version of Xyrem is introduced, our sales of Xyrem would be adversely affected.

In October 2010, the FDA sent us a complete response letter, or CRL, regarding our NDA for JZP-6. The

CRL stated that the FDA cannot approve the NDA in its present form. In the letter, the FDA discussed a number
of topics, including the need for additional clinical studies. We have not yet finalized our plans with respect to
JZP-6, and at this time, we do not know if we will continue its development.

We are continuing the development of JZP-8 and we are currently planning for an additional Phase II study

for later in 2011. In addition, we are looking for appropriate opportunities to in-license or acquire additional
products and product candidates to leverage our existing commercial and development capabilities.

48

Results of Operations

Comparison of 2010 and 2009

Product sales, net

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Xyrem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Luvox CR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of product sales (excluding amortization of acquired

developed technology) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on extinguishment of debt . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(1) Comparison to prior period is not meaningful.

2010

2009

$170,006
142,630
27,376
2,637
1,138

(In thousands)
$115,108
96,763
18,345
2,203
11,138

13,559
25,612
68,996
7,825
6
12,728
2
12,287

9,638
36,561
58,652
7,668
34
22,796
4
—

Increase/
(Decrease)

Increase/
(Decrease)

$ 54,898
45,867
9,031
434
(10,000)

3,921
(10,949)
10,344
157
(28)
(10,068)
(2)
12,287

48%
47%
49%
20%
(90%)

41%
(30%)
18%
2%
(82%)
(44%)
(50%)
N/A(1)

K
-
0
1
m
r
o
F

Product Sales, Net

Xyrem product sales increased in 2010 compared to 2009, primarily due to price increases and to a lesser
extent a 7% increase in sales volume. Most of the increase in Luvox CR product sales was due to increases in
volume with the remainder due to price increases. In the fourth quarter of 2010 we recognized $2.0 million of
previously deferred revenue as a result of a change in the timing of when Luvox CR revenue is recognized.
While we expect total product sales to increase in 2011 over 2010, the rate of growth of product sales or sales
volumes, or both could be less than that experienced in 2010.

Royalties, Net,

Royalties increased in 2010 compared to 2009 due to an increase in royalties from sales of Xyrem in Europe

by UCB Pharma Limited, or UCB, under a license agreement. We expect modest growth in royalty income in
2011 as compared with 2010.

Contract Revenues

Contract revenues in 2010 and 2009 include previously deferred upfront payments under our agreement
with UCB, which are being recognized as contract revenues ratably through 2019, the expected performance
period under our agreement with UCB. In 2009, upon achievement of a milestone, we recognized as revenue a
$10.0 million milestone payment we received from UCB in 2008.

Cost of Product Sales

Cost of product sales increased in 2010 compared to 2009, primarily due to our increased sales volumes, and

included $674,000 of previously deferred costs recognized as a result of a change in the timing of when Luvox
CR revenue is recognized. As a percentage of product sales, costs were 8.0% and 8.4% in 2010 and 2009,
respectively. We do not expect cost of product sales as a percentage of sales to change significantly in 2011
compared to 2010.

49

Research and Development Expenses

Research and development costs were lower in 2010 compared to 2009, primarily due to lower spending on

JZP-6 and a $978,000 credit resulting from the government therapeutic discovery tax credit, partially offset by
higher spending on solid oral dosage forms of sodium oxybate. As a result, our direct project costs decreased
$12.9 million in 2010 compared to 2009, when we were actively conducting our second JZP-6 Phase III clinical
trial and enrolling patients in a long-term safety study. Headcount-related expenses and administrative costs
incurred in the research and development organization increased $2.0 million in 2010 compared to 2009. We
expect research and development spending in 2011 to be slightly lower than spending in 2010 and to consist
primarily of expenses associated with development work on our JZP-8 product candidate and, to a lesser extent,
solid oral dosage forms of sodium oxybate.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were higher in 2010 compared to 2009, primarily due to
increases in headcount-related expenses and, to a lesser extent, expenses related to our previously planned launch
of our JZP-6 product candidate. We expect that selling, general and administrative expenses will be higher in
2011 than in 2010 due to legal expenses associated with protecting our sodium oxybate business, additional
investments in Xyrem marketing and promotion and an increase in stock-based compensation expense.

Intangible Asset Amortization

Our intangible assets consist primarily of developed technology related to Xyrem and Luvox CR which are

amortized on a straight-line basis over their estimated useful lives. We expect intangible asset amortization in
2011 to be similar to 2010.

Interest Income

Interest income was lower in 2010 compared to 2009 due to lower average interest rates.

Interest Expense

Interest expense relates primarily to interest on our long-term debt and, to a small extent, interest on our
liability under a 2007 government litigation settlement. In 2010, we entered into a new term loan agreement and
retired our outstanding senior secured debt. As a result of these actions, we reduced the principal amount of our
long-term debt outstanding from $119.5 million as of December 31, 2009, to $41.7 million as of December 31,
2010, and we reduced the rate at which we pay interest on our debt from a fixed rate of 15% to a variable rate
that was 5.75% under our new term loan as of December 31, 2010. As a result, interest expense was substantially
lower in 2010 as compared to 2009.

Loss on Extinguishment of Debt

The loss on extinguishment of debt relates to our early repayment of the senior secured notes in May and

June 2010 and is comprised of $8.5 million of prepayment premiums and fees, and $3.8 million of non-cash
expense related to the write-off of unamortized debt discount and debt issuance costs.

50

Comparison of 2009 and 2008

Product sales, net

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Xyrem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Luvox CR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antizol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of product sales (excluding amortization of acquired

developed technology and intangible asset impairment) . . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset impairment
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other (expense) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(1) Comparison to prior period is not meaningful.

2009

2008

$115,108
96,763
18,345
—
2,203
11,138

(In thousands)
$ 64,637
53,803
5,728
5,106
1,739
1,138

9,638
36,561
58,652
7,668
—
34
22,796
(4)

—

13,924
69,963
111,401
12,828
29,763
1,834
19,742
16
3,918

Increase/
(Decrease)

Increase/
(Decrease)

$ 50,471
42,960
12,617
(5,106)
464
10,000

(4,286)
(33,402)
(52,749)
(5,160)
(29,763)
(1,800)
3,054
(20)
(3,918)

78%
80%
220%
N/A(1)
27%
N/A(1)

(31%)
(48%)
(47%)
(40%)
N/A(1)
(98%)
15%
N/A(1)
N/A(1)

K
-
0
1
m
r
o
F

Product Sales, Net

Xyrem product sales increased in 2009 compared to 2008, primarily due to price increases and a 10%

increase in sales volume. Most of the increase in Luvox CR product sales was due to increases in volume
following its launch in 2008 with the remainder due to price increases. In 2008, we sold our rights to and
interests in Antizol® and Antizol-Vet®, along with the associated product registrations, commercial inventory
and trademarks, and did not record products sales for Antizol® subsequent to that date.

Royalties, Net

Royalties increased in 2009 compared to 2008 due to an increase in royalties from sales of Xyrem by UCB.

Contract Revenues

In 2009, we recognized as revenue a $10.0 million milestone payment we received from UCB in 2008.

Cost of Product Sales

Cost of product sales decreased in 2009 compared to 2008 as a result of higher Luvox CR manufacturing

scale up costs in 2008 and a charge of $3.5 million in 2008 for excess Luvox CR inventory.

Research and Development Expenses

Research and development expenses were lower in 2009 compared to 2008 as we focused our development

efforts on our JZP-6 product candidate and curtailed spending on our other development projects. Direct
development costs decreased by $24.9 million. Headcount-related expenses and administrative costs incurred in
the research and development organization decreased $8.5 million in 2009 compared to 2008, primarily due to
our lower staffing levels in 2009.

51

Selling, General and Administrative Expenses

Selling, general and administrative expenses were lower in 2009 compared to 2008. In 2008, we reduced the

size of our sales force, which resulted in a $29.8 million reduction in 2009 sales and sales support costs
compared to 2008. In addition, direct marketing expenses for Luvox CR were $16.4 million lower in 2009
compared with 2008, the year we launched Luvox CR.

Intangible Asset Amortization

Amortization costs in 2009 were lower compared to 2008 primarily due to a $29.8 million intangible asset

impairment charge associated with Luvox CR recorded in 2008.

Intangible Asset Impairment

The intangible asset impairment charge in 2008 resulted from an impairment of the intangible asset

associated with Luvox CR.

Interest Income

Interest income was lower in 2009 compared to 2008 due to lower average cash balances and to lower

average interest rates.

Interest Expense

Interest expense in 2009 and 2008 related primarily to interest on the then outstanding senior secured notes

and, to a small extent, interest on our liability under a 2007 government litigation settlement. The increase in
interest expense in 2009 as compared to 2008 was primarily due to interest expense recorded on the additional
$40.0 million principal amount of the then outstanding senior secured notes we issued in March 2008 and to a
lesser extent a higher average interest rate.

Gain on Sale of Product Rights

In 2008, we sold our rights to and interests in Antizol® and Antizol-Vet®, along with the associated product

registrations, commercial inventory and trademarks, for $5.8 million and recorded a gain of $3.9 million.

Non-GAAP Financial Measures

To supplement our financial results presented on a GAAP basis, we use the non-GAAP measures adjusted
net income (loss) and adjusted net income (loss) per diluted share as shown in the table below. These measures
exclude the following: revenue related to upfront and milestone payments, the gross margin impact of a change
in the timing of when Luvox CR revenue is recognized, a gain on sale of product rights, a loss on extinguishment
of debt, amortization and impairment of intangible assets, stock-based compensation, and non-cash interest
expense associated with a debt discount and debt issuance costs. We believe these non-GAAP financial measures
are helpful in understanding our past financial performance and our potential future results. They are not meant
to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction
with our consolidated financial statements prepared in accordance with GAAP. Our management regularly uses
these supplemental non-GAAP financial measures internally to understand, manage and evaluate our business
and make operating decisions. Compensation of our executives is based in part on the performance of our
business based on these non-GAAP measures. In addition, we believe that the use of these non-GAAP measures
enhances the ability of investors to compare our results both from period to period. Adjusted net income (loss)
and adjusted net income (loss) per diluted share, as used by us, may be calculated differently from, and therefore
may not be directly comparable to, similarly titled measures used by our competitors and other companies.

52

A reconciliation of GAAP net income (loss) to adjusted net income (loss), a non-GAAP financial measure,

and related per share amounts follows:

GAAP net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Add:

Year Ended December 31,

2010

2009

2008

(In thousands, except per share amounts)
$ (6,836) $(184,339)
$32,778

Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset impairment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on extinguishment of debt

7,825
—
8,219
2,406
12,287

7,668
—
5,957
2,810
—

Deduct:

Contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Luvox CR revenue recognition timing change . . . . . . . . . . . . . . . . . . . .
Gain on sale of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(1,138)
(1,345)
—

(11,138)
—
—

12,828
29,763
8,106
2,060
—

(1,138)
—
(3,918)

Adjusted net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$61,032

$ (1,539) $(136,638)

GAAP net income (loss) per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . .

Adjusted net income (loss) per diluted share . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

0.83

1.55

$

$

(0.23) $

(7.19)

(0.05) $

(5.33)

Shares used in computing GAAP and adjusted net income (loss) per diluted
share amounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

39,411

30,018

25,646

K
-
0
1
m
r
o
F

Liquidity and Capital Resources

During 2010, we took a number of measures designed to strengthen our balance sheet and improve our

liquidity and financial condition. In May 2010, we issued 7,000,000 shares of our common stock in an
underwritten public offering for net proceeds of $56.8 million, and in June 2010 we entered into a new credit
agreement which provides for a $50.0 million term loan and a revolving credit facility maturing in June 2013,
secured by substantially all of our assets. We used the proceeds from the offering and the new term loan, along
with some of our available cash, to prepay in full all of our then outstanding senior secured notes.

As of December 31, 2010, we had cash and cash equivalents of $44.8 million. We believe that our existing

cash balances and cash we expect to generate from operations will be sufficient to fund our operations and to
meet our existing obligations for the foreseeable future. The adequacy of our cash resources depends on many
assumptions, including primarily our assumptions with respect to product sales and expenses as well as the other
factors set forth in Part I Item 1A of this Annual Report on Form 10-K under the heading “To grow our business,
we will need to commit substantial resources, which could result in future losses or otherwise limit our
opportunities or affect our ability to operate our business.” Our assumptions may prove to be wrong or other
factors may adversely affect our business, and as a result we could exhaust or significantly decrease our available
cash resources which could, among other things, force us to raise additional funds and/or force us to reduce our
expenses, either of which could have a material adverse effect on our business.

As of December 31, 2010, $41.7 million principal amount was outstanding on our term loan which is
repayable in quarterly installments of $4.2 million, and $7.4 million was outstanding under the revolving credit
facility. The average daily amount outstanding under the revolving credit facility since its inception in June 2010
through December 31, 2010, was $2.0 million. The borrowing availability under the revolving credit facility is
currently $15.0 million. The revolving credit facility has a commitment fee payable on the undrawn amount
which is currently 0.5% per annum. Interest on the term loan and the revolving credit facility was payable at a
variable rate which was 5.75% in 2010 and is currently 3.75%. Interest on the fully repaid senior secured notes
was payable at a fixed rate of 15%.

53

Our credit agreement contains customary operating covenants, including covenants that restrict our ability

to: incur indebtedness and liens; effect mergers, consolidations and other fundamental changes; dispose of
significant assets or enter into sale-leaseback transactions; pay dividends or make other restricted payments;
make loans, advances or certain investments, including acquisitions of companies and products; or enter into
transactions with affiliates. The credit agreement also requires us to comply with financial covenants requiring us
to maintain a minimum consolidated fixed charge coverage ratio, a maximum consolidated leverage ratio and
minimum liquidity, each as defined in the credit agreement. Our failure to comply with any of the operating and
financial covenants contained in the credit agreement would constitute an event of default under the credit
agreement. The credit agreement contains other customary events of default. Upon the occurrence of one or more
events of default all or part of the obligations under the credit agreement may be declared immediately due and
payable and borrowings under the credit agreement may be stopped. We are currently in compliance with all
material covenants under the credit agreement.

To grow our business over the longer-term, we will need to commit substantial resources to product
acquisition and in-licensing costs, to expensive and time-consuming product development and clinical trials of
our product candidates, and to expanding our commercial operations. We may need to raise additional funds to
license or acquire additional products, product candidates or companies or seek to raise additional funds for
general corporate purposes. Raising additional capital could be accomplished through one or more public or
private debt or equity financings, collaborations, partnering arrangements or development financings or a draw
down of funds under our committed equity financing facility, or CEFF, with Kingsbridge Capital Limited which
expires in December 2012. Under the CEFF, we have the ability to draw down amounts up to $75.0 million,
subject to certain conditions and limitations. Any equity financing would be dilutive to our stockholders, and the
consent of the lender under our credit agreement could be required.

The following table shows a summary of our cash flows for the periods indicated:

Year Ended December 31,

2010

2009

2008

Net cash provided by (used in) operating activities . . . . . . . . . . . . . . . . . . . . . .
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash (used in) provided by financing activities . . . . . . . . . . . . . . . . . . . . . .

$ 58,868
(2,143)
(27,526)

(In thousands)
$(15,878) $(130,232)
(11,942)
64,132

(6,124)
12,694

Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . . . . . . . . . .

$ 29,199

$ (9,308) $ (78,042)

In each of 2010, 2009 and 2008, net cash provided by or used in operating activities primarily reflected our

net income or loss, adjusted for non-cash items including depreciation, amortization, impairment losses, losses on
disposal of property and equipment, non-cash interest expense, loss on extinguishment of debt, stock-based
compensation and gains on sales of product rights, and changes in working capital and the provision for our
liability from the settlement of government litigation in 2007. In 2010, 2009 and 2008, operating cash outflows
included $3.0 million, $2.5 million, and $2.0 million, respectively, paid to the government as part of the
settlement.

Net cash used in investing activities in 2010 included $4.0 million paid to Solvay Pharmaceuticals, Inc., or

Solvay, which was acquired by Abbott Laboratories, or Abbott, for the rights to market Luvox CR partially offset
by a decrease in restricted cash. Net cash used in investing activities in 2009 included $6.0 million paid to Solvay
and an increase in restricted cash, offset by the maturity of an investment in a marketable security. Net cash used
in investing activities in 2008 included $27.0 million paid to Solvay, the purchase of property and equipment of
$1.7 million, partially offset by the release of $12.0 million of cash that was previously restricted under the
agreement governing the then outstanding senior secured notes, and proceeds of $5.8 million from the sale of our
product rights to Antizol and Antizol-Vet.

Net cash used in financing activities in 2010 included the principal repayment of the senior secured notes of
$119.5 million offset by proceeds from a common stock offering of $56.8 million and net cash inflows from our

54

term loan of $40.1 million. Net cash provided by financing activities in 2009 included net proceeds of $6.8
million from a private placement of common stock and warrants and $5.5 million in net borrowings under our
prior revolving bank line of credit. Net cash provided by financing activities in 2008 related primarily to the sale
of $40.0 million aggregate principal amount of the then outstanding senior secured notes for net proceeds of
$38.5 million, and $24.5 million of net proceeds from a registered direct public offering of common stock and
warrants.

Contractual Obligations

The following table reflects a summary of our contractual obligations as of December 31, 2010:

Contractual Obligations(1)

Payments due by period

Total

Less than
1 Year

1-3 Years

3-5 Years

More than
5 years

Term loan—principal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Term loan—interest(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Liability under government settlement . . . . . . . . . . . . . . . . .
Purchased product rights liability(3)
. . . . . . . . . . . . . . . . . .
Revolving credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease obligations(4) . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase obligations(5)

$41,668
2,216
11,500
9,000
7,350
4,511
2,080

$16,664
1,395
4,164
4,500
7,350
1,915
2,080

(In thousands)
$25,004
821
7,336
4,500
—
2,472
—

$—

$—

—
—
—
124
—

—
—
—
—
—

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$78,325

$38,068

$40,133

$124

$—

K
-
0
1
m
r
o
F

(1) We have not included milestone or royalty payments or contractual payment obligations in the table above if

the amount and timing of such obligations are unknown or uncertain.

(2) Borrowings under the term loan bear interest at a variable rate which was 5.75% at December 31, 2010 and
subsequently decreased to 3.75% under the terms of our credit agreement. We have calculated future
interest payments assuming that interest on the term loan will be paid at a rate of 3.75%, which may not
represent actual interest payments made.

(3) This represents payments due to Abbott under a product license agreement. These amounts exclude

$5.0 million we would pay Abbott if net sales of Luvox CR have reached a cumulative amount of
$100.0 million on or before December 31, 2014 and no AB-rated generic version of Luvox CR has been or
is being sold in the United States as of December 31, 2014 because we do not know if we will have to pay it.

(4)

Includes the minimum lease payments for our corporate office building and automobile lease payments for
our sales force. In addition to the minimal lease payments on our office building we are obligated to pay for
operating expenses for the lease property, which are not included in the table above.

(5) Consists of commitments to third party manufacturers of Xyrem and Luvox CR.

Critical Accounting Policies and Significant Estimates

Revenue Recognition

Revenues are recognized when there is persuasive evidence that an arrangement exists, delivery has

occurred, the price is fixed and determinable and collection is reasonably assured. Revenue from sales
transactions where the buyer has the right to return the product is recognized at the time of sale only if (i) the
seller’s price to the buyer is substantially fixed or determinable at the date of sale, (ii) the buyer has paid the
seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product,
(iii) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or
damage of the product, (iv) the buyer acquiring the product for resale has economic substance apart from that
provided by the seller, (v) the seller does not have significant obligations for future performance to directly bring
about resale of the product by the buyer, and (vi) the amount of future returns can be reasonably estimated.

55

Product Sales, Net

Xyrem—Domestic. We sell Xyrem in the United States to a single central pharmacy, Express Scripts
Specialty Distribution Services and its affiliate Curascript, Inc., or Express Scripts. In 2010, sales of Xyrem to
Express Scripts accounted for 84% of our net product sales. We recognize revenues from sales of Xyrem within
the United States upon transfer of title, which occurs when Express Scripts removes product from our consigned
inventory location at its facility for shipment directly to a patient.

We accept returns from and provide Express Scripts with a credit for any product returned by patients to
Express Scripts with defects that were not reasonably discoverable upon receipt of the consigned product by
Express Scripts. Based on our experience over the past five years, product returns to Express Scripts from
patients are extremely rare; during 2010 we issued less than $20,000 of credits to Express Scripts for returned
product.

Xyrem—International. We sell limited quantities of Xyrem to UCB for sale in territories outside of North

America, and to Valeant, for sale in Canada, under license and distribution agreements. The agreements provide
our international licensees with a fixed period of time after delivery to inspect and reject shipments for failure to
meet specifications. We do not recognize revenue on the sales to our international licensees until the right of
return has lapsed, which occurs when we are notified of their acceptance, or when the time for them to inspect or
reject a shipment has lapsed, if earlier. We recognized revenue of $716,000, $1.0 million and $769,000 from
international sales of Xyrem during 2010, 2009 and 2008, respectively.

Luvox CR. We grant rights to our wholesaler customers to return product six months prior to and up to

twelve months after product expiration and issue credits which may be applied against existing or future
invoices. From product launch in 2008 until the fourth quarter of 2010, we did not believe we were able to
reasonably estimate expected returns of Luvox CR at the time of shipment, and therefore we recognized revenue
when units were dispensed through prescriptions, at which point the product was not subject to return. We
purchased dispensing data from an independent prescription tracking service which we used to estimate units
dispensed. As of October 1, 2010, we believed we had sufficient historical data on returns of Luvox CR to
reasonably estimate a return rate when a unit is shipped. As a result, as of October 1, 2010, we started
recognizing revenue upon shipment to our wholesaler customers and recorded an estimated amount of product
returns. We recognized $2.0 million of previously deferred net product sales and $674,000 of previously deferred
product costs in the fourth quarter of 2010. We recorded a $3.5 million liability for estimated future returns as of
December 31, 2010.

Items Deducted from Gross Sales. Revenues from sales of products within the United States are recorded net

of estimated allowances for returns, specialty distributor fees, wholesaler fees, prompt payment discounts,
government rebates, government chargebacks, patient rebates and rebates under managed care plans. Calculating
certain of these items involves estimates and judgments based on sales or invoice data, contractual terms,
historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that
would impact the amount of the actual rebates, our expectations regarding future utilization rates for these
programs and channel inventory data. Because we derive most of our revenues from sales of Xyrem in the United
States to one specialty pharmacy customer, Express Scripts, we have a much higher level of knowledge about
each prescription than if we sold the product through the normal pharmaceutical wholesaler channel as we do
with Luvox CR. As a result, we do not exercise a high degree of judgment in estimating most of the items that
are deducted from gross sales. The two most significant items deducted from gross revenue where we exercise
judgment are government rebates, which include Medicaid and TRICARE rebates, and estimated returns of
Luvox CR.

56

K
-
0
1
m
r
o
F

The following table shows activity related to government rebates and estimated returns of Luvox CR:

Balance at December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current year provision related to sales in current year . . . . . . . . . . . . . . . . . . . .
Current year provision related to sales in prior year . . . . . . . . . . . . . . . . . . . . . .
Payments/credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balance at December 31, 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current year provision related to sales in current year . . . . . . . . . . . . . . . . . . . .
Current year provision related to sales in prior year . . . . . . . . . . . . . . . . . . . . . .
Payments/credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balance at December 31, 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current year provision related to sales in current year . . . . . . . . . . . . . . . . . . . .
Current year provision related to sales in prior year . . . . . . . . . . . . . . . . . . . . . .
Payments/credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Government
Rebates
Payable

Sales
Returns
Reserve

(In thousands)

$

64
500
3
(396)

171
3,158
619
(1,678)

2,270
11,083
(100)
(6,665)

$ —
—
—
—

—
—
—
—

—
3,921
—
(382)

Balance at December 31, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 6,588

$3,539

Contract Revenues

Nonrefundable fees where we have no continuing performance obligations are recognized as revenues when
there is persuasive evidence of an arrangement and collection is reasonably assured. In situations where we have
continuing performance obligations, nonrefundable fees are deferred and recognized ratably over our estimated
performance period. We recognize at-risk milestone payments, which are typically related to regulatory,
commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is
accomplished and collection is reasonably assured. Refundable fees are deferred and recognized as revenues
upon the later of when they become nonrefundable or when our performance obligations are completed.

We have an agreement with UCB under which UCB has the right to market Xyrem for the treatment of
narcolepsy and for the treatment of fibromyalgia in various countries outside the United States. In 2008 we
received a $10.0 million nonrefundable milestone payment which we recognized as revenue in 2009 upon
achievement of the milestone. We recognized contract revenues of $1.1 million during each of 2010, 2009, and
2008 related to two upfront payments from UCB totaling $15.0 million related to Xyrem for the treatment of
fibromyalgia. As of December 31, 2010, $10.2 million was recorded as deferred revenues related to these upfront
payments and is being recognized ratably through 2019, the end of the expected performance period under the
agreement. There has been no change in the expected performance period under our agreement with UCB since
its establishment in 2006 at the time of the initial upfront payments. A change in our estimate of the performance
period would result in a change in contract revenues.

Inventory Valuation

Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method

for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis
in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of
excess quantities is subjective and primarily dependent on our estimates of future demand for the product. If our
estimate of future demand is too high we may have to write down the carrying value of inventory and record
additional charges to cost of product sales. We recorded charges to cost of product sales related to Luvox CR
totaling $82,000 and $4.2 million, during 2009 and 2008, respectively, for inventory and purchase orders we
judged to be in excess of expected requirements.

57

Goodwill and Intangible Assets

Goodwill

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities
assumed. We have determined that we operate in a single segment and have a single reporting unit associated
with the development and commercialization of pharmaceutical products. The annual test for goodwill
impairment is a two-step process. The first step is a comparison of the fair value of the reporting unit with its
carrying amount, including goodwill. If this step indicates impairment, then in the second step, the loss is
measured as the excess of recorded goodwill over its implied fair value. Implied fair value is the excess of the
fair value of the reporting unit over the fair value of all identified assets and liabilities. We test goodwill for
impairment annually in October and when events or changes in circumstances indicate that the carrying value
may not be recoverable.

Intangible Assets

Intangible assets consist of purchased developed technology and trademarks. The method of amortization

reflects the pattern in which the economic benefits of the intangible asset are consumed. If that pattern cannot be
reliably determined, we use a straight-line amortization method. Our intangible assets are amortized on a
straight-line basis over their estimated useful lives, which range from three to ten years. The estimated useful
lives associated with intangible assets are consistent with the estimated lives of the products and may be
modified when circumstances warrant. Once an intangible asset is fully amortized, the gross costs and
accumulated amortization are removed from the consolidated balance sheet. We evaluate purchased intangibles
and other long-lived assets, other than goodwill, for impairment whenever events or changes in circumstances
indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized
when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual
disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves
estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of
a change in the estimated useful life of the asset, a change in amortization expense.

Our two most significant intangible assets are related to Xyrem for the treatment of cataplexy associated

with narcolepsy and the Xyrem trade name, collectively the Xyrem intangibles, which were recorded as part of
an acquisition in 2005. As of December 31, 2010 those two assets had a carrying value of $17.8 million, or 81%
of our total intangible asset carrying amount of $22.0 million. At the time of the acquisition we estimated the life
of the Xyrem intangibles to be 9.5 years, or through December 31, 2014, which corresponded to the time period
during which we expected the assets to generate cash flows in our valuation analysis.

As of December 31, 2010, the gross carrying amount of goodwill was $38.2 million and the gross carrying

amounts and net book values of intangible assets were as follows:

Developed technology—Xyrem . . . . . . . . . . . . . . . . . . . . . . .
Developed technology—Luvox CR . . . . . . . . . . . . . . . . . . . .
Trademarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31, 2010

Gross Carrying
Amount

Accumulated
Amortization

Net Book
Value

$39,700
9,700
2,600

$52,000

(In thousands)
$23,014
5,446
1,507

$16,686
4,254
1,093

$29,967

$22,033

Weighted
Average
Remaining
Useful Life

(In years)
4.0
1.4
4.0

58

Stock-Based Compensation

We have elected to use the Black-Scholes option pricing model to calculate the fair value of stock option

grants under our equity incentive plans and grants under our 2007 Employee Stock Purchase Plan, or ESPP, and
we are using the straight-line method to allocate compensation cost to reporting periods. The fair value of stock
options was estimated using the following assumptions:

Year Ended December 31,

2010

2009

2008

Weighted-average volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted-average expected term (years) . . . . . . . . . . . . . . . . . . . . . . . .
Range of risk-free rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

85%
6.0

91%
6.1
1.5-3.1% 1.8-3.1% 2.7-3.4%
0.0%

60%
6.1

0.0%

0.0%

We completed our initial public offering in 2007 and our common stock therefore has a trading history
which is shorter than the weighted-average expected term of our stock option grants. A public market for options
on our common stock did not exist before 2009, and the market for options with more than one year to expiration
is not very liquid. In 2008 we used the historic volatility of a peer group to estimate the future volatility for our
stock option grants and we used the historic and implied volatility of a peer group in addition to the historic
volatility of our own common stock to estimate volatility for grants under our ESPP. In 2009, we used the
historic volatility of a peer group and the historic volatility of our own common stock to estimate future volatility
for stock option grants and we used the implied volatility of our own common stock to estimate the volatility for
grants under our ESPP. In 2010, we used the historic volatility of a peer group, the historic volatility of our own
common stock and the implied volatility of our own common stock to estimate future volatility for stock option
grants and we used the implied volatility of our own common stock to estimate the volatility for grants under our
ESPP.

K
-
0
1
m
r
o
F

We have limited historical information with which to develop reasonable expectations about the expected
term of our stock options. As a result, for stock option grants made during 2010, 2009 and 2008, the expected
term was estimated by assuming stock options would be exercised at the mid-point between the vest date and the
contractual term.

The risk-free interest rate assumption was based on zero coupon U.S. Treasury instruments whose term was
consistent with the expected term of our stock option grants. The expected dividend yield assumption was based
on our history and expectation of no dividend payouts.

Accrued Liabilities

As part of the process of preparing financial statements, we are required to estimate accrued liabilities. This
process involves identifying goods received and services that have been performed on our behalf and estimating
the level of service performed and the associated cost incurred for such service as of each balance sheet date in
our financial statements. Examples of estimated accrued liabilities include the cost of marketing and promotional
materials, contract service fees, such as amounts paid to clinical monitors, data management organizations,
clinical research organizations and fees paid to contract manufacturers in conjunction with the production of
clinical materials, and professional service fees, such as fees to lawyers and accountants. In connection with such
service fees, our estimates are most affected by our understanding of the status and timing of services provided.
The majority of our service providers invoice us in arrears for services performed. To the extent that we do not
identify certain costs that have begun to be incurred or we under- or over-estimate the level of services performed
or the costs of such services, our reported expenses for such period would be too low or too high. The date on
which certain services commence, the level of services performed on or before a given date and the cost of such
services are often subject to our judgment. We make these judgments in accordance with the facts and
circumstances known to us through our internal processes. Our internal processes require substantially all of our
spending for services to be under contracts with our service providers and to be documented and tracked under

59

internally-generated purchase orders based on designated spending authorizations. As of each balance sheet date,
employees who are responsible for managing the contracts, and who are in contact with the outside service
providers as to progress or stage of completion of the services and the agreed upon fee to be paid for such
services, review current contracts and the related open purchase orders. We adjust for spending not already
reflected in our accounting records in accordance with generally accepted accounting principles. To date, there
have been no material differences between the amounts of expenses accrued at our balance sheet dates and the
amount at which such expenses were subsequently invoiced. Although we do not expect our current estimates to
be materially different when invoiced, our understanding of the status and timing of services provided relative to
the actual timing and levels of service provided may vary and may result in adjustments in future periods.

Income Taxes

We utilize the liability method of accounting for income taxes. Under this method, deferred tax assets and

liabilities are determined based on differences between financial reporting and the tax bases of assets and
liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are
expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of
a deferred tax asset will not be realized. Despite achieving profitability in 2010, we continue to maintain a full
valuation allowance on our net operating losses and other deferred tax assets. Realization of our deferred tax
assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain.
If we continue to generate income, we may conclude that it is more likely than not that all or a portion of our
deferred tax assets are realizable, and we will reverse the valuation allowance and recognize a related tax benefit
at such time. We believe that a release of the valuation allowance, in full or in part, may occur in 2011. This
determination depends on a variety of factors, some of which are subjective. We have also provided for uncertain
tax positions that we believe are not more likely than not to be sustained upon examination by tax authorities, the
effect of which are less significant.

Recent Accounting Pronouncements

In October 2009, the FASB issued authoritative guidance which amends the revenue recognition guidance to
require companies to allocate revenue in multiple-element arrangements based on an element’s estimated selling
price if vendor-specific or other third-party evidence is not available. The guidance became effective for us
beginning January 1, 2011 and is being applied prospectively to multiple-deliverable revenue arrangements
entered into on or after January 1, 2011. The adoption of this guidance is not expected to have a material impact
on our results of operations and financial position.

Off-Balance Sheet Arrangements

Since our inception, except for standard operating leases, we have not engaged in any off-balance sheet

arrangements, including the use of structured finance, special purpose entities or variable interest entities.

Related Parties

Senior Secured Notes. In 2010, we repaid in full all of our then outstanding senior secured notes, of which

$6.8 million principal amount was paid to an entity affiliated with Kohlberg, Kravis & Roberts & Co. L.P., or
KKR, a significant stockholder. In addition, in 2010 we paid prepayment penalties and a fee to the holders of the
senior secured notes totaling $8.5 million, of which $484,000 was paid to the KKR affiliate. In 2008, we paid
$327,000 to the KKR affiliate, as partial prepayment of the principal amount of the senior secured notes held by
the KKR affiliate. Cash paid for interest with respect to then outstanding senior secured notes held by the KKR
affiliate was $461,000, $1.3 million, and $796,000 in 2010, 2009, and 2008, respectively. All payments to KKR
were in proportion to its ownership of the senior secured notes.

60

K
-
0
1
m
r
o
F

In 2009, the exercise price of all warrants to purchase common stock issued to the holders of the then
outstanding senior secured notes was reduced to $9.34 per share as a result of an amendment to the agreement
governing the senior secured notes. This included warrants to purchase 70,156 shares of our common stock held
by the KKR affiliate the exercise price of which was reduced from $20.36 to $9.34 per share.

2009 and 2010 Common Stock Offerings. In a private placement we completed in 2009, 1,858,486 shares of
common stock and a warrant to purchase 929,243 shares of common stock were acquired by Longitude Venture
Partners, L.P. and 37,248 shares of common stock and a warrant to purchase 18,624 shares of common stock
were acquired by Longitude Capital Associates, L.P. In July 2009, Patrick G. Enright was elected to our board of
directors in connection with the closing of the private placement. Mr. Enright is a managing member of
Longitude Capital Partners, LLC, the sole general partner of Longitude Venture Partners, L.P. and Longitude
Capital Associates, L.P. In addition, in 2010 we issued 7,000,000 shares of our common stock in an underwritten
public offering of which 838,323 shares were purchased from the underwriter by Longitude Capital Partners,
LLC. The remaining shares were purchased from the underwriter by third party investors on the same terms and
conditions.

2008 Common Stock Offering. In a registered direct public offering we completed in 2008, a total of 60% of

the investment was made by certain of our existing stockholders with which certain members of our board of
directors are affiliated and/or associated; the remaining units were purchased by third party institutional investors
on the same terms and conditions. In the offering, entities affiliated with KKR purchased units consisting of
1,328,527 shares of common stock and warrants to purchase 597,837 shares of common stock exercisable at
$7.37 per share through July 2014.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk is confined to our cash equivalents and restricted cash, all of which have
maturities of less than one year and bear interest rates at variable rates and are denominated in, and pay interest
in, U.S. dollars. The fair value of items exposed to market risk was $25.0 million and $5.1 million as of
December 31, 2010 and 2009, respectively. The goals of our investment policy are liquidity and capital
preservation. We limit our credit and liquidity risks through our investment policy and through regular reviews of
our portfolio against our policy. Our investment policy allows us to maintain a portfolio of cash equivalents and
short-term investments in a variety of securities, including U.S. government agencies, corporate bonds,
commercial paper and money market funds. Our cash equivalents and restricted cash as of December 31, 2010
and 2009 consisted primarily of money market funds. The effect of a 100 basis point change in the average yield
earned on our cash equivalents and short-term investments would have the effect of increasing our interest
income by less than $250,000 and, due to the nature of the investments, would not have had an impact on their
fair value.

We pay interest on borrowings under a term loan and revolving credit facility at a variable rate, subject to

certain minimums, that was 5.75% in 2010 and is currently 3.75%. The rate is currently variable based on short-
term (less than six months maturity) Eurodollar interest rates which would have to increase by between 25-50
basis points for us to avoid paying interest at the minimum 3.75% rate. If rates increase above that minimum rate,
each 100 basis point increase in interest rates will cause interest expense in 2011 to increase by approximately
$350,000.

Operating expenses and capital expenditures denominated in currencies other than U.S. dollars are

insignificant. We receive royalties on certain net product sales that are denominated in other currencies, primarily
in Euros, but these royalties comprise a small portion of our revenues.

61

Item 8.

Financial Statements and Supplementary Data

Our consolidated financial statements as listed below are attached to this Annual Report on Form 10-K as

pages F-1 through F-28.

Jazz Pharmaceuticals, Inc.
Reports of Independent Registered Public Accounting Firm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Balance Sheets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Stockholders’ Equity (Deficit)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Page

F-1
F-2
F-3
F-4
F-6
F-7

62

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We have carried out an evaluation, under the supervision, and with the participation of, management

including our principal executive officer and principal financial officer, of our disclosure controls and procedures
(as defined in Rule 13a-15(e)) of the Securities Exchange Act of 1934, as amended, or Exchange Act) as of the
end of the period covered by this annual report on Form 10-K. Based on their evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of
December 31, 2010.

Limitations on the Effectiveness of Controls. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of
inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and
procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure
control system are met and, as set forth above, our principal executive officer and principal financial officer have
concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure
controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure
control system were met.

K
-
0
1
m
r
o
F

Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting occurred during our fiscal quarter ended

December 31, 2010 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

Management’s Report on Internal Control over Financial Reporting

The following report is provided by management in respect of Jazz Pharmaceuticals’ internal control over

financial reporting (as defined in Rule 13a-15(f) of the Exchange Act):

1. Jazz Pharmaceuticals’ management is responsible for establishing and maintaining adequate internal
control over financial reporting.

2. Jazz Pharmaceuticals’ management has used the Committee of Sponsoring Organizations of the
Treadway Commission, or the COSO framework, to evaluate the effectiveness of internal control over
financial reporting. Management believes that the COSO framework is a suitable framework for its
evaluation of financial reporting because it is free from bias, permits reasonably consistent qualitative and
quantitative measurements of Jazz Pharmaceuticals’ internal control over financial reporting, is sufficiently
complete so that those relevant factors that would alter a conclusion about the effectiveness of Jazz
Pharmaceuticals’ internal control over financial reporting are not omitted and is relevant to an evaluation of
internal control over financial reporting.

3. Management has assessed the effectiveness of Jazz Pharmaceuticals’ internal control over financial
reporting as of December 31, 2010 and has concluded that such internal control over financial reporting was
effective. There were no material weaknesses in internal control over financial reporting identified by
management.

4. Ernst & Young LLP, our independent registered public accounting firm has audited our consolidated
financial statements included herein and has issued an audit report on our internal control over financial
reporting which is included below.

63

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of
Jazz Pharmaceuticals, Inc.

We have audited Jazz Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31,

2010, based on criteria established in Internal Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (the COSO criteria). Jazz Pharmaceuticals, Inc.’s
management is responsible for maintaining effective internal control over financial reporting, and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying
Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion
on the company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether effective internal control over financial reporting was maintained in all material respects. Our
audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, testing and evaluating the design and operating effectiveness of internal control based
on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the
company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.

In our opinion, Jazz Pharmaceuticals, Inc. maintained, in all material respects, effective internal control over

financial reporting as of December 31, 2010, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board

(United States), the balance sheets of Jazz Pharmaceuticals, Inc. as of December 31, 2010 and 2009 and the
related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for each of the three
years in the period ended December 31, 2010 of Jazz Pharmaceuticals, Inc. and our report dated March 8, 2011
expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Palo Alto, California
March 8, 2011

64

K
-
0
1
m
r
o
F

Item 9B. Other Information

None.

PART III

Certain information required by Part III is omitted from this Annual Report on Form 10-K since we intend to file our

definitive proxy statement for our 2011 annual meeting of stockholders, pursuant to Regulation 14A of the Securities
Exchange Act of 1934, as amended, not later than 120 days after the end of the fiscal year covered by this Annual Report
on Form 10-K, and certain information to be included in the proxy statement is incorporated herein by reference.

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this item with respect to our executive officers may be found under the caption,

“Executive Officers of the Registrant” in Item 1 of this Annual Report on Form 10-K. The information required by
this item relating to our directors and nominees for director may be found under the section entitled “Proposal 1—
Election of Directors” in the proxy statement for our 2011 annual meeting of stockholders. Such information is
incorporated herein by reference. The information required by this item relating to our audit committee, audit
committee financial expert and procedures by which stockholders may recommend nominees to our board of
directors, may be found under the section entitled “Corporate Governance and Board Matters” appearing in the
proxy statement for our 2011 annual meeting of stockholders. Such information is incorporated herein by reference.
Information regarding compliance with Section 16(a) of the Securities Exchange Act of 1934, as amended, may be
found under the section entitled “Section 16(a) Beneficial Ownership Reporting Compliance” appearing in our
proxy statement for our 2011 annual meeting of stockholders. Such information is incorporated herein by reference.

The Jazz Pharmaceuticals Code of Conduct applies to all officers, directors and employees, including our

principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions. The Code of Conduct is available on our website at www.jazzpharmaceuticals.com
under the section entitled “Company” at “Corporate Responsibility”. Stockholders may request a free copy of the
Code of Conduct by submitting a written request to Jazz Pharmaceuticals, Inc., Attention: Investor Relations,
3180 Porter Drive, Palo Alto, California 94304. If we make any substantive amendments to the Code of Conduct
or grant any waiver from a provision of the Code of Conduct to any executive officer or director, we will
promptly disclose the nature of the amendment or waiver on our website.

Item 11. Executive Compensation

The information required by this item is included in our proxy statement for our 2011 annual meeting of

stockholders under the sections entitled “Executive Compensation,” “Director Compensation,” “Corporate
Governance and Board Matters—Compensation Committee Interlocks and Insider Participation” and “Corporate
Governance and Board Matters—Compensation Committee Report” and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters

The information required by this item is included in our proxy statement for our 2011 annual meeting of
stockholders under the sections entitled “Security Ownership of Certain Beneficial Owners and Management”
and “Equity Compensation Plan Information” and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is included in our proxy statement for our 2011 annual meeting of

stockholders under the sections entitled “Certain Relationships and Related Transactions” and “Corporate
Governance and Board Matters—Independence of Jazz Pharmaceuticals’ Board of Directors” and is incorporated
herein by reference.

Item 14. Principal Accounting Fees and Services

The information required by this item is incorporated herein by reference to the information included in our
proxy statement for our 2011 annual meeting of stockholders under the section entitled “Proposal 2—Ratification
of Selection of Independent Registered Public Accounting Firm.”

65

Item 15. Exhibits and Financial Statement Schedules

(a) The following documents are filed as part of this Annual Report on Form 10-K

PART IV

1.

Index to Financial Statements:

See Index to Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K.

2.

Financial Statement Schedules:

The following financial statement schedule of Jazz Pharmaceuticals, Inc. is filed as part of this Annual
Report on Form 10-K and should be read in conjunction with the consolidated financials statements of Jazz
Pharmaceuticals.

Schedule II: Valuation and Qualifying Accounts

All other schedules are omitted because they are not applicable, not required under the instructions, or the

requested information is shown in the consolidated financial statements or related notes thereto.

(b) Exhibits—The following exhibits are included herein or incorporated herein by reference:

Exhibit
Number

2.1

3.1

3.2

4.1

4.2

4.3A

4.3B

4.3C

Description of Document

Agreement and Plan of Merger dated as of April 18, 2005, by and among the Registrant, Twist
Merger Sub, Inc. and Orphan Medical, Inc. (incorporated by reference to exhibit 2.1 in the
Registrant’s registration statement on Form S-1 (File No. 333-141164), as filed with the SEC on
March 9, 2007).

Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by
reference to exhibit 3.1 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for
the period ended June 30, 2007, as filed with the SEC on August 10, 2007).

Amended and Restated Bylaws (incorporated herein by reference to exhibit 3.4 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

Reference is made to Exhibits 3.1 and 3.2.

Specimen Common Stock Certificate (incorporated herein by reference to exhibit 4.2 in the
Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with the
SEC on May 17, 2007).

Third Amended and Restated Investor Rights Agreement, made effective as of June 6, 2007, by and
between the Registrant and the other parties named therein (incorporated herein by reference to
exhibit 4.3 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2007, as filed with the SEC on August 10, 2007).

Waiver and Amendment Agreement, dated as of March 12, 2008, by and between the Registrant and
the other parties named therein (incorporated herein by reference to exhibit 4.3B in the Registrant’s
annual report on Form 10-K (File No. 001-33500) for the period ended December 31, 2007, as filed
with the SEC on March 31, 2008).

Waiver and Amendment Agreement, dated as of May 7, 2008, by and between the Registrant and the
other parties named therein (incorporated herein by reference to exhibit 4.3C in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on May 9, 2008).

66

K
-
0
1
m
r
o
F

Exhibit
Number

4.3D

4.4A

4.4B

4.5A

4.5B†

4.5C

4.6A

4.6B

4.6C

4.7

4.8

4.9A

4.9B

Description of Document

Waiver and Amendment Agreement, dated as of July 6, 2009 by and between the Registrant and the
other parties named therein (incorporated herein by reference to exhibit 4.3D in the Registrant’s
quarterly report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2009, as filed
with the SEC on August 14, 2009).

Form of Series BB Preferred Stock Warrant of the Registrant (incorporated by reference to
exhibit 4.6 to the Registrant’s registration statement on Form S-1 (File No. 333-141164), as filed
with the SEC on March 9, 2007).

Form of Series BB Preferred Stock Warrant of the Registrant, as amended (incorporated herein by
reference to exhibit 4.4B in the Registrant’s annual report on Form 10-K (File No. 001-33500) for
the period ended December 31, 2007, as filed with the SEC on March 31, 2008).

Form of Common Stock Warrant of the Registrant (incorporated herein by reference to exhibit 4.5D
in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2007, as filed with the SEC on March 31, 2008).

Registration Rights Agreement, dated as of March 17, 2008, by and between the Registrant and the
other parties named therein (incorporated herein by reference to exhibit 4.5E in the Registrant’s
annual report on Form 10-K (File No. 001-33500) for the period ended December 31, 2007, as filed
with the SEC on March 31, 2008).

Amendment and Waiver Agreement, dated as of November 10, 2009, by and among the Registrant,
JPI Commercial, LLC and the other parties named therein (incorporated by reference to exhibit 4.5F
in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on
November 10, 2009).

Warrant issued to Kingsbridge Capital Limited, dated May 7, 2008 (incorporated herein by reference
to exhibit 4.6A in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the
SEC on May 9, 2008).

Registration Rights Agreement, dated as of May 7, 2008, by and between the Registrant and
Kingsbridge Capital Limited (incorporated herein by reference to exhibit 4.6B in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on May 9, 2008).

Amendment Agreement No. 1, dated as of November 20, 2009, by and between the Registrant and
Kingsbridge Capital Limited (incorporated by reference to exhibit 4.6C in the Registrant’s current
report on Form 8-K (File No. 001-33500), as filed with the SEC on November 23, 2009).

Form of Registered Direct Common Stock Warrant (incorporated herein by reference to exhibit 4.7
in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on
July 16, 2008).

NOL Preservation Lock-Up Agreement, effective as of July 7, 2009, by and between the Registrant
and the other parties named therein (incorporated herein by reference to exhibit 4.8 in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 7,
2009).

Form of Common Stock Warrant of the Registrant issued on July 7, 2009 (incorporated herein by
reference to exhibit 4.9 in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed
with the SEC on July 7, 2009).

Investor Rights Agreement, dated July 7, 2009 by and between the Registrant and the other parties
named therein (incorporated herein by reference to exhibit 10.88 in the Registrant’s current report on
Form 8-K (File No. 001-33500), as filed with the SEC on July 7, 2009).

67

Exhibit
Number

10.1+

10.2+

10.3+

10.4+

10.5+

10.6+

10.7+

10.8+

10.9†

10.10†

10.11

10.12

10.13

Description of Document

2003 Equity Incentive Plan, as amended (incorporated herein by reference to exhibit 10.21 in the
Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with the
SEC on May 17, 2007).

Form of Option Exercise and Stock Purchase Agreement and Forms of Grant Notices under the 2003
Equity Incentive Plan (incorporated herein by reference to exhibit 10.22 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

2007 Equity Incentive Plan (incorporated herein by reference to exhibit 10.23 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

Form of Option Agreement and Form of Option Grant Notice under the 2007 Equity Incentive Plan
(incorporated herein by reference to exhibit 10.24 in the Registrant’s registration statement on
Form S-1, as amended (File No. 333-141164), as filed with the SEC on May 24, 2007).

2007 Non-Employee Directors Stock Option Plan (incorporated herein by reference to exhibit 10.25
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on May 17, 2007).

Form of Stock Option Agreement and Form of Option Grant Notice under the 2007 Non-Employee
Directors Stock Option Plan (incorporated herein by reference to exhibit 10.26 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

2007 Employee Stock Purchase Plan (incorporated herein by reference to exhibit 10.27 in the
Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with the
SEC on May 17, 2007).

2007 Employee Stock Purchase Plan Offering Document (incorporated herein by reference to exhibit
10.28 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as
filed with the SEC on May 17, 2007).

Amended and Restated Xyrem License and Distribution Agreement, dated as of June 30, 2006, by
and between the Registrant and UCB Pharma Limited (incorporated herein by reference to exhibit
10.41 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as
filed with the SEC on May 31, 2007).

License Agreement, dated as of January 31, 2007, by and between the Registrant and Solvay
Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.13 in the Registrant’s quarterly
report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2010, as filed with the
SEC on May 6, 2010).

Supply Agreement, dated as of January 31, 2007, by and between the Registrant and Solvay
Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.43 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 24, 2007).

Trademark License Agreement, dated as of January 31, 2007, by and between the Registrant and
Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.44 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 24, 2007).

Assignment, Assumption and Consent, dated as of January 31, 2007, by and among the Registrant,
Solvay Pharmaceuticals, Inc. and Elan Pharma International Limited (incorporated herein by
reference to exhibit 10.45 in the Registrant’s registration statement on Form S-1, as amended (File
No. 333-141164), as filed with the SEC on March 27, 2007).

68

K
-
0
1
m
r
o
F

Exhibit
Number

10.14†

10.15†

10.16†

10.17†

10.18†

10.19†

10.20

10.21A

10.21B

10.21C

10.21D

Description of Document

License Agreement, dated as of December 22, 1997, by and between Solvay Pharmaceuticals, Inc.
and Elan Corporation, plc. (incorporated herein by reference to exhibit 10.46 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 31, 2007).

Amendment to License Agreement, dated as of March 1, 1999, by and between Solvay
Pharmaceuticals, Inc. and Elan Corporation, plc. (incorporated herein by reference to exhibit 10.47
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on March 27, 2007).

Letter Amendment No. 2 to License Agreement, dated April 13, 2000, by and between Solvay
Pharmaceuticals, Inc and Elan Pharmaceutical Technologies (incorporated herein by reference to
exhibit 10.48 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-
141164), as filed with the SEC on March 27, 2007).

Amendment Agreement No. 3 to License Agreement, dated as of November 7, 2006, by and between
Solvay Pharmaceuticals, Inc. and Elan Corporation plc. (incorporated herein by reference to exhibit
10.49 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as
filed with the SEC on May 31, 2007).

Xyrem Manufacturing Services and Supply Agreement, dated as of March 13, 2007, by and between
the Registrant and Patheon Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.50
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on May 31, 2007).

Quality Agreement, dated as of March 13, 2007, by and between the Registrant and Patheon
Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.51 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
March 27, 2007).

Commercial Lease, dated as of June 2, 2004, by and between the Registrant and The Board of
Trustees of the Leland Stanford Junior University (incorporated herein by reference to exhibit 10.52
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on March 27, 2007).

Civil Settlement Agreement, dated July 13, 2007, among the United States of America acting
through the entities named therein, the Registrant and Orphan Medical, Inc. (incorporated herein by
reference to exhibit 10.57A in the Registrant’s current report on Form 8-K (File No. 001-33500), as
filed with the SEC on July 18, 2007).

Non-Prosecution Agreement, dated July 13, 2007, between the United States Attorney’s Office for
the Eastern District of New York and the Registrant (incorporated herein by reference to
exhibit 10.57B in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the
SEC on July 18, 2007).

Plea Agreement, dated July 13, 2007, between the United States Attorney for the Eastern District of
New York and Orphan Medical, Inc. (incorporated herein by reference to exhibit 10.57C in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 18,
2007).

Corporate Integrity Agreement, dated July 13, 2007, between the Office of Inspector General of the
Department of Health and Human Services and the Registrant (incorporated herein by reference to
exhibit 10.57D in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the
SEC on July 18, 2007).

69

Exhibit
Number

10.22+

10.23+

10.24†

10.25

10.26

10.27

10.28+

10.29†

10.30

10.31

10.32

Description of Document

Form of Letter, amending outstanding options granted under the Registrant’s 2003 Equity Incentive
Plan (incorporated herein by reference to exhibit 10.60 in the Registrant’s quarterly report on
Form 10-Q (File No. 001-33500) for the period ended June 30, 2007, as filed with the SEC on
August 10, 2007).

Form of Restricted Stock Unit Award under the Registrant’s 2007 Equity Incentive Plan
(incorporated herein by reference to exhibit 10.64 in the Registrant’s quarterly report on Form 10-Q
(File No. 001-33500) for the period ended September 30, 2007, as filed with the SEC on
November 9, 2007).

Amendment Number 4 to Development, License and Supply Agreement, dated as of October 26,
2007, by and between the Registrant and Elan Pharma International, Inc. (incorporated herein by
reference to exhibit 10.66 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for
the period ended December 31, 2007, as filed with the SEC on March 31, 2008).

Amendment No. 1 to Amended and Restated Xyrem License and Distribution Agreement, dated as
of December 21, 2007, by and between the Registrant and UCB Pharma Limited (incorporated
herein by reference to exhibit 10.68 in the Registrant’s annual report on Form 10-K (File No.
001-33500) for the period ended December 31, 2007, as filed with the SEC on March 31, 2008).

Amendment No. 1 to License Agreement, dated as of March 12, 2008, by and between the Registrant
and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.69 in the
Registrant’s annual report on Form 10-K (File No. 001-33500) for the period ended December 31,
2007, as filed with the SEC on March 31, 2008).

Common Stock Purchase Agreement, dated as of May 7, 2008, by and between the Registrant and
Kingsbridge Capital Limited (incorporated herein by reference to exhibit 10.70 in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on May 9, 2008).

Form of Stock Award Grant Notice and Stock Award Agreement under the Registrant’s 2007 Equity
Incentive Plan (incorporated herein by reference to exhibit 10.73 in the Registrant’s quarterly report
on Form 10-Q (File No. 001-33500) for the period ended March 31, 2008, as filed with the SEC on
May 15, 2008).

Master Services Agreement dated May 6, 2008, by and among the Registrant, Express Scripts
Specialty Distribution Services, Inc. and CuraScript, Inc. (incorporated herein by reference to
exhibit 10.74 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended March 31, 2008, as filed with the SEC on May 15, 2008).

Amendment No. 2 to Amended and Restated Xyrem License and Distribution Agreement, dated
July 23, 2008, by and between the Registrant and UCB Pharma Limited (incorporated herein by
reference to exhibit 10.75 in the Registrant’s current report on Form 8-K (File No. 001-33500), as
filed with the SEC on July 24, 2008).

Amendment No. 2 to License Agreement, dated as of October 17, 2008, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to
exhibit 10.77 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2008, as filed with the SEC on November 14, 2008).

Amendment No. 3 to License Agreement, dated as of December 19, 2008, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to
exhibit 10.78 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the period
ended December 31, 2008, as filed with the SEC on March 26, 2009).

70

Exhibit
Number

10.33

10.34+

10.35

10.36

10.37

10.38

10.39

10.40

10.41

10.42

10.43

10.44†

Description of Document

Amendment No. 4 to License Agreement, dated as of February 5, 2009, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to
exhibit 10.79 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the period
ended December 31, 2008, as filed with the SEC on March 26, 2009).

Amended and Restated Executive Change in Control and Severance Benefit Plan (incorporated
herein by reference to exhibit 10.81 in the Registrant’s annual report on Form 10-K (File No.
001-33500) for the period ended December 31, 2008, as filed with the SEC on March 26, 2009).

Revision of Payment Terms of the Plea Agreement dated as of July 17, 2007 between the U.S.
Attorney for the Eastern District of New York and Orphan Medical, Inc. (incorporated herein by
reference to exhibit 10.82 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for
the period ended December 31, 2008, as filed with the SEC on March 26, 2009).

Amendment to Settlement Agreement, signed by the Company on February 6, 2009, among the
United States of America acting through the entities named therein, the Registrant and Orphan
Medical, Inc. (incorporated herein by reference to exhibit 10.83 in the Registrant’s annual report on
Form 10-K (File No. 001-33500) for the period ended December 31, 2008, as filed with the SEC on
March 26, 2009).

K
-
0
1
m
r
o
F

Form of Registered Direct Subscription Agreement (incorporated by reference to exhibit 10.1 in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 16,
2008).

First Amendment of Lease, dated June 1, 2009, by and between the Registrant and Wheatley-Fields,
LLC, successor in interest to the Board of Trustees of the Leland Stanford Junior University
(incorporated herein by reference to exhibit 10.86 in the Registrant’s current report on Form 8-K
(File No. 001-33500), as filed with the SEC on June 4, 2009).

Securities Purchase Agreement, dated July 6, 2009, by and between the Registrant and the
purchasers listed on the signature pages thereto (incorporated herein by reference to exhibit 10.87 in
the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 7,
2009).

Form of Indemnification Agreement between the Registrant and its officers and directors
(incorporated herein by reference to exhibit 10.89 in the Registrant’s current report on Form 8-K
(File No. 001-33500), as filed with the SEC on July 7, 2009).

Amendment No. 5 to License Agreement, dated as of June 23, 2009, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to
exhibit 10.90 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2009, as filed with the SEC on August 14, 2009).

Amendment No. 5 to License Agreement, dated as of October 23, 2009, by and between the
Registrant and Elan Pharma International Limited (incorporated by reference to exhibit 10.91 in the
Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period ended September 30,
2009, as filed with the SEC on November 6, 2009).

Offer Letter from the Registrant to Kathryn Falberg (incorporated herein by reference to exhibit
10.92 in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on
December 3, 2009).

Supply Agreement, dated as of April 1, 2010, by and between the Registrant and Siegfried (USA)
Inc. (incorporated herein by reference to exhibit 10.54 in the Registrant’s quarterly report on
Form 10-Q (File No. 001-33500) for the period ended March 31, 2010, as filed with the SEC on
May 6, 2010).

71

Exhibit
Number

10.45

10.46+

10.47+

10.48+

10.49+

10.50+

10.51+

10.52

10.53+

10.54+

10.55+

21.1

23.1

24.1

31.1

31.2

32.1

+
†

*

Description of Document

Senior Secured Credit Facilities Credit Agreement, dated as of June 28, 2010, among the Registrant,
JPI Commercial, LLC, the several lenders from time to time parties thereto and Silicon Valley Bank,
as Administrative Agent (incorporated herein by reference to exhibit 10.56 in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 1, 2010).

Amended and Restated 2007 Non-Employee Directors Stock Option Plan (incorporated herein by
reference to exhibit 10.2 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for
the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Form of Stock Option Agreement and Form of Option Grant Notice under the Amended and
Restated 2007 Non-Employee Directors Stock Option Plan (incorporated herein by reference to
exhibit 10.1 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2010, as filed with the SEC on November 5, 2010).

2007 Employee Stock Purchase Plan, as amended and restated (incorporated herein by reference to
exhibit 10.3 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2010, as filed with the SEC on November 5, 2010).

2007 Employee Stock Purchase Plan Offering Document, as amended and restated (incorporated
herein by reference to exhibit 10.4 in the Registrant’s quarterly report on Form 10-Q (File No. 001-
33500) for the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Amended and Restated Directors Deferred Compensation Plan (incorporated herein by reference to
exhibit 10.5 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2010, as filed with the SEC on November 5, 2010).

Non-Employee Director Compensation Arrangements, as amended and restated (incorporated herein
by reference to exhibit 10.6 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500)
for the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Amendment No. 1 to Master Services Agreement, dated as of August 31, 2010, by and among the
Registrant, Express Scripts Specialty Distribution Services, Inc. and CuraScript, Inc. (incorporated
herein by reference to exhibit 10.7 in the Registrant’s quarterly report on Form 10-Q (File No. 001-
33500) for the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Separation Agreement, dated January 6, 2011, by and between the Registrant and Robert Myers.

Jazz Pharmaceuticals, Inc. Cash Bonus Plan, as amended as of February 8, 2011.

2010 and 2011 Executive Officer Compensation Arrangements.

Subsidiaries of the Registrant.

Consent of Independent Registered Public Accounting Firm.

Power of Attorney (included on the signature page hereto).

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated
under the Securities Exchange Act of 1934, as amended.

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated
under the Securities Exchange Act of 1934, as amended.

Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

Indicates management contract or compensatory plan.
Confidential treatment has been granted for portions of this exhibit. Omitted portions have been filed
separately with the Securities and Exchange Commission.
The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not
be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended.

72

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly

caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 8, 2011

Jazz Pharmaceuticals, Inc.
(Registrant)

/S/ BRUCE C. COZADD

Bruce C. Cozadd
Chairman and Chief Executive Officer and Director
(Principal Executive Officer)

/S/ KATHRYN E. FALBERG

Kathryn E. Falberg
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)

K
-
0
1
m
r
o
F

73

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes

and appoints Bruce C. Cozadd, Kathryn E. Falberg. and Carol A. Gamble, and each of them, as his or her true and
lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and
all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with
exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each
and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she
might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of
them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, the following persons on behalf of the

registrant and in the capacities and on the dates indicated have signed this report below:

Signature

Title

Date

/s/ BRUCE C. COZADD

Bruce C. Cozadd

/s/ KATHRYN E. FALBERG

Kathryn E. Falberg

/s/

JOAN E. COLLIGAN
Joan E. Colligan

/s/ Paul L. Berns
Paul L. Berns

/s/ SAMUEL D. COLELLA

Samuel D. Colella

/s/ BRYAN C. CRESSEY

Bryan C. Cressey

/s/ PATRICK G. ENRIGHT

Patrick G. Enright

Chairman, Chief Executive Officer
and Director
(Principal Executive Officer)

Senior Vice President and Chief
Financial Officer
(Principal Financial Officer)

Controller and Principal
Accounting Officer
(Principal Accounting Officer)

Director

Director

Director

Director

/s/ MICHAEL W. MICHELSON

Director

Michael W. Michelson

/s/

JAMES C. MOMTAZEE
James C. Momtazee

/s/ KENNETH W. O’KEEFE

Kenneth W. O’Keefe

/s/ ALAN M. SEBULSKY

Alan M. Sebulsky

/s/

JAMES B. TANANBAUM, M.D.
James B. Tananbaum, M.D.

/s/ RICK E WINNINGHAM

Rick E Winningham

Director

Director

Director

Director

Director

/s/ NATHANIEL M. ZILKHA

Director

Nathaniel M. Zilkha

74

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

March 8, 2011

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of
Jazz Pharmaceuticals, Inc.

We have audited the accompanying consolidated balance sheets of Jazz Pharmaceuticals, Inc. as of
December 31, 2010 and 2009, and the related consolidated statements of operations, stockholders’ equity
(deficit) and cash flows for each of the three years in the period ended December 31, 2010. Our audits also
included the financial statement schedule listed in the Index at Item 15(a)2. These financial statements and
schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on
these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement. An audit also includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the

consolidated financial position of Jazz Pharmaceuticals, Inc. at December 31, 2010 and 2009, and the
consolidated results of its operations and its cash flows for each of the three years in the period ended
December 31, 2010, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the
related financial statement schedule, when considered in relation to the basic financial statements taken as a
whole, presents fairly in all material respects the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board

(United States), Jazz Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31, 2010,
based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission and our report dated March 8, 2011, expressed an unqualified
opinion thereon.

K
-
0
1
m
r
o
F

/s/ Ernst & Young LLP

Palo Alto, California
March 8, 2011

F-1

JAZZ PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)

December 31,

2010

2009

Current assets:

ASSETS

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, net of allowances of $482 and $288 at December 31, 2010

and 2009, respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 44,794
400

$ 15,595
2,988

22,081
5,046
1,858
279
74,458
690
22,033
38,213
335

12,313
3,426
1,653
979
36,954
1,124
29,858
38,213
1,247

Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 135,729

$ 107,396

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current liabilities:

Revolving credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of long-term debt (including $1,355 pertaining to a related party at
December 31, 2009) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchased product rights liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Liability under government settlement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred rent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue, non-current . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchased product rights liability, non-current
Liability under government settlement, non-current
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt, less current portion (including $5,196 pertaining to a related party at

7,350
3,049
23,572

16,064
4,500
4,128
1,273

59,936
82
9,053
4,500
6,978

$

9,399
2,158
14,296

23,759
4,000
2,954
2,675

59,241
29
10,191
9,000
10,658

December 31, 2009) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

24,629

91,107

Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):

Preferred stock, $0.0001 par value; 20,000,000 shares authorized at December 31,

2010; no shares issued and outstanding at December 31, 2010 . . . . . . . . . . . . . . .
Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31,

2010; 39,959,255 and 31,255,274 shares issued and outstanding at
December 31, 2010 and 2009, respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated deficit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total stockholders’ equity (deficit)

—

—

4
505,413
(474,866)
30,551

3
434,811
(507,644)
(72,830)

Total liabilities and stockholders’ equity (deficit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 135,729

$ 107,396

The accompanying notes are an integral part of these consolidated financial statements.

F-2

JAZZ PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)

Year Ended December 31,
2009

2008

2010

Revenues:

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Product sales, net
Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$170,006
2,637
1,138

$115,108
2,203
11,138

$ 64,637
1,739
1,138

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

173,781

128,449

67,514

Operating expenses:

Cost of product sales (excluding amortization of acquired developed

technology and intangible asset impairment) . . . . . . . . . . . . . . . . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset impairment

13,559
25,612
68,996
7,825
—

9,638
36,561
58,652
7,668
—

13,924
69,963
111,401
12,828
29,763

K
-
0
1
m
r
o
F

Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

115,992

112,519

237,879

Income (loss) from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense (including $570, $1,183 and $1,179 for the years ended

December 31, 2010, 2009 and 2008, respectively, pertaining to a
related party) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other (expense) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on extinguishment of debt (including $701 pertaining to a related

57,789
6

15,930
34

(170,365)
1,834

(12,728)
(2)

(22,796)
(4)

—

—

—

(19,742)
16
3,918

—

party) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(12,287)

Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 32,778

$ (6,836) $(184,339)

Net income (loss) per share:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

0.90

0.83

$

$

(0.23) $

(7.19)

(0.23) $

(7.19)

Weighted-average common shares used in computing net income (loss) per

share:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

36,343

30,018

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

39,411

30,018

25,646

25,646

The accompanying notes are an integral part of these consolidated financial statements.

F-3

JAZZ PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF
STOCKHOLDERS’ EQUITY (DEFICIT)
(In thousands, except share amounts)

Common Stock

Shares

Amount

Additional
Paid-in
Capital

Accumulated
Other
Comprehensive
Income

Accumulated
Deficit

Total
Stockholders’
Equity (Deficit)

Balance at December 31, 2007 . . . . . . . . . 24,620,829
Lapse of repurchase rights to shares issued

$

2

$371,440

$ 19

$(316,469)

$ 54,992

under restricted stock purchase
agreements . . . . . . . . . . . . . . . . . . . . . . .
Warrants to purchase common stock issued

in conjunction with senior secured
notes . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Stock issued/issuable under directors

—

—

30

—

—

1,928

deferred compensation plan . . . . . . . . . .

2,843 —

237

Issuance of common stock in conjunction
with exercise of stock options for cash
and restricted stock units . . . . . . . . . . . . .
Issuance of common stock under employee
stock purchase plan . . . . . . . . . . . . . . . . .
Issuance of common stock and warrants in
conjunction with registered direct public
offering, net of issuance costs . . . . . . . . .
Stock-based compensation . . . . . . . . . . . . .
Conversion of common stock subject to

repurchase to common stock . . . . . . . . . .

Comprehensive loss:

Net loss . . . . . . . . . . . . . . . . . . . . . . . .
Unrealized loss on available-for-sale

securities . . . . . . . . . . . . . . . . . . . . .

Comprehensive loss . . . . . . . . . . . . . . . . . .

153,400 —

299,756 —

3,848,289
—

—

—

—

1

—

—

—

—

1,001

1,166

24,513
6,859

749

—

—

—

—

—

—

—

—
—

—

—

—

—

—

—

—

—
—

—

30

1,928

237

1,001

1,166

24,514
6,859

749

(184,339)

(184,339)

(15)

—

(15)

(184,354)

3

407,923

4

(500,808)

(92,878)

Balance at December 31, 2008 . . . . . . . . . 28,925,117
Lapse of repurchase rights to shares issued
under employment agreements . . . . . . . .

—

—

12,492

Modification of warrants to purchase

common stock issued in conjunction
with amended senior secured notes . . . . .

Stock issued/issuable under directors

—

—

1,254

deferred compensation plan . . . . . . . . . .

3,826 —

Issuance of common stock in conjunction
with exercise of stock options for cash
and restricted stock units . . . . . . . . . . . . .
Issuance of common stock under employee
stock purchase plan . . . . . . . . . . . . . . . . .
Issuance of common stock and warrants in
conjunction with private placement
offering, net of issuance costs . . . . . . . . .
Stock-based compensation . . . . . . . . . . . . .
Comprehensive loss:

Net loss . . . . . . . . . . . . . . . . . . . . . . . .
Unrealized loss on available-for-sale

securities . . . . . . . . . . . . . . . . . . . . .

Comprehensive loss . . . . . . . . . . . . . . . . . .

20,722 —

409,875 —

1,895,734 —
—
—

—

—

—

—

243

40

348

6,782
5,729

—

—

—

—

—

—

—

—
—

—

—

—

—

—

—

—
—

12,492

1,254

243

40

348

6,782
5,729

(6,836)

(6,836)

(4)

—

(4)

(6,840)

(72,830)

Balance at December 31, 2009 . . . . . . . . . 31,255,274

3

434,811

—

(507,644)

F-4

JAZZ PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF
STOCKHOLDERS’ EQUITY (DEFICIT)—(Continued)
(In thousands, except share amounts)

Common Stock

Shares

Amount

Additional
Paid-in
Capital

31,255,274

3

434,811

—

—

198

955,129

—

3,682

Balance at December 31, 2009 . . . .
Stock issuable under directors

deferred compensation plan . . . . .

Issuance of common stock in

conjunction with exercise of stock
options . . . . . . . . . . . . . . . . . . . . . .

Issuance of common stock in
conjunction with vesting of
restricted stock units . . . . . . . . . . .

Issuance of common stock under

13,398

—

—

—

529

employee stock purchase plan . . .

519,813

Issuance of common stock in

conjunction with offering, net of
issuance costs . . . . . . . . . . . . . . . .

Issuance of common stock in

conjunction with cashless exercise
of warrants . . . . . . . . . . . . . . . . . .

Issuance of common stock in

conjunction with exercise of
warrants . . . . . . . . . . . . . . . . . . . . .
Stock-based compensation . . . . . . . .
Net income and comprehensive

income . . . . . . . . . . . . . . . . . . . . . .

7,000,000

1

56,816

65,641

—

—

150,000
—

—

—
—

—

1,380
7,997

—

Accumulated
Other
Comprehensive
Income

—

—

—

—

—

—

—

—
—

—

Accumulated
Deficit

Total
Stockholders’
Equity (Deficit)

(507,644)

(72,830)

—

—

—

—

—

—

—
—

198

3,682

—

529

56,817

—

1,380
7,997

32,778

32,778

K
-
0
1
m
r
o
F

Balance at December 31, 2010 . . . .

39,959,255

$ 4

$505,413

$—

$(474,866)

$ 30,551

The accompanying notes are an integral part of these consolidated financial statements.

F-5

JAZZ PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

Year Ended December 31,
2009

2008

2010

Operating activities
Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating

$ 32,778

$ (6,836) $(184,339)

activities:

Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on disposal of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt, non-cash interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on extinguishment of debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes in assets and liabilities:

Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred rent
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Liability under government settlement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

886
7,825
—
279
8,219
2,406
12,287
—

(9,768)
(1,644)
426
—
891
9,276
(2,540)
53
(2,506)

1,429
7,668
—

14
5,957
2,810
—
—

(5,670)
883
2,610
(1,748)
(3,578)
(6,676)
(10,786)
29
(1,984)

2,198
12,828
29,763
968
8,106
2,060
—
(3,918)

(1,254)
(2,180)
237
(80)
2,880
(5,937)
9,690
—
(1,254)

Net cash provided by (used in) operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

58,868

(15,878)

(130,232)

Investing activities

Purchases of property and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Decrease (increase) in restricted cash and investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Transfer of restricted cash to marketable securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from maturities of marketable securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from sale of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Financing activities

Repayment of senior secured notes (including $6,816 and $327 for the years ended

December 31, 2010 and 2008, respectively, paid to a related party) . . . . . . . . . . . . . . . . .
Prepayment penalties and fees (including $484 paid to a related party) . . . . . . . . . . . . . . . .
Proceeds from offerings of common stock, net of issuance costs . . . . . . . . . . . . . . . . . . . . .
Proceeds from term loan, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayment of term loan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from employee stock purchases and exercise of stock options and warrants . . . . .
Net (repayments under) proceeds from revolving credit facilities . . . . . . . . . . . . . . . . . . . . .
Proceeds from sale of senior secured notes and warrants, net of issuance costs . . . . . . . . . .

(731)
(4,000)
2,588
—
—
—

(2,143)

(119,496)
(8,484)
56,817
48,427
(8,332)
5,591
(2,049)
—

(53)
(6,000)
(1,075)
—
1,004
—

(6,124)

—
—
6,782
—
—
388
5,524
—

Net cash (used in) provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(27,526)

12,694

(1,739)
(27,000)
12,026
(4,440)
3,436
5,775

(11,942)

(504)
—
24,514
—
—
1,168
416
38,538

64,132

Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash and cash equivalents, at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

29,199
15,595

(9,308)
24,903

(78,042)
102,945

Cash and cash equivalents, at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 44,794

$ 15,595

$ 24,903

Supplemental disclosure of cash flow information:

Cash paid for interest (including $461, $1,349 and $796 for the years ended December 31,
2010, 2009 and 2008, respectively, paid to a related party) . . . . . . . . . . . . . . . . . . . . . . . .

Supplemental disclosure of non-cash investing and financing activities:

$ 10,234

$ 24,488

$ 12,802

Liability for purchase of product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Warrants to purchase common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Modification to warrants to purchase common stock issued in conjunction with senior

secured notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$
$

$

— $ 5,000
— $ 2,700

$ 14,000
9,250
$

— $ 1,254

$

—

The accompanying notes are an integral part of these consolidated financial statements

F-6

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Description of Business

We are a specialty pharmaceutical company focused on the identification, development and

commercialization of pharmaceutical products to meet important unmet medical needs. Since we were founded
in 2003, we have built a commercial and development organization and assembled a portfolio of products and
product candidates that currently includes our two marketed products, Xyrem (sodium oxybate) oral solution and
Luvox CR (fluvoxamine maleate) Extended-Release Capsules, and product candidates in various stages of
clinical development.

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of Jazz Pharmaceuticals, Inc. and its wholly-

owned subsidiaries, Orphan Medical, LLC, formerly Orphan Medical, Inc., or Orphan Medical, and JPI
Commercial, LLC after elimination of intercompany transactions and balances. Our fiscal year ends on
December 31.

K
-
0
1
m
r
o
F

Certain amounts in the consolidated statements of cash flows for 2009 and 2008 have been reclassified to
conform to the presentation for 2010. Amounts previously reported as the changes in senior secured notes have
been reclassified and reported as non-cash interest expense and changes in other assets and accrued liabilities in
the consolidated statements of cash flows.

Significant Risks and Uncertainties

We are subject to risks common to companies in the pharmaceutical industry with development and
commercial operations including, but not limited to, risks and uncertainties related to commercial success and
acceptance of our products by patients, physicians and payors, competition from branded and generic products,
regulatory approvals, regulatory requirements, including those of the United States Food and Drug
Administration, or FDA, and the United States Drug Enforcement Administration dependence on key customers
and sole source suppliers and protection of intellectual property rights. In addition, most of our revenues are
derived from sales of one product, Xyrem. During 2010, an abbreviated new drug application, or ANDA, was
filed with the FDA by a third party seeking to market a generic form of Xyrem. We have sued that third party for
infringement of our patents, and the litigation is ongoing. We cannot predict the timing or outcome of this
litigation. If an ANDA for Xyrem is approved and a generic version of Xyrem is introduced, our sales of Xyrem
would be adversely affected.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles

requires management to make estimates and assumptions that affect the amounts and disclosures reported in the
consolidated financial statements and accompanying notes. Management bases its estimates on historical
experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ
materially from those estimates.

Concentrations of Risk

Financial instruments that potentially subject us to concentrations of credit risk consist of cash equivalents

and restricted cash, and accounts receivable. Our investment policy limits investments to certain types of debt
securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and

F-7

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

places restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event
of a default by the financial institutions holding our cash and cash equivalents and issuers of investments to the
extent recorded on the balance sheet.

We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts

receivable as necessary. We extend credit to pharmaceutical wholesale distributors and a specialty
pharmaceutical distribution company, primarily in the United States, and to international distributors in the
normal course of business. Customer creditworthiness is monitored and collateral is not required. Historically,
we have not experienced significant credit losses on our accounts receivable. One customer, Express Scripts
Specialty Distribution Services and its affiliate Curascript, Inc., or Express Scripts, accounted for 79% and 77%
of gross accounts receivable as of December 31, 2010 and 2009, respectively.

We rely on certain sole suppliers for drug substance and certain sole manufacturing partners for each of our

marketed products and certain of our product candidates.

Cash Equivalents and Restricted Cash

We consider all highly liquid investments, readily convertible to cash, that mature within three months or
less from date of purchase to be cash equivalents. At December 31, 2010, restricted cash was in the form of a
certificate of deposit required to secure spending on credit cards used by employees.

Cash equivalents and restricted cash are considered available-for-sale and are recorded at fair value, based

on quoted market prices. Unrealized gains and losses, net of tax, are recorded in other comprehensive income
(loss) and included as a separate component of stockholders’ equity (deficit). We use the specific-identification
method for calculating realized gains and losses on securities sold.

Inventories

Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method

for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis
in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of
excess quantities is subjective and primarily dependent on our estimates of future demand for a particular
product. If the estimate of future demand is too high, we may have to increase the reserve for excess inventory
for that product and record a charge to cost of product sales. For product candidates that have not been approved
by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and
development expense. For products that have been approved by the FDA, inventory used in clinical trials is
expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval costs related
to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded
as research and development expense. All direct manufacturing costs incurred after approval are capitalized into
inventory.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using

the straight-line method over the estimated useful lives of the assets, which are three to five years. Leasehold
improvements are amortized over the shorter of the noncancelable term of our operating lease or their economic
useful lives. Maintenance and repairs are charged to operations as incurred.

F-8

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Goodwill and Intangible Assets

Goodwill

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities
assumed. We have determined that we operate in a single segment and have a single reporting unit associated
with the development and commercialization of pharmaceutical products. The annual test for goodwill
impairment is a two-step process. The first step is a comparison of the fair value of the reporting unit with its
carrying amount, including goodwill. If this step indicates impairment, then in the second step, the loss is
measured as the excess of recorded goodwill over its implied fair value. Implied fair value is the excess of the
fair value of the reporting unit over the fair value of all identified assets and liabilities. Management tests
goodwill for impairment annually in October and whenever events or changes in circumstances indicate that the
carrying value may not be recoverable.

Intangible Assets

Intangible assets consist primarily of purchased developed technology and trademarks. Intangible assets are

amortized on a straight-line basis over their estimated useful lives, which range from three to ten years. The
estimated useful lives associated with intangible assets are consistent with the estimated lives of the products and
may be modified when circumstances warrant. Once an intangible asset is fully amortized, the gross costs and
accumulated amortization are removed from the consolidated balance sheet. We evaluate purchased intangibles
and other long-lived assets, other than goodwill, for impairment whenever events or changes in circumstances
indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized
when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual
disposition are less than its carrying amount. The amount of any impairment is measured as the difference
between the carrying value and the fair value of the impaired asset. See Note 5 for additional information
regarding intangible asset impairment charges.

Revenue Recognition

Revenues are recognized when there is persuasive evidence that an arrangement exists, delivery has

occurred, the price is fixed and determinable and collection is reasonably assured. Revenue from sales
transactions where the buyer has the right to return the product is recognized at the time of sale only if (i) the
seller’s price to the buyer is substantially fixed or determinable at the date of sale, (ii) the buyer has paid the
seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product,
(iii) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or
damage of the product, (iv) the buyer acquiring the product for resale has economic substance apart from that
provided by the seller, (v) the seller does not have significant obligations for future performance to directly bring
about resale of the product by the buyer, and (vi) the amount of future returns can be reasonably estimated.

In evaluating arrangements with multiple elements we consider whether components of the arrangement

represent separate units of accounting based upon whether certain criteria are met, including whether the
delivered element has stand-alone value to the customer and whether there is objective and reliable evidence of
the fair value of the undelivered items. This evaluation requires subjective determinations and requires
management to make judgments about the fair value of individual elements and whether such elements are
separable from other aspects of the contractual relationship. The consideration received in such arrangements is
allocated among the separate units of accounting based on their respective fair values when there is reliable
evidence of fair value for all elements of the arrangement. If there is no evidence of fair value for all the elements
of the arrangement, consideration is allocated based on the residual value method for the delivered elements.

F-9

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Under the residual method, the amount of revenues allocated to the delivered elements equals the total
arrangement consideration less the aggregate fair value of any undelivered elements. The applicable revenue
recognition criteria are applied to each of the separate units.

Payments received in advance of work performed or milestones achieved are recorded as deferred revenues

and recognized when the service is provided or the milestone is achieved, as applicable.

Product Sales, Net

We sell Xyrem in the United States to a single central pharmacy, Express Scripts. We recognize revenues

from sales of Xyrem within the United States upon transfer of title, which occurs when Express Scripts removes
product from our consigned inventory location at its facility for shipment directly to a patient. We accept returns
from Express Scripts of any product returned by patients to Express Scripts with defects that were not reasonably
discoverable upon receipt of the consigned product by Express Scripts. Based on our experience over the past
five years since we acquired the rights to Xyrem, product returns to Express Scripts from patients are rare. We
provide Express Scripts with a credit for product returned by patients. During 2010, we issued credits for
returned product totaling less than $20,000.

We sell limited quantities of Xyrem to UCB Pharma Limited, or UCB, for sale in territories outside of North

America, and to Valeant Canada Limited, for sale in Canada, under license and distribution agreements. The
agreements provide our international licensees with a fixed period of time after delivery to inspect and reject
shipments for failure to meet specifications. We do not recognize revenue on the sales to our international
licensees until the right of return has lapsed, which occurs when we are notified of their acceptance, or when the
time for them to inspect or reject a shipment has lapsed, if earlier.

We grant rights to our wholesaler customers to return product six months prior to and up to twelve months
after product expiration and issue credits which may be applied against existing or future invoices. Prior to the
fourth quarter of 2010, we did not believe we were able to reasonably estimate expected returns of Luvox CR at
the time of shipment, and therefore we recognized revenue when units were dispensed through prescriptions, at
which point the product was not subject to return. We purchase dispensing data from an independent prescription
tracking service which we used to estimate units dispensed. As of October 1, 2010 we believed we had sufficient
historical data on returns of Luvox CR to reasonably estimate a return rate when a unit is shipped. As a result, as
of October 1, 2010, we started recognizing revenue upon shipment to our wholesaler customers and recorded an
estimated amount of product returns. We recognized $2.0 million of previously deferred net product sales and
$674,000 of previously deferred product costs in the fourth quarter of 2010. We recorded a $3.5 million liability
for estimated future returns as of December 31, 2010.

Revenues from sales of products within the United States are recorded net of estimated allowances for
returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government
chargebacks, patient rebates and rebates under managed care plans. Calculating certain of these items involves
estimates and judgments based on sales or invoice data and historical experience. Adjustments to estimates for
these allowances have not been material.

Royalties, Net

We receive royalties from third parties based on sales of our products under licensing and distribution
arrangements. For those arrangements where royalties are reasonably estimable, we recognize revenues based on
estimates of royalties earned during the applicable period, and adjusts for differences between the estimated and
actual royalties in the following quarter. Historically, these adjustments have not been significant.

F-10

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Contract Revenues

Nonrefundable fees where we have no continuing performance obligations are recognized as revenues when
there is persuasive evidence of an arrangement and collection is reasonably assured. In situations where we have
continuing performance obligations, nonrefundable fees are deferred and are recognized ratably over our
projected performance period. We recognize at-risk milestone payments, which are typically related to
regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the
milestone is accomplished and collection is reasonably assured. Refundable fees are deferred and recognized as
revenues upon the later of when they become nonrefundable or when our performance obligations are completed.

Cost of Product Sales

Cost of product sales includes third party manufacturing and distribution costs, the cost of drug substance,

royalties due to third parties on product sales, product liability and cargo insurance, FDA user fees, freight,
shipping, handling and storage costs and salaries and related costs of employees involved with production.
During 2009 and 2008, we recorded charges to cost of product sales related to Luvox CR for inventory we judged
to be in excess of expected requirements of $82,000 and $4.2 million, respectively. Excluded from cost of
product sales, as shown on the consolidated statements of operations, is amortization of acquired developed
technology of $7.2 million, $6.6 million and $11.5 million for 2010, 2009 and 2008, respectively. Also excluded
from cost of product sales is an intangible asset impairment charge of $29.8 million related to Luvox CR
recorded in 2008. See Note 5 for additional information regarding the impairment charge.

K
-
0
1
m
r
o
F

Research and Development

Research and development expenses consist of expenses incurred in identifying, developing and testing our

product candidates. These expenses consist primarily of fees paid to contract research organizations and other
third parties to assist us in managing, monitoring and analyzing results from our clinical trials, clinical trial costs
paid to sites and investigators’ fees, costs of non-clinical studies, including toxicity studies in animals, costs of
contract manufacturing services, costs of materials used in clinical trials and non-clinical studies, fees paid to
third parties for development candidates or drug delivery or formulation technologies that we have licensed,
allocated expenses, such as facilities and information technology that support our research and development
activities, and related personnel expenses, including stock-based compensation. Research and development costs
are expensed as incurred, including payments made under our license agreements. For product candidates that
have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and
recorded as research and development expense. For products that have been approved by the FDA, inventory
used in clinical trials is expensed at the time the inventory is packaged for the trial and therefore is not included
in inventory.

Advertising Expenses

We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses for

2010, 2009 and 2008 were $1.6 million, $448,000 and $11.0 million, respectively.

Income Taxes

We utilize the liability method of accounting for income taxes. Under this method, deferred tax assets and

liabilities are determined based on differences between financial reporting and the tax bases of assets and
liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are
expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of
a deferred tax asset will not be realized.

F-11

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and all changes in stockholders’ equity (deficit)

during a period, except for those changes resulting from investments by stockholders or distributions to
stockholders. For each 2010, 2009 and 2008, the difference between comprehensive income (loss) and net
income (loss) was insignificant.

Net Income (Loss) Per Common Share

Basic and diluted net income (loss) per common share is computed using the weighted-average number of

shares of common stock outstanding as follows (in thousands, except per share amounts):

Year Ended December 31,

2010

2009

2008

Numerator:

Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$32,778

$ (6,836) $(184,339)

Denominator:

Weighted-average common shares outstanding . . . . . . . . . . . . . . . . . . . . . .
Less: weighted-average common shares outstanding subject to

36,343

30,018

26,524

repurchase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

—

(878)

Weighted-average common shares outstanding—basic . . . . . . . . . . . . . . . .
Dilutive effect of employee equity incentive and purchase plans . . . . . . . .
Dilutive effect of warrants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

36,343
1,720
1,348

30,018
—
—

Weighted-average common shares outstanding—diluted . . . . . . . . . . . . . .

39,411

30,018

25,646
—
—

25,646

Net income (loss) per share:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

0.90

$ (0.23) $

(7.19)

0.83

$ (0.23) $

(7.19)

Potentially dilutive securities consisting of stock options, common stock subject to repurchase and warrants
were not included in the diluted net loss per share for 2009 and 2008 because the inclusion of such shares would
have had an anti-dilutive effect.

Potentially dilutive common shares from employee stock plans and warrants are determined by applying the
treasury stock method to the assumed exercise of warrants and stock options, the assumed vesting of outstanding
restricted stock units, and the assumed issuance of common stock under our employee stock purchase plan. The
following table represents the weighted-average shares of our common stock that were excluded from the
computation of diluted net income (loss) per share for the periods presented because including them would have
an anti-dilutive effect (in thousands):

Warrants to purchase common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 3,759
2,843
Options to purchase common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3,211
—
Common stock subject to repurchase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . —
38
Restricted stock units . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . —

2,144
3,687
828
94

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,211

6,640

6,753

Year Ended December 31,

2010

2009

2008

F-12

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As of December 31, 2010, we had warrants outstanding and exercisable as follows:

Warrants issued in conjunction with:
$80.0 million senior secured notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$40.0 million senior secured notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity financing facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Public offering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Private offering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

June 2012
785,728
562,192
March 2013
70,000 November 2013
July 2014
July 2016

1,620,119
947,867

$9.34
$9.34
$9.20
$7.37
$4.00

No. of
Shares

Expiration Date

Exercise
Price

Stock-Based Compensation

We account for compensation cost for all stock-based awards at fair value on the date of grant. The fair
value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method
for stock options and restricted stock units and using the ratable method for awards under our employee stock
purchase program. The estimation of stock awards that will ultimately vest requires judgment, and to the extent
actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. We primarily consider historical experience when estimating
expected forfeitures.

K
-
0
1
m
r
o
F

Recent Accounting Pronouncements

In October 2009, the FASB issued authoritative guidance which amends the revenue recognition guidance to
require companies to allocate revenue in multiple-element arrangements based on an element’s estimated selling
price if vendor-specific or other third-party evidence is not available. The guidance became effective for us
beginning January 1, 2011 and is being applied prospectively to multiple-deliverable revenue arrangements
entered into on or after January 1, 2011. The adoption of this guidance is not expected to have a material impact
on our results of operations and financial position.

3. Fair Value Measurement

Available-for-sale investments consisted of the following (in thousands):

Money market funds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$25,046

$25,046

$5,072

$ 5,072

December 31, 2010

December 31, 2009

Amortized
Cost

Estimated Fair
Value

Amortized
Cost

Estimated Fair
Value

Available-for-sale investments . . . . . . . . . . . . . . . . . . . . . . .
Cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Reported as

Amounts classified as cash and cash equivalents . . . . . . . . .
Amounts classified as restricted cash . . . . . . . . . . . . . . . . . .

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F-13

December 31,
2010

$25,046
19,748
400

$45,194

December 31,
2010

$44,794
400

$45,194

December 31,
2009

$ 5,072
10,523
2,988

$18,583

December 31,
2009

$15,595
2,988

$18,583

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table summarizes, by major security type, our available-for-sale investments that are
measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):

December 31, 2010

December 31, 2009

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Total Estimated
Fair Value

Total Estimated
Fair Value

Money market funds . . . . . . . . . . . . . . . . . . . . . . .

$25,046

$25,046

$5,072

$5,072

As of December 31, 2010 and 2009, the carrying amount of our long-term debt was $40.7 million and
$114.9 million, respectively, and the estimated fair value was $40.9 million and $123.6 million, respectively. The
fair value was estimated using a discounted cash flow analysis based on our estimated incremental borrowing
rates for similar types of borrowing arrangements.

4. Certain Balance Sheet Items

Inventories consisted of the following (in thousands):

Raw materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Work in process . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finished goods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Property and equipment consisted of the following (in thousands):

Leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer equipment
Computer software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Furniture and fixtures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Construction-in-progress . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2010

2009

$2,986
705
1,355

$5,046

$1,245
676
1,505

$3,426

December 31,

2010

2009

$

763
1,483
4,010
593
73

$

704
1,479
3,715
586
28

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total
Less accumulated depreciation and amortization . . . . . . . . . .

6,922
(6,232)

6,512
(5,388)

Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . .

$

690

$ 1,124

Accrued liabilities consisted of the following (in thousands):

December 31,

2010

2009

Accrued research and development expense . . . . . . . . . . . . .
Accrued personnel expense . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued selling, general and administrative expense . . . . . .
Sales returns reserves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Government rebates reserve . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 1,449
8,060
1,598
3,539
6,588
2,338

$ 2,862
6,545
891
—
2,270
1,728

Total accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$23,572

$14,296

F-14

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

5. Goodwill and Intangible Assets

The gross carrying amount of goodwill was as follows (in thousands):

Goodwill

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$38,213

$38,213

December 31,

2010

2009

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):

Developed technology—Xyrem . . . . . . . . .
Developed technology—Luvox CR . . . . . .
Agreements not to compete . . . . . . . . . . . .
Trademarks . . . . . . . . . . . . . . . . . . . . . . . . .

December 31, 2010

December 31, 2009

Gross
Carrying
Amount

$39,700
9,700
—
2,600

Accumulated
Amortization

Net Book
Value

$23,014
5,446
—
1,507

$16,686
4,254
—
1,093

Gross
Carrying
Amount

$39,700
9,700
3,900
2,600

Accumulated
Amortization

Net Book
Value

$18,842
2,443
3,523
1,234

$20,858
7,257
377
1,366

K
-
0
1
m
r
o
F

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $52,000

$29,967

$22,033 $55,900

$26,042

$29,858

Based on intangible assets recorded as of December 31, 2010, and assuming the underlying assets will not
be impaired in the future and that we will not change the expected lives of the assets, future amortization costs
were estimated as follows (in thousands):

Year Ending December 31,

2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Estimated
Amortization
Expense

$ 7,448
5,696
4,445
4,444

$22,033

In 2009, we amended our product license agreement with Solvay Pharmaceuticals, Inc., or Solvay, which
was subsequently acquired by Abbott Laboratories, or Abbott, for the rights to market Luvox CR and Luvox in
the United States such that the existing $14.0 million current payment obligation, a $5.0 million obligation
related to a milestone of uninterrupted supply of Luvox CR and future royalty and other obligations were
replaced with an obligation to pay a total of $19.0 million. As a result, we recorded an increase of $5.0 million in
the value of the intangible asset associated with Luvox CR in 2009.

In 2008, as a result of lower than anticipated sales of Luvox CR, we evaluated the intangible asset

associated with Luvox CR for impairment and reduced the gross carrying amount and accumulated amortization
of this intangible asset by $36.3 million and $6.5 million, respectively, which resulted in a $29.8 million
intangible asset impairment charge. The most significant input used in the calculation of the fair value of the
intangible asset associated with Luvox CR was projected net sales of Luvox CR which were estimated by
extrapolating the current growth trends of the product and applying judgment as to the appropriate future growth
rate among other factors. Selection of a risk appropriate discount rate also involves significant judgment. We
used a discount rate of 20% to estimate fair value in 2008.

F-15

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

6. Debt and Financing Obligations

Retired Senior Secured Notes

In March 2008, we sold $40.0 million aggregate principal amount of senior secured notes and issued
warrants to purchase 562,192 shares of our common stock with an exercise price of $14.23 per share and which
expire in March 2013. The $2.0 million fair value of the warrants was recorded in stockholders’ deficit and was
estimated using the Black-Scholes option pricing model with the following assumptions: a risk-free rate 2.2%,
volatility 51%, a term of 5.0 years and a dividend yield of 0.0%. The senior secured notes bore interest at
15% per annum, payable quarterly in arrears, and were due on June 24, 2011. In addition, in 2008, a total of
$80.0 million aggregate principal amount of senior secured notes of Orphan Medical issued in 2005 that bore
interest at 15% per annum, due on June 24, 2011 were exchanged for the same principal amount of notes issued
by JPI Commercial, LLC. As a result of these transactions, a total of $120.0 million aggregate principal amount
of senior secured notes, or Senior Notes, was outstanding. We refer to the agreement that governed all of the
Senior Notes as the Senior Note Agreement.

In August 2008, we paid certain holders of the Senior Notes $504,000 aggregate principal amount as their

pro rata share of the proceeds from the sale of our rights to Antizol® and Antizol-Vet®.

In 2009, we amended the Senior Note Agreement. In connection with the amendment, amongst other
changes, we reduced the exercise price of warrants to purchase 1,347,920 shares of common stock, originally
issued in conjunction with the Senior Notes, to $9.34 per share. We determined that the amendment should be
accounted for as a modification of the existing Senior Notes. The $1.3 million fair value of the warrant
modification was recorded as a debt discount and in stockholders’ deficit. The fair value was estimated using the
Black-Scholes option pricing model with the following assumptions; risk-free rates of 1.2 and 1.6%, volatility of
90%, expected terms of 2.6 and 3.3 years, and a dividend yield of 0.0%.

As of December 31, 2009, the $119.5 million principal amount of the Senior Notes was recorded net of a
debt discount of $4.6 million. Interest expense associated with the Senior Notes was recorded using the interest
method and included non-cash interest related to the debt discount and debt issuance costs. The effective interest
rate on the Senior Notes subsequent to the amendment to the Senior Note Agreement in 2009 was 21.2%.

In March, May and June 2010, we repaid $3.0 million, $53.0 million and $63.5 million principal amount of

the Senior Notes, respectively, thereby paying in full our obligations to the holders of the Senior Notes. In
addition to the principal repayments in May and June 2010, we paid prepayment penalties and fees totaling
$8.5 million, and recorded non-cash charges related to unamortized debt discount and debt issuance costs of
$3.8 million in 2010.

Term Loan and Revolving Credit Facility

In June 2010, we entered into a credit agreement with a lender which provides for a term loan in an

aggregate principal amount of $50.0 million and a $15.0 million revolving credit facility, both of which mature in
June 2013. On June 30, 2010, we borrowed $57.4 million under the credit agreement, consisting of the term loan
of $50.0 million and $7.4 million under the revolving credit facility, and we used all of the borrowed funds,
together with cash on hand, to repay all of the remaining outstanding Senior Notes. We also terminated our
previous revolving line of credit. Borrowings under the term loan and revolving credit facility bear interest at a
variable rate based on the higher of the prime rate or the federal funds rate plus 0.5% plus, in each case, a margin
ranging from 1% to 2.5% or, at our option, the Eurodollar rate plus a margin ranging from 3% to 5%. The
revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.5% to 0.75% per
annum. The interest rate margins and the commitment fee will vary based on our consolidated leverage ratio, as
defined in the credit agreement.

F-16

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The borrowing availability under the revolving credit facility will vary according to the levels of our eligible

accounts receivable and other terms and conditions described in the credit agreement and was limited to
$8.0 million as of December 31, 2010, including a $650,000 unused letter of credit related to automobiles leased
by our sales organization, and $15.0 million thereafter. Borrowings under the revolving credit facility and the
term loan are secured by substantially all of our assets. The term loan is repayable in twelve equal quarterly
installments of $4.2 million beginning on September 30, 2010. If we prepay the term loan (in whole or in part),
or if we terminate or reduce the lender’s commitments to make loans under the revolving credit facility, we must
pay a prepayment fee equal to (a) 2% of the aggregate amount of the term loan prepaid or commitments
terminated or reduced during the first year of the credit agreement, and (b) 1% of the aggregate amount of the
term loan prepaid or commitments terminated or reduced during the second year of the credit agreement.

The credit agreement contains customary operating covenants, including covenants that restrict our ability

to: incur indebtedness and liens; effect mergers, consolidations and other fundamental changes; dispose of
significant assets or enter into sale-leaseback transactions; pay dividends or make other restricted payments;
make loans, advances or certain investments including acquisitions of companies and products; or enter into
transactions with affiliates. The credit agreement also requires us to comply with various financial covenants
including a minimum liquidity covenant, which requires us to maintain cash and availability under the revolving
line of credit of not less than $10.0 million until March 31, 2011 and not less than $20.0 million thereafter. As of
December 31, 2010, we were in compliance with all material covenants under the credit agreement.

K
-
0
1
m
r
o
F

As of December 31, 2010, the $41.7 million principal amount of the term loan was recorded net of a debt
discount of $1.0 million related to fees paid to the lender under the credit agreement as of December 31, 2010. As
of December 31, 2010, the interest rate on the term loan was 5.75%. Interest expense associated with the term
loan is recorded using the interest method and includes non-cash interest related to the debt discount and debt
issuance costs. The effective interest rate on the term loan during 2010 was 7.8%. The current portion of the
carrying amount of the term loan was $16.1 million as of December 31, 2010.

As of December 31, 2010, $7.4 million was outstanding under the revolving credit facility, which bore
interest at 5.75%. As of December 31, 2009, $9.4 million was outstanding under our previous revolving bank line
of credit, which bore interest at 6.5%.

7. Other Long Term Liabilities

Deferred Revenue

We have an agreement with UCB under which UCB has the right to market Xyrem for the treatment of
narcolepsy and for the treatment of fibromyalgia in various countries outside the United States. In 2008, we
received a $10.0 million nonrefundable milestone payment received, which we recognized as revenue in 2009
upon achievement of the related milestone. We recognized contract revenues of $1.1 million during each of 2010,
2009, and 2008 related to two upfront payments from UCB totaling $15.0 million related to Xyrem for the
treatment of fibromyalgia. As of December 31, 2010, $10.2 million was recorded as deferred revenues related to
this agreement, of which $1.1 million is a current liability. The deferred revenue balance is being recognized
ratably through 2019, the end of the expected performance period under the agreement.

Purchased Product Rights Liability

In 2007, we entered into a product license agreement with Solvay for the rights to market Luvox CR and

Luvox in the United States which agreement was subsequently amended a number of times. Under the amended
agreement we paid $4.0 million, $6.0 million and $27.0 million in 2010, 2009 and 2008, respectively, and will
pay $4.5 million in each of 2011 and 2012.

F-17

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Liability Under Government Litigation Settlement

In 2007, we and Orphan Medical entered into agreements with a number of government entities to settle
various matters associated with an investigation relating to the sale and marketing of Xyrem by Orphan Medical,
which we acquired in June 2005. Under these agreements we paid $3.0 million, $2.5 million, and $2.0 million in
2010, 2009 and 2008, respectively, and as of December 31, 2010, we owe $4.2 million and $7.3 million in 2011
and 2012, respectively.

8. Commitments and Contingencies

Indemnification

In the normal course of business, we enter into agreements that contain a variety of representations and
warranties and provide for general indemnification, including indemnification associated with product liability or
infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves
future claims that may be made but have not yet been made against us. To date, we have not paid any claims or
been required to defend any action related to these indemnification obligations.

We have agreed to indemnify our officers, directors and certain other employees for losses and costs
incurred in connection with certain events or occurrences, including advancing money to cover certain costs,
subject to certain limitations. The maximum potential amount of future payments we could be required to make
under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our
exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of
coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other
policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly,
we have not recognized any liabilities relating to these obligations as of December 31, 2010 and 2009,
respectively. No assurances can be given that the covering insurers will not attempt to dispute the validity,
applicability, or amount of coverage without expensive litigation against these insurers, in which case we may
incur substantial liabilities as a result of these indemnification obligations.

Lease and Other Commitments

We have a noncancelable operating lease for our corporate office building located in Palo Alto, California
which expires in September 2012, is renewable through 2016 and is subject to an annual rent escalation clause.
We are also obligated to make payments under noncancelable operating leases for automobiles used by our sales
force. Rent expense under all operating leases was $2.3 million, $2.7 million and $5.2 million in 2010, 2009 and
2008, respectively.

Future minimum lease payments under our noncancelable operating leases at December 31, 2010, were as

follows (in thousands):

Year ending December 31,

2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Lease
Payments

$1,915
1,615
857
124
—

$4,511

F-18

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As of December 31, 2010 and 2009, we had $2.1 million and $3.6 million, respectively, of noncancelable
purchase commitments under agreements with contract manufacturers, all of which were due within one year.

Legal Proceedings

On October 18, 2010, we received a Paragraph IV Patent Certification notice, or Paragraph IV Certification,
from Roxane Laboratories, Inc., or Roxane, that it filed an ANDA with the FDA requesting approval to market a
generic version of Xyrem. Roxane’s Paragraph IV Certification alleges that all five patents listed for Xyrem in
Orange Book on the date of the Paragraph IV Certification are invalid, unenforceable or not infringed by
Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to
Roxane’s Paragraph IV Certification in the United States District Court for the District of New Jersey. We are
seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem. In accordance
with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Roxane, FDA approval of
Roxane’s ANDA will be stayed until the earlier of (i) 30 months from our October 18, 2010 receipt of Roxane’s
Paragraph IV certification notice or (ii) a District Court decision finding that the identified patents are invalid,
unenforceable or not infringed. On January 14, 2011, we received an additional Paragraph IV Certification from
Roxane alleging that the additional method of use patent for the use of Xyrem in the treatment of narcolepsy that
issued in December 2010 and is listed in the Orange Book would not be infringed by Roxane’s proposed generic
product. We amended our lawsuit against Roxane on February 4, 2011 to include the additional patent in the
litigation in response to Roxane’s additional Paragraph IV Certification. We cannot predict the outcome of this
litigation.

In August and September 2009, we received Paragraph IV Certifications from Actavis Elizabeth, LLC, or
Actavis, and from Anchen Pharmaceuticals, Inc., or Anchen, advising that each has filed an ANDA with the FDA
seeking approval to market a generic version of Luvox CR. We have not been informed as to the timing or status
of the FDA’s review of either party’s filing, or whether either filer has complied with FDA requirements for
proving bioequivalence, or which party was first to file its ANDA with the FDA. Actavis’ Paragraph IV
Certification alleged that the United States patent covering Luvox CR, which is owned by Elan Pharma
International Limited, or Elan, and licensed to us, is invalid on the basis that the inventions claimed therein were
obvious. Anchen’s Paragraph IV Certification alleged that the Elan patent would not be infringed by Anchen’s
manufacture, use or sale of the generic product for which the ANDA was submitted and that the Elan patent is
invalid on the basis that the inventions claimed therein were obvious. On October 6, 2009, we and Elan, as
plaintiffs, filed a lawsuit against Actavis, Anchen, and Anchen Incorporated, the parent of Anchen, in the United
States District Court for the District of Delaware claiming infringement of the patent by the defendants. On
October 14, 2009, we and Elan, as plaintiffs, also filed a lawsuit in the United States District Court for the
Central District of California against Anchen and Anchen Incorporated claiming infringement of the Elan patent.

On August 25, 2010, we and Elan entered into settlement agreements with Anchen. Under the agreements, we,

Elan and Anchen have agreed to dismiss all of the claims brought in the litigation without prejudice, Anchen has
agreed not to contest the validity or enforceability of the Elan patent in the United States, and we, Elan and Anchen
have agreed to release each other from all claims arising in the litigation or relating to the product Anchen intends to
market under its ANDA. Settlement agreements of ANDA litigation can be reviewed by the Federal Trade
Commission and the U.S. Department of Justice at their discretion. In addition, we have granted a sublicense to
Anchen of our rights to have manufactured, market and sell a generic version of Luvox CR in the United States. The
sublicense is non-transferable, non-sublicensable and royalty-free and is exclusive even as to us and Elan (except with
respect to Luvox CR) for a period of time. The sublicense will commence on February 15, 2013 or earlier upon the
occurrence of certain events. On October 5, 2010, the United States District Court for the Central District of California
dismissed the case against Anchen without prejudice. On the same date, the United States District Court for the District
of Delaware also dismissed the case against Anchen without prejudice.

F-19

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The lawsuit against Actavis is pending in the United States District Court for the District of Delaware. We

cannot predict the outcome of this litigation.

From time to time we are involved in legal proceedings arising in the ordinary course of business. We
believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse
effect on our results of operations or financial condition.

9. Common Stock

Public Offering

In 2010, we completed a public offering of 7,000,000 shares of common stock at a price of $8.35 per share

for net proceeds of $56.8 million.

Committed Equity Financing Facility

In 2008, we entered into a committed equity financing facility, or CEFF, with Kingsbridge Capital Limited,
or Kingsbridge which expires in December 2012, unless earlier terminated under certain circumstances. In 2009,
we amended the CEFF and in conjunction with this amendment we reduced the exercise price of a warrant to
purchase 220,000 shares of common stock previously issued to Kingsbridge from $11.20 to $9.20 per share. The
$850,000 fair value of the warrant to purchase 220,000 shares of common stock at $11.20 per share issued in
2008 was recorded in stockholders’ deficit and was estimated using the Black-Scholes option pricing model with
the following assumptions: a risk free rate of 3.2%, volatility of 52%, a term of 5.5 years and a dividend yield of
0%. We have not yet utilized the CEFF.

Unregistered Sales of Equity Securities

In 2009, we completed a private placement of units consisting of 1,895,734 shares of common stock and

warrants to purchase 947,867 shares of our common stock at a price of $3.6925 per unit for net proceeds of
$6.8 million. The warrants are exercisable for $4.00 per share of common stock at any time through July 2016,
subject to certain restrictions. The $2.7 million fair value of the warrants was recorded in stockholders’ deficit
and was estimated using the Black-Scholes option pricing model with the following assumptions: a risk free rate
of 3.1%, volatility of 92%, a term of 7.0 years and a dividend yield of 0%.

Common Stock Subject to Repurchase

In 2008, as a result of the resignation of an executive officer covered by an employment agreement,
$749,000 related to 49,697 shares of common stock subject to repurchase by us in certain limited circumstances
was reclassified from common stock subject to repurchase to additional paid-in capital. In 2009, as a result of the
expiration of the employment contracts with certain of our executive officers, $12.5 million related to 827,761
shares of common stock subject to repurchase by us in certain limited circumstances was reclassified from
common stock subject to repurchase to additional paid-in capital.

Registered Direct Public Offering

In 2008, we completed a registered direct public offering of units consisting of 3,848,289 shares of common

stock and warrants to purchase 1,731,724 shares of our common stock at a price of $6.75625 per unit for net
proceeds of $24.5 million. The warrants are exercisable for $7.37 per share of common stock at any time prior to
July 2014. The $6.4 million fair value of the warrants was recorded in stockholders’ deficit and was estimated
using the Black-Scholes option pricing model with the following assumptions: a risk free rate of 3.62%, volatility
of 58%, a term of 6.5 years and a dividend yield of 0%.

F-20

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Authorized But Unissued Common Stock

We have reserved the following shares of authorized but unissued common stock:

2007 Equity Incentive Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2007 Employee Stock Purchase Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amended and Restated 2007 Non-Employee Directors Stock Option Plan . . .
Amended and Restated Directors Deferred Compensation Plan . . . . . . . . . . . .
Exercise of warrants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of
December 31,
2010

7,080,599
100,881
467,294
200,000
3,985,906

Total reserved shares of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

11,834,680

10. Stock-Based Compensation

2007 Equity Incentive Plan

In 2007, our board of directors adopted, and our stockholders approved, the 2007 Equity Incentive Plan, or

the 2007 Plan, which provides for the grant of incentive stock options, nonstatutory stock options, restricted
stock awards, restricted stock unit awards, or RSUs, stock appreciation rights, performance stock awards and
other forms of equity compensation to employees, including officers, non-employee directors and consultants.
All of the grants under the 2007 Plan were granted to employees and vest ratably over service periods of three to
five years and expire no more than ten years after the date of grant. A total of 8,223,848 shares of our common
stock have been authorized for issuance under the 2007 Plan as of December 31, 2010. The number of shares of
our common stock reserved for issuance automatically increases on January 1 of each year, from January 1, 2008
to January 1, 2017, by the lesser of (a) 4.5% of the total number of shares of our common stock outstanding on
December 31 of the preceding calendar year or (b) 3,000,000 shares, or a lesser amount determined by our board
of directors. On January 1, 2011, shares reserved for issuance under the 2007 Plan increased by 1,798,166 shares
pursuant to this automatic share increase provision.

2007 Employee Stock Purchase Plan

In 2007, employees became eligible to participate in the ESPP. The ESPP allows eligible employee

participants to purchase shares of our common stock at a discount of 15% through payroll deductions. The ESPP
consists of a fixed offering period of 24 months with four purchase periods within each offering period. In
September 2009, the compensation committee of our board of directors approved an increase in the number of
shares available for issuance under our ESPP during any six month purchase period from 150,000 to 260,000
effective with the purchase period that began on June 1, 2009 and for the following three purchase periods. In
subsequent purchase periods 175,000 shares will be available for issuance. A total of 1,400,000 shares of our
common stock have been authorized for issuance under the ESPP as of December 31, 2010. The number of
shares reserved for issuance under the 2007 ESPP automatically increases on each January 1 each year, from
January 1, 2008 to January 1, 2017, by the lesser of (a) 1.5% of the total number of shares of our common stock
outstanding on December 31 of the preceding calendar year or (b) 350,000, or a lesser amount determined by our
board of directors. On January 1, 2011, the number of shares reserved for issuance under the 2007 ESPP
increased by 350,000 shares pursuant to this automatic share increase provision.

Amended and Restated 2007 Non-Employee Directors Stock Option Plan

In 2007, our board of directors adopted, and our stockholders approved, the 2007 Non-Employee Directors

Stock Option Plan, or the 2007 Directors Option Plan. The 2007 Directors Option Plan provides for the automatic

F-21

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

grant of nonstatutory stock options to purchase shares of our common stock to our non-employee directors which
vest over a period of one to three years. In addition, the 2007 Directors Option Plan provides the source of shares
to fund distributions made prior to August 15, 2010 under the Directors Deferred Compensation Plan described
below. A total of 473,963 shares of our common stock have been authorized for issuance under the 2007
Directors Option Plan as of December 31, 2010. The number of shares of common stock reserved for issuance
automatically increases on January 1 of each year by the number used during the previous year (or such lesser
amount as may be approved by our board of directors). In no event may the amount of any such annual increase
exceed 200,000 shares. On January 1, 2011, the number of shares reserved for issuance under the 2007 Directors
Option Plan increased by 197,500 shares pursuant to this automatic share increase provision.

Amended and Restated Directors Deferred Compensation Plan

In 2007, our board of directors adopted the Directors Deferred Compensation Plan, the Directors Plan. The

Directors Plan allows each non-employee director to elect to defer receipt of his or her retainer fee to a future
date or dates. Amounts deferred are credited as shares of common stock to a phantom stock account the number
of which are based on the amount of the retainer fees deferred divided by the market value of our common stock
on the first trading day of the first open window period following the date the retainer fees are deemed earned.
We recorded expense of $198,000, $243,000 and $236,000 related to retainer fees earned and deferred in 2010,
2009 and 2008, respectively. Upon termination of a director’s service, the deferred shares are issued. As of
December 31, 2010, 101,460 shares of common stock were unissued related to retainer fees deferred. We
reserved 200,000 shares for issuance under the Directors Plan in August 2010, 175,834 of which are available for
issuance as of January 1, 2011.

Stock Based Compensation

The table below shows the assumptions used in the Black-Scholes option pricing model and the resulting

weighted-average grant date fair value of stock options granted in each of the past three years:

Year Ended December 31,

2010

2009

2008

Weighted-average volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted-average expected term (years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Range of risk-free rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted-average grant date fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

85%
6.0

91%
6.1
1.5-3.1% 1.8-3.1% 2.7-3.4%
0.0%
4.82

0.0%
1.34

0.0%
7.84

60%
6.1

$

$

We completed our initial public offering in 2007 and our common stock therefore has a trading history
which is shorter than the weighted-average expected term of our stock option grants. A public market for options
on our common stock did not exist before June 2009, and for the market options with more than one year to
expiration is not very liquid. As a result, in 2008 we used the historic volatility of a peer group to estimate the
future volatility for our stock option grants and we used the historic and implied volatility of a peer group in
addition to the historic volatility of our own common stock to estimate volatility for grants under our ESPP. In
2009, we used the historic volatility of a peer group and the historic volatility of our own common stock to
estimate future volatility for stock option grants and we used the implied volatility of our own common stock to
estimate the volatility for grants under our ESPP. And in 2010 we used the historic volatility of a peer group, the
historic volatility of our own common stock and the implied volatility of our own common stock to estimate
future volatility for stock option grants and we used the implied volatility of our own common stock to estimate
the volatility for grants under our ESPP.

F-22

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

We have limited historical information to develop reasonable expectations about future exercise patterns

and post-vesting employment termination behavior. As a result, for stock option grants made during each of
2010, 2009 and 2008, the expected term was estimated by assuming stock options would be exercised at the
mid-point between the vest date and the contractual term.

The risk-free interest rate assumption was based on zero coupon U.S. Treasury instruments whose term was
consistent with the expected term of our stock option grants. The expected dividend yield assumption was based
on our history and expectation of dividend payouts.

Stock-based compensation expense related to stock options, RSUs, shares of common stock credited to the

directors’ phantom stock accounts under the Directors Plan and grants under our ESPP was as follows (in
thousands):

Year Ended December 31,

2010

2009

2008

Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of product sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$5,924
2,004
291

$4,400
1,456
101

$5,712
2,207
187

Total stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$8,219

$5,957

$8,106

No income tax benefit related to stock-based compensation was recognized in the statement of operations
for 2010, 2009 and 2008. Employee stock-based compensation costs of $22,000 and $46,000 as of December 31,
2010 and 2009, respectively, were capitalized as a component of inventory and included in the consolidated
balance sheets.

The following table summarizes information as of December, 31, 2010 and activity during 2010, related to

stock option plans:

Shares
Subject to
Outstanding
Options

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
($000)

Outstanding at January 1, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . .
Options granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2010 . . . . . . . . . . . . . . . . . . . . . . .
Vested and expected to vest at December 31, 2010 . . . . . . . . . .
Exercisable at December 31, 2010 . . . . . . . . . . . . . . . . . . . . . . .

4,934,377
1,677,700
(955,129)
(83,112)
(33,377)

5,540,459
5,116,118
2,646,597

$ 8.95
10.84
3.86
7.51
13.59

10.39
10.51
12.90

7.4
7.3
6.1

$56,904
52,386
23,389

Aggregate intrinsic value shown in the table above is equal to the difference between the exercise price of
the underlying stock options and the fair value of our common stock for stock options that were in the money.
The aggregate intrinsic value of stock options exercised was $9.7 million, $18,000 and $18,000, during 2010,
2009 and 2008, respectively. We issued new shares of common stock upon exercise of stock options.

As of December 31, 2010, total compensation cost related to unvested stock option grants not yet

recognized was $10.8 million, which is expected to be recognized over a weighted-average period of 2.2 years.
As of December 31, 2010, total compensation cost related to grants under the ESPP not yet recognized was
$393,000, which is expected to be recognized over a weighted-average period of less than one year.

F-23

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

11. Income Taxes

In 2010, we made no provision for income taxes due to our utilization of federal net operating loss

carryforwards to offset both regular taxable income and alternative minimum taxable income and our utilization
of deferred state tax benefits. Prior to 2010, we made no provision for income taxes due to our history of losses.
All of our income and losses result from domestic operations.

A reconciliation between income tax at the United States federal statutory income tax rate and our provision

for income taxes is as follows:

Income tax at federal statutory rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Add (deduct):
Research and other tax credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Meals and entertainment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other
Utilization of federal net operating loss carryforwards . . . . . . . . . . . . . . . . . . . . .
Increase in federal valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2010

2009

2008

$ 11,472

$(2,392) $(64,503)

(380)
293
1,083
(373)
(16,975)
4,880

(965)
264
1,401
52
—
1,640

(2,613)
694
1,887
61
—
64,474

Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ — $ — $ —

Deferred income taxes reflect the tax effects of net operating loss and tax credit carryforwards and the net

temporary differences between the carrying amounts of assets and liabilities for financial reporting and the
amounts used for income tax purposes.

Significant components of our deferred tax assets and liabilities were as follows (in thousands):

December 31,

2010

2009

Deferred tax assets:

Federal and state net operating loss carryforwards . . . . . . . . . . . . . . . .
Federal and state tax credit carryforwards . . . . . . . . . . . . . . . . . . . . . . .
Deferred contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 120,473
14,720
3,995
4,297
12,034

$ 134,368
14,525
4,802
2,721
6,245

Total deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

155,519
(155,519)

162,661
(162,661)

Net deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

—

$

—

Realization of our deferred tax assets is dependent upon the generation of future taxable income, if any, the
amount and timing of which are uncertain. Based on available objective evidence, management believes it more
likely than not that our deferred tax assets are not recognizable and will not be recognizable until we have
sufficient taxable income. Accordingly, the net deferred tax assets have been fully offset by a valuation
allowance. The valuation allowance decreased by $7.1 million and $2.1 million in 2010 and 2009, respectively,
and increased by $59.1 million in 2008. The decrease in the valuation allowance in 2010 was primarily due to the
utilization of net operating losses.

F-24

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

At December 31, 2010, we had net operating loss carryforwards for federal income tax purposes of

$319.8 million, which expire in the period from 2011 to 2030, and federal tax credits of $15.9 million, which expire
in the period from 2011 to 2030. We also have state net operating loss carryforwards of $231.5 million, which
expire beginning in 2011, and state tax credits of $4.8 million that have no expiration date. Utilization of our net
operating loss carryforwards and tax credit carryforwards is subject to annual limitation due to the ownership
change limitations provided by the Internal Revenue Code and similar state provisions. Such an annual limitation
may result in the expiration of the net operating loss before utilization. Because our acquisition of Orphan Medical
in 2005 triggered an ownership change, $38.0 million of the acquired Orphan Medical net operating loss
carryforward is only available ratably through 2019 based upon the annual limitation under Section 382 of the
Internal Revenue Code. Similarly, $5.0 million of acquired Orphan Medical tax credits are available only from 2019
to 2024. We have completed detailed reviews of our ownership changes in accordance with the Internal Revenue
Code, and we have confirmed that it is more likely than not that we have not experienced an ownership change from
the time of the acquisition of Orphan Medical in June 2005 through December 31, 2010.

We are required to recognize the financial statement effects of a tax position when it is more likely than not,
based on the technical merits, that the position will be sustained upon examination. As a result, we have reduced
our gross deferred tax assets for certain tax benefits which we judge may not be sustained upon examination, and
we have provided an offset through equal reductions in our deferred tax asset valuation allowance. A
reconciliation of our unrecognized tax benefits follows (in thousands):

K
-
0
1
m
r
o
F

December 31,

2010

2009

2008

Balance at the beginning of the year . . . . . . . . . . . . . . . . . . . . . . . . . . $4,711 $4,010 $2,060
871
Additions based on tax positions related to the current year . . . . . . . .
164
1,110
Additions for tax positions of prior years . . . . . . . . . . . . . . . . . . . . . . —
(31)
Lapse of applicable statute of limitations . . . . . . . . . . . . . . . . . . . . . . .

560
147
(6)

(23)

Balance at the end of the year

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $4,852 $4,711 $4,010

There were no interest or penalties related to unrecognized tax benefits. Substantially all of the

unrecognized tax benefit, if recognized, would affect our tax expense before taking valuation allowance into
consideration. We do not anticipate that the amount of existing unrecognized tax benefits will significantly
increase or decrease within the next 12 months. Because of net operating loss carryforwards, substantially all of
our tax years remain open to federal and state tax examination. We file income tax returns in the United States
federal jurisdiction and various state jurisdictions, which typically have three tax years open at any point in time.

12. Related Party Transactions

Senior Notes. In 2010, we repaid in full all of our then outstanding Senior Notes, of which $6.8 million

principal amount was paid to an entity affiliated with Kohlberg, Kravis & Roberts & Co. L.P., or KKR, a
significant stockholder. In addition, in 2010 we paid prepayment penalties and a fee to the holders of the Senior
Notes totaling $8.5 million of which $484,000 was paid to the KKR affiliate. In 2008, we paid $327,000 to the
KKR affiliate, as partial prepayment of the principal amount of the Senior Notes held by the KKR affiliate. Cash
paid for interest with respect to then outstanding Senior Notes held by the KKR affiliate was $461,000, $1.3
million, and $796,000 in 2010, 2009, and 2008, respectively. All payments to KKR were in proportion to its
ownership of the Senior Notes.

The exercise price of all warrants to purchase common stock issued to the holders of the then outstanding

senior secured notes was reduced to $9.34 per share as a result of an amendment to the agreement governing the
senior secured notes in 2009. This included warrants to purchase 70,156 shares of our common stock held by the
KKR affiliate the exercise price of which was reduced from $20.36 to $9.34 per share.

F-25

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

2009 and 2010 Common Stock Offerings. In a private placement we completed in 2009, 1,858,486 shares of
common stock and a warrant to purchase 929,243 shares of common stock were acquired by Longitude Venture
Partners, L.P. and 37,248 shares of common stock and a warrant to purchase 18,624 shares of common stock
were acquired by Longitude Capital Associates, L.P. In July 2009, Patrick G. Enright was elected to our board of
directors in connection with the closing of the private placement. Mr. Enright is a managing member of
Longitude Capital Partners, LLC, the sole general partner of Longitude Venture Partners, L.P. and Longitude
Capital Associates, L.P. In addition, in 2010 we issued 7,000,000 shares of our common stock in an underwritten
public offering of which 838,323 shares were purchased from the underwriter by Longitude Capital Partners,
LLC. The remaining shares were purchased from the underwriter by third party investors on the same terms and
conditions.

2008 Common Stock Offering. In a registered direct public offering we completed in 2008, a total of 60% of

the investment was made by certain of our existing stockholders with which certain members of our board of
directors are affiliated and/or associated; the remaining units were purchased by third party institutional investors
on the same terms and conditions. In the offering, entities affiliated with KKR purchased units consisting of
1,328,527 shares of common stock and warrants to purchase 597,837 shares of common stock exercisable at
$7.37 per share through July 2014.

13. 401(k) Plan

We provide a qualified 401(k) savings plan for our employees. All employees are eligible to participate,
provided they meet the requirements of the plan. While we may elect to match employee contributions, no such
matching contributions have been made through December 31, 2010.

14. Segment and Other Information

We have determined that we operate in one business segment which is the development and

commercialization of pharmaceutical products.

The following is a summary of our product sales, net (in thousands):

Xyrem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Luvox CR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antizol(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$142,630
27,376
—

$ 96,763
18,345
—

$53,803
5,728
5,106

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$170,006

$115,108

$64,637

Year Ended December 31,

2010

2009

2008

(1) We sold our rights to and interests in Antizol and Antizol-Vet in 2008.

The following table presents a summary of total revenues attributed to domestic and foreign sources (in

thousands):

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$169,317
4,169
295

$114,080
14,011
358

$62,894
2,860
1,760

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$173,781

$128,449

$67,514

Year Ended December 31,

2010

2009

2008

F-26

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table presents a summary of revenues from customers who represent at least 10% of our total

revenues:

Express Scripts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UCB(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2010

82%
*

2009

75%
11%

2008

79%
*

(1)

In 2009, we recognized, as revenue, a $10.0 million nonrefundable milestone payment received from UCB
in 2008.

*

Represented less than 10% of our total revenues.

15. Quarterly Financial Data (Unaudited)

The following interim financial information presents our 2010 and 2009 results of operations on a quarterly

basis (in thousands, except per share amounts):

March 31

June 30

September 30 December 31

2010

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross margin(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income (loss)
Net income (loss) per share, basic . . . . . . . . . . . . . . . . . . . . . . . .
Net income (loss) per share, diluted . . . . . . . . . . . . . . . . . . . . . .

$ 35,173
31,401
1,464
0.05
0.04

$40,486
36,726
(6,388)
(0.18)
(0.18)

$44,753
40,747
13,243
0.34
0.32

$53,369
47,573
24,459
0.62
0.56

March 31

June 30

September 30 December 31

2009

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross margin(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net (loss) income per share, basic . . . . . . . . . . . . . . . . . . . . . . . .
Net (loss) income per share, diluted . . . . . . . . . . . . . . . . . . . . . .

$ 22,076
19,376
(12,988)
(0.45)
(0.45)

$37,280
23,903
2,171
0.07
0.07

$30,809
27,654
(1,672)
(0.05)
(0.05)

$38,284
34,537
5,653
0.18
0.17

(1) Gross margin excludes amortization of acquired developed technology of $1.8 million in each of the three
month periods ended March 31, 2010, June 30, 2010, September 30, 2010 and December 31, 2010,
respectively.

(2) Gross margin excludes amortization of acquired developed technology of $1.5 million, $1.6 million, $1.8

million and $1.8 million in the three months ended March 31, 2009, June 30, 2009, September 30, 2009 and
December 31, 2009, respectively.

The tables above include the following unusual or infrequently occurring items:

• A loss on extinguishment of debt of $12.3 million in the three months ended June 30, 2010;

• Revenue of $2.0 million and related deferred product costs of $674,000 recognized as a result of a

change in the timing of when Luvox CR revenue is recognized in the three months ended December 31,
2010; and

• Contract revenues of $10.0 million recognized as revenue in the three months ended June 30, 2009

related to nonrefundable milestone payment received from UCB in July 2008.

F-27

Schedule II

Valuation and Qualifying Accounts
(In thousands)

Balance at
beginning
of period

Additions

Additions
charged to
costs and
expenses(3) Deductions

Balance at
end of
period

For the year ended December 31, 2010

Allowance for doubtful accounts . . . . . . . . .(1)
Allowance for sales discounts . . . . . . . . . . .(1)
Allowance for chargebacks . . . . . . . . . . . . .(1)
Allowance for wholesaler fees . . . . . . . . . . .(2)
Allowance for patient rebates . . . . . . . . . . .(2),(4)
Allowance for managed care rebates . . . . . .(2)

For the year ended December 31, 2009

Allowance for doubtful accounts . . . . . . . . .(1)
Allowance for sales discounts . . . . . . . . . . .(1)
Allowance for chargebacks . . . . . . . . . . . . .(1)
Allowance for wholesaler fees . . . . . . . . . . .(2),(4)

For the year ended December 31, 2008

Allowance for doubtful accounts . . . . . . . . .(1)
Allowance for sales discounts . . . . . . . . . . .(1)
Allowance for chargebacks . . . . . . . . . . . . .(1)
Allowance for customer rebates . . . . . . . . . .(1)
Allowance for wholesaler fees . . . . . . . . . . .(2)

Notes

$ 50
238
—
613
—
—

$ 50
126
—
426

$ 50
101
13
12
43

$—
—
—
(63)
63
18

$—
—
—
43

$—
—
—
—
—

$

(9)
3,829
233
5,347
2,243
95

$ 111
2,068
82
4,362

$

30
1,375
208
21
4,040

$

9
(3,647)
(221)
(5,004)
(2,036)
(81)

$ (111)
(1,956)
(82)
(4,218)

$

(30)
(1,350)
(221)
(33)
(3,657)

$ 50
420
12
893
270
32

$ 50
238
—
613

$ 50
126
—
—
426

(1) Shown as a reduction of accounts receivable.
(2)
(3) All charges except doubtful accounts are reflected as a reduction of revenue or a charge to cost of products

Included in accrued liabilities.

sold.
In 2009, the allowance for wholesaler fees included the allowance for patient rebates.

(4)

The schedule above does not include government rebates and product returns reserve which are reported in

our Management’s Discussion and Analysis of Financial Condition and Results of Operations section.

F-28

K
-
0
1
m
r
o
F

Exhibit
Number

2.1

3.1

3.2

4.1

4.2

4.3A

4.3B

4.3C

4.3D

4.4A

4.4B

4.5A

4.5B†

4.5C

EXHIBIT INDEX

Description of Document

Agreement and Plan of Merger dated as of April 18, 2005, by and among the Registrant, Twist
Merger Sub, Inc. and Orphan Medical, Inc. (incorporated by reference to exhibit 2.1 in the
Registrant’s registration statement on Form S-1 (File No. 333-141164), as filed with the SEC on
March 9, 2007).

Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by
reference to exhibit 3.1 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for
the period ended June 30, 2007, as filed with the SEC on August 10, 2007).

Amended and Restated Bylaws (incorporated herein by reference to exhibit 3.4 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

Reference is made to Exhibits 3.1 and 3.2.

Specimen Common Stock Certificate (incorporated herein by reference to exhibit 4.2 in the
Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with the
SEC on May 17, 2007).

Third Amended and Restated Investor Rights Agreement, made effective as of June 6, 2007, by and
between the Registrant and the other parties named therein (incorporated herein by reference to
exhibit 4.3 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2007, as filed with the SEC on August 10, 2007).

Waiver and Amendment Agreement, dated as of March 12, 2008, by and between the Registrant and
the other parties named therein (incorporated herein by reference to exhibit 4.3B in the Registrant’s
annual report on Form 10-K (File No. 001-33500) for the period ended December 31, 2007, as filed
with the SEC on March 31, 2008).

Waiver and Amendment Agreement, dated as of May 7, 2008, by and between the Registrant and the
other parties named therein (incorporated herein by reference to exhibit 4.3C in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on May 9, 2008).

Waiver and Amendment Agreement, dated as of July 6, 2009 by and between the Registrant and the
other parties named therein (incorporated herein by reference to exhibit 4.3D in the Registrant’s
quarterly report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2009, as filed with
the SEC on August 14, 2009).

Form of Series BB Preferred Stock Warrant of the Registrant (incorporated by reference to exhibit
4.6 to the Registrant’s registration statement on Form S-1 (File No. 333-141164), as filed with the
SEC on March 9, 2007).

Form of Series BB Preferred Stock Warrant of the Registrant, as amended (incorporated herein by
reference to exhibit 4.4B in the Registrant’s annual report on Form 10-K (File No. 001-33500) for
the period ended December 31, 2007, as filed with the SEC on March 31, 2008).

Form of Common Stock Warrant of the Registrant (incorporated herein by reference to exhibit 4.5D
in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2007, as filed with the SEC on March 31, 2008).

Registration Rights Agreement, dated as of March 17, 2008, by and between the Registrant and the
other parties named therein (incorporated herein by reference to exhibit 4.5E in the Registrant’s
annual report on Form 10-K (File No. 001-33500) for the period ended December 31, 2007, as filed
with the SEC on March 31, 2008).

Amendment and Waiver Agreement, dated as of November 10, 2009, by and among the Registrant,
JPI Commercial, LLC and the other parties named therein (incorporated by reference to exhibit 4.5F
in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on
November 10, 2009).

Exhibit
Number

4.6A

4.6B

4.6C

4.7

4.8

4.9A

4.9B

10.1+

10.2+

10.3+

10.4+

10.5+

10.6+

10.7+

Description of Document

Warrant issued to Kingsbridge Capital Limited, dated May 7, 2008 (incorporated herein by reference
to exhibit 4.6A in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the
SEC on May 9, 2008).

Registration Rights Agreement, dated as of May 7, 2008, by and between the Registrant and
Kingsbridge Capital Limited (incorporated herein by reference to exhibit 4.6B in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on May 9, 2008).

Amendment Agreement No. 1, dated as of November 20, 2009, by and between the Registrant and
Kingsbridge Capital Limited (incorporated by reference to exhibit 4.6C in the Registrant’s current
report on Form 8-K (File No. 001-33500), as filed with the SEC on November 23, 2009).

Form of Registered Direct Common Stock Warrant (incorporated herein by reference to exhibit 4.7
in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on
July 16, 2008).

NOL Preservation Lock-Up Agreement, effective as of July 7, 2009, by and between the Registrant
and the other parties named therein (incorporated herein by reference to exhibit 4.8 in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 7,
2009).

Form of Common Stock Warrant of the Registrant issued on July 7, 2009 (incorporated herein by
reference to exhibit 4.9 in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed
with the SEC on July 7, 2009).

Investor Rights Agreement, dated July 7, 2009 by and between the Registrant and the other parties
named therein (incorporated herein by reference to exhibit 10.88 in the Registrant’s current report on
Form 8-K (File No. 001-33500), as filed with the SEC on July 7, 2009).

2003 Equity Incentive Plan, as amended (incorporated herein by reference to exhibit 10.21 in the
Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with the
SEC on May 17, 2007).

Form of Option Exercise and Stock Purchase Agreement and Forms of Grant Notices under the 2003
Equity Incentive Plan (incorporated herein by reference to exhibit 10.22 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

2007 Equity Incentive Plan (incorporated herein by reference to exhibit 10.23 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

Form of Option Agreement and Form of Option Grant Notice under the 2007 Equity Incentive Plan
(incorporated herein by reference to exhibit 10.24 in the Registrant’s registration statement on Form
S-1, as amended (File No. 333-141164), as filed with the SEC on May 24, 2007).

2007 Non-Employee Directors Stock Option Plan (incorporated herein by reference to exhibit 10.25
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on May 17, 2007).

Form of Stock Option Agreement and Form of Option Grant Notice under the 2007 Non-Employee
Directors Stock Option Plan (incorporated herein by reference to exhibit 10.26 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 17, 2007).

2007 Employee Stock Purchase Plan (incorporated herein by reference to exhibit 10.27 in the
Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with the
SEC on May 17, 2007).

K
-
0
1
m
r
o
F

Exhibit
Number

10.8+

10.9†

10.10†

10.11

10.12

10.13

10.14†

10.15†

10.16†

10.17†

10.18†

10.19†

Description of Document

2007 Employee Stock Purchase Plan Offering Document (incorporated herein by reference to exhibit
10.28 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on May 17, 2007).

Amended and Restated Xyrem License and Distribution Agreement, dated as of June 30, 2006, by
and between the Registrant and UCB Pharma Limited (incorporated herein by reference to
exhibit 10.41 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-
141164), as filed with the SEC on May 31, 2007).

License Agreement, dated as of January 31, 2007, by and between the Registrant and Solvay
Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.13 in the Registrant’s quarterly
report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2010, as filed with the
SEC on May 6, 2010).

Supply Agreement, dated as of January 31, 2007, by and between the Registrant and Solvay
Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.43 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 24, 2007).

Trademark License Agreement, dated as of January 31, 2007, by and between the Registrant and
Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.44 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 24, 2007).

Assignment, Assumption and Consent, dated as of January 31, 2007, by and among the Registrant,
Solvay Pharmaceuticals, Inc. and Elan Pharma International Limited (incorporated herein by
reference to exhibit 10.45 in the Registrant’s registration statement on Form S-1, as amended (File
No. 333-141164), as filed with the SEC on March 27, 2007).

License Agreement, dated as of December 22, 1997, by and between Solvay Pharmaceuticals, Inc.
and Elan Corporation, plc. (incorporated herein by reference to exhibit 10.46 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
May 31, 2007).

Amendment to License Agreement, dated as of March 1, 1999, by and between Solvay
Pharmaceuticals, Inc. and Elan Corporation, plc. (incorporated herein by reference to exhibit 10.47 in
the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with
the SEC on March 27, 2007).

Letter Amendment No. 2 to License Agreement, dated April 13, 2000, by and between Solvay
Pharmaceuticals, Inc and Elan Pharmaceutical Technologies (incorporated herein by reference to exhibit
10.48 in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on March 27, 2007).

Amendment Agreement No. 3 to License Agreement, dated as of November 7, 2006, by and between
Solvay Pharmaceuticals, Inc. and Elan Corporation plc. (incorporated herein by reference to exhibit 10.49
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed with
the SEC on May 31, 2007).

Xyrem Manufacturing Services and Supply Agreement, dated as of March 13, 2007, by and between
the Registrant and Patheon Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.50
in the Registrant’s registration statement on Form S-1, as amended
(File No. 333-141164), as filed with the SEC on May 31, 2007).

Quality Agreement, dated as of March 13, 2007, by and between the Registrant and Patheon
Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.51 in the Registrant’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on
March 27, 2007).

Exhibit
Number

10.20

10.21A

10.21B

10.21C

10.21D

10.22+

10.23+

10.24†

10.25

10.26

10.27

10.28+

Description of Document

Commercial Lease, dated as of June 2, 2004, by and between the Registrant and The Board of
Trustees of the Leland Stanford Junior University (incorporated herein by reference to exhibit 10.52
in the Registrant’s registration statement on Form S-1, as amended (File No. 333-141164), as filed
with the SEC on March 27, 2007).

Civil Settlement Agreement, dated July 13, 2007, among the United States of America acting
through the entities named therein, the Registrant and Orphan Medical, Inc. (incorporated herein by
reference to exhibit 10.57A in the Registrant’s current report on Form 8-K (File No. 001-33500), as
filed with the SEC on July 18, 2007).

Non-Prosecution Agreement, dated July 13, 2007, between the United States Attorney’s Office for
the Eastern District of New York and the Registrant (incorporated herein by reference to exhibit
10.57B in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC
on July 18, 2007).

Plea Agreement, dated July 13, 2007, between the United States Attorney for the Eastern District of
New York and Orphan Medical, Inc. (incorporated herein by reference to exhibit 10.57C in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 18,
2007).

Corporate Integrity Agreement, dated July 13, 2007, between the Office of Inspector General of the
Department of Health and Human Services and the Registrant (incorporated herein by reference to
exhibit 10.57D in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the
SEC on July 18, 2007).

Form of Letter, amending outstanding options granted under the Registrant’s 2003 Equity Incentive
Plan (incorporated herein by reference to exhibit 10.60 in the Registrant’s quarterly report on Form
10-Q (File No. 001-33500) for the period ended June 30, 2007, as filed with the SEC on August 10,
2007).

Form of Restricted Stock Unit Award under the Registrant’s 2007 Equity Incentive Plan
(incorporated herein by reference to exhibit 10.64 in the Registrant’s quarterly report on Form 10-Q
(File No. 001-33500) for the period ended September 30, 2007, as filed with the SEC on
November 9, 2007).

Amendment Number 4 to Development, License and Supply Agreement, dated as of October 26,
2007, by and between the Registrant and Elan Pharma International, Inc. (incorporated herein by
reference to exhibit 10.66 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for
the period ended December 31, 2007, as filed with the SEC on March 31, 2008).

Amendment No. 1 to Amended and Restated Xyrem License and Distribution Agreement, dated as of
December 21, 2007, by and between the Registrant and UCB Pharma Limited (incorporated herein by
reference to exhibit 10.68 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the
period ended December 31, 2007, as filed with the SEC on March 31, 2008).

Amendment No. 1 to License Agreement, dated as of March 12, 2008, by and between the Registrant
and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit 10.69 in the
Registrant’s annual report on Form 10-K (File No. 001-33500) for the period ended December 31,
2007, as filed with the SEC on March 31, 2008).

Common Stock Purchase Agreement, dated as of May 7, 2008, by and between the Registrant and
Kingsbridge Capital Limited (incorporated herein by reference to exhibit 10.70 in the Registrant’s
current report on Form 8-K (File No. 001-33500), as filed with the SEC on May 9, 2008).

Form of Stock Award Grant Notice and Stock Award Agreement under the Registrant’s 2007 Equity
Incentive Plan (incorporated herein by reference to exhibit 10.73 in the Registrant’s quarterly report
on Form 10-Q (File No. 001-33500) for the period ended March 31, 2008, as filed with the SEC on
May 15, 2008).

K
-
0
1
m
r
o
F

Exhibit
Number

10.29†

10.30

10.31

10.32

10.33

10.34+

10.35

10.36

10.37

10.38

10.39

10.40

Description of Document

Master Services Agreement dated May 6, 2008, by and among the Registrant, Express Scripts
Specialty Distribution Services, Inc. and CuraScript, Inc. (incorporated herein by reference to exhibit
10.74 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period ended
March 31, 2008, as filed with the SEC on May 15, 2008).

Amendment No. 2 to Amended and Restated Xyrem License and Distribution Agreement, dated
July 23, 2008, by and between the Registrant and UCB Pharma Limited (incorporated herein by
reference to exhibit 10.75 in the Registrant’s current report on Form 8-K (File No. 001-33500), as
filed with the SEC on July 24, 2008).

Amendment No. 2 to License Agreement, dated as of October 17, 2008, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit
10.77 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2008, as filed with the SEC on November 14, 2008).

Amendment No. 3 to License Agreement, dated as of December 19, 2008, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit
10.78 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2008, as filed with the SEC on March 26, 2009).

Amendment No. 4 to License Agreement, dated as of February 5, 2009, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit
10.79 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2008, as filed with the SEC on March 26, 2009).

Amended and Restated Executive Change in Control and Severance Benefit Plan (incorporated
herein by reference to exhibit 10.81 in the Registrant’s annual report on Form 10-K (File No.
001-33500) for the period ended December 31, 2008, as filed with the SEC on March 26, 2009).

Revision of Payment Terms of the Plea Agreement dated as of July 17, 2007 between the U.S.
Attorney for the Eastern District of New York and Orphan Medical, Inc. (incorporated herein by
reference to exhibit 10.82 in the Registrant’s annual report on Form 10-K (File No. 001-33500) for
the period ended December 31, 2008, as filed with the SEC on March 26, 2009).

Amendment to Settlement Agreement, signed by the Company on February 6, 2009, among the
United States of America acting through the entities named therein, the Registrant and Orphan
Medical, Inc. (incorporated herein by reference to exhibit 10.83 in the Registrant’s annual report on
Form 10-K (File No. 001-33500) for the period ended December 31, 2008, as filed with the SEC on
March 26, 2009).

Form of Registered Direct Subscription Agreement (incorporated by reference to exhibit 10.1 in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 16, 2008).

First Amendment of Lease, dated June 1, 2009, by and between the Registrant and Wheatley-Fields,
LLC, successor in interest to the Board of Trustees of the Leland Stanford Junior University
(incorporated herein by reference to exhibit 10.86 in the Registrant’s current report on Form 8-K
(File No. 001-33500), as filed with the SEC on June 4, 2009).

Securities Purchase Agreement, dated July 6, 2009, by and between the Registrant and the purchasers
listed on the signature pages thereto (incorporated herein by reference to exhibit 10.87 in the
Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on July 7,
2009).

Form of Indemnification Agreement between the Registrant and its officers and directors
(incorporated herein by reference to exhibit 10.89 in the Registrant’s current report on Form 8-K
(File No. 001-33500), as filed with the SEC on July 7, 2009).

Exhibit
Number

10.41

10.42

10.43

10.44†

10.45

10.46+

10.47+

10.48+

10.49+

10.50+

10.51+

10.52

Description of Document

Amendment No. 5 to License Agreement, dated as of June 23, 2009, by and between JPI
Commercial, LLC and Solvay Pharmaceuticals, Inc. (incorporated herein by reference to exhibit
10.90 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period ended
June 30, 2009, as filed with the SEC on August 14, 2009).

Amendment No. 5 to License Agreement, dated as of October 23, 2009, by and between the
Registrant and Elan Pharma International Limited (incorporated by reference to exhibit 10.91 in the
Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period ended September 30,
2009, as filed with the SEC on November 6, 2009).

Offer Letter from the Registrant to Kathryn Falberg (incorporated herein by reference to exhibit
10.92 in the Registrant’s current report on Form 8-K (File No. 001-33500), as filed with the SEC on
December 3, 2009).

Supply Agreement, dated as of April 1, 2010, by and between the Registrant and Siegfried (USA)
Inc. (incorporated herein by reference to exhibit 10.54 in the Registrant’s quarterly report on Form
10-Q (File No. 001-33500) for the period ended March 31, 2010, as filed with the SEC on May 6,
2010).

Senior Secured Credit Facilities Credit Agreement, dated as of June 28, 2010, among the Registrant,
JPI Commercial, LLC, the several lenders from time to time parties thereto and Silicon Valley Bank,
as Administrative Agent (incorporated herein by reference to exhibit 10.56 in the Registrant’s current
report on Form 8-K (File No. 001-33500), as filed with the SEC on July 1, 2010).

Amended and Restated 2007 Non-Employee Directors Stock Option Plan (incorporated herein by
reference to exhibit 10.2 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for
the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Form of Stock Option Agreement and Form of Option Grant Notice under the Amended and Restated
2007 Non-Employee Directors Stock Option Plan (incorporated herein by reference to exhibit 10.1 in
the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2010, as filed with the SEC on November 5, 2010).

2007 Employee Stock Purchase Plan, as amended and restated (incorporated herein by reference to
exhibit 10.3 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2010, as filed with the SEC on November 5, 2010).

2007 Employee Stock Purchase Plan Offering Document, as amended and restated (incorporated
herein by reference to exhibit 10.4 in the Registrant’s quarterly report on Form 10-Q (File No.
001-33500) for the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Amended and Restated Directors Deferred Compensation Plan (incorporated herein by reference to
exhibit 10.5 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2010, as filed with the SEC on November 5, 2010).

Non-Employee Director Compensation Arrangements, as amended and restated (incorporated herein
by reference to exhibit 10.6 in the Registrant’s quarterly report on Form 10-Q (File No. 001-33500)
for the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

Amendment No. 1 to Master Services Agreement, dated as of August 31, 2010, by and among the
Registrant, Express Scripts Specialty Distribution Services, Inc. and CuraScript, Inc. (incorporated
herein by reference to exhibit 10.7 in the Registrant’s quarterly report on Form 10-Q (File No.
001-33500) for the period ended September 30, 2010, as filed with the SEC on November 5, 2010).

10.53+

Separation Agreement, dated January 6, 2011, by and between the Registrant and Robert Myers.

10.54+

Jazz Pharmaceuticals, Inc. Cash Bonus Plan, as amended as of February 8, 2011.

10.55+

2010 and 2011 Executive Officer Compensation Arrangements.

Exhibit
Number

Description of Document

21.1

23.1

24.1

31.1

31.2

32.1

Subsidiaries of the Registrant.

Consent of Independent Registered Public Accounting Firm.

Power of Attorney (included on the signature page hereto).

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated
under the Securities Exchange Act of 1934, as amended.

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated
under the Securities Exchange Act of 1934, as amended.

Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

+

†

*

Indicates management contract or compensatory plan.

Confidential treatment has been granted for portions of this exhibit. Omitted portions have been filed
separately with the Securities and Exchange Commission.

The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not
be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended.

K
-
0
1
m
r
o
F

Subsidiaries of the Registrant

EXHIBIT 21.1

Orphan Medical, LLC

JPI Commercial, LLC

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-143553,

333-150008, 333-158242, 333-165354 and 333-168799) pertaining to the 2003 Equity Incentive Plan, 2007
Equity Incentive Plan, 2007 Employee Stock Purchase Plan, 2007 Non-Employee Directors Stock Option Plan
and Amended and Restated Directors Deferred Compensation Plan and the Registration Statements (Post-
Effective Amendment No. 1 to Form S-1 on Form S-3 No. 333-163999, Post-Effective Amendment No. 1 to
Form S-1 on Form S-3 No. 333-161350, Post-Effective Amendment No. 1 to Form S-1 on Form S-3 No. 333-
161333 and Post-Effective Amendment No. 1 to Form S-3 No. 333-151593 ) of Jazz Pharmaceuticals, Inc. and in
the related Prospectuses of our reports dated March 8, 2011, with respect to the consolidated financial statements
and schedule of Jazz Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of
Jazz Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2010.

/s/ ERNST & YOUNG LLP

Palo Alto, California
March 8, 2011

K
-
0
1
m
r
o
F

I, Bruce C. Cozadd, certify that:

CERTIFICATION

EXHIBIT 31.1

1.

I have reviewed this annual report on Form 10-K of Jazz Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and

procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant’s internal control over financial reporting.

Date: March 8, 2011

By:

/s/ BRUCE C. COZADD

Bruce C. Cozadd
Chairman and Chief Executive Officer

CERTIFICATION

EXHIBIT 31.2

I, Kathryn E. Falberg, certify that:

1.

I have reviewed this annual report on Form 10-K of Jazz Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the registrant and have:

K
-
0
1
m
r
o
F

a) Designed such disclosure controls and procedures, or caused such disclosure controls and

procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant’s internal control over financial reporting.

Date: March 8, 2011

By:

/s/ KATHRYN E. FALBERG

Kathryn E. Falberg
Senior Vice President and Chief Financial Officer

CERTIFICATION(1)

EXHIBIT 32.1

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
Section 1350), Bruce C. Cozadd, Chairman and Chief Executive officer of Jazz Pharmaceuticals, Inc.(the
“Company”), and Kathryn E. Falberg, Senior Vice President and Chief Financial Officer of the Company, each
hereby certifies that, to the best of his or her knowledge:

1.

2.

The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, to which
this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

The information contained in the Periodic Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of the 8th of March 2011.

/S/ BRUCE C. COZADD

Bruce C. Cozadd
Chairman and Chief Executive Officer

/S/ KATHRYN E. FALBERG

Kathryn E. Falberg
Senior Vice President and Chief Financial Officer

(1) This certification accompanies the Annual Report on Form 10-K to which it relates, are not deemed filed

with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of
Jazz Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general
incorporation language contained in such filing. A signed original of this written statement required by
section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Jazz Pharmaceuticals, Inc. and will be
retained by Jazz Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff
upon request.

COMPANY INFORMATION

Board of Directors

Paul L. Berns
President and Chief Executive Officer
Allos Therapeutics, Inc.

Samuel D. Colella
Managing Director, Versant Ventures

Bruce C. Cozadd
Chairman and Chief Executive Officer
Jazz Pharmaceuticals, Inc.

Bryan C. Cressey
Partner, Cressey and Company, LLC

Patrick G. Enright
Managing Director, Longitude Capital

Michael W. Michelson
Member, KKR Management LLC

James C. Momtazee
Member, KKR Management LLC
Kenneth W. O’Keefe
Managing Director, Beecken Petty O’Keefe & Company

Alan M. Sebulsky
Managing Partner, Apothecary Capital LLC

Management

Bruce C. Cozadd
Chairman and Chief Executive Officer

Russell J. Cox
Senior Vice President, Sales and Marketing

Michael A. DesJardin
Senior Vice President, Product Development

Mark G. Eller, Ph.D.
Senior Vice President, Research and Clinical Development

Kathryn E. Falberg 
Senior Vice President and Chief Financial Officer

Carol A. Gamble
Senior Vice President, General Counsel and Corporate Secretary

Janne L. T. Wissel
Senior Vice President, Chief Regulatory Officer and Chief Compliance Officer

Diane R. Guinta, Ph.D.
Vice President, Clinical Research and Development

P. J. Honerkamp
Vice President, Deputy General Counsel

Edwin W. Luker
Vice President, Sales

James B. Tananbaum, M.D.
Founder and Chief Executive Officer Foresite Capital Management, LLC

Annette L. Madrid, M.D.
Vice President, Clinical and Experimental Medicine and Chief Medical Officer

Rick E Winningham
Chairman and Chief Executive Officer, Theravance, Inc.

Nathaniel M. Zilkha
Global Co-Head of Special Situations Investing
Kohlberg Kravis Roberts & Co. L.P.

Common Stock
Jazz Pharmaceuticals Inc. Common Stock is traded on the 
NASDAQ Global Market under the symbol JAZZ.

Registrar and Transfer Agent
Computershare
P.O. Box 43023 
Providence, RI 02940 
781-575-4238
www.Computershare.com

Independent Registered Public Accountants
Ernst & Young LLP, Palo Alto, CA

Annual Meeting
The annual meeting of stockholders will be held at 11:00 a.m. 
on May 24, 2011 at 3180 Porter Drive, Palo Alto, CA 94304.

Heather P. McGaughey
Vice President, Human Resources

Joel M. Rothman
Vice President, Development Operations

Karen J. Wilson
Vice President, Finance and Principal Accounting Officer

Jazz Pharmaceuticals Corporate Headquarters
3180 Porter Drive
Palo Alto, CA 94304
650-496-3777
www.jazzpharmaceuticals.com

For More Information
Information about Jazz Pharmaceuticals can be found on the Internet at 
www.jazzpharmaceuticals.com. Inquiries regarding Jazz Pharmaceuticals 
and its activities may be directed to the Investor Relations Department at 
investorinfo@jazzpharma.com or 650-496-2800. Communications concerning 
stock and transfer requirements, lost certificates or changes of address should 
be directed to the Transfer Agent.

Safe Harbor
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities 
Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. In some cases, you can identify forward-looking statements by 
terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential” and similar expressions 
intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements related to our growth potential, future financial 
performance, future product sales and product candidate development. These forward-looking statements are based on our current expectations and inherently involve 
significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a 
result of these risks and uncertainties, which include, without limitation, risks related to: our dependence on sales of Xyrem, and our ability to increase sales of Xyrem 
and Luvox CR products; competition, including potential generic competition; our dependence on single source suppliers and manufacturers; our ability to protect our 
intellectual property and defend our patents; the uncertain and time-consuming clinical development and regulatory process for our product candidates; regulatory 
risks; our cash flow estimates, the sufficiency of our cash resources; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in our 
Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities 
and Exchange Commission on March 8, 2011 as attached to this report. We undertake no duty or obligation to update any forward-looking statements contained in this 
report as a result of new information, future events or changes in our expectations.

3180 Porter Drive
Palo Alto, CA 94304
650.496.3777

www.jazzpharmaceuticals.com